---
document_datetime: 2024-07-11 11:42:17
document_pages: 183
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/truqap-epar-public-assessment-report_en.pdf
document_name: truqap-epar-public-assessment-report_en.pdf
version: success
processing_time: 142.5347157
conversion_datetime: 2025-12-23 01:14:36.487425
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 April 2024 EMA/236868/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Truqap

International non-proprietary name: Capivasertib

Procedure No. EMEA/H/C/006017/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................8                                 |                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................         | 8                                                                                                             |
| 1.2. basis, dossier content                                                                                                | ......................................................................................... 8                   |
| 1.3. Information on paediatric requirements.................................................................               | 8                                                                                                             |
| 1.4. Information relating to orphan market exclusivity                                                                     | ................................................... 8                                                         |
| 1.4.1. Similarity                                                                                                          | ....................................................................................................... 8     |
| 1.5. Applicant's request(s) for consideration                                                                              | ................................................................. 8                                           |
| 1.5.1. New active substance status                                                                                         | ............................................................................. 8                               |
| 1.6. Scientific advice.................................................................................................    | 9                                                                                                             |
| 1.7. Steps taken for the assessment of the product                                                                         | ....................................................... 9                                                     |
| 2. Scientific discussion                                                                                                   | ..............................................................................11                              |
| 2.1. Problem statement...........................................................................................          | 11                                                                                                            |
| 2.1.1. Disease or condition.......................................................................................         | 11                                                                                                            |
| 2.1.2. Epidemiology and risk factors..........................................................................             | 11                                                                                                            |
| 2.1.3. Biologic features............................................................................................       | 11                                                                                                            |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis...........................................                     | 12                                                                                                            |
| 2.1.5. Management.................................................................................................         | 13                                                                                                            |
| 2.2. About the product ............................................................................................        | 14                                                                                                            |
| 2.3. Type of application and aspects on development...................................................                     | 14                                                                                                            |
| 2.4. Quality aspects ................................................................................................      | 15                                                                                                            |
| 2.4.1. Introduction                                                                                                        | ................................................................................................. 15          |
| 2.4.2. Active Substance...........................................................................................         | 15                                                                                                            |
| General information ................................................................................................       | 15                                                                                                            |
| Manufacture, characterisation and process control.......................................................                   | 16                                                                                                            |
| Specification                                                                                                              | .......................................................................................................... 16 |
| Stability ................................................................................................................ | 17                                                                                                            |
| 2.4.3. Finished Medicinal Product ..............................................................................           | 17                                                                                                            |
| Description of the product and pharmaceutical development.........................................                         | 17                                                                                                            |
| Manufacture of the product and process controls.........................................................                   | 18                                                                                                            |
| Product specification ...............................................................................................      | 18                                                                                                            |
| Stability of the product............................................................................................       | 19                                                                                                            |
| Adventitious agents ................................................................................................       | 19                                                                                                            |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                          | 19                                                                                                            |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ..................... 19                                                                                      |
| 2.4.6. Recommendations for future quality development                                                                      | .............................................. 19                                                             |
| 2.5. Non-clinical aspects..........................................................................................        | 19                                                                                                            |
| 2.5.1. Introduction .................................................................................................      | 19                                                                                                            |
| 2.5.2. Pharmacology...............................................................................................         | 20                                                                                                            |
| 2.5.3. Pharmacokinetics ..........................................................................................         | 25                                                                                                            |
| 2.5.4. Toxicology....................................................................................................      | 29                                                                                                            |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................                   | 37                                                                                                            |
| 2.5.6. Discussion on non-clinical aspects....................................................................              | 38                                                                                                            |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................                | 43                                                                                                            |

<div style=\"page-break-after: always\"></div>

| 2.6. Clinical aspects                                                                                                   | ................................................................................................ 43   |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 2.6.1. Introduction .................................................................................................   | 43                                                                                                    |
| 2.6.2. Clinical pharmacology ....................................................................................       | 46                                                                                                    |
| 2.6.3. Discussion on clinical pharmacology .................................................................            | 75                                                                                                    |
| 2.6.4. Conclusions on clinical pharmacology                                                                             | ............................................................... 81                                    |
| 2.6.5. Clinical efficacy                                                                                                | ............................................................................................. 81      |
| 2.6.6. Discussion on clinical efficacy                                                                                  | .........................................................................133                          |
| Dose finding and dose recommendation....................................................................134             |                                                                                                       |
| Design and conduct of clinical studies                                                                                  | .......................................................................134                            |
| Efficacy data and additional analyses........................................................................138        |                                                                                                       |
| 2.6.7. Conclusions on the clinical efficacy..................................................................141        |                                                                                                       |
| 2.6.8. Clinical safety                                                                                                  | ..............................................................................................141     |
| 2.6.9. Discussion on clinical safety                                                                                    | ...........................................................................163                        |
| 2.6.10. Conclusions on the clinical safety                                                                              | ..................................................................171                                 |
| 2.7. Risk Management Plan.....................................................................................172       |                                                                                                       |
| 2.7.1. Safety concerns                                                                                                  | ...........................................................................................172        |
| 2.7.2. Pharmacovigilance plan.................................................................................172       |                                                                                                       |
| 2.7.3. Risk minimisation measures...........................................................................173         |                                                                                                       |
| 2.7.4. Conclusion...................................................................................................174 |                                                                                                       |
| 2.8. Pharmacovigilance...........................................................................................174    |                                                                                                       |
| 2.8.1. Pharmacovigilance system.............................................................................174         |                                                                                                       |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                           | ...................................174                                                                |
| 2.9. Product information.........................................................................................174    |                                                                                                       |
| 2.9.1. User consultation..........................................................................................174   |                                                                                                       |
| 2.9.2. Additional monitoring....................................................................................174     |                                                                                                       |
| 3. Benefit-Risk Balance............................................................................174                  |                                                                                                       |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................174           |
| 3.1.1. Disease or condition......................................................................................174    |                                                                                                       |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................175                                               |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................175             |
| 3.2. Favourable effects...........................................................................................176   |                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................176                                                         |
| 3.4. Unfavourable effects........................................................................................177    |                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................178                                                            |
| 3.6. Effects Table                                                                                                      | ..................................................................................................178 |
| 3.7. Benefit-risk assessment and discussion                                                                             | ..............................................................180                                     |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................180                                                        |
| 3.7.2. Balance of benefits and                                                                                          | risks..........................................................................181                    |
| 3.7.3. Additional considerations on the benefit-risk balance                                                            | .........................................181                                                          |
| 3.8. Conclusions....................................................................................................181 |                                                                                                       |
| 4. Recommendations...............................................................................181                    |                                                                                                       |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADME Absorption distribution metabolism excretion ADR Adverse drug reaction AE Adverse event AESI Adverse event of special interest AJCC American Joint Committee on Cancer AKT Serine/threonine specific protein kinase ALP Alkaline phosphatase APD Action potential duration API Active pharmaceutical ingredient AUC Area under the plasma concentration-time curve AUC0-12h Area under the plasma concentration-time curve from zero to 12 hours AUC12h,ss Area under the plasma concentration-time curve for 12 hours at steady state AUCinf Area under the plasma concentration-time curve from time zero to infinity BCS Biopharmaceutics Classification System BD Twice daily BICR Blinded independent central review CBR Clinical benefit rate CDK Cyclin-dependent kinase CDx Companion diagnostic CHMP Committee for Medicinal Products for Human Use CHO Chinese hamster ovary Cmax Maximum observed plasma (peak) drug concentration Cmax,ss Maximum concentration at steady state CMC Chemistry, manufacturing and controls CI Confidence interval CIOMS Council for International Organizations of Medical Sciences COVID-19 Coronavirus disease 2019 CTCAE Common terminology criteria for adverse events CYP Cytochrome P450 DCO Data cut-off DDI Drug-drug interaction DLT Dose-limiting toxicity

<div style=\"page-break-after: always\"></div>

DoR Duration of response EC European Commission ECG Electrocardiogram ECOG Eastern Cooperative Oncology Group eCRF Electronic case report form EMA European Medicines Agency EoP2 End of phase II EORTC QLQ-C30 EORTC Quality of Life Questionnaire-Core 30 items ER Oestrogen receptor ER+ Oestrogen receptor-positive ESR Externally sponsored research EU European Union FAS Full analysis set FaSSIF Fasted state simulated intestinal fluid FDA Food and Drug Administration FFPE Formalin-fixed paraffin-embedded FTIH First time in human FT-IR Fourier transform infrared spectroscopy GCP Good clinical practice GLDH Glutamate dehydrogenase GMR Geometric mean ratio HbA1C Glycosylated haemoglobin HER2Human epidermal growth factor receptor 2-negative hERG Ether-a-go-go-related gene HR+ Hormone receptor-positive HRQoL Health-related quality of life IC50 Half-maximal inhibitory concentration ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICP-MS Inductively coupled plasma mass spectrometry IDMC Independent data monitoring committee IHC Immunohistochemistry IM Intramuscular HPLC High performance liquid chromatography

<div style=\"page-break-after: always\"></div>

HS-GC Headspace gas chromatography ISHNo evidence of amplification on in situ hybridisation ITT Intention to treat IV Intravenous KF Karl Fischer titration LC Liquid chromatography LDPE Low density polyethylene LHRH Luteinizing hormone releasing hormone MAA Marketing Authorisation Application mCRPC Metastatic castration-resistant prostate cancer MRHD Maximal recommended human dose MTD Maximum tolerated dose mTOR Mammalian target of rapamycin MTP Multiple testing procedure NCA Noncompartmental PK analysis NCCN National Comprehensive Cancer Network NDA New drug application NIR Near infrared spectroscopy NMR Nuclear magnetic resonance NOAEL No observed adverse effect level NOR Normal operating range NR Not reported OR Odds ratio ORR Objective response rate OS Overall survival Overnight fast  Fast from 8 hours before to 4 hours after dosing pAKT Phosphorylated serine/threonine-specific protein kinase Partially fasted  Fast from 2 hours before to 1 hour after dosing PAR Proven acceptable range PBPK Physiologically based pharmacokinetic modelling PCE Polychromatic erythrocytes PD Pharmacodynamic(s) PFS Progression-free survival

<div style=\"page-break-after: always\"></div>

PFS2 Time from randomisation to second progression or death Ph. Eur. European Pharmacopoeia PIK3CA Gene encoding the phosphatidylinositol 3kinase α catalytic subunit PI3K Phosphatidylinositol 3-kinase PK Pharmacokinetic(s) PopPK Population pharmacokinetics PPI Proton pump inhibitor PRO Patient-reported outcome PTEN Phosphatase and tensin homologue QoL Quality of life RECIST v1.1 Response Evaluation Criteria in Solid Tumours version 1.1 RH Relative humidity RP2D Recommended Phase II dose RTOR Real-Time Oncology Review SAE Serious adverse event SAP Statistical analysis plan SAS Safety analysis set SERD Selective oestrogen receptor degrader SmPC Summary of product characteristics TNBC Triple-negative breast cancer TX Toxicokinetic ULN Upper limit of normal US United States UV Ultraviolet Vs Versus WBC White blood cells WHO World Health Organization

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant AstraZeneca AB submitted on 20 April 2023 an application for marketing authorisation to the  European  Medicines  Agency  (EMA)  for  Capivasertib  AstraZeneca  AB,  through  the  centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 14 October 2021.

The applicant applied for the following indication:

Capivasertib is indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen (see section 5.1).

## 1.2. basis, dossier content

The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own  tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0214/2019 on the granting of a (product-specific) waiver.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal  products  because  there  is  no  authorised  orphan  medicinal  product  for  a  condition related to the proposed indication.

## 1.5. Applicant's request(s) for consideration

## 1.5.1. New active substance status

The applicant requested the active substance capivasertib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 1.6. Scientific advice

The applicant received the following scientific advice on the  development relevant for the indication subject to the present application:

| Date       | Reference                 | SAWP co-ordinators                     |
|------------|---------------------------|----------------------------------------|
| 17/10/2019 | EMEA/H/SA/3985/2/2019/III | Dr Kristian Wennmalm, Dr Paolo Foggi   |
| 17/09/2020 | EMEA/H/SA/3985/4/2020/III | Prof. Dieter Deforce, Dr Olli Tenhunen |

The scientific advice pertained to the following non-clinical, and clinical aspects:

- The proposed toxicology programme, based on ICH S9 guideline principles, to support a MAA in HR+/HER2- advanced breast cancer;
- The design of the planned double-blind, placebo-controlled, randomised, international Phase 3 study  (D3615C00001),  intended  to  provide  confirmatory  evidence  of  the  clinical  benefit  of capivasertib in combination with fulvestrant vs fulvestrant alone for the treatment of patients with HR+/HER2- locally advanced or metastatic breast cancer, in particular: the choice of the patient population and line of treatment for the proposed indication to address the unmet medical need; the inclusion of both CDK 4/6 inhibitors naïve and pre -treated patients; the choice of placebo plus fulvestrant as  comparator; the stratification  factors;  the  targeted  magnitude  of benefit and maturity of the PFS and OS analyses; the overall multiple testing procedure; the proposed assessment of patientreported outcomes (PROs) to support a label claim;
- The safety monitoring plan and anticipated safety database.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Janet Koenig

Co-Rapporteur:  Alexandre Moreau

CHMP Peer reviewer(s): N/A

The Rapporteur appointed by the PRAC was:

PRAC Rapporteur: Sonja Hrabcik

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                             | 20 April 2023     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                               | 18 May 2023       |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                           | 14 August 2023    |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                        | 29 August 2023    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                           | 21 August 2023    |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                | 14 September 2023 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                    | 20 December 2023  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                        | 30 January 2024   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 8 February 2024   |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanationto be sent to the applicant on                                                                 | 22 February 2024  |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                        | 25 March 2024     |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on               | 11 April 2024     |
| The CHMP Rapporteurs circulated the updated CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on       | 19 April 2024     |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Truqap on | 25 April 2024     |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product on                                              | 25 April 2024     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

The applicant seeks a marketing authorisation) for the medicinal product Truqap (capivasertib) with the following therapeutic indication:

'Truqap is indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen (see section 5.1)'.

## 2.1.2. Epidemiology and risk factors

Breast cancer (BC) is the leading cause of cancer in women and the leading cause of cancer deaths in women (Bray et al, CA : A Cancer Journal for Clinicians , 2018). In men, breast cancer is rare (Siegel et al 2022). The incidence and prevalence of patients with invasive breast cancer, as well as estimates for the  prevalence  of  subjects  with  Oestrogen  receptor  positive  (ER+)/Human  epidermal  growth  factor receptor 2-negative (HER2-) breast cancer, are presented in the below table.

Table 1 Epidemiology of ER+/HER2- breast cancer (x 1,000)

|                                                                                   | US      | EUa   |   Japana | Global   |
|-----------------------------------------------------------------------------------|---------|-------|----------|----------|
| Incidence: New yearly cases of invasive breast cancer                             | 253282b | 531   |       92 | 2,261    |
| Prevalence of imvasive breast cancer                                              | 1,071a  | 2,138 |      328 | 7,791    |
| Prevalence ofER+,HER2-breast cancer (approximately 70% of invasive breast cancer) | 750     | 1,497 |      230 | 5,454    |

Abbreviations: ER+=estrogen receptor positive; EU=European Union; HER2-=human epidermal growth factor receptor 2 negative; SEER=Surveillance, Epidemiology, and End Results; US=United States.

InternationalAgencyforResearchon Cancer andWorld Health Organization 2021

b National Cancer Institute and Surveillance, Epidemiology, and End Results (SEER) Program 2021

For women diagnosed with early BC (eBC), the 5-year survival probability is ∼ 96% in Europe. However, when metastatic BC (mBC) is diagnosed, the 5-year survival rate is in the range of 38% (Allemani et al, Lancet , 2018). About 157,100 women were estimated to have died from breast cancer in the EU in 2020 (Ferlay et al, International Journal of Cancer , 2021). In terms of absolute numbers, mBC was still the leading cause of death from all cancers in women, accounting for ∼ 3.6% of all deaths in women and 1.8% of all deaths in Europe in 2015 (Dafni et al, Breast Care , 2019).

## 2.1.3. Biologic features

BC is a heterogeneous disease comprising different subtypes, which can be identified through molecular biomarkers that also act as predictive factors. It is categorised into different histopathologic subtypes based on the expression of the oestrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor overexpression or gene amplification. Oestrogen receptor (ER), and progesterone receptor (PR) are together referred to as hormone receptor (HR). HR+, HER2- breast cancer is the most frequent subtype of breast cancer; approximately 70% of all breast cancers are HR+, HER2- (Howlader et al 2014).

<div style=\"page-break-after: always\"></div>

ER is a transcription factor that regulates the expression of oestrogen-responsive genes by binding to a specific DNA sequence found in their regulatory regions. Two major isoforms of the oestrogen receptor have been identified, ER α and ER β: however, the role of ER β in cancer remains unclear. The two isoforms are encoded by two genes located on different chromosomes (ESR1 on chromosome 6 and ESR2 on chromosome 14) and regulate different specific genes.

Endocrine therapy (ET) comprises different strategies as suppression of oestrogen production or directly targeting the oestrogen receptor (ER):

- -Steroidal/nonsteroidal  aromatase  inhibitors  (AI)  (e.g.  exemestane/letrozole  and  anastrozole  and exemestane) exert their action  by  blocking  androgen  to  oestrogen  conversion,  thus  lowering  the levels of circulating oestradiol (E2) and, therefore, reducing the activation of ER.
- -Direct targeting of ERα is achieved by selective oestrogen receptor modulator (SERM) (e.g. tamoxifen) and selective oestrogen receptor degrader (SERD) (e.g. fulvestrant). SERMs compete with oestrogen for ER binding and show mixed agonist/antagonist capabilities in a tissue-specific fashion. Meanwhile, SERDs create an unstable protein complex that induces ER protein degradation via the proteasome.

The AKT serine/threonine protein kinases (AKT1, AKT2, AKT3) are key downstream effectors of the PI3K/AKT/PTEN pathway, promoting cell proliferation, survival, metabolism, and gene expression (Brown and Banerji 2017, Engelman 2009, Lindsley 2010, Liu et al 2009, Vanhaesebroeck et al 2012). They are activated  in  a  wide  range  of  solid  and  haematological  malignancies.  In  breast  cancer,  AKT  pathway activation is largely due to input from signals upstream of AKT, including activating mutations in the catalytic  subunit  of  PI3K  (PIK3CA)  or  deleterious  mutations  in  PTEN,  or  through  non-genomic mechanisms such as downregulation  of  PTEN  protein  expression  or  enhanced  activation  of  receptor tyrosine kinases (Shi et al 2022, Yi and Lauring 2016).

There is evidence of a reciprocal activation between the ER pathway and the PI3K AKT pathway which can  influence  therapeutic  response  to  each  monotherapy  agent.  AKT  signalling  may  be  upregulated following exposure to ER inhibitors independent of genetic alterations, and the therapeutic benefit of inhibiting PI3K-AKT signalling may be limited through increased ER signalling (Bosch et al 2015, Miller et al 2010, Ribas et al 2015).

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

The  diagnosis  of  breast  cancer  is  based  on  clinical  examination  in  combination  with  imaging  and confirmed  by  pathological  assessment.  Disease  stage  is  assessed  according  to  the  tumour,  node, metastasis (TNM) system.

Recent ASCO/College of American Pathologists guidelines still support the classification of ER+ breast cancer being &gt;1% by immunohistochemistry staining. However, 'there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive'.

Other therapeutically  relevant  biomarkers  that  may  be  evaluated  in  patients  with  ER+,  HER2-  mBC currently include PIK3CA, ESR1, NTRK, MSI-H/dMMR, TMB-H, RET, BRCA1/2 and PALB2.

Key clinical factors to consider when determining the choice for systemic treatment for women are (i) pre- versus postmenopausal status at the time of presentation, (ii) de novo metastatic versus recurrence, (iii) disease-free interval and type of adjuvant therapy, (iv) tumour burden including bone-only versus visceral  disease,  (v)  performance  status  and  medical  comorbidities,  and  (vi)  for  patients  who  have progressed on frontline treatment to consider the previous treatments they received and the response, duration of response, and tolerability to those previous therapies (Andrew et al, JCO Oncology Practice , 2021).

<div style=\"page-break-after: always\"></div>

## 2.1.5. Management

Advanced breast cancer comprises both locally advanced (inoperable) and metastatic breast cancer. It remains virtually incurable (Gennari et al 2021). The primary goals of systemic treatment for advanced breast  cancer  (aBC)  are  prolongation  of  survival,  alleviation  of  symptoms,  and  maintenance  or improvement in quality of life, while balancing the toxicity associated with treatment (UpToDate 2023).

The preferred treatment for advanced HR+, HER2- breast cancer is sequential endocrine-based therapy in the majority of cases, except for patients with visceral crisis / imminent organ failure or where there is concern about (or evidence of) endocrine therapy resistance. For these patients, chemotherapy is the preferred option (NCCN 4.2023; Gennari et al, Annals of Oncology, 2021).

The combination of endocrine therapy (i.e. aromatase inhibitor or fulvestrant) with a CDK4/6 inhibitor (i.e.  albemaciclib,  ribociclib  or  abemaciclib)  is  currently  considered  the  standard  of  care  first-line treatment for advanced disease in the majority of patients, with improved PFS and OS seen in several trials (Gennari et al 2021, Hortobagyi et al 2021, Im et al 2019, Slamon et al 2020, Sledge et al 2020). Regarding the choice of using aromatase inhibitor or fulvestrant as endocrine therapy, the following applies:

- -For patients who did not relapse on an aromatase inhibitor, or within 12 months of stopping adjuvant aromatase  inhibitor  therapy,  a  CDK4/6  inhibitor  is  generally  deployed  in  combination  with  an aromatase inhibitor.
- -In patients who relapsed on adjuvant aromatase inhibitor therapy, or within 12 months of stopping adjuvant  aromatase  inhibitor  therapy,  fulvestrant  is  advised  as  a  combination  partner  with  the CDK4/6 inhibitor (Gennari et al 2021).

The optimal sequence of endocrine-based therapy after progression on CDK4/6 inhibitors is uncertain and limited data is available in the post-CDK4/6 inhibitor setting. It is dependent on disease burden, which agents were used previously [in the (neo)adjuvant or advanced settings], duration of response (DoR)  to  previous  ET  (for  use  of  second-line  single-agent  ET),  patient  preference  and  treatment availability. Subsequent available treatment options with some scientific evidence include (incomplete list)  fulvestrant  (+  CDK  4/6  inhibitor  if  not  previously  used),  everolimus  +  endocrine  therapy (exemestane),  fulvestrant  +  alpelisib  (if  PIK3CA  mutated  tumours),  elacestrant  (if  ESR1  mutated tumours) and chemotherapy. As a consequence, subsequent treatment with endocrine monotherapy, including fulvestrant, remains an option in current international guidelines (NCCN 2023), but is not the preferred  option,  as  it  has  recently  shown  short  PFS  outcomes  in  CDK4/6  inhibitor  pre-treated populations (Bidard et al 2022, Kalinsky et al 2022, Lindeman et al 2021, Tolaney et al 2022).

Premenopausal women must have ovarian suppression/ablation when treated with aromatase inhibitors.

This  application  for  capivasertib  is  the  first  for  an  AKT-inhibitor.  Several  AKT-inhibitors  are  under development in different  indications  as  the  PI3K/AKT/PTEN  pathway  is  a  central  signal  transduction pathway  in  cell  proliferation  and  survival.  Other  medicinal  products  targeting  the  PI3K/AKT/PTEN pathway target PIK3CA inhibitors and mTOR inhibitors (Coleman, 2021). The PIK3CA inhibitor alpelisib (in combination with fulvestrant) and the mTOR inhibitor everolimus (in combination with exemestane) are approved for advanced and metastatic breast cancer.

<div style=\"page-break-after: always\"></div>

## 2.2. About the product

Capivasertib is a potent, selective inhibitor of the kinase activity of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3). AKT is a pivotal node in the phosphatidylinositol 3-kinase (PI3K) signalling  cascade  regulating  multiple  cellular  processes  including  cellular  survival,  proliferation,  cell cycle,  metabolism,  gene  transcription  and  cell  migration.  AKT  activation  in  tumours  is  a  result  of upstream activation from other signalling pathways, mutations of AKT1 , loss of p and tensin homolog (PTEN) function and mutations in the catalytic subunit of PI3K ( PIK3CA ).

The final indication for Truqap is:

'TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations  following  recurrence  or  progression  on  or  after  an  endocrine-based regimen (see section 5.1).

In  pre-  or  perimenopausal  women,  TRUQAP  plus  fulvestrant  should  be  combined  with  a  luteinising hormone releasing hormone (LHRH) agonist.

For  men,  administration  of  LHRH  agonist  according  to  current  clinical  practice  standards  should  be considered.'

Treatment with TRUQAP should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.

Patients with ER-positive, HER2-negative advanced breast cancer should be selected for treatment with TRUQAP based on the presence of one or more PIK3CA/AKT1/PTEN -alterations which should be assessed by a CE-marked IVD with the corresponding intended purpose. If the CE-marked IVD is not available, an alternative validated test should be used.

## Posology

The recommended dose of TRUQAP is 400 mg (two 200 mg tablets) twice daily, approximately 12 hours apart (total daily dose of 800 mg), for 4 days followed by 3 days off treatment. See Table 2.

Table 2 TRUQAP dosing schedule for each week

| Day     | 1                     | 2          | 3          | 4          | 5*   | 6*   | 7*   |
|---------|-----------------------|------------|------------|------------|------|------|------|
| Morning | 2 x 200 mg            | 2 x 200 mg | 2 x 200 mg | 2 x 200 mg |      |      |      |
| Evening | 2 x 200 mg 2 x 200 mg |            | 2 x 200 mg | 2 x 200 mg |      |      |      |

* No dosing on day 5, 6 and 7.

TRUQAP should be coadministered with fulvestrant. The recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter.

## Missed dose

If a dose of TRUQAP is missed, it can be taken within 4 hours after the time it is usually taken. After more than 4 hours, the dose should be skipped. The next dose of TRUQAP should be taken at the usual time. There should be at least 8 hours between doses.

## 2.3. Type of application and aspects on development

This application under an article 8(3) legal basis of Directive 2001/83/EC (as a complete and independent application) is based on data from the primary analysis of PFS (DCO1) from the ongoing single pivotal phase 3 study D3615C00001 (CAPItello-291), together with supportive data from other studies in the capivasertib (AZD5363) clinical development programme.

<div style=\"page-break-after: always\"></div>

Specific CHMP guidelines relevant for the current application: Guideline on the evaluation of anticancer medicinal products in man (EMA/CHMP/205/95 Rev.5, 22 September 2017).

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as film-coated tablets containing 160 mg or 200 mg of capivasertib as active substance.

Other ingredients are:

Core tablet: microcrystalline cellulose (E460i), dibasic calcium phosphate, croscarmellose sodium (E468) and magnesium stearate (E470b).

Tablet  coating:  hypromellose,  titanium  dioxide  (E171),  macrogol  3350,  polydextrose,  copovidone, medium-chain triglycerides, black iron oxide (E172), red iron oxide (E172), yellow and iron oxide (E172).

The product is available in aluminium/aluminium blister as described in section 6.5 of the SmPC.

## 2.4.2. Active Substance

## General information

The  chemical  name  of  capivasertib  is  4-aminoN -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide corresponding to the molecular formula C21H25ClN6O2. It has a relative molecular mass of 428.92 g/mol and the following structure:

<div style=\"page-break-after: always\"></div>

## Figure 1: active substance structure

<!-- image -->

The chemical structure of capivasertib was elucidated by a combination of  1 H- and  13 C-NMR spectroscopy, mass spectrometry, infrared spectroscopy, UV spectroscopy and elemental analysis. Single crystal x-ray diffraction was used to confirm the absolute stereochemistry. The solid-state properties of the active substance were measured by thermogravimetric analysis, differential scanning calorimetry, and dynamic vapour sorption.

The active substance is a white to off-white non-hygroscopic crystalline solid exhibiting pH dependent solubility in biorelevant aqueous media with higher solubility at acidic pH. Particle size is controlled in the active substance specification. Several polymorphic forms were identified during development studies and the proposed commercial form is thermodynamically stable with respect to the others.

## Manufacture, characterisation and process control

Capivasertib is synthesised by a single manufacturer in a convergent process using well defined starting materials with acceptable specifications.

Adequate in-process controls are applied during the synthesis. he specifications and control methods for intermediate  products,  starting  materials  and  reagents  have  been  presented  and  are  considered adequate.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. Fate and purge studies informed and justified the limits for impurities in specifications.

The active substance is packaged in a container that complies with Commission Regulation (EU) 10/2011, as amended.

## Specification

The active substance specification includes tests for description (visual), identity (FT-IR), assay (LC), impurities (LC), chiral impurity (chiral LC), residual solvents (HS-GC), water content (KF), and particle size distribution (laser diffraction).

The specification for the active substance capivasertib contains all relevant parameter to sufficiently describe, qualify and quantify the active substance and potential impurities. The range for assay and the limits for individual impurities are in accordance with ICH Q3A.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for testing has been presented.

<div style=\"page-break-after: always\"></div>

## Stability

Stability data from batches of active substance from the proposed manufacturer stored in the intended commercial package for up to 24 months under long term conditions (25ºC / 60% RH), for up to 24 months under intermediate conditions (30 ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The following parameters were tested: description, assay, impurities, chiral impurity, water content, particle size distribution and polymorphic  form.  The  analytical  methods  used  were  the  same  as  for  release  and  were  stability indicating.  Batches  were  also  tested  annually  for  microbiological  activity  and  water  activity  using appropriate methods. All tested parameters were within specification at all timepoints under all conditions and no trends were observed.

Photostability  testing  following  the  ICH  guideline  Q1B  was  performed  showing  that  capivasertib  is photostable. The active substance is also stable to thermal stress.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  supplier  is sufficiently stable. The stability results justify the proposed retest period of 36 months in the proposed container. The applicant has chosen to include a temperature restriction of not more than 30 o C.

## 2.4.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

Capivasertib 160 mg tablets are presented as beige, round, biconvex, film-coated tablets, approximately 10 mm in diameter. The tablets are marked with 'CAV' above '160' on one side and plain on the reverse.

Capivasertib  200  mg  tablets  are  presented  as  beige,  capsule-shaped,  biconvex,  film-coated  tablets, approximately 14.5 x 7.25 mm. The tablets are marked with 'CAV200' on one side and plain on the reverse.

The tablets are sufficiently distinguishable by size, shape and imprinting.

The function of each component and a reference to their quality standards is indicated. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.4.1 of this report.

The aim of development was an immediate release solid oral dosage form containing the requisite active substance content. Capivasertib is a BCS class IV compound (low solubility, low permeability). Studies demonstrated that particle size has little impact on dissolution, finished product formulation, and the resultant tablet attributes within the ranges studied. Particle size is limited in line with active substance used in these studies. The proposed specification criterion is clinically relevant and confirms acceptable product performance.

Bridging between formulations was demonstrated in a clinical bioequivalence study. Dissolution profiles in all tested media were considered equivalent.

During the development of the manufacturing process, manufacturing steps were evaluated on their potential impact on the quality attributes of the finished product (description, uniformity of dosage units, dissolution) based on failure mode risk analysis. The proven acceptable ranges (PARs) for the process parameters were taken from these development studies.

<div style=\"page-break-after: always\"></div>

Systemic development of the dissolution method was discussed. In vitro in vivo correlation data assisted in the selection of the dissolution method and acceptance criteria. The proposed method is considered sufficiently discriminatory and is adequate for quality control purposes.

The primary packaging is aluminium/aluminium blisters. The materials comply with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The finished product is manufactured by a standard process. PARs, NORs and target set-points have been assigned to relevant process parameters based on the development studies, as requested by the CHMP during the procedure. The in-process controls are adequate for this type of manufacturing process and  pharmaceutical  form.  It  has  been  demonstrated  that  the  manufacturing  process  is  capable  of producing the finished product of intended quality in a reproducible manner. Formal validation will be conducted on 3 consecutive production scale batches of finished product post-approval. A validation protocol has been submitted which is considered acceptable.

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form including description (visual inspection), identification (NIR, LC/UV), assay (NIR, LC), degradation products (LC), dissolution UV) and uniformity of dosage units (Ph. Eur.).

The specifications and associated limits are set in line with ICH and EU guidance. The absence of tests for chiral purity, microbiological attributes and water content has been adequately justified.

The potential presence of elemental impurities in the finished product has been assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Analysis data 3 batches of each  strength  using  a  validated  ICP-MS  method  was  provided,  demonstrating  that  each  relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and  the  presented  batch  data,  no  elemental  impurity  controls  are  included  in  the  finished  product specification.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers  for  marketing  authorisation  holders/applicants  on  the  CHMP  Opinion  for  the  Article  5(3)  of Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal  products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). The product is indicated for advanced cancer in line with ICH S9, and thus, ICH Q3B limits for nitrosamine impurities would apply. It has been justified that there is no appreciable risk of generating nitrosamine impurities at in relevant amounts.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for testing has been presented.

Batch analysis results confirm the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The  finished  product  is  released  on  the  market  based  on  the  above  release  specifications,  through traditional final product release testing.

<div style=\"page-break-after: always\"></div>

## Stability of the product

Stability data from 3 pilot scale batches of 160 mg tablets and 3 production scale batches of 200 mg tablets, stored for up to 36 months under long term conditions (25ºC / 60% RH), for up to 36 months under intermediates conditions (30ºC / 75% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are identical  to  those  proposed  for  marketing  and  were  packed  in  the  primary  packaging  proposed  for marketing. Samples were tested for description, assay, degradants, chiral impurity, dissolution, water content, hardness, microbiological activity and water activity. The analytical methods used in stability studies  which  are  different  from  those  already  described  in  the  specification  section  (assay  and degradation  products  by  LC,  chiral  impurity,  water  content)  are  provided  with  their  corresponding validation  data  and  are  considered  acceptable.  No  meaningful  changes  to  any  of  the  measured parameters and no trends were observed.

Photostability  testing  was  carried  out  according  to  the  conditions  defined  in  the  ICH  Guideline  on Photostability Testing of New Drug Substances and Products. The finished product is photostable.

Based on available stability data, the proposed shelf-life of 48 months without specific storage conditions as stated in the SmPC (section 6.3 and 6.4) is acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried  out  indicate  consistency  and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.6. Recommendations for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Capivasertib has been evaluated in a comprehensive non-clinical package of in vitro and in vivo studies that  were  designed  to  characterise  its  pharmacology,  safety  pharmacology,  pharmacokinetics  and toxicity.

<div style=\"page-break-after: always\"></div>

Non-clinical  studies  relevant  for  the  non-clinical  safety  assessment  of  capivasertib  (pivotal  safety pharmacology studies, pivotal repeat-dose toxicology studies, embryo-foetal development study in rats, validation of bioanalytical methods, rat quantitative whole-body autoradiography (QWBA) study and rat mass balance study) were conducted in compliance with good laboratory practice (GLP) principles.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

## In vitro activity

The potency and selectivity of capivasertib as a serine/threonine kinase AKT (AKT1, AKT2 and AKT3) inhibitor were determined by biochemical assays using isolated enzyme complexes. Capivasertib showed a strong inhibition of all AKT isoforms: AKT1, AKT2 and AKT3 with IC50 values of 3.2, 8.5 and 7.7 nM, respectively. Other kinase targets with the IC50 in low nanomolar range included PKA (IC50 = 6.6 nM) and p70S6K (IC50 was 5.8 nM in a radioactive filter binding assay and 8.9 nM in a recombinant kinase assay). ROCK1 and ROCK2 were also inhibited, albeit with a lower potency (IC50 was 126 and 56 nM, respectively). Screening in several kinase panels with up to 402 targets also identified interactions with MSK1/2, MKK1 (MEK1), RSK1/2/3, PKC, PrKX, PKG1 α / β , CLK2, KIT, LATS2, and YSK4. Most of them belong  to  the  AGC  kinase  family.  The  majority  of  capivasertib  targets  are  involved  in  PI3K/AKT  or MEK/ERK  signalling.  The  latter  may  be  beneficial  as  co-activation  of  the  ERK  pathway  can  modify response to PI3K and AKT inhibitors (Soares et al. 2015).

Capivasertib inhibited the activation of downstream targets of AKT, namely GSK3 β, PRAS40 and S6, in various cancer cell lines with IC50 values in the range 0.07 - 2.57 µM. The effect on these AKT substrates was even more pronounced in LNCaP hormone sensitive PTEN null prostate cancer cells with IC50 between 0.08 and 0.36 µM. As ROCK inhibition may activate AKT through PTEN suppression (Yang and Kim 2014), it was important to evaluate the selectivity of capivasertib for AKT over ROCK. Indeed, capivasertib did not inhibit the phosphorylation of cofilin (S3), which is a downstream target of ROCK in MDA-MB-468 breast cancer cells (IC50 &gt; 19.8 µM). IC50 for the inhibition of the phosphorylation of the PKA substrate VASP in different cell lines lay between 1.44 and 10.58 µM. Direct activity of capivasertib on p70S6K and its downstream substrate S6 was evaluated in TSC2 null and TCS2 knockout cells, in which AKT is no longer  able  to  regulate  mTORC1/p70S6K  signalling.  Capivasertib  was  less  effective  in  inhibiting  S6 phosphorylation in TCS2-deficient cells (IC50 around 800 nM) as compared to the wild-type cells (IC50 = 110  nM).  Although  most  of  these  studies  were  based  on  Western  blot  analysis,  which  is  a  semiquantitative  technique,  the  results  are  consistent  and  the  conclusions  are  agreed.  Thus,  beside  the targets downstream of AKT, capivasertib also inhibits p70S6K and PKA but the potency in tumour cells is  reduced  compared  to  AKT  target  inhibition.  In  cellular  assays  and  animal  models,  significantly increased phosphorylation of AKT by capivasertib rather than reduction in pAKT levels was observed.

Screening of anti-proliferative activity of capivasertib in a panel of 177 cell lines demonstrated the best results  in  breast  cancer  cells.  There  was  a  statistically  significant  correlation  between  sensitivity  to capivasertib and mutations in the PIK3CA (p = 0.03) and PTEN (p = 0.02) among all cell lines examined. In the other two cell line panels, the activity was observed also in wild-type PIK3CA, AKT1 and PTEN cells, albeit less often than in cells with alterations in these genes: 44% of altered cell lines in a breast cancer cell line panel were responsive to capivasertib compared to 12% of WT cell lines, in another panel with different tumour types activity was noted in 67% of mutated lines and in 57% of WT cell lines. Lower IC50 was associated with PTEN altered breast cell lines (p = 0.022) but not in the cell panel of multiple cancer types. In palbociclib-naive and palbociclibresistant ER+ PI3Kα mutant cell lines, the addition  of  capivasertib  to  fulvestrant  or  palbociclib  increased  efficacy  compared  to  the  single  agent treatments. Combination of capivasertib and fulvestrant was more effective than each agent alone in these cell lines also when tested in a long-term cell growth assay using a 4-day on/3-day off capivasertib treatment schedule similar to the clinical setting.

<div style=\"page-break-after: always\"></div>

The  major  human  metabolite  AZ14102143,  an  ether  glucuronide  of  capivasertib,  did  not  affect  the phosphorylation of PRAS40, S6 or GSK3β at the concentrations up to 10 µM and is thus considered a pharmacologically inactive metabolite.

## In vivo activity

When administered orally once or twice daily capivasertib inhibited tumour growth in various mouse xenograft models in a dose-dependent manner. Tumour regression was observed in 786-0 PTEN null renal cancer xenografts (125% tumour growth inhibition at 150 mg/kg BID), in PIK3CA mutant/PTEN null HGC-27 gastric cancer xenografts (106% and 108% tumour growth inhibition at 100 and 150 mg/kg BID, respectively), and HCC-1954 breast cancer xenografts (111% and 129% tumour growth inhibition at 75 and 150 mg/kg BID, respectively). In xenograft models, capivasertib inhibited phosphorylation of PRAS40, GSK3 β and S6 in a time- and dose-dependent manner, with 50% PRAS40 inhibition at plasma concentrations of capivasertib around 0.1 - 0.2 µM. This is well below the clinical unbound Cmax of 0.717 µM demonstrating pharmacological activity of capivasertib at clinically achievable plasma drug levels. The  impact  of  dosing  schedule  on  capivasertib's  efficacy  was  evaluated  in  BT474c  breast  cancer xenografts in mice but with different results. In one study, a high intermittent dose (300 mg/kg once daily 4 days on/3 days off) achieved regression with tumour regrowth during the OFF period whereas the highest continuous dose (150 mg/kg BID) only led to tumour growth inhibition and tumour stasis, despite  the  higher  overall  drug  load  upon  continuous  schedule  (1200  mg/kg/week  and  2100 mg/kg/week, respectively). In another study in the same xenograft model, tumour growth inhibition at 300 mg/kg QD 4 on/3 off was inferior to the continuous 150 mg/kg BID dosing. Multiple experiments were performed to mitigate the influence of experiment to experiment variation. Across the whole data set multiple dose schedules (QD and BID, different intermittent dosing schedules) were compared, and conclusions based on modelling of the total data set. In patient-derived ER+ breast cancer xenografts, capivasertib in combination with fulvestrant elicited a dose-dependent tumour inhibition response, which was superior to the single agent fulvestrant. This was accompanied by an increase in pAKT levels and a reduction in pPRAS40 and pS6 at different dose levels dependent on the model. In  a  model  of  tumour  with  primary  endocrine  resistance,  continuous  administration  of  50  mg/kg capivasertib twice daily resulted in a significant reduction in tumour growth compared to vehicle control. Combination  with  fulvestrant  further  improved  the  outcome  significantly  (to  80%  tumour  growth inhibition) compared to capivasertib and fulvestrant monotherapy. In a panel of ER+ breast cancer in vivo models including palbociclib-sensitive and palbociclib-resistant models as well as PI3KCA, AKT1 and PTEN altered and unaltered models, the combination of capivasertib and fulvestrant showed improved activity compared to each agent alone. The combination benefit was seen in PI3KCA, AKT1 and PTEN mutated and also tumours without alterations, although generally better activity on the combination was noted in altered models.

<div style=\"page-break-after: always\"></div>

## 2.5.2.2. Secondary pharmacodynamic studies

Table 3 Effect of capivasertib in in vitro radioligand binding, enzyme, and electrophysiological assays

| Target a                                      |   ICso (μmol/L) | Ki (μmol/L)   | slope   |
|-----------------------------------------------|-----------------|---------------|---------|
| ROCK1, Protein Serine/Threonine Kinase        |            0.47 | n.d.          | n.d.    |
| FGFR1, Protein tyrosine Kinase                |            6.06 | n.d.          | n.d.    |
| Melanocortin MC5                              |            7.77 | 7.29          | 0.933   |
| YES1, Protein Tyrosine Kinase                 |           11.1  | n.d.          | n.d.    |
| UGT1A1, UDP Glucuronosyltransferase           |           12.8  | n.d.          | n.d.    |
| PDE4, Phosphodiesterase                       |           37.5  | n.d.          | n.d.    |
| Calcium channel L-type, Benzothiazepine (Rat) |           40.8  | 36.2          | 0.963   |
| Proteasome                                    |           62.3  | n.d.          | n.d.    |

All human except where noted

n.d = Not determined

In a panel of 333 in vitro radioligand binding and enzyme assays consisting of various receptors, enzymes and ion channels, significant activity with IC50 values between 6.06 and 62.3 μM was detected for 7 targets  including  PDE4,  FGFR1,  Melanocortin  MC5,  UGT1A1,  Proteasome,  Calcium  Channel  L-type benzothiazepine Receptor and YES1. These IC50 values are more than 8.4-fold higher than the unbound clinical Cmax of 0.717 μM. Therefore, the interactions with these targets are not considered clinically relevant. In the secondary pharmacology screening, ROCK1 was also identified as a potential target with the IC50 value of 0. 47 μM. This concentration is within the clinical range but capivasertib had no effect on the downstream targets of ROCK, therefore, its interaction with ROCK is not considered clinically relevant (see also section 2.5.2.1. In an electrophysiological assay, capivasertib inhibited voltage-gated cardiac ion channels hCav3.2 and hNav1.5 by 25.5% and 29.6%, respectively, at 100 µM.

## 2.5.2.3. Safety pharmacology programme

In vivo and in vitro safety pharmacology studies were performed to assess the cardiac safety, respiratory effects,  and  neurological  effects  of  capivasertib.  Other  safety  pharmacology  studies  investigated  the effects of capivasertib on the gastrointestinal system and the urinary system.

## Cardiovascular System

GLP study 0354SZ used the patch clamp technique to investigate the effects of capivasertib on the voltage-dependent potassium channel encoded by the human ether-a-go-go-related gene ( hERG ), which was expressed in Chinese Hamster Ovary (CHO) cells. Capivasertib exerted concentration-dependent hERG channel activity with the IC50 value of 73.0 μ M. This is more than 100-fold of the unbound clinical Cmax.

In GLP study 1101ZD, the effects of single oral administration of 5, 30 and 40 mg/kg capivasertib to male beagle dogs on arterial blood pressure, left ventricular (LV) systolic and end diastolic pressure, LVdp/dt+ (an index of myocardial contractility), LVdp/dt- (an index of myocardial relaxation), heart rate and ECG parameters (PR, QRS and QT) were recorded by telemetry. Capivasertib at 5 mg/kg decreased heart rate by 17 and 14% at 2 and 8 h, respectively. Following administration of 30 and 40 mg/kg capivasertib, there were peak decreases in systolic and diastolic blood pressure of 20 to 25% and 28 to 30%, respectively,  which  reversed  at  4  h.  Heart  rate  decreased  at  all  doses  but  the  reduction  was reversible. 30 and 40 mg/kg capivasertib caused a sustained statistically significant prolongation of the QT interval (6 to 13%) and QTcR (5 to 12%). There were sustained increases in LVdp/dt+ with peaks of 45 and 56% at 6 and 8 hours. Both glucose and insulin levels were elevated post 30 and 40 mg/kg dose. The NOAEL was considered to be 5 mg/kg. The total Cmax in dogs at the NOAEL was 1.45 μM, which corresponds to unbound Cmax of 0.28 μM, being below the expected clinical exposure.

<div style=\"page-break-after: always\"></div>

GLP study 1167ZD aimed to evaluate the effects of oral administration of 30 mg/kg capivasertib (three dosing occasions) to conscious male beagle dogs on arterial blood pressure, heart rate, left ventricular parameters,  lead  II  electrocardiogram  (ECG),  body  temperature  and  to  see  whether  the  effects  on myocardial  contractility  could  be  reduced  by  the  intravenous  administration  of  either  atenolol  or verapamil. Capivasertib resulted in an increase in left ventricular (LV) dp/dtmax of 34 - 65%. QT and QTcR were both prolonged by 4 - 16% and 5 - 11%, respectively. Intravenous infusion of atenolol significantly  reduced  LVdp/dtmax  by  17%  compared  to  the  time-matched  vehicle  data.  LVdp/dtmax returned to the baseline levels 4 h post-infusion compared to the vehicle control where contractility had not  recovered  until  8  h  post-infusion.  IV  administration  of  verapamil  decreased  LVdp/dtmax  by  a maximum of 18%. Increases in glucose (2.5- to 2.8-fold) and insulin (129- to 170-fold) levels were observed at 4 h after administration of capivasertib. Atenolol and verapamil significantly reduced glucose increases (1.2- and 1.5-fold increase, respectively) compared to vehicle (2.6-fold increase). Insulin level increase was also reduced by atenolol (27-fold increase) and to a lesser extent by verapamil (47-fold increase), compared to vehicle (140-fold increase).

Study  2192SV  tested  the  effects  of  capivasertib  on  action  potential  parameters  in  dog  ventricular myocytes.  Although  capivasertib  exerted  biphasic  effects  on  action  potential  duration  (APD),  these effects were not statistically significant. At lower concentrations (0.3 30 μM), there was an increase in APD90 (16.93% at 30 μM), while at a higher concentration of 100 μM a decrease in APD90 of 5.18% seen. Similar biphasic effects were found for APD70 and APD50.

Study  0255SB  tested  capivasertib's  effect  on  ventricular  monophasic  action  potentials  recorded  in Langendorff heart model from female New Zealand white rabbits. Capivasertib caused a reduction in the APD at 60% of repolarisation (APD60) with a 'bell-shaped' concentration-effect curve. A concentrationrelated increase in coronary blood flow was noted. There was a low-frequency incidence of the indicators of  proarrhythmic  risk  (triangulation,  reverse-use  dependence  or  instability)  but  no  early  afterdepolaris ations. At some capivasertib concentrations greater than 1 μM, ventricular tachycardia was seen in 50% of hearts; the reasons behind this effect remain unclear as any effects on conduction were absent. Up  to  30  µM,  the  TdP  proarrhythmic  score  was  less  than  25  (the  threshold  for  concern  defined  by Lawrence et al. 2006).

Study  2820SR  tested  capivasertib's  effects  on  coronary  flow,  heart  rate  and  cardiac  contractility  in isolated rat hearts perfused in the Langendorff model. At 3, 10 and 30 μM, capivasertib resulted in a significant  dose-related  but  reversible  increase  in  coronary  flow  (respectively  +34.7%,  +80%  and +101.7% compared to baseline). No statistically significant effects on cardiac contractility were noted up to 10 μM. At 30 μM, a small increase of differential left ventricular pressure (+14%, p=0.051), no effect on mean left ventricular pressure, a small increase of dP/dt min (+10%, p&lt;0.001) and dP/dt max (+13%, p&lt;0.001) were observed but these effects were reversible. No statistically significant effects on heart rate were noted. Verapamil at the concentration o f 1 μM attenuated the observed effects.

Study PH/E/12009 assessed the impact of capivasertib on rat aortae. The compound induced direct relaxation of preconstricted rat aortae, with a minimally active concentration between 1 and 3 μM and significant relaxation at 30 μM and above.

Study 0159SG evaluated the effects of capivasertib on ventricular monophasic action potentials and the surface  electrocardiogram  in  male  anaesthetised  guinea-pigs,  which  received  either  two  consecutive infusions of vehicle, or two consecutive infusions of capivasertib at the dose 3.5, 35 or 17.5 mg/kg, respectively. Capivasertib given at 3.5 mg/kg produced no treatment-related effects. Administration of 35 mg/kg capivasertib caused the death of two animals. Prior to death, a pronounced reduction in blood pressure (44%) and heart rate (27%) were recorded and significant ECG waveform changes were seen, indicating a marked ischaemic insult. A trend (31%) towards an increase in AV conduction time was noted towards the end of the 35 mg/kg infusion. The dose was lowered to 17.5 mg/kg and the remaining animals s urvived. Maximum total plasma concentrations of capivasertib were 7.36, 42.90 and 90.01 μM during administration of 3.5, 17.5 and 35 mg/kg, respectively.

<div style=\"page-break-after: always\"></div>

Study0209SG assessed the effects of capivasertib on arterial blood pressure, heart rate, electrocardiogram  (ECG)  and  left  ventricular  parameters  in  male  anaesthetised  guinea-pigs,  which received a single intravenous infusion of either 10 or 3.33 mg/kg capivasertib. Capivasertib administered at 3.33 and 10 mg/kg led to reductions in blood pressure by 16 and 38%, in heart rate by 10 and 24%, left  ventricular  systolic  pressure  by  19  and  30%  and  contractility  by  41  and  47%,  respectively.  No increase in contractility as was seen in dogs in study 1101ZD was observed in guinea-pigs. A rise in glucose levels was noted at both dose levels. Study 3316SR determined the suitability of changes in rat QA interval as a predictor of left ventricular dP/dt changes observed in dogs after capivasertib treatment. Rats received oral doses of 25, 75, and 150 mg/kg of capivasertib in a cross-over design. Capivasertib decreased heart rate by 21% after the 25 mg/kg dose and decreased arterial pressure 19 to 30 % after both 75 and 150 mg/kg doses without any further significant changes in heart rate. Capivasertib produced non-significant decreases in QA interval, indicative of increased cardiac contractility. Thus, changes in QA interval cannot be used as a surrogate for increases in cardiac contractility. Biologically and statistically significant reductions in blood pressure were found after administration of the 75 mg/kg dose. The 25 mg/kg dose was considered the NOAEL since the associated heart rate reductions were not seen as biologically significant. The effects of 150 mg/kg p.o. capivasertib on cardiovascular parameters were assessed in conscious, unrestrained rats implanted with a radio telemetry device in study PH/E/13611. Transient, mild changes in blood pressure and heart rate were noted but these findings appeared coincidental to increased animal activity and were not thought to be due to pharmacology. One rat was found dead several hours after dosing, but due to experience in other rat studies and the lack of any previous adverse signs in the animal, the finding was considered not related to the test compound. Cardiovascular effects (QTc interval prolongation, increased cardiac contractility, and decreased blood pressure) were seen in dogs at plasma concentrations approximately 1.4 to 2.7 times the expected clinical exposure in humans at the recommended dose of 400 mg twice daily (based on unbound Cmax). Central nervous &amp; respiratory systems As part of GLP study 2692SR, the effects of capivasertib in the rat on the nervous system (using a modified Irwin screen), on the respiratory system using whole body plethysmography and on gastric emptying and intestinal transit using a charcoal meal were studied. Rats were treated with vehicle or capivasertib at the dose levels of 30, 100 or 150 mg/kg by oral gavage. In the modified Irwin screen, decreased spontaneous activity and decreased touch response was noted in the 100 and 150 mg/kg groups. The NOEL was considered to be 30 mg/kg. At this dose level, the rat unbound Cmax was 0.65 μ M, which is in the range of the expected clinical Cmax. Body weight was decreased in the 100 and 150 mg/kg groups. There were no effects on respiratory parameters at any dose level tested. Capivasertib caused a statistically significant inhibition of gastric emptying at 100 and 150 mg/kg, with increases in stomach contents of  168% and 192% compared to vehicle.  This was accompanied  by decreases in intestinal transit, with a statistically significant reduction of 41% at 150 mg/kg. Animals had group mean exposures of 0.624, 4.03 and 4.28 μ M capivasertib in the Irwin arm of the study, or 0.946, 3.32 and 7.08 μ M in the respiratory arm of the study, or 2.33, 6.09 and 6.06 μ M in the charcoal meal arm of the study (following 30, 100 or 150 mg/kg capivasertib, respectively). In the modified Irwin screen and in the charcoal meal arm of the study, a NOEL of 30 mg/kg capivasertib was identified. A NOEL of at least 150 mg/kg capivasertib was set in the respiratory arm. The unbound animal Cmax at the NOEL was 3.8 μ M, which is 5.3-fold higher than the expected human exposure.

<div style=\"page-break-after: always\"></div>

## Other organ systems

GLP study 09-6713 examined the effects of vehicle and 30, 100 or 150 mg/kg oral capivasertib on urine and electrolyte excretion in male Han Wistar rats. Capivasertib administration led to a marked glucosuria at ≥100 mg/kg with concurrent diuresis. Increases in fractional excretion were seen at all doses for sodium  and  chloride,  and  at  ≥100  mg/kg  for  potassium  and  phosphorus.  In  addition,  albumin concentration was marginally increased at ≥100 mg/kg. Decrease in plasma potassium and increases in plasma phosph orous and urea nitrogen were seen at ≥100 mg/kg. It was thus not possible to determine a NOEL.

## 2.5.2.4. Pharmacodynamic drug interactions

No drug interaction study was conducted in animals (see section 2.5.6. .

## 2.5.3. Pharmacokinetics

The absorption, distribution, metabolism and excretion of capivasertib has been studied in the mouse, rat and dog in vivo and in mouse, rat, dog and human tissues and biomaterials in vitro. In vitro studies were  conducted  to  determine  plasma  protein  binding,  blood-plasma  partitioning,  cross-species metabolism including the enzymes involved, interactions with cytochrome P450 (CYP) and uridine 5'diphospho  glucuronosyl  transferase  (UGT)  enzymes,  and  interactions  with  transporter  proteins. Absorption was evaluated within the toxicokinetic (TK) monitoring of the 1, 6 and 9-month repeat dose toxicity studies (see section 2.5.4.

## Absorption

Study BE000747-32 investigated intestinal permeability of 250 µM capivasertib in the Ussing chamber using excised intestinal segments from human jejunum. The average permeability of capivasertib in this study  was  4.3  x  10-6  cm/s  indicating  a  low  to  moderate  fraction  absorbed  in  vivo  in  humans.  The permeability of [ 14C ] -capivasertib yielded a higher Papp value of 6.9 x 10-6 cm/s. This difference may be explained by metabolism in the intestinal tissue, an apparent extraction ratio of 38% indicates that approximately 40% of the compound is lost (metabolised) during the transport over the gut membrane.

The  in  vitro  permeability  assay  utilising  intestinal  segments  from  human  jejunum  indicated  that capivasertib  is  likely  to  have  a  low  to  moderate  fraction  absorbed  in  vivo  in  humans  and  that approximately 40% of the drug is likely to be metabolised upon transfer over the gut membrane.

No dedicated pharmacokinetic studies to evaluate the absorption of capivasertib were conducted. The absorption of capivasertib in vivo was investigated within the toxicokinetic evaluation in the toxicology studies (see section 2.5.4). Several pharmacodynamic and all pivotal in vivo safety pharmacology studies included pharmacokinetic evaluation (see section 2.5.2.

## Distribution

In vitro study KPJ011 investigated the extent of binding of [14C]-capivasertib to human serum albumin, human alpha 1-acid glycoprotein, and to proteins in freshly prepared whole human (male and female) plasma  and  in  frozen  plasma  of  mouse  (male),  rat  (male),  dog  (male)  and  human  (male)  in  the concentration range 0.5 - 20 µg/mL (for mouse, rat and dog) and 0.05 - 5.0 µg/mL (for human plasma, serum albumin and α1 -acid glycoprotein). Equilibrium dialysis method was utilised for this purpose. The plasma/blood cell partitioning of the radioactive capivasertib in male human blood at a concentration of 0.5 µg/mL was evaluated after incubation for 120 minutes. The non-specific binding of [ 14 C]-capivasertib to  the  equilibrium  dialysis  apparatus  was  found  to  be  approximately  8%, which  was  still  considered acceptable by the applicant. The overall mean extent of plasma protein binding of [ 14 C]-capivasertib decreased in the following order: mouse 83.3% to 85.7% &gt; dog 77.1% to 80.8% &gt; rat 74.9% to 76.5%. Plasma protein binding in human was similar to dog: fresh male human plasma 78.1% to 78.9%, frozen male human plasma 77.1% to 77.9%, fresh female human plasma 76.8% to 77.5%. The mean unbound fraction in human plasma was determined as 22.3%. The extent of protein binding to human serum albumin was in the range 70.0% to 71.3%, binding to alpha 1-acid glycoprotein was lower (24.2% to 33.5%). Therefore, albumin is likely the major human binding protein in vivo. The mean plasma : blood ratio of radioactivity concentration was 0.714 and the mean proportion of [ 14 C]-capivasertib associated with blood cells in vitro was 61%. Study BS003919-61  investigated human  plasma  protein binding of major human  metabolite AZ14102143 at the concentration of 5 µM after 18 h incubation using equilibrium dialysis. The free fraction was found to be 0.368±0.0292. In  study  BS002913-71,  equilibrium  dialysis  method  was  used  to  characterise  protein  binding  of capivasertib in human liver microsomes after 4 h incubation. The unbound fraction was determined as 0.622±0.031. Study BS003400-59 assessed protein binding of capivasertib at the concentration of 1 µM in human hepatocytes incubated with the compound for 4 h using equilibrium dialysis. The unbound fraction was calculated as 0.647 ± 0.019. Study KMR012 investigated the time-dependent tissue distribution in rats after single oral administration of 10 mg/kg [14C]-capivasertib to male Lister Hooded and to male and female Han Wistar rats using a quantitative whole-body autoradiography. Total radioactivity was rapidly absorbed from the gastrointestinal tract and first widely distributed throughout the animal body. In pigmented rats, the highest concentrations were generally associated with the bile, liver, kidney, caecum wall, small intestine wall, urinary bladder and uveal tract of the eye remaining in the latter at least until 504 hours. Beside this apparent association with the melanin, there was no notable persistence of radioactivity in tissues. In male and female albino rats, the highest concentrations were generally associated with the bile, kidney, liver, small intestine wall, adrenal gland, oesophagus, pituitary and caecum wall. Plasma protein binding of [ 14 C]-capivasertib decreased in the following order: mouse (83.3-85.7%) &gt; human (76.8-78.9%) ≈ dog (77.1-80.8%) &gt; rat (74.9-76.5%). The mean unbound fraction in human plasma was determined as 22.3%. In human plasma, serum albumin is a major binding partner (the extent of binding 70.0-73.1%). The free fraction of major human metabolite AZ14102143 in human plasma was determined as 0.368±0.0292. The mean plasma : blood ratio was 0.714 and the mean proportion of [ 14 C]-capivasertib associated with blood cells in vitro was 61%. The unbound fraction of capivasertib in human liver microsomes and in human hepatocytes was 0.622±0.031 and 0.647 ± 0.019, respectively. However, high stability and high recovery determined in those studies point at low nonspecific binding. Following  single  oral  administration  of  10  mg/kg  [ 14 C]-capivasertib  to  male  Lister  Hooded  rats,  the highest concentrations were found in bile, liver, kidney, caecum wall, small intestine wall, urinary bladder and uveal tract of the eye, the latter suggesting association with melanin. In male and female Han Wistar rats, the highest concentrations were generally associated with bile, kidney, liver, small intestine wall,

<div style=\"page-break-after: always\"></div>

adrenal gland, oesophagus, pituitary and caecum wall.

## Metabolism

## In vitro metabolism

<div style=\"page-break-after: always\"></div>

Study KMN010 assessed the in vitro metabolism of [14C]-capivasertib in fresh rat, dog and human hepatocytes as well as in cryopreserved human hepatocytes at the concentration of 10 μM. Metabolism of  [14C]-capivasertib  was  most  rapid  in  rat  and  dog  hepatocytes  (58.6%  and  62.3%  remaining, respectively) and slower in human hepatocytes (77.7 - 78.8% remaining). The major metabolite in dog and human was a glucuronide conjugate of [14C]-capivasertib. The major metabolite in the rat was a sulfate conjugate of [14C]-capivasertib. In addition, six mono-oxygenated metabolites were identified, as well as a hydrated, mono-oxygenated  metabolite. Glucuronide and sulfate conjugates of monooxygenated metabolites were also observed. No human-specific metabolites were observed.

Study  BS002337-76  estimated  the  contribution  of  phase  1  and  phase  2  enzymes  to  the  in  vitro metabolism  of  capivasertib  in  human  hepatocytes.  The  results  revealed  that  capivasertib  metabolic clearance  is  mediated  approximately  for  44%  by  phase  1  enzyme  mechanisms  (predominately oxidation), and for 53% by phase 2 enzymes (predominantly glucuronidation).

Study KMX013 investigated the metabolism of [14C]-capivasertib in human liver microsomes and with heterologously  expressed  human  cytochrome  P450  (CYP)  and  uridine  5'-diphospho  glucuronosyl transferase (UGT) isoforms to identify the enzymes responsible for the drug metabolism. The formation of monooxygenated metabolites in human liver microsomes was inhibited in the presence of CYP3A4/5 and  CYP2C9  antibodies  (71-88%  and  19-29%  inhibition  of  metabolite  formation,  respectively).  The experiments with heterologously expressed CYP isoforms confirmed that CYP3A4 was the major isoform involved in the formation of the metabolites, with a more minor contribution from CYP3A5 and CYP2C9 for some metabolites. In addition, some monooxygenated metabolites were produced by heterologously expressed CYP1A1. The major glucuronide conjugate of [14C]-capivasertib was observed after incubation with UGT1A9 and UGT2B7. A minor glucuronide metabolite was seen following incubation with UGT1A4.

Study BS002337-75 assessed the relative contribution of the major CYP isoforms to the metabolism of capivasertib through monitoring of substrate depletion in SilensomesTM, human liver microsomes where a specific CYP isoform is inhibited. Full abolishment of metabolic clearance in CYP3A4- SilensomesTM suggests that this isoform is primarily responsible for the CYP-mediated metabolism of capivasertib.

Study BS000901-99 aimed to estimate the relative contribution of each UGT isoform, UGT1A1, UGT1A3, UGT1A4,  UGT1A6,  UGT1A9,  UGT2B7,  and  UGT2B15,  to  the  biotransformation  of  capivasertib  using activated recombinantly expressed human UGTs. Capivasertib was found to be a substrate of UGT1A1, UGT1A3,  UGT1A4,  UGT1A9,  and  UGT2B7.  The  major  human  metabolite,  an  ether  glucuronide,  was formed by UGT2B7 contributing 84% and UGT1A9 with a contribution of 13%. UGT1A4 was the major enzyme involved in formation of a minor glucuronide contributing 100%. These data are in line with the results of study KMX013.

## In vivo metabolism

Study  YHM/003-4894KV  aimed  to  profile  and  characterise  the  metabolites  of  [14C]-capivasertib  in plasma, urine, faeces and bile following oral (10 mg/kg) administration to intact and bile duct cannulated (BDC) male and female rats, and intravenous (1 mg/kg) administration to BDC male and female rats. Parent capivasertib was identified as the major circulating drug-related component in intact rats and accounted for 63% of the plasma radioactivity AUC. In male rats, the most abundant metabolites were products of mono-oxidation on the piperidine ring (M17) and mono-oxidation on the pyrrolo-pyrimidine region  of  the  molecule  (M9).  In  female  rats,  the  most  abundant  metabolite  resulted  from  sulphate conjugation (M12). In intact rats, the largest proportion of the orally administered radioactive dose was excreted unchanged (33 and 49% of the dose in male and female animals, respectively), with the largest proportion being recovered in the faeces (28 and 46%) suggesting that oral absorption may not be complete. In the male animal faeces and bile, the most abundant metabolites were oxidation products. A  sulphate  conjugate  M12  was  the  most  abundant  metabolite  detected  in  the  female  excreta.  It accounted for 20% of the dose in the female animals and 1% in the male animals. The major human metabolite, glucuronide conjugate M11, was only detected in small quantities in BDC rats.

<div style=\"page-break-after: always\"></div>

Metabolism  of  [ 14 C]-capivasertib  was  most  rapid  in  rat  and  dog  hepatocytes  (58.6%  and  62.3% remaining,  respectively)  and  slower  in  human  hepatocytes  (77.7  -  78.8%  remaining).  The  major metabolite  in  dog  and  human  was  an  ether  glucuronide  conjugate  of  [ 14 C]-capivasertib.  The  major metabolite in the rat was a sulfate conjugate. In addition, oxidative metabolites and their glucuronide and sulfate conjugates were identified.

Capivasertib metabolic clearance is mediated approximately for 44% by phase 1 enzyme mechanisms (predominately oxidation), and for 53% by phase 2 enzymes (predominantly glucuronidation). The major human metabolite, an ether glucuronide, is formed predominantly by UGT2B7 with a minor contribution of  UGT1A9.  CYP3A4  is  primarily  responsible  for  the  CYP-mediated  metabolism  of  capivasertib.  In addition, capivasertib is a substrate of UGT1A1, UGT1A3, UGT1A4 but their contribution to the overall metabolism of the compound is rather low.

In intact rats, unchanged capivasertib was the main component of the drug-related material in plasma and excreta. The major metabolites of capivasertib in male rats were oxidation products, whereas female rats mainly formed a sulfate conjugate. The major human metabolite, glucuronide AZ14102143, was only detected in bile duct-cannulated animals. No metabolism studies were performed in other species.

## Excretion

GLP study KMR016 assessed the routes and rates of excretion of [14C]-capivasertib and its radioactive metabolites in urine and faeces of male and female Han Wistar rats following either a single oral (10 mg/kg) or intravenous (1 mg/kg) dose. Faecal recovery of radioactivity from intravenously dosed rats was  lower  than  after  oral  administration  (see  below  table.).  Consequently,  the  mean  recovery  of administered  radioactivity  in  urine  following  oral  administration  was  lower  than  after  intravenous administration. The ratio of blood: plasma radioactivity after oral administration suggested 35 to 45% blood cell binding. The total radioactivity concentrations in blood and plasma of female animals were generally lower than in male animals.

Study  182569-4330KR  investigated  excretion  of  [14C]-capivasertib  following  oral  (10  mg/kg)  and intravenous (1 mg/kg) administration to male and female bile-duct cannulated (BDC) Han Wistar rats. After oral dosing, biliary excretion was the predominant route of elimination. Urinary excretion was minor (8 - 13%). Given the levels of radioactivity in urine and bile, it can be estimated that 53 - 66% of the administered oral dose was absorbed. Following intravenous administration, biliary elimination was also the predominant route. The fraction of urinary elimination was higher than that of faecal excretion.

Table 4 Excretion routes of capivasertib in rats

| Study ID   |   Dose (mg/kg) | Route   | Species    |   N | Urine (% dose)   | Faeces (% dose)   | Bile (% dose)   | Recovery (% dose)   |
|------------|----------------|---------|------------|-----|------------------|-------------------|-----------------|---------------------|
| KMR016     |             10 | oral    | HW rats M  |   3 | 3.48 ± 0.17      | 91.9 ± 0.55       | n.a.            | 95.9 ± 0.57         |
| KMR016     |             10 | oral    | HW rats F  |   3 | 2.69 ± 0.18      | 91.5 ± 2.24       | n.a.            | 95.4 ± 1.91         |
| KMR016     |              1 | i.v.    | HW rats M  |   3 | 16.8 ± 1.77      | 75.9 ± 3.28       | n.a.            | 95.2 ± 5.14         |
| KMR016     |              1 | i.v.    | HW rats F  |   3 | 15.3 ± 1.25      | 82.2 ± 1.09       | n.a.            | 100 ± 0.56          |
| 4330KR     |             10 | oral    | BDC rats M |   1 | 7.6              | 43.0              | 45.4            | 99.1                |
| 4330KR     |             10 | oral    | BDC rats F |   2 | 12.9             | 32.6              | 53.0            | 99.9                |
| 4330KR     |              1 | i.v.    | BDC rats M |   2 | 25.8             | 10.6              | 65.3            | 104.2               |
| 4330KR     |              1 | i.v.    | BDC rats F |   2 | 24.0             | 13.4              | 63.5            | 104.7               |

<div style=\"page-break-after: always\"></div>

In intact rats, capivasertib was predominantly excreted via faeces, with renal elimination contributing 317%. Following intravenous administration, the fraction of urinary excretion was higher than after oral dosing. In bile-duct cannulated rats, the proportion of biliary excretion was 45-65% indicating major elimination via bile. The fraction of renal elimination in bile-duct cannulated animals was higher compared to faecal excretion.

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

No stand-alone single dose toxicity studies have been performed.

## 2.5.4.2. Repeat dose toxicity

## Rat

In  the  1  month  oral  GLP-compliant  toxicology  study  the  potential  toxicity  and  toxicokinetics  of capivasertib in Han Wistar rats were evaluated after daily oral dose levels of 0, 10, 30 or 100 mg/kg. A one-month recovery period was included. Males had generally higher exposure levels than females (~2fold AUC), except at 10 mg/kg on Day 1. Capivasertib-related effects occurred at the highest dose tested (100  mg/kg/day)  and  included  changes  in  body  weight  (weight  loss),  food  consumption  (reduced), increase in water consumption, haematology (reduced lymphocyte and white blood cell counts in males), serum  chemistry  (elevated  enzymes:  AST,  alkaline  phosphatase  (ALP),  glutamate  dehydrogenase (GLDH)), higher urine volume, macroscopic and microscopic observations in liver, pancreas, thymus, pituitary gland, adrenals, and reproductive system of males. The only changes of note at the end of the off-dose recovery period were reductions in the weight of the testes (26%) and epididymides (18%).

In the one month study, there were sex differences in exposure (based on AUC(0-last)) to capivasertib with  greater  plasma  levels  in  males  than  females.  Measurement  of  insulin  in  female  animals  and measurement of HbA1C levels were not assessed in either sex since data are available from the chronic six month rat study conducted at equivalent or higher doses.

In  the  6-month  oral  GLP-compliant  toxicology  study,  the  potential  toxicity  and  toxicokinetics  of capivasertib in Han Wistar rats were evaluated when administered by daily oral administration at dose levels of 0, 10, 30, 100 (males only) or 150 mg/kg/day (females only). Capivasertib exposures, Cmax and AUC increased in a broadly dose-proportional manner across the respective dose range in males and females, although a high variation in AUC was observed at 30 mg/kg/day in females. Because of the inclusion of only 3 animals per dose, these data might reflect an inter-animal variation. At 100 mg/kg (males) and 150 mg/kg (females), clinical signs consisted of body weight loss, food reduction, increase in water consumption, haematology (reduced WBC, males only), serum chemistry (elevated AST , lower total protein), higher urine volume, macroscopic and microscopic observations in kidney, liver, endocrine pancreas, adrenal gland, thyroid gland, pituitary gland (males only), bone marrow and thymus, and reproductive system of males (testis and epididymis).

## Dog

The  objective  of  the  GLP-compliant  28-day  toxicity  study  was  to  evaluate  the  potential  toxicity  of capivasertib when administered orally by gavage at doses of 0, 3, 10 and 30 mg/kg once daily to Beagle dogs. The study included a one month recovery period. On days 1 and 28, capivasertib exposure in terms of mean Cmax and AUC(0-last) increased slightly more than in proportion to the dose of capivasertib in the dose range of 3 to 10 mg/kg (3.6- to 4.8-fold for a 3.3-fold increase in dose). No gender differences were noted. Capivasertib-related changes at 30 mg/kg/day included body weight loss, reduced food consumption, changes in haematology (increase in platelet numbers), serum chemistry (minor increase in  potassium  in  males  and  minor  increase  in  ALP  in  females),  decrease  in  urine  specific  gravity, macroscopic and microscopic observations in testes, epididymis, prostate, thyroid gland, adrenal gland, pancreas, liver and thymus.

<div style=\"page-break-after: always\"></div>

Lesions in the prostate, thyroid gland, pancreas, liver and thymus were not present at the end of the recovery period in contrast to the changes observed in testes and epididymis, which were still present at the end of the recovery period.

Capivasertib  induced  a  reduction  of  systolic  left  ventricular  diameter,  an  increase  of  ejection  and shortening fractions and a moderate decrease of cardiac output after dosing at 10 and 30 mg/kg/day. The effects were more pronounced in Week 1 than in Week 4 and were reversed at the end of the recovery period.

In the 9-months GLP-compliant oral toxicology study, capivasertib was administered by oral gavage at 0, 1.5, 5.0 and 15 mg/kg/day. Systemic exposure increased in a generally dose-proportional manner between  1.5  and  15  mg/kg/day;  however,  even  at  the  maximu m  feasible  dose  of  15  mg/kg/day, exposures did not reach the levels as observed in the 6 month rat study. All in all, only a small margin of exposure (Rat: Males: 1.44, Females: 1.22; Dog: Males: 1.02, Females: 0.78) could be detected in these  studies,  especially  with  respect  to  the  increased  glycosylated  haemoglobin  and  pathological changes in the male reproductive organs. No sex-related differences and no differences in Tmax or T1/2 of  capivasertib  across  the  dose  range  were  noted.  Capivasertib-related  changes  at  15  mg/kg/day included  microscopic  changes  in  the  testis  and  epididymis,  organ  weight  changes  in  testis  (lower), epididymis (lower), liver (higher) and adrenal gland (higher). Vacuolation of the Langerhans islets of the pancreas occurred already at a dose of ≥5 mg/kg/day. Liver lesions were present in both rats and dogs with accompanying changes in liver enzymes. Findings in the liver were also present in the short-term studies in rats and dogs. These changes were not present at the end of the recovery period in both species in the 1 month rat and 1 month dog study and no abnormalities were observed in patients.

## 2.5.4.3. Genotoxicity

Genotoxicity testing of capivasertib was carried out in two in vitro (gene mutation tests in bacteria, mammalian chromosome aberration test) studies and three in vivo (two rat chromosome aberration / micronuclei tests including a kinetochore labelling of micronucleated polychromatic erythrocytes (PCEs), Comet assay) studies in compliance with GLP. In the in vivo studies, capivasertib was orally administered, which coincides with the intended clinical route. Dose selection was based on the maximum tolerated dose (MTD) determined in repeat-dose toxicity studies up to 6 months of treatment. No toxicokinetic (TK) data was determined in the in vivo studies but extrapolation from TK data obtained from repeatdose toxicity studies in rats revealed a margin of exposure of approximately 1 at MTD (150 mg/kg) compared to the clinical exposure. Only male rats were used since no sex differences concerning toxicity and TK were observed in the repeat-dose toxicity studies.

## In vitro

For  the  detection  of  gene  mutations  in  bacteria,  an  AMES  test  (study  2332BV)  was  conducted. Independent of precipitation or cytotoxicity observed at high concentrations, capivasertib was negative for relevant increase in reverse mutations with and without metabolic activation in all tester strains up to the top concentration of 4100 µg/ml under the conditions of the study.

Additionally, a mammalian cell mutation test with mouse lymphoma L5178Y cells (study 2333MV) was conducted at concentrations up to 193 µg/ml ± S9. No precipitation up to the top concentrations could be observed. RTG at the highest concentration were between 10 - 20 % and all cultures analysed were negative for inducing chromosomal aberrations (chromosomal aberrations, polyploidy, endoreduplication) or an increase in mutant frequency with or without metabolic activation under the conditions of the study.

<div style=\"page-break-after: always\"></div>

The negative and positive controls in both studies were inside the historical control data of the study facility.

## In vivo

In  the  in  vivo  studies,  clinical  signs  of  toxicity  observed  during  treatment  confirmed  exposure  to capivasertib.

In the first rat bone marrow micronucleus assay (study 2718QR), capivasertib revealed an increase in the number of micronucleated PCEs at the highest dose tested, which corresponded to the MTD (150 mg/kg) in repeat-dose toxicity studies in rats. A subsequent kinetochore labelling of micronucleated PCEs according  to  Hayashi  2000  and  the  IWGTP  (study  2759KV)  revealed  that  the  majority  (86%)  of micronuclei  induced  in  the  bone  marrow  were  kinetochore  positive,  indicative  of  an  aneugenic (chromosome loss) thresholded mode of action. The NOEL was 75 mg/kg.

In contrast to the previous rat bone marrow micronucleus assay, in the second assay (study 4075QR) capivasertib revealed no increase in the number of micronucleated PCEs as compared to vehicle up to the MTD of 150 mg/kg in male rats. The negative and positive controls in both studies were inside the historical control data of the study facility. In both assays, no bone marrow toxicity was observed.

Based on toxicokinetic data (AUC) determined in repeat-dose toxicity studies in rats, in the first assay a margin of exposure of approximately ≤ 1 (75 mg/kg) and in the second assay between 1 and 2 at the MTD (150 mg/kg) compared to the clinical exposure was achieved.

In  an  in  vivo  COMET  assay,  no  statistically  significant  increases  in  percent  tail  intensities  could  be observed. Therefore, capivasertib was negative for an increase in DNA damage, up to the MTD in rats (150 mg/kg). Due to the small number of studies (COMET) of the testing facility, the vehicle control group mean was slightly above the historical control value whereas the positive control was inside the historical control data.

Based  on  toxicokinetic  data  (AUC)  determined  in  repeat-dose  toxicity  studies  in  rats,  a  margin  of exposure of approximately between 1 and 2 at MTD (150 mg/kg) compared to the clinical exposure was achieved.

In conclusion, capivasertib showed no mutagenic or genotoxic potential in vitro. When dosed orally to rats, capivasertib induced micronuclei in the bone marrow via an aneugenic mode of action.

## 2.5.4.4. Carcinogenicity

No carcinogenicity studies have been submitted in support of this application.

Neither pre-neoplastic nor neoplastic lesions were observed in chronic toxicity studies in rats and dogs up to the highest doses tested. Reversible liver hypertrophy in rats and hypertrophy/hyperplasia of the pancreatic islet cells in rats and dogs were caused by the known PD activity of PI3K/AKT inhibitors. Capivasertib was genotoxic at approximately clinical exposures in a rat bone marrow micronucleus assay with an aneugenic mode of action.

<div style=\"page-break-after: always\"></div>

## 2.5.4.5. Reproductive and developmental toxicity

No fertility and pre-postnatal development studies have been submitted in support of this application. However, the impact of capivasertib on male fertility was evaluated as part of the 6 month rat toxicity study (study 527477). A modified preliminary study on embryo-foetal development that included an assessment of the littering phase was performed in the rat to cover embryo-foetal development as well as early postnatal survival/growth.

A full paediatric waiver has been granted for capivasertib, therefore no juvenile toxicity study has been conducted.

Capivasertib was administered orally, the therapeutic route of administration.

An overview of the performed reproductive toxicology studies is given in the below table.

Table  5  Overview  of  reproductive  and  developmental  toxicity  studies  performed  with capivasertib

<!-- image -->

| Study type and duration                                         | Route of administration   | Species   | Study number (AZ reference number)   | GLP compliant   |
|-----------------------------------------------------------------|---------------------------|-----------|--------------------------------------|-----------------|
| Repeat dose toxicity:                                           |                           |           |                                      |                 |
| Sixmonth(inchudingmale fertility)                               | Onl                       | Rat       | 527477 (3784PR)                      |                 |
| Reproductiveanddevelopmental toxicity:                          |                           |           |                                      |                 |
| PreliminaryEmbryofetal Development and Pre and Post Natal Study | Onal                      | Rat       | 496879 (3783RR)                      |                 |

The study designs and results are summarised in the below table.

Fertility and early embryonic development

Table 6 Six-month repeat-dose toxicity in rats: male fertility

| Study ID / Study type/ GLP                                            | Species; Number/ group       | Route & [mg/kg/ d]     | Dosing period                                                                            | Major findings   | NOAEL [mg/kg/d]                                                                     |
|-----------------------------------------------------------------------|------------------------------|------------------------|------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------|
| Study 527477 Male Fertility assessed in 6 month repeat dose study GLP | Han Wistar rat 15/sex/ group | 0, 10, 30 and 100 oral | Males: Days 1 to 182 (premating after 70 days of beginning of dosing) Females: untreated | None             | Male NOAEL for gonadal function, mating behaviour and reproductive performance: 100 |

The objectives of study 527477 were the evaluation of repeated dose toxicity, the evaluation of the effects of capivasertib on gonadal function, mating behaviour and reproductive performance in male Wistar rats. For each female the time taken to show a positive mating sign and the number of failed opportunities to mate (oestruses passed without a sign of mating) were evaluated.

Oral (gavage) treatment of the male Wistar rat with capivasertib at doses of 10, 50 or 100 mg/kg/day was not associated with any effect on male gonadal function, mating behaviour or fertility in any group.

The lower epididymis, testis and thymus weights all correlated with histology findings observed in these organs. In the absence of histological correlation with the reduced prostate weights, the toxicologically significance was considered to be unclear.

<div style=\"page-break-after: always\"></div>

The  no  observed  effect  level  (NOEL)  for  gonadal  function,  mating  behaviour  and  reproductive performance in the male Wistar rat was 100 mg/kg/day.

## Toxicokinetics

All TK animals dosed with capivasertib were exposed to capivasertib. Systemic exposure increased in a broadly dose-proportional manner across the respective dose range in males and females (see 6-month repeat dose toxicity in rats in section 2.5.4.2. ).

Table 7 Toxicokinetics and multiples to clinical exposure for male fertility in six-month repeatdose toxicity in rats

| Sunmaryofkeytoxicologyfindings                                                                                                                                                                    | Doselevel mg/kg/day   | Total AUC(0-24) (μmol.h/L)   | Multiplesto totalclinical AUCa   | Total Cmax (μmol/L)   | Multiplesto totalclinical Cmax b   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------|----------------------------------|-----------------------|------------------------------------|
| 6monthratstudy(527477)                                                                                                                                                                            |                       |                              |                                  |                       |                                    |
| NOAELfor males(background testespathology in 1 male)                                                                                                                                              | 10 M F                | 2.16 2.77                    | 0.06 0.08                        | 0.648 0.997           | 0.20 0.31                          |
| As above for both sexes,plus low white cells (males),higher liverenzymes,glycosylatedhaemoglobin andpolyuria. Pathologicalchangesinbonemarrow,thymus,pituitary (males)andmalesreproductiveorgans. | 100 M 150 F           | 48.7 41.5                    | 1.44 1.22                        | 10.5 15.3             | 3.26 4.75                          |

## Embryo-fœtal development

Effects on embryo-foetal development and early postnatal survival/growth were assessed in a modified rat embryo-foetal development study, which included a littering phase.

<div style=\"page-break-after: always\"></div>

Table 8 Preliminary embryo-foetal development and pre- and post-natal study in rats

| Study ID / Study type/ GLP                                             | Species; Number/ group                                                                                                                           | Route & [mg/kg/ d]                                    | Dosing period                                                         | Major findings                                                                                                                                                                                                                                                                                                                                             | NOAEL [mg/kg/d]                                                                                           |
|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Study 496879 Embryo-foetal- development Study And Post Natal Study GLP | Wistar rat 8/females/ Group for Phase 1 and Phase 2 each Satellite group for toxico- kinetics (2-3/group) Phase 1 on GD16 Phase 2 pups on LD 7-8 | Phase 1: 0, 10,30 and 150 Phase 2: 0, 10 and 150 oral | Phase 1: (GD 6-16) C-section Day 21 Phase 2 (GD 6-Day 6 of lactation) | Phase 1: ≥10 mg/kg/d: ↓ BW gain, ↓ food consumption ↑ Maternal blood glucose at day 16 150 mg/kg/d: ↑ minor foetal visceral variations, ↑ post implantation loss ↑ early embryonic deaths ↓ gravid uterine and foetal weights Phase 2: ≥10 mg/kg/d: ↓ BW gain, ↓ food consumption ↑ Maternal blood glucose at day 16 150 mg/kg/d: ↓ litter and pup weights | Phase 1 Maternal: 30 Embryo-foetal development: 30 Phase 2 Maternal: 10 Embryo- foetal/pre- postnatal: 10 |

BW = Body weight; GD = Gestation day; ↑ = increase; ↓ = decrease; LD= lactation day Effects on embryo-foetal development and early postnatal survival/growth were assessed in a modified rat embryo-foetal development study, which included a littering phase. The aim of this study was to evaluate the effect of capivasertib on mated female rats when administered from Day 2 to Day 16 of gestation (Phase 1) or from Day 6 of gestation to at least Day 6 of lactation (Phase 2).

Maternal toxicity (reduced body weight gain, reduced food consumption and increase in blood glucose) was seen at ≥ 10 mg/kg/day. Administration of capivasertib to rats prior to implantation until Day 16 of gestation resulted in minor foetal visceral variations (predominantly foetuses with a left-sided umbilical artery), an increase in post-implantation loss, together with reduced gravid uterine and foetal weights at 150 mg/kg/day.

Administration of capivasertib to dams during gestation and through to early lactation caused a reduction in litter and pup weights at ≥ 10 mg/kg/day. There were no compound-related pup abnormalities up to 150 mg/kg/day.

Exposure to capivasertib was confirmed in suckling pups indicating a potential for excretion in milk.

Based on the results of this study, when capivasertib was administered from Day 2 to 16 of gestation the maternal NOAEL and the embryo-foetal NOEL were considered by the applicant to be 30 mg/kg/day. When capivasertib was administered from Day 6 of gestation to at least Day 6 of lactation the maternal NOAEL and the reproductive NOEL were considered by the applicant to be 10 mg/kg/day.

## Toxicokinetics

Table 9 TK results in female rats following oral administration of capivasertib (Phase 1)

<div style=\"page-break-after: always\"></div>

| Dose level (mg/kg/day)        | 10             | 30           | 150          |
|-------------------------------|----------------|--------------|--------------|
| Day of gestation              | 16             | 16           | 16           |
| Females                       |                |              |              |
| Median tmax (range) (h)       | 0.5 (0.5, 0.5) | 0.5 (0.5, 2) | 0.5 (0.5, 1) |
| Mean Cmax (SD) (μmol/L)       | 0.655 (0.483)  | 3.69 (3.15)  | 5.79 (2.34)  |
| Mean AUC(o-t) (SD) (μmol.h/L) | 1.46 (0.216)   | 6.42 (2.24)  | 25.6 (9.65)  |

TK results from pups on lactation day 7-8:

On Day 7-8 of lactation capivasertib was not detected at 2 or 24 h post dose in blood plasma of the majority of pups at 10 mg/kg, whereas, at 150 mg/kg/day capivasertib was quantifiable in the majority of pups; however, concentrations were generally close to the limit of quantification.

Table 10 Exposure to capivasertib and multiples to clinical exposure

| Sunnaryofkeytoxicologyfindings                                               | Doselevel mg/kg/day                                                   | Total AUC(0-24) (μmol.h/L)                                            | Multiples to total clinical AUCa                                      | Total Cmax (μumol/L)                                                  | Multiplesto totalclinical Cmax                                        |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| Embryofetal development and pre-and post-natal studyin therat(496879)        | Embryofetal development and pre-and post-natal studyin therat(496879) | Embryofetal development and pre-and post-natal studyin therat(496879) | Embryofetal development and pre-and post-natal studyin therat(496879) | Embryofetal development and pre-and post-natal studyin therat(496879) | Embryofetal development and pre-and post-natal studyin therat(496879) |
| Phase 1                                                                      |                                                                       |                                                                       |                                                                       |                                                                       |                                                                       |
| Increasedmaternal bloodglucoseonSD16                                         | 10                                                                    | 1.46                                                                  | 0.04                                                                  | 0.655                                                                 | 0.20                                                                  |
| As above. ConsideredmateinalNOAELandembryofetalNOEL                          | 30                                                                    | 6.42                                                                  | 0.19                                                                  | 3.69                                                                  | 1.15                                                                  |
| As abovepluspostimplantationloss andreducedgravid uterine and fetal weights. | 150                                                                   | 25.6                                                                  | 0.76                                                                  | 5.79                                                                  | 1.80                                                                  |
| Phase 2                                                                      |                                                                       |                                                                       |                                                                       |                                                                       |                                                                       |
| Maternal NOAELandreproductiveNOEL                                            | 10                                                                    | ND                                                                    |                                                                       | ND                                                                    |                                                                       |
| Increased maternal glucose. Reduced litter and pup weights.                  | 150                                                                   | ND                                                                    |                                                                       | ND                                                                    |                                                                       |

Capivasertib  potentially  caused  hyperglycaemia  in  maternal  animals,  reduced  body  weight  gain  and reduced food consumption at ≥ 10 mg/kg/day in Phase 1 and Phase 2 dams. The NOEL for these changes in general, across both sexes, was 10 mg/kg/day over 1 and 6 months.

Administration of capivasertib prior to implantation until Day 16 of gestation resulted in minor foetal visceral variations, an increase in post-implantation loss, together with reduced gravid uterine and foetal weights. These effects were seen at a dose level of 150 mg/kg/day, which caused maternal toxicity. When  capivasertib  was  administered  to  pregnant  rats  at  150 mg/kg/day  throughout  gestation  and through early lactation, there was a reduction in litter and pup weights. At 150 mg/kg/day, capivasertib plasma concentrations in pregnant rats were approximately 0.8 times the exposure in humans at the recommended dose of 400 mg twice daily (based on total AUC).

AKT (serine/threonine specific protein kinase) is a pivotal enzyme regulating cell proliferation, survival, metabolism, protein synthesis and gene expression. Capivasertib is an inhibitor of all 3 isoforms of AKT and  therefore  the  adverse  effects  observed  following  administration  of  capivasertib  to  pregnant  or lactating rats are likely due to the pharmacological action of the compound.

## 2.5.4.6. Toxicokinetic data

All TK animals dosed with capivasertib were exposed to capivasertib. Systemic exposure increased in a broadly dose-proportional manner across the respective dose range in males and females (see 6-month repeat dose toxicity in rats).

<div style=\"page-break-after: always\"></div>

Table  11  Toxicokinetics  and  multiples  to  clinical  exposure  for  male  fertility  in  six-month repeat-dose toxicity in rats

| Summaryofkeytoxicologyfindings                                                                                                                                                                   | Doselevel mg/kg/day   | Total AUC(0-24) (μmol.h/L)   | Multiplesto totalclinical AUCa   | Total Cmax (μumol/L)   | Multiplesto totalclinical Cmax b   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------|----------------------------------|------------------------|------------------------------------|
| 6monthratstudy(527477)                                                                                                                                                                           |                       |                              |                                  |                        |                                    |
| NOAELfor males (background testespathology in1 male)                                                                                                                                             | 10 M F                | 2.16 2.77                    | 0.06 0.08                        | 0.648 0.997            | 0.20 0.31                          |
| As above for both sexes,plus low white cells (males),higher liverenzymes,glycosylatedhaemoglobinandpolyuria. Pathologicalchangesinbonemarrow,thymus.pituitary (males)andmalesreproductiveorgans. | 100 M 150 F           | 48.7 41.5                    | 1.44 1.22                        | 10.5 15.3              | 3.26 4.75                          |

Toxicokinetic data were evaluated not only for capivasertib but also for the main human metabolite, the direct ether glucuronide conjugate.

## 2.5.4.7. Local tolerance

No stand-alone local tolerance studies have been submitted in support of this application.

## 2.5.4.8. Other toxicity studies

## Studies on impurities

The  entire  potential  for  genotoxic  impurities  of  capivasertib  generated  in  the  drug  substance manufacturing process or produced as a degradation product in the drug substance or drug product were assessed in silico by structure-activity relationship evaluation with DEREK (Nexus 6.1.0) and Leadscope (3.2.5) and an additional expert evaluation of each prediction. In case of a positive forecast, additional in vitro genotoxicity assays (AMES test) were conducted.

Potential impurities and degradation products revealed no genotoxicity potential by structure activity relationship and expert evaluation. These impurities were treated as class 5 impurities according to ICH M7 (R2).'

## Phototoxicity

A radiolabelled excretion mass balance and tissue distribution study (KMR012, quantitative whole-body autoradiography) in male pigmented rats revealed distribution of capivasertib to the skin and the eyes (uveal tract) with high affinity for melanin in pigmented tissues.

Capivasertib was reversibly bound to melanin with persistence up to 168 h in the skin and 504 h in the eyes.

Maximum absorption of capivasertib in the UV-vis spectrum was measured at approximately 220 and 288 nm in acetonitrile. The corresponding molar extinction coefficients (MEC) were about 31525 and 18058  l×mol -1 ×cm -1 and  thus,  according  to  the  current  ICHS10  guideline  photosafety  testing  is requested.

An in vitro 3T3 NRU phototoxicity tests using Balb/c 3T3 mouse fibroblasts did not demonstrate any phototoxic potential. Further, capivasertib was photostable in a photostability test in accordance with ICH Q1B.

<div style=\"page-break-after: always\"></div>

## 2.5.5. Ecotoxicity/environmental risk assessment

## Table 12 Summary of main study results

| Substance (INN/Invented Name): capivasertib                         | Substance (INN/Invented Name): capivasertib    | Substance (INN/Invented Name): capivasertib                                                | Substance (INN/Invented Name): capivasertib                            |
|---------------------------------------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| CAS-number (if available): 1143532-39-1                             | CAS-number (if available): 1143532-39-1        | CAS-number (if available): 1143532-39-1                                                    | CAS-number (if available): 1143532-39-1                                |
| PBT screening                                                       |                                                | Result                                                                                     | Conclusion                                                             |
| Bioaccumulation potential- log K ow                                 | OECD107                                        | log Dow (pH 5) 1.28 log Dow (pH 7) 2.38 log Dow (pH 9) 2.46                                | Potential PBT (N)                                                      |
| PBT-assessment                                                      | PBT-assessment                                 | PBT-assessment                                                                             | PBT-assessment                                                         |
| Parameter                                                           | Result relevant for conclusion                 |                                                                                            | Conclusion                                                             |
| Bioaccumulation                                                     | log Kow                                        | 2.46                                                                                       | not B according to screening criteria                                  |
|                                                                     | BCF                                            | k.A.                                                                                       |                                                                        |
| Persistence                                                         | DT50 (OECD 308)                                | DT50 = 24.9 d (20°C)                                                                       | not P                                                                  |
| Toxicity                                                            | NOEC fish                                      | 1 mg/L                                                                                     | not T                                                                  |
| PBT-statement:                                                      | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB                                             | The compound is not considered as PBT nor vPvB                         |
| Phase I                                                             | Phase I                                        | Phase I                                                                                    | Phase I                                                                |
| Calculation                                                         | Value                                          | Unit                                                                                       | Conclusion                                                             |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.384                                          | µ g/L                                                                                      | > 0.01 threshold (Y)                                                   |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate                                             | Phase II Physical-chemical properties and fate                         |
| Study type                                                          | Test protocol                                  | Results                                                                                    | Remarks                                                                |
| Adsorption-Desorption                                               | OECD 106                                       | Koc soil = 21100; 453000 Koc sediment = 3780; 23300 Koc sludge = 702; 1070                 | Terrestrial studies not triggered                                      |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems    | OECD 308                                       | DT 50, water = 2.9/4.57 d DT 50, sediment = 32.4/18.8 d DT 50, whole system = 9.47/ 24.9 d | system I/II; 20°C, data in II not reliable as mass balance incomplete; |

<div style=\"page-break-after: always\"></div>

|                                               |                          | % shifting to sediment 78.9/57.75 %CO2 = 6.75/7.68 %NER = 73.2/41.2 Transformation products >10%: TP Region TP Region   | increasing max. 24.4%,   | till test end day 21,    | parent + NER on d 21; at test end at test end TPs not identified   |
|-----------------------------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------------------------------------------------|
| Phase IIa Effect studies                      | Phase IIa Effect studies | Phase IIa Effect studies                                                                                                | Phase IIa Effect studies | Phase IIa Effect studies | Phase IIa Effect studies                                           |
| Study type                                    | Test protocol            | Endpoint                                                                                                                | value                    | Unit                     | Remarks                                                            |
| Algae, Growth Inhibition Test                 | OECD 201                 | NOEC                                                                                                                    | 27                       | mg/L                     | R. subcapitata ; growth rate                                       |
| Daphnia sp . Reproduction Test                | OECD 211                 | NOEC                                                                                                                    | 11                       | mg/L                     | D. magna ; reproduction                                            |
| Fish, Early Life Stage Toxicity Test          | OECD 210                 | NOEC                                                                                                                    | 3.2                      | mg/L                     | P. promelas ; growth/length                                        |
| Activated Sludge, Respiration Inhibition Test | OECD 209                 | NOEC                                                                                                                    | 1000                     | mg/L                     | total respiration                                                  |
| Phase IIb Studies                             | Phase IIb Studies        | Phase IIb Studies                                                                                                       | Phase IIb Studies        | Phase IIb Studies        | Phase IIb Studies                                                  |
| Sediment dwelling organism                    | OECD 218                 | NOEC                                                                                                                    | 893 6869                 | mg/kg                    | C. riparius ; Emergence, o.c. 1.3% normalised to 10% o.c. content  |

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

Capivasertib was demonstrated to inhibit all three AKT isoforms, AKT1, AKT2 and AKT3, in a biochemical assay. As a result, capivasertib inhibited the activation of AKT downstream targets, GSK3 β, PRAS40 and S6, in various cancer cell lines. In a kinase profiling assay, capivasertib also showed activity on several other targets involved in PI3K/AKT or MEK/ERK signalling. Of them, functional inhibition of p70S6K and PKA was observed but the potency in tumour cells was lower compared to AKT target inhibition.

The predictions of the human population pharmacokinetic model suggest that capivasertib's exposure at the proposed clinical dose and schedule would not lead to PKA inhibition and would not achieve inhibition of p70S6K.

The applicant explained that capivasertib's binding to the AKT kinase domain inhibits phosphorylation of the downstream substrates but does not prevent phosphorylation of AKT itself by the upstream kinases.

<div style=\"page-break-after: always\"></div>

In several cancer cell line panels, capivasertib demonstrated the best activity in breast cancer cells. Capivasertib was active in wild-type and PIK3CA , AKT1 and PTEN mutated cells but the activity was generally better in altered cell lines. In one panel, there was a statistically significant correlation between sensitivity to capivasertib and mutations in the PIK3CA and PTEN . Addition of capivasertib to fulvestrant or palbociclib increased the efficacy in palbociclib-naive and palbociclib-resistant ER+ PI3K α mutant cell lines compared to the single agent treatments. The major human metabolite AZ14102143, an ether glucuronide of capivasertib, was pharmacologically inactive as it had no effect on phosphorylation of AKT downstream targets. Oral capivasertib inhibited tumour growth in various mouse xenograft models including patient-derived ER+ breast cancer xenografts in a dose-dependent fashion. This was accompanied by the inhibition of phosphorylation of AKT downstream targets in a time- and dose-dependent manner demonstrating a pharmacodynamic effect at clinically achievable plasma drug levels. Combination of capivasertib with fulvestrant showed improved efficacy compared to single agents in PIK3CA , AKT1 and PTEN mutated models and also in tumours without alterations, although generally better efficacy on the combination was observed in altered models. Unexpectedly, there was a significant increase in AKT phosphorylation. The applicant explained that capivasertib binding to AKT kinase domain inhibits phosphorylation of the downstream substrates but does not prevent phosphorylation of AKT itself by the upstream kinases. A dose- and time-dependent increase in blood glucose levels was also noted in xenograft models, which is consistent with the results of other studies. The  impact  of  dosing  schedule  on  capivasertib's  efficacy  was  evaluated  in  BT474c  breast  cancer xenografts in mice but with different results. The applicant explained the variability observed across all the experiments performed to determine whether equivalent efficacy could be achieved between a range of intermittent doses and a continuous dose of capivasertib. Therefore, data from individual experiments should not be viewed in isolation but rather as a component part of the full comparison of intermittent versus continuous dosing. The  overall  conclusion  drawn  from  the  whole  data  set  to  inform  the  clinical  dose  setting  was  that intermittent dosing could be as effective as continuous when taking into the account the total dose given. Whilst in some experiments 300mg/kg QD 4 days on 3 days off was used, this was modified to 150 or 130mg/kg BID as this was considered to be a more clinically achievable regimen. These principles were adopted in the dose escalation performed in the early clinical development. Secondary  pharmacodynamics  screening  revealed  significant  activity  on  7  targets  with  IC50  values between 6.06 and 62.3 μ M. These IC50 values are more than 8.4-fold higher than the unbound clinical Cmax of 0.717 μ M and the interactions with these targets are thus not considered clinically relevant. ROCK1 was also identified as a potential target with the IC50 value of 0.47 μ M. This concentration is within  the  clinical  range  but  capivasertib  had  no  effect  on  the  downstream  targets  of  ROCK.  This interaction is therefore not considered clinically relevant. At 100 µM capivasertib inhibited voltage-gated cardiac ion channels hCav3.2 and hNav1.5 by 25.5% and 29.6%, respectively, in an electrophysiological assay. This finding has no clinical relevance as 100 µM by far exceeds plasma levels of capivasertib in patients. Capivasertib exerted concentration-dependent hERG channel activity with the IC50 value of 73.0 μ M. This is more than 100-fold of the unbound clinical Cmax. In male Beagle dogs, oral dosing of 30 and 40 mg/kg capivasertib led to a reversible reduction in systolic and diastolic blood pressure and heart rate and caused a sustained statistically significant prolongation of the QT interval. Both glucose and insulin levels were increased after administration of 30 and 40 mg/kg. The NOAEL was set at 5 mg/kg. The unbound

Cmax in dogs at the NOAEL was 0.28 μ M, which is below the expected clinical exposure.

<div style=\"page-break-after: always\"></div>

Cardiovascular effects (QTc interval prolongation, increased cardiac contractility, and decreased blood pressure) were seen in dogs at plasma concentrations approximately 1.4 to 2.7 times the expected clinical exposure in humans at the recommended dose of 400 mg twice daily (based on unbound Cmax).

In rats, decreased spontaneous activity and decreased touch response as well as reduced body weight were observed at the doses of 100 and 150 mg/kg. The NOEL in this CNS study was considered to be 30 mg/kg. At this dose level, the rat unbound Cmax was 0.65 μ M, which is in the range of the expected clinical Cmax. There were no effects on respiratory parameters in rats up to 150 mg/kg, which was the NOEL. The unbound animal Cmax at the NOEL was 3.8 μ M being 5.3-fold the expected human exposure. Capivasertib led to a statistically significant inhibition of gastric emptying at 100 and 150 mg/kg and a significant  decrease  in  intestinal  transit  at  150  mg/kg.  The  NOEL  in  the  gastrointestinal  study  was determined as 30 mg/kg. At this dose level, the exposure was comparable to the clinical exposure. In addition, rats experienced marked glucosuria with concurrent diuresis after oral administration of 100 and 150 mg/kg capivasertib.

## Pharmacokinetics

Capivasertib is likely to have a low to moderate fraction absorbed in vivo in humans. The absorption was investigated in the toxicokinetic part of the toxicology studies as well as in several pharmacodynamic and the pivotal safety pharmacology studies. No stand-alone pharmacokinetic studies were conducted, which is considered acceptable.

Plasma protein binding of [ 14 C]-capivasertib decreased in the following order: mouse &gt; human ≈ dog &gt; rat. The free fraction of capivasertib in human plasma was determined as 22.3% with the main binding partner being human serum albumin. The unbound fraction of the major human metabolite AZ14102143 was 36.8%. The mean proportion of [ 14 C]-capivasertib associated with blood cells in vitro was 61%. The unbound fraction of capivasertib in human liver microsomes and in human hepatocytes was 0.622±0.031 and  0.647  ±  0.019,  respectively.  Non-specific  binding  of  capivasertib  to  the  equilibrium  dialysis apparatus (8%) was observed in one study but considered acceptable by the applicant. In other protein binding studies, non-specific binding was indeed not specifically investigated. However, high stability and high  recovery  determined  in  those  studies  point  at  low  non-specific  binding.  This  is  considered acceptable.

In rats administered [ 14 C]-capivasertib, radioactivity distributed to excretory organs and was associated with melanin. Metabolism of [ 14 C]-capivasertib was faster in rat and dog hepatocytes than in human hepatocytes. The major metabolite in dog and human was an ether glucuronide conjugate of [ 14 C]capivasertib. The major metabolites in rat was a sulfate conjugate. In vivo, unchanged capivasertib was the main component of the drug-related material in plasma and excreta of rats. In male rats, the major metabolites of capivasertib were oxidation products, in female rats it was a sulfate conjugate. The major human  metabolite,  glucuronide  AZ14102143,  was  only  detected  in  bile  duct-cannulated  rats.  A metabolism study in the dog would have been expected to be conducted as part of the non-clinical programme for  capivasertib  however  such  lack  is  considered  acceptable.  The  applicant  justified  the absence of a metabolism study in the dog by arguing that ether glucuronides are more water soluble than the parent compound and are also pharmacologically inactive and also that according to ICH S9, no need for such evaluation is generally warranted (in some cases, metabolites that have been identified in humans have not been qualified in non-clinical studies).

Heterologously expressed CYP2D6 also appeared to be involved in the formation of the mono-oxygenated metabolites but this was not confirmed in the inhibitory antibody experiments.

The inhibition of CYP1A1 in human liver microsomes was not studied due to a very low expression of this isoform in liver and extrahepatic tissues.

<div style=\"page-break-after: always\"></div>

In intact rats, capivasertib was predominantly excreted via faeces. In bile-duct cannulated rats, biliary excretion represented the major proportion of total elimination. Toxicology One consequence of the inhibition of the PI3K/AKT pathway is hyperglycaemia due to changes in the insulin-mediated  glucose  homeostasis,  which  depends  on  PI3K  signalling.  Thus,  increased  levels  of glucose and insulin were seen in both rats and dogs. Although hyperglycosylation is considered as the result of the pharmacodynamic effect of capivasertib, a warning regarding the risk of hyperglycaemia with capivasertib, including the potential need to intensify anti-diabetic treatment and closely monitor patients with diabetes mellitus has been included in section 4.4. of the SmPC. Further toxicities included increased levels of fructosamine (rats), glycosylated haemoglobin (rats and dogs), glycogen accumulation in the liver (rats and dogs), liver hypertrophy (rats), hypertrophy/hyperplasia or vacuolation of the pancreatic islet cells (rats and dogs) and glucosuria. All of them were also related to the glucose perturbation. An additional on-target adverse event was polyuria in both rat studies with increased water consumption accompanied by glucosuria and proteinuria. These changes were not present at the end of the recovery period in the 1-month study. However, additional kidney changes (decreased cell size/nuclear crowding of tubular cells; decreased kidney weight and size) were present in the 6 -months rat study. As the study with the longer duration did not include a recovery period the findings are difficult to interpret. However, AKT is known to play a role in proximal tubular glucose and phosphate transport. Increases in cardiac contractility were observed in the dog telemetry and dog 1-month toxicity studies. These findings were not present at the end of the recovery period but the underlying mechanism is unknown. The applicant argued that QT prolongation is not considered to be clinically relevant since the findings occurred at exposures higher than the clinically therapeutic dose of 400 mg twice daily. It is endorsed that the margin of exposure is higher than for the observed hyperglycaemia. However, a 2fold exposure based on AUC cannot be regarded as high enough to be interpreted as clinically irrelevant. In addition, the combination of capivasertib with drugs having QT prolongation potential might result in adverse events in the clinical setting. Thus, given the lack of information with respect to QT prolongation, from a preclinical point of view, a statement has been included in section 4.4 of the SmPC on the clinical consequences of diarrhoea which may include dehydration, hypokalaemia and acute kidney injury which have all, together with cardiac arrhythmias (with hypokalaemia as risk factor) been reported during treatment with capivasertib. As  mentioned  in  the  2019  CHMP  Scientific  Advice  letter,  the  connection  between  inhibitors  of  the PI3K/AKT/mTOR  pathway  and  effects  on  individual  cardiac  ion  currents  in  the  development  of prolongation of QT interval is an area of active research and it is acknowledged that cardiac effects were not noticed in the 9months dog study and no safety signal in clinical studies were observed; however this  study  did  not  include  a  recovery  group  (similar  to  the  long-term  rat  study).  Furthermore, concomitant administration of capivasertib with other drugs that are known for QT prolongation may enhance risk factors for TdP and the QT toxicity. A warning about cardiovascular effects observed in dogs has been included in section 5.3 of the SmPC. The relevant information concerning genotoxicity is indicated in the relevant section 5.3 of the SmPC.

Capivasertib had no effect on fertility in male rats. Effects on female fertility have not been studied in animals. In females, repeat-dose toxicity studies have reported some weight changes of the uterus in rats which were attributed to oestrous cycle changes. Histopathological examination conducted in rat and dog studies did not show any treatment-related effects on female reproductive organs, which may be indicative of an adverse effect on female fertility.

<div style=\"page-break-after: always\"></div>

Capivasertib caused degenerative changes in the testes in both rats (1-month study) and dogs (1- and 9-month  study)  with  associated  findings  in  the  epididymis  and  a  reduction  in  organ  weight.  These changes did not recover. In  the  one  month  rat  study,  there  were  sex  differences  in  exposure  (based  on  AUC(0-last))  to capivasertib with greater plasma levels in males than females. Measurement of insulin in female animals and  measurement  of  HbA1C  levels  would  have  been  interesting,  but  only  data  from  the  long-term toxicology studies are available. Nevertheless, it would have been interesting to collect data in the short term toxicology study. Toxicokinetic data were evaluated not only for capivasertib but also for the main human metabolite, the direct ether glucuronide conjugate. However, such data were only presented for mice. As intact rats do not form the metabolite, the absence of these data in rats is considered acceptable. However, it would have been helpful to generate such data in the dog considering that the glucuronide metabolite was formed in dog hepatocytes and in view of the fact that no meaningful margins of safety were found in the  appropriate  studies.  However,  it  is  acknowledged  that,  according  to  ICH  S9,  no  need  for  such evaluation is generally warranted ( In some cases, metabolites that have been identified in humans have not been qualified in nonclinical studies. For these metabolites, a separate evaluation is generally not warranted for patients with advanced cancer ). Thus, the absence of the toxicokinetic evaluation of the metabolite is considered acceptable. The major target organs or systems for toxicity were insulin signalling (increased levels of glucose and insulin in rats and dogs), the male reproductive organs (tubular degeneration in rats and dogs), and the renal system in rats (polyuria, decreased tubular epithelial cell size, decreased kidney size and weight). The findings present following 1 month of dosing were largely reversible within 1 month of cessation of dosing. Findings occurred at plasma concentrations lower or similar to those in humans (approximately 0.14 to 2 times) at the recommended dose of 400 mg twice daily (based on total AUC). Capivasertib was not genotoxic in vitro and did not induce increases in DNA damage in the liver of Han Wistar rats. However, capivasertib was positive in one in vivo micronucleus assay whereas the second test was negative. Kinetochore labelling of micronucleated PCEs revealed an aneugenic threshold mode of action. All mutagenic and potentially mutagenic impurities were assessed for risk according to ICH M7. The relevant information concerning genotoxicity testing is indicated in the relevant section 5.3 of the SmPC. The carcinogenic potential of capivasertib has not been studied which is in accordance with ICH S9. Capivasertib caused adverse effects following administration to pregnant or lactating rats (degenerative changes  in  the  testes,  hyperglycaemia  in  maternal  animals,  increase  in  post-implantation  loss  plus reduced gravid uterine and foetal weights). Regarding impairment of fertility in rats, in the 6-month toxicology study no functional effect on male fertility was demonstrated. However, the sensitivity of mating assays to effects on fertility in rodents is known to be low given the extremely high sperm production in this species and the fact that these animals remain fertile even with sperm reductions of up to 90% (Mangelsdorf et al., 2003), whereas smaller reductions in human fertility parameters might have a greater effect on fertility. Capivasertib has resulted in testicular toxicity and may impair fertility in males of reproductive potential. Effects on female fertility have not been studied in animals. In females, repeat-dose toxicity studies have reported some weight changes of the uterus in rats which were attributed to oestrous cycle changes. Histopathological  examination  conducted  in  rat  and  dog  studies  did  not  show  any  treatment-related effects on female reproductive organs, which may be indicative of an adverse effect on female fertility.

<div style=\"page-break-after: always\"></div>

Preliminary studies on embryonic and foetal development in rats and a pre- and postnatal study have been  carried  out.  The  applicant  explained  that  further  embryo-foetal  development  studies  were  not conducted with capivasertib as it has been shown to be embryolethal. Indeed, post-implantation loss increased at the high dose level in animals treated from GD 2 to GD 16. Historical control data for similar preliminary studies conducted at the same test facility have been provided.

In a rat embryofoetal study, capivasertib caused an increase in post implantation loss, an increase in early  embryonic  deaths,  together  with  reduced  gravid  uterine  and  foetal  weights,  and  minor  foetal visceral variations. These effects were seen at a dose level of 150 mg/kg/day which caused maternal toxicity, and where plasma concentrations were approximately 0.8 times the exposure in humans at the recommended dose of 400 mg twice daily (based on total AUC). When capivasertib was administered to pregnant rats at 150 mg/kg/day throughout gestation and through early lactation, there was a reduction in litter and pup weights.

Exposure to capivasertib was confirmed in suckling pups which may indicate the potential for excretion of capivasertib in human milk.

No stand-alone local tolerance studies have been submitted in support of this application. Since the proposed route of administration is oral, this is considered acceptable.

Capivasertib  is  intended  for  the  treatment  of  cancer  patients  with  serious  and  life-threatening malignancies. For indications falling under the scope of ICH S9, the guideline ICH Q3A (R2) should be applied for the control of (potential) mutagenic impurities. In the case of capivasertib, the applicant decided to assess the potential mutagenic impurity profile according to ICH M7 (R2), which is more conservative  and  therefore  acceptable.  Therefore,  a  potential  for  phototoxicity  of  capivasertib  is considered unlikely.

Capivasertib did not demonstrate any phototoxic potential.

Capivasertib exceeds the Phase I PEC trigger of 0.01 µg/L. A Phase II ERA was provided by the applicant. The logKOW remained below 4.5, thus a PBT assessment is not considered necessary. The data presented by the applicant show that capivasertib does not present an environmental risk following patient use.

## 2.5.7. Conclusion on the non-clinical aspects

The non-clinical data package evaluating the pharmacology and toxicity of capivasertib is considered acceptable to support the marketing authorisation.

Capivasertib is not a PBT substance. Considering the above data, capivasertib is not expected to pose a risk to the environment.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 13 Studies contributing PK and/or PD data

| Study number (name) Study title                                                                                                                                                                                                                                                                                                                                                                           | DCOdate                                                                                                                       | Objectives of the study           | Study design and type of control              | Route of administration and dosing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D3615C00001 (CAPItello-291) A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an | Ongoing DCO1: 15 August 2022                                                                                                  | Efficacy, safety, PK, HRQoL       | Double-blind, randomised, placebo- controlled | Capivasertib/placebo 400 mg oral BD Days 1 to 4 in each week of a 28-day treatment cycle. Fulvestrant 500 mg on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle.                                                                                                                                                                                                                                                                                                                                               |
| FTIH Study (D3610C00001) A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies                                                                                                                                  | Part A and Part B: 07 July 2014 Part C: 15 September 2016 Part D: 22 August 2017 Part E: 07 August 2018 Part F: 26 April 2019 | Safety, tolerability, efficacy,PK | Open-label                                    | Parts Aand B: Schedule 1: continuous dosing, starting dose 80 mg BD. Dose range: 80 mg to 600 mg BD. Schedule 2: intermittent dosing, 4 days on, 3 days off (480 and 640 mg BD) OR 2 days on, 5 days off (640 and 800 mg BD) Schedule 3 (optional; not conducted): alternative intermittent schedule. Parts C and D: Intermittent dosing 480 mg BD 4 days on, 3 days off. Parts E and F: Intermittent dosing 400 mg BD 4 days on, 3 days off in combination with fulvestrant at 500 mg IM on Days 1, 15, 29, and once monthly thereafter. |

<div style=\"page-break-after: always\"></div>

Table 14 Overview of the clinical studies evaluating efficacy of capivasertib in subjects with HR+/HER2- advanced/metastatic breast cancer

| Study ID Number of Sites/Countries Study Start/ Status                                                                                                                                                                                                                                                  | Study Design                                                                | Treatments Administered                                                                                                                                                                                                                                                                                 | Efficacy Objectives                                                                                                                                                                                                                                                                                                                                                                                      | Number of Subjects (Actual)                                                                                              | Study Population                                                                                                                                                                                                     | Efficacy Endpoints                                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal study                                                                                                                                                                                                                                                                                           | Pivotal study                                                               | Pivotal study                                                                                                                                                                                                                                                                                           | Pivotal study                                                                                                                                                                                                                                                                                                                                                                                            | Pivotal study                                                                                                            | Pivotal study                                                                                                                                                                                                        | Pivotal study                                                                                                                                                                                     |
| D3615C00001 (CAPItello- 291) 181 centres in 19 countries (Europe: Belgium, France, Germany, Hungary, Italy, Poland, Russian Federation, Spain, UK ROW: Argentina, Australia, Canada. China, Israel, Japan, Peru, South Korea, Taiwan, US) FPFV: Apr 2020 DCO: Aug 2022 Complete for PFS, ongoing for OS | randomis ed, double- blind, placebo- controlled phase 3 study event- driven | exp. arm (n=355): capivasertib 400 mg BD PO (dosed D1-D4 in a weekly dosing schedule) comp. arm (n=353): placebo (as capivasertib) backbone therapy: fulvestrant 500 mg IM once per 28 days (+ loading dose on C1D15) in addition in pre-/ peri- menopausal women LHRH agonist (as to local guidelines) | primary: compare the effect of capivasertib relative to placebo both as add- on to fulvestrant by assessment of PFS in the overall population and in the PIK3CA/AKT1/PTEN altered population. key secondary: compare the effect of capivasertib relative to placebo both as add- on to fulvestrant by assessment of OS and ORR in the overall population and in the PIK3CA/AKT1/PTEN altered population. | 708 patients (incl. 289 patients with PIK3CA/A KT1/PTEN alteration) 1:1 randomisati on to either capivasertib or placebo | adult patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after aromatase inhibitor therapy, with or without prior use of a CDK4/6 inhibitor | primary: PFS (INV) in the overall population AND PFS (INV) in the PIK3CA/AKT1/ PTEN altered subgroup key secondary: OS in the overall population AND OS in the PIK3CA/AKT1/ PTEN altered subgroup |

<div style=\"page-break-after: always\"></div>

| Study ID Number of Sites/Countries Study Start/ Status                                                                                                          | Study Design                                                                                                                              | Treatments Administered                                                                                                                                                                                                          | Efficacy Objectives                                                                                                                                                                                                                                                                                                                           | Number of Subjects (Actual)                                                       | Study Population                                                                                                                                                                                                                              | Efficacy Endpoints                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| Supportive study (externally sponsored)                                                                                                                         | Supportive study (externally sponsored)                                                                                                   | Supportive study (externally sponsored)                                                                                                                                                                                          | Supportive study (externally sponsored)                                                                                                                                                                                                                                                                                                       | Supportive study (externally sponsored)                                           | Supportive study (externally sponsored)                                                                                                                                                                                                       | Supportive study (externally sponsored)                   |
| FAKTION 19 centres, all in UK First patient screened: March 2015 DCO (primary analysis): Jan 2019 Phase Ib: Closed Phase II: Ongoing (primary results reported) | Phase 1b part (n=8): Dose- escalation safety run-in Phase 2 part: randomis ed (1:1), double- blind, placebo- controlled proof-of- concept | Phase 2 part exp. arm (n=69): capivasertib 400 mg BD PO (dosed D1-D4 in a weekly dosing schedule) comp. arm (n=71): placebo (as capivasertib) backbone therapy: fulvestrant 500 mg IM once per 28 days (+ loading dose on C1D15) | Phase 2 part Primary: To assess the relative anti-tumour activity of capivasertib vs placebo both as add- on to fulvestrant in terms of PFS using RECIST 1.1 Secondary: To examine the relative efficacy of capivasertib vs placebo both as add- on to fulvestrant in subpopulations of patients ± activation of the tumour PI3K/PTEN pathway | Phase 2 part: 140 patients (1:1 randomisati on to either capivasertib or placebo) | Phase 2 part post- menopausal women with locally advanced (inoperable) or metastatic ER+/HER2- breast cancer following recurrence or progression on or after aromatase inhibitor therapy, including no patients with a prior CDK4/6 inhibitor | Phase 2 part Primary: PFS (INV) in the overall population |

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Absorption

## Healthy volunteers

In Part 1 of study D3614C00007 ('A Phase I Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [ 14 C]AZD5363 (Capivasertib) in Healthy Male Subjects' the absolute  bioavailability  and  the  PK  parameters  of  a  single  unlabelled  oral  dose  and  a  radiolabelled intravenous (IV) microdose of Capivasertib was investigated.

## Table 15 Geometric mean (geometric  CV%) plasma pharmacokinetic parameters following a single oral dose of 400 mg capivasertib ((2 × 200 mg film-coated tablets): pharmacokinetic analysis set - part 1

| Parameter   | Capivasertib [N =6]   |
|-------------|-----------------------|

<div style=\"page-break-after: always\"></div>

| t a (h) lag             | 0.000 (0.00-0.00)   |
|-------------------------|---------------------|
| a t max (h)             | 1.742 (0.75-3.00)   |
| C max (ng/mL)           | 547 (29.7)          |
| AUC 0-t (ng.h/mL)       | 2950 (26.1)         |
| AUC 0-t /D (ng.h/mL/mg) | 7.39 (26.1)         |
| AUC(ng.h/mL)            | 2990 (25.6)         |
| AUC/D (ng.h/mL/mg)      | 7.49 (25.6)         |
| T 1/2 (h)               | 12.864 (11.3)       |
| CL/F (L/h)              | 134 (25.6)          |
| Vz/F (L)                | 2480 (23.3)         |
| MRT 0-t (h)             | 9.164 (14.6)        |
| MRT(h)                  | 10.139 (15.2)       |
| MAT (h)                 | 4.655 (31.5)        |
| F (%)                   | 28.549 (22.0)       |

a Median (range)

Table 16 Geometric mean (geometric CV%) plasma pharmacokinetic parameters following a single intravenous infusion of 100 μ g [ 14 C]AZD5363 (capivasertib): pharmacokinetic analysis set - part 1

| Parameter               | [ 14 C]AZD5363(capivasertib) [N=6]   |
|-------------------------|--------------------------------------|
| a t max (h)             | 0.275 (0.12-0.33)                    |
| C max (pg/mL)           | 2600 (21.8)                          |
| AUC 0-t (pg.h/mL)       | 2540 (15.0)                          |
| AUC 0-t /D (pg.h/mL/µg) | 25.4 (15.0)                          |
| AUC(pg.h/mL)            | 2620 (15.0)                          |
| AUC/D(pg.h/mL/µg)       | 26.2 (15.0)                          |
| T 1/2 (h)               | 6.864 (5.8)                          |
| CL (L/h)                | 38.1 (15.0)                          |
| V z (L)                 | 378 (17.9)                           |
| V ss (L)                | 205 (15.8)                           |
| MRT 0-t (h)             | 4.37 (9.3)                           |
| MRT(h)                  | 5.38 (8.0)                           |

a  Median (range)

The absolute bioavailability of Capivasertib following a 400 mg Capivasertib oral dose was 29%.

Table 17 Capivasertib statistical analysis results -assessment of bioavailability: pharmacokinetic analysis set - part 1

|                           |         |    |          |              | Pairwise Comparisons   | Pairwise Comparisons   | Pairwise Comparisons   |
|---------------------------|---------|----|----------|--------------|------------------------|------------------------|------------------------|
| Pharmacokinetic Parameter | Regimen | N  | Adj Mean | Geo 90% CI   | Pair                   | Ratio                  | 90% CI                 |
| AUC/D(ng.h/mL/mg)         | Oral    | 6  | 7.49     | (6.40, 8.75) |                        |                        |                        |

<div style=\"page-break-after: always\"></div>

| AUC/D (pg.h/mL/ug)   | IV   | 6 26.2   | (22.4, 30.7)   | Oral / IV   | 28.55   | (23.87, 34.15)   |
|----------------------|------|----------|----------------|-------------|---------|------------------|

Note that for the purpose of this comparison, although oral AUC/D is presented in ng.h/mL/mg units and IV is presented in pg.h/mL/ μ g units, these are equivalent in magnitude.

## Subjects with advanced solid malignancies

Study D3610C00001 (FTIH) was a Phase I, open-label, multicentre study with 6 parts (Parts A, B, C, D, E, and F) to assess the safety, tolerability, preliminary anti-tumour activity and characterise the PK of capivasertib  when  administered  orally  in  patients  with  advanced  solid  malignancies.  Parts  A  to  D

investigated capivasertib monotherapy and Parts E and F investigated capivasertib + fulvestrant. Following single oral doses of capivasertib, median tmax values ranged from 1.00 to 2.17 hours. The apparent terminal half-life was approximately 10 hours (range: 6.85 to 15.0 hours) and was independent of dose. Taking into consideration the small cohort sizes and the data variability, the gmean Cmax and AUC data from patients that had received 80 mg, 160 mg, 240 mg, 320 mg, 400 mg, 480 mg, 600 mg, 640 mg, or 800 mg AZD5363 appeared to be generally dose-proportional. In the pivotal phase III study D3615C00001 (CAPItello-291 study), PK samples were collected at Cycle 1 Week 1 Day 1 postdose at 1 hour and 4 hours; and pre -dose at Cycle 1 Week 3 Day 1, cycle 2 Week 1 Day 1, and Cycle 2 Week 3 Day 1 (sparse sampling). Capivasertib plasma concentration variables Ctrough (pre-dose), C1h, C4h (post-dose) were analysed in the Overall Population (PK Analysis Set). Additionally, rich PK sampling in a subpopulation of Japanese patients was performed pre-dose and up to 12 hours post-dose at Cycle 1 Week 1 Day 1, and pre-dose at Cycle 1 Week 3 Day 1, Cycle 2 Week 1 Day 1, and Cycle 2 Week 3 Day 1. Capivasertib plasma concentration variables, Ctrough (pre-dose), C1h, and C4h (post-dose) were analysed in the Overall Population. The AUC0-12h, Cmax and tmax were derived using a noncompartmental PK analysis (NCA) in a subpopulation of 6 Japanese patients with rich

PK sampling (Japan Intensive PK Analysis Set).

<div style=\"page-break-after: always\"></div>

Figure 2 Box-plot of plasma concentration (ng/mL) of capivasertib versus time (PK analysis set)

<!-- image -->

The middle line in the box represents the median. Upper and lower border of the box represent upper and lower quartile, respectively.

The whiskers represent the ranges for the bottom 25% and the top 25% of the data values, excluding outliers (values &gt; 20 times the IQR).

All data from C1W1D1 Japanese Intensive PK patients are excluded.

In the subpopulation of Japanese patients, following a single oral dose, Capivasertib was rapidly absorbed with a median tmax of 1.49 hours. The geometric mean Cmax was 1697 ng/mL and the geometric mean AUC0-12h was 6050 ng·h/mL. The variability was moderate (55.1% CV and 44.6% CV, respectively) (n = 6).

Capivasertib is therefore rapidly absorbed with peak concentration (Cmax) observed at approximately 1-2 hours in patients. The mean absolute bioavailability is 29%.

## Accumulation

Following intermittent dosing of 480 mg BD 4 days on, 3 days off in clinical study D3610C00001, the mean AUC0-12h on Day 4 was 1.76-fold (range 0.92 to 2.52) that of the AUC0-12h on the first day of dosing.

## Steady State

Due to the small numbers of patients that had calculable Cmin ratios (30 patients from the 90 patients in the PK dataset) and the data variability, it was not possible to use these data to demonstrate that steady state had been achieved for all cohorts and schedules. The ratios of Cmin; Day 15 to Day 7 (continuous dosing), Day 11 to Day 4 (4 on/3 off intermittent dosing schedules) and Day 9 to Day 2 (2 on/5 off intermittent dosing schedules) were generally supportive of PK steady state: values ranged from 0.394 to 4.24 with gmean values, where calculable, being close to unity (values ranged from 0.8051 to 1.457). Based on the t1/2 of AZD5363 (around 10 hours) it would be expected to take about 2 days to achieve steady state.

<div style=\"page-break-after: always\"></div>

Given  the  findings  from  the  Cmin  ratio  data  and  the  absence  of  a  clear  temporal  change  in pharmacokinetics, it was concluded that the data were supportive of steady state being approached during the on-drug phase of all schedules tested.

## BCS-class

Capivasertib was considered to be a BCS class 4 compound (low solubility/low permeability) according to the BCS and available solubility, in vitro permeability, and absolute bioavailability data.

## Bioequivalence

During the course of the development programme, 3 different immediate release formulations were used. The details of the composition of these formulations and further information are described in detail in section 2.4.3.

Initial Phase I and some of the Phase II clinical studies were performed using a capsule presentation ('Phase I capsule') which consisted of a hard capsule shell filled with capivasertib drug substance. For one of the Phase I clinical studies, the Phase II clinical studies, and the relative bioavailability study, an immediate release tablet presentation was developed ('Phase II tablet'). The Phase III/commercial tablet ('Phase  III/commercial  tablet')  is  an  optimised  film-coated  tablet  formulation.  The  commercial capivasertib film-coated tablets are quantitatively identical to the Phase III clinical film-coated tablets but are differentiated through use of debossing; the clinical tablets are plain, while the commercial tablets will be debossed.

Potential differences were investigated in study D3610C00007 (A Phase I, Open-Label, Multicentre Study to  Compare  Two  Dosage  Formulations  of  AZD5363  and  to  Establish  the  Effect  of  Food  on  the Pharmacokinetic  Exposure,  Safety  and  Tolerability  of  AZD5363  in  Patients  with  Advanced  Solid Malignancies (OAK)).

<div style=\"page-break-after: always\"></div>

Table 18 Summary of PK parameters of AZD5363 (Part A) (Pharmacokinetics analysis set)

| Treatment/ Condition               | Visit          | Summary statistic    | Css.mar (μg/mL)   |   Css.min |   AUCss (/D(Tu/D)(Tu/) | CL/F   | tss,mar (h)   |
|------------------------------------|----------------|----------------------|-------------------|-----------|------------------------|--------|---------------|
| AZD5363 480 mg bd 4on/3off/Tablet  | Cycle 1        | n                    | 11                |     11    |                  11    | 11     | 11            |
| AZD5363 480 mg bd 4on/3off/Tablet  | Day 4          | Geometric mean 1779  |                   |    192.6  |                8536    | NC     | NC            |
| AZD5363 480 mg bd 4on/3off/Tablet  |                | CV (%)               | 46.24             |     55.6  |                  47.69 | NC     | NC            |
| AZD5363 480 mg bd 4on/3off/Tablet  |                | Arithmetic mean 1934 |                   |    218.4  |                9323    | 61.79  | NC            |
| AZD5363 480 mg bd 4on/3off/Tablet  |                | sd                   | 792.5             |    121.1  |                3905    | 28.60  | NC            |
| AZD5363 480 mg bd 4on/3off/Tablet  |                | Med                  | 1920              |    197    |                9410    | NC     | 1.03          |
| AZD5363 480 mg bd 4on/3off/Tablet  |                | Min                  | 848               |     94.9  |                4050    | 31.6   | 0.58          |
| AZD5363 480 mg bd 4on/3off/Tablet  |                | Max                  | 3210              |    506    |               15200    | 119    | 2.00          |
| AZD5363 480 mg bd 4on/3off/Capsule | Cycle 1 Day 11 | n                    | 11                |     11    |                  11    | 11     | 11            |
| AZD5363 480 mg bd 4on/3off/Capsule |                | Geometric mean 1745  |                   |    271.5  |                9445    | NC     | NC            |
| AZD5363 480 mg bd 4on/3off/Capsule |                | CV (%)               | 40.20             |     57.66 |                  44.61 | NC     | NC            |
| AZD5363 480 mg bd 4on/3off/Capsule |                | Arithmetic mean 1865 |                   |    308.2  |               10230    | 55.26  | NC            |
| AZD5363 480 mg bd 4on/3off/Capsule |                | ps                   | 700.9             |    166.1  |                4251    | 24.69  | NC            |
|                                    |                | Med                  | 1720              |    313    |                9180    | NC     | 2.00          |
|                                    |                | Min                  | 901               |    106    |                4280    | 26.8   | 1.00          |
|                                    |                | Max                  | 3160              |    710    |               17900    | 112    | 4.00          |

Abbreviations: AUCss, area under the curve at steady state; bd, twice daily; CLss/F, plasma clearance at steady state; Css,max, maximum concentration study treatment in plasma at steady state after multiple dosing; Css,min, minimum concentration  study treatment in plasma at steady state after multiple dosing; CV, coefficient of variation; Max, ma ximum; Med, median; Min, minimum; sd, standard deviation; tss,max, terminal steady state time to Cmax; NC, not calculated.

Table  19  Geometric  mean  and  90%  CI  for  ratio  of  tablet  to  capsule  -  tablet  formulation comparison (Part A) (Pharmacokinetics analysis set)

| Pharmacokinetic parameter   |   Tablet n |   LS Mean |   n |   Capsule LS Mean |   90% CI of Point estimate of geometric mean ratio of tablet to capsule | geometric mean ratio of tablet to capsule   |   Intra- patient variability (%) |
|-----------------------------|------------|-----------|-----|-------------------|-------------------------------------------------------------------------|---------------------------------------------|----------------------------------|
| AUC ss (h*μg/mL)            |         11 |      9.05 |  11 |              9.15 |                                                                    0.9  | 0.77, 1.06                                  |                            20.29 |
| C ss,max (μg/mL)            |         11 |      7.48 |  11 |              7.46 |                                                                    1.02 | 0.86, 1.20                                  |                            21.75 |

Abbreviations: AUCss, area under the curve at steady state; CI, confidence interval; Css,max, maximum concentration study treatment  in plasma at steady state after multiple dosing; LS, least squares.

Influence of food

Clinical studies D3610C00007 and D3614C00005 investigated the potential influence of food.

In Part B of study D3610C00007, during the first week of Cycle 1, patients were dosed with the Phase II tablet formulation, according to standard fasting restrictions (i.e. no food from 2 hours before to 1 hour after dosing), with the exception of Day 4. On Day 4, following an overnight fast (minimum of 8 hours), patients received their first dose with no food permitted for 4 hours post-dose.

During the second week of Cycle 1, patients received capivasertib according to the same schedule and fasting restrictions as for Week 1 with the exception of Day 11 on which, following an overnight fast

<div style=\"page-break-after: always\"></div>

(minimum of 8 hours), patients received their first daily dose 30 minutes after starting a standardised meal  containing  605  kcal,  of  which  24%  (36  g)  were  proteins,  26%  (18  g)  fat,  and  50%  (76  g) carbohydrates. No further food was permitted for 4 hours post-dose.  PK blood samples were taken at Cycle 1 Days 1, 4, 8 and 11.

Table  20  Geometric  mean  and  90%  CI  for  ratio  of  fed  to  fasted  -  food  effect  (Part  B) (Pharmacokinetics analysis set)

| Pharmacokinetic   | Fed   | Fed     | Fasted   | Point   | Point    | 90% CI of estimate of geometric geometric mean ratio mean ratio Fed to   | Intra- patient variability   |
|-------------------|-------|---------|----------|---------|----------|--------------------------------------------------------------------------|------------------------------|
| parameter         | n     | LS Mean | LS n     |         | Mean Fed | Fasted                                                                   | (%)                          |
| AUC ss (h*μg/mL)  | 9     | 9.00    | 9        | 9.12    | 0.89     | 0.76, 1.05                                                               | 19.03                        |
| C ss,max (μg/mL)  | 9     | 7.12    | 9        | 7.52    | 0.67     | 0.55, 0.82                                                               | 22.98                        |

Abbreviations: AUCss, area under the curve at steady state; CI, confidence interval; Css,max, maximum concentration study treatment in plasma at steady state after multiple dosing; LS, least squares.

Study D3614C00005 (An Open-label, Randomized, Crossover Study in Healthy Subjects to Evaluate the Effect of Food and Acid Reducing Agent(s) on the Pharmacokinetics of Capivasertib) was a Phase I, 2part, adaptive, open-label, randomised, crossover study to evaluate the effect of food and acid-reducing agents on the PK of capivasertib in healthy subjects.

Table 21 Food/PPI Study (D3614C00005): statistical comparison of key PK parameters (PK analysis set)

|                                                     | GMR(90%CI)      | GMR(90%CI)      | GMR(90%CI)      |
|-----------------------------------------------------|-----------------|-----------------|-----------------|
| Treatment comparison                                | AUC inf         | AUC last        | C max           |
| Part 1:                                             | 1.323           | 1.327           | 1.233           |
| High-fat, high-calorie meal versus overnight fast   | (1.223, 1.431)  | (1.226, 1.436)  | (1.078, 1.410)  |
| Part 1 and Part 2:                                  | 1.132           | 1.134           | 0.8536          |
| High-fat, high-calorie meal versus partially fasted | (0.9917, 1.293) | (0.9919, 1.297) | (0.6977, 1.044) |
| Part 2:                                             | 1.144           | 1.150           | 1.208           |
| Low-fat, low-calorie meal versus overnight fast     | (1.048, 1.249)  | (1.050, 1.260)  | (0.9864, 1.479) |
| Part 2:                                             | 0.9590          | 0.9578          | 0.8647          |
| Low-fat, low-calorie meal versus partially fasted   | (0.8760, 1.050) | (0.8719, 1.052) | (0.7024, 1.064) |

When capivasertib was administered after a high-fat, high-calorie meal (approximately 1000 kcal), the fed to fasted ratio was 1.32 and 1.23, for AUC and Cmax, respectively, compared to when given after an overnight fast. When capivasertib was administered after a low-fat, low-calorie meal (approximately 400 kcal), the exposure was similar to that after fasted administration with fed to fasted ratios of 1.14 and 1.21, for AUC and Cmax, respectively. Co-administration with food did not result in clinically relevant changes to the exposure.

## Distribution

The  geometric  mean  (geometric  CV%)  volume  of  distribution  (Vss)  was  205  L  (15.8%)  after  IV administration to healthy subjects.

<div style=\"page-break-after: always\"></div>

Based on non-clinical data, capivasertib is not extensively bound to plasma proteins (percentage unbound 22.3%). The plasma to blood ratio was 0.714.

## Elimination

In FTHI study D3610C00001 the mean terminal half-life in patients was 9.9 hours after a single dose of capivasertib 400 mg, ranging from 8.4 to 11.2 hours across the doses and schedules investigated (based on NCA). In ADME study D3614C00007, the geometric mean apparent terminal half-life was 5.4 h for plasma total radioactivity and 12.3 h for capivasertib.

The mean total plasma clearance is 38.1 L/h after a single IV administration to healthy subjects.

Population  PK  analysis  estimated  mean  total  oral  plasma  clearance  at  60.0  L/h  after  single  oral administration, with an inter-individual variability of 36.2%. Clearance was estimated to decrease by 8% after 7 days of repeated dosing of 400 mg BD.

Based on population PK analysis, the effective half-life after multiple dosing is estimated to be 8.3 hours.

Renal clearance contributed to 21% of the total clearance in healthy subjects and the geometric mean renal clearance of capivasertib was 8.30 L/h.

Following single oral dose of 400 mg, the mean total recovery of radioactive dose was 45% from urine and 50% from faeces. Renal clearance was 21% of total clearance.

In study D3610C00001, taking plasma protein binding of AZD5363 into account, renal clearance was high  compared  to  the  glomerular  filtration  rate  indicating  that  renal  excretion  may  have  an  active component. The median tmax for capivasertib and plasma total radioactivity was 2.07 h.

## Metabolism

Results from in vitro studies suggest that capivasertib is primarily metabolised by CYP3A4 and UGT2B7 enzymes. Human metabolites of capivasertib were detected and quantified in Day 8 AUC pooled plasma samples from patients receiving 400 mg BD from the FTIH study D3610C00001. The major metabolite in human plasma was identified as an ether glucuronide (AZ14102143) that accounted for 83% of total drug-related material using nuclear magnetic resonance spectroscopy, and was inactive against AKT. A minor oxidative metabolite ('+3[O]') was detected and quantified at much lower levels (2%), while capivasertib accounted for 15% of total circulating drug-related material.

No active metabolites have been identified.

In urine, the major response was characterised as the ether glucuronide, and it was estimated that it represented 19% to 37% of the dose in urine.

Capivasertib is primarily eliminated by metabolism.

## Dose proportionality and time dependencies

Based on NCAs of data generated in FTHI study D3610C00001, capivasertib exposure (AUC and Cmax) is  dose-proportional over the range 80 to 800 mg after single dose administration in patients. After multiple-dose administration of 80 to 600 mg BD continuously, the AUC increased slightly more than in proportion to the dose. See figures below:

## Figure 3 Capivasertib exposure versus dose following single-dose administration

<div style=\"page-break-after: always\"></div>

## AUC

<!-- image -->

Data from all schedules are included in the regression.

## Cmax

<!-- image -->

Data from all schedules are included in the regression.

<div style=\"page-break-after: always\"></div>

Figure 4 Capivasertib exposure versus dose following multiple-dose administration

## AUC

<!-- image -->

Data from the intermittent schedules are shown for comparison but were not included in the regression.

## Cmax

<!-- image -->

Data from the intermittent schedules are shown for comparison but were not included in the regression.

## Special populations

Clinical pharmacology studies to specifically evaluate the role of impaired renal function, impaired hepatic function, age and gender have not been conducted. However, population PK analysis was performed using pooled data from of Phase I, II and III studies.

## Impaired renal function

A formal clinical study to investigate the impact of renal impairment on the PK of capivasertib has not been performed. The justification provided by the applicant is based on the fact that capivasertib is only renally cleared to a small extent (renal clearance was 21% of total clearance in healthy subjects (in ADME study D361400007)) and only 3.8% to 7.4% of an oral dose was excreted unchanged in urine in patients  (in  FTIH  study  D3610C00001).  In  study  D3610C00001,  taking  plasma  protein  binding  of AZD5363 into account, renal clearance was high compared to the glomerular filtration rate indicating that renal excretion may have an active component.

<div style=\"page-break-after: always\"></div>

The  population  PK  analysis  included  patients  with  normal  renal  function  at  baseline  (424  [54.3%] patients),  mild  renal  impairment  (267  [34.2%]  patients),  moderate  renal  impairment  (85  [10.9%] patients), and patients with missing information (5 [0.6%] patients). Creatinine clearance did not have a significant effect on CL in the popPK analysis. Comparison of exposures revealed that the AUCss ratio was 1.01 (95% CI: 0.97, 1.06) and the Cmax,ss ratio was 1.01 (95% CI: 0.97, 1.05) in patients with mild renal impairment (creatinine clearance 51 to 80 mL/min) compared to patients with normal renal function. The AUCss ratio was 1.16 (95% CI: 1.08, 1.24) and the Cmax,ss ratio was 1.16 (95% CI: 1.09, 1.23) in patients with moderate renal impairment (creatinine clearance 31 to 50 mL/min) compared to patients with normal renal function. Based on these results, AUC and Cmax were 1% higher in patients with mild renal impairment (creatinine clearance 60 to 89 mL/min), compared to patients with normal renal function. AUC and Cmax were 16% higher in patients with moderate renal impairment (creatinine clearance 30 to 59 mL/min), compared to patients with normal renal function. There is no data in severe renal impairment or end-stage renal disease (creatinine clearance &lt; 30 ml/min). Impaired hepatic function A formal clinical study to investigate the impact of hepatic impairment on the PK of capivasertib has not been performed. The population PK analysis included patients with normal hepatic function at baseline (505 [64.7%] patients), mild hepatic impairment (268 [34.3%] patients), moderate hepatic impairment (7 [0.9%] patients), and patients with missing information (1 [0.1%] patients). The analysis indicated that there was no statistically significant effect of hepatic impairment at baseline on the PK of capivasertib and that the estimated differences were small. The AUCss ratio was 1.05 (95% CI: 1.01, 1.10) and the Cmax,ss rat io was 1.05 (95% CI: 1.01, 1.09) in patients with mild hepatic impairment (bilirubin ≤ ULN and AST &gt; ULN, or bilirubin &gt; 1 ULN to ≤ 1.5 ULN) compared to patients with normal hepatic function. The AUCss ratio was 1.17 (95% CI: 0.94, 1.47) and the Cmax,ss ratio was 1.13 (95% CI: 0.93, 1.36) in patients with moderate hepatic impairment (bilirubin &gt; 1.5 ULN to ≤ 3 ULN), compared to patients with normal hepatic function. Based  on  these  results,  AUC  and  Cmax  were  5%  higher  in  patients  with  mild  hepatic  impairment (bilirubin ≤ ULN and AST &gt; ULN, or bilirubin &gt; 1 ULN to ≤ 1.5 ULN), compared to patients with normal hepatic function (bilirubin ≤ ULN and AST ≤ ULN). AUC was 17% and Cmax was 13% higher in patients with moderate hepatic impairment (bilirubin &gt; 1.5 ULN to ≤ 3 ULN), compared to patients with normal hepatic function. There is limited data in patients with moderate hepatic impairment and no data in severe hepatic impairment. Effect of race, age, gender and weight Study  D3610C00004  (A  Phase  I,  Open-Label,  Multicentre  Study  to  Assess  the  Safety,  Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Japanese Patients with Advanced Solid Malignancies) was a Phase I, open label, multicentre study which was planned to consist of 2 parts: Part A (dose escalation) and Part B (dose expansion [optional, not conducted]). Plasma samples were collected pre-dose and up to 48 hours postdose (single dose of capivasertib) and up to 12 hours post-dose (multiple doses of capivasertib) and an NCA to derive the PK parameters after single and multiple dosing of capivasertib was performed. The study results informed the pop pk analysis. In the Japanese safety/PK study (D3610C00004), systemic exposure to capivasertib in Asian patients with  advanced  solid  malignancies  was  similar  to  that  in  patients  of  White  race  with  advanced  solid malignancies in Part A and Part B of the FTIH study (D3610C00001): after repeated dosing, the dose-

<div style=\"page-break-after: always\"></div>

normalised ratio (Asian/White) was 1.11 (90% CI: 0.96, 1.28) and 1.19 (90% CI: 1.01, 1.41) for AUC and Cmax, respectively (pooled data across doses).

The number of patients included in the pooled population PK analysis are presented by age category and study in the table below.

Table 22 Number of patients by age category and study

| PK Trials   | Age 65-74 (Older number number)   | subjects /total   | Age 75-84 (Older number number)   | subjects /total   | Age 85+ (Older number number)   | subjects /total   |
|-------------|-----------------------------------|-------------------|-----------------------------------|-------------------|---------------------------------|-------------------|
| D3610C00001 | 57/280                            |                   | 7/280                             |                   | 1/280                           |                   |
| D3610C00002 | 18/90                             |                   | 1/90                              |                   | 0/90                            |                   |
| D3610C00004 | 4/41                              |                   | 0/41                              |                   | 0/41                            |                   |
| D3610C00007 | 8/30                              |                   | 2/30                              |                   | 0/30                            |                   |
| D3615C00001 | 86/340                            |                   | 21/340                            |                   | 0/340                           |                   |
| Total       | 173/781                           |                   | 31/781                            |                   | 1/781                           |                   |

Based on population pharmacokinetic analysis, AUC and Cmax showed that race (including White and Japanese patients), gender or age did not significantly impact the capivasertib exposure. There was a statistically significant correlation of apparent oral clearance of capivasertib to body weight. Compared to a patient with a body weight of 66 kg, a 47 kg patient is predicted to have 12% higher AUC. There is no basis for dose modification based on body weight as the predicted effect on capivasertib exposure was small.

No dose adjustment is required for elderly patients. There are limited data in patients aged ≥ 75 years.

## Pharmacokinetic interaction studies

The effect of extrinsic factors on capivasertib PK was assessed in vivo in studies listed below:

<div style=\"page-break-after: always\"></div>

Table 23 In vivo studies to assess the effect of extrinsic factors on capivasertib PK

<!-- image -->

| Study identifier                      | Study popula tion                    | Key design features                                                                                                                                                                                                                                                     | Study treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Status                               | Locatio n in Module 5   |
|---------------------------------------|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-------------------------|
| Midazolam DDI study (D3614C000 03)    | Patients with advanced solid tumours | Phase I, open-label, fixed- sequence, multicentre study to assess the PK of midazolam when administered alone and in combination with repeated doses of capivasertib (N = 21 treated)                                                                                   | Part A: C1D1: single oral dose midazolam (1 mg); C1D2 to C1D7: capivasertib 400 mg BD, 4 days on, 3 days off; C1D8 to C1D15: single oral doses of midazolam (1 mg, C1D8 and C1D12) during intermittent capivasertib treatment (400 mg BD, C1D9 to C1D12 on, C1D13 to C1D15 off) Part B: capivasertib 400 mg BD, 4 days on, 3 days off, as monotherapy or in combination with standard of care treatment, until disease progression or other discontinuation criteria are met. | of Part A: Completed Part B: Ongoing | 5.3.3.4                 |
| Itraconazole DDI study (D3614C00 004) | Healthy subjects                     | Phase I, open-label, fixed sequence study healthy subjects assess the PK capivasertib alone and in combination with itraconazole (N = 11 treated)                                                                                                                       | in to of Capivasertib 80 mg single dose on Day 1 and Day 6 Itraconazole 200 mg BD on Day 3, followed by once daily doses in morning for 4 days                                                                                                                                                                                                                                                                                                                                | Completed                            | 5.3.3.4                 |
| Food/PPI study (D3614C000 05)         | Healthy subjects                     | Phase I, open-label, randomised, crossover study in healthy subjects to evaluate the effect of food and acid- reducing agent(s) on the PK of capivasertib. 2-part study (adaptive design), each part 3- way crossover (Part 1: N = 23 treated + Part 2: N = 24 treated) | Capivasertib tablet, 3 single doses of 400 mg per part: Part 1: capivasertib overnight fasted, capivasertib after high-fat high-calorie meal, capivasertib fasted + rabeprazole. Part 2 (based on the findings of Part 1): capivasertib overnight fasted, capivasertib after low-fat low- calorie meal, capivasertib partially fasted; not administered: capivasertib + famotidine, capivasertib fed + rabeprazole.                                                           | Completed                            | 5.3.3.4                 |

Source: Excerpt 5.2 Tabular Listing of All Clinical Studies

Results from published clinical studies by 'Kolinsky et al. 2020 1 ' and 'Jones et al. 2020 2 ' have also been discussed.

1 Kolinsk et al.; A phase I dose -escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castrationresistant prostate cancer; Ann Oncol 2020;31:619 -625 2 R H Jones et al.; Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial; Vol Lancet Onco logy 2020:21:345-357

<div style=\"page-break-after: always\"></div>

Table 24 Summary statistics for midazolam PK parameters with and without capivasertib

| Parameter (unit)   | Summary   | C1D1 [N =21]   | C1D8 [N =19]   | C1D12 [N =18]   |
|--------------------|-----------|----------------|----------------|-----------------|
| AUCinf (h*ng/mL)   | gMean     | 22.95 [n = 15] | 26.08 [n = 14] | 39.31 [n = 14]  |
| AUCinf (h*ng/mL)   | gCV%      | 55.56          | 45.98          | 36.65           |
| AUClast (h*ng/mL)  | gMean     | 21.27 [n=15]   | 23.07 [n=14]   | 34.44 [n=14]    |
| AUClast (h*ng/mL)  | gCV%      | 51.89          | 43.04          | 33.64           |
| Cmax (ng/mL)       | gMean     | 8.002 [n=15]   | 9.016 [n=14]   | 9.673 [n=14]    |
| Cmax (ng/mL)       | gCV%      | 35.74          | 47.31          | 40.62           |
| t ½ λz (h)         | gMean     | 6.740 [n = 15] | 7.980 [n = 14] | 7.203 [n = 14]  |
| t ½ λz (h)         | gCV%      | 28.67          | 63.06          | 39.78           |
| tmax (h)           | Median    | 0.53 [n = 15]  | 0.47 [n = 14]  | 0.55 [n = 14]   |
| tmax (h)           | Min, Max  | 0.25 - 0.90    | 0.18 - 0.75    | 0.25 - 1.08     |

C1D1: Day 1 of Cycle 1; single oral dose of midazolam (1 mg).

C1D8: Day 8 of Cycle 1; single oral dose of midazolam (1 mg) on 3rd off day of intermittent capivasertib treatment (400 mg bid).

C1D12: Day 12 of Cycle 1; single oral dose of midazolam (1 mg) on 4th on day of intermittent capivasertib treatment (400 mg bid).

AUCinf = Maximum observed plasma (peak) drug concentration; AUClast = Area under the plasma concentration-time curve from zero to last observed timepoint; bid = twice daily; C = Cycle; Cmax = Maximum observed plasma (peak) drug concentration; CV% = Coefficient of variation; D = Day; gCV% = Geometric coefficient of variation; n = number of observations in analysis; N = number of patients per visit; t½λz = Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve; tmax = Time to reach maximum observed (peak) plasma concentration.

## Capivasertib effect on other drugs (capivasertib=perpetrator)

CYP inhibition (capivasertib=perpetrator)

Study D3614C00003 (An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients with Advanced Solid  Tumours)  is  an  ongoing  Phase  I  open-label,  fixed-sequence,  multicentre  study  to  assess  the pharmacokinetics (PK) of midazolam when administered alone and in combination with repeated doses of  capivasertib  in  patients  with  advanced  solid  tumours  and  who  may  be  suitable  for  capivasertib treatment.

Table 25 Statistical comparison of key PK parameters for midazolam (PK analysis set)

|                  |            |    |         |                | Comparison of treatments   | Comparison of treatments   | Comparison of treatments   |
|------------------|------------|----|---------|----------------|----------------------------|----------------------------|----------------------------|
| Parameter (unit) | Time point | n  | LS mean | 95% CI         | Comparison                 | Geometric mean ratio (%)   | 90% CI                     |
| AUCinf           | C1D1       | 15 | 22.95   | (18.08, 29.13) | NA                         | NA                         | NA                         |
|                  | C1D8       | 14 | 26.29   | (20.63, 33.49) | C1D8 vs C1D1               | 114.5                      | (96.53, 135.9)             |

<div style=\"page-break-after: always\"></div>

|              | N = 13       |    |        |                |               |       |                |
|--------------|--------------|----|--------|----------------|---------------|-------|----------------|
|              | C1D12 N = 14 | 14 | 40.67  | (31.93, 51.82) | C1D12 vs C1D1 | 177.2 | (149.4, 210.3) |
| Cmax (ng/mL) | C1D1 N = 15  | 15 |  8.002 | (6.476, 9.887) | NA            | NA    | NA             |
|              | C1D8 N = 13  | 14 |  8.938 | (7.205, 11.09) | C1D8 vs C1D1  | 111.7 | (94.75, 131.7) |
|              | C1D12 N = 14 | 14 |  9.928 | (8.003, 12.31) | C1D12 vs C1D1 | 124.1 | (105.2, 146.3) |

C1D1: Day 1 of Cycle 1; single oral dose of midazolam (1 mg).

C1D8: Day 8 of Cycle 1; single oral dose of midazolam (1 mg) on 3rd off day of intermittent capivasertib treatment (400 mg bid).

C1D12: Day 12 of Cycle 1; single oral dose of midazolam (1 mg) on 4th on day of intermittent capivasertib treatment (400 mg bid).

Results based on mixed effects model following a natural logarithmic transformation of the PK parameters with fixed effect for day and random effect for patient.

CI  =  Confidence  interval;  LS  =  least-squares;  n  =  number  of  patients  in  analysis;  N  =  number  of  patients  per visit.AUCinf = Maximum observed plasma (peak) drug concentration; C = Cycle; Cmax = Maximum observed plasma (peak) drug concentration; D= Day; n = number of observations in analysis; N = number of patients per visit; NA = not applicable; PK = pharmacokinetic(s).

Transporter (capivasertib=perpetrator)

The potential of capivasertib to interact with transporters has not been investigated in clinical studies.

## Effect of other drugs on capivasertib (capivasertib=victim)

## CYP3A4 inhibitors (capivasertib=victim)

Study  D3614C00004  was  an  'Open-label,  Fixed  Sequence  Study  in  Healthy  Subjects  to  Assess  the Pharmacokinetics of Capivasertib When Administered Alone and In Combination with Itraconazole'.

<div style=\"page-break-after: always\"></div>

Table 26 Summary statistics for capivasertib PK parameters with and without itraconazole

| Parameter         | Summary    | Capivasertib                                     | Capivasertib                                  |
|-------------------|------------|--------------------------------------------------|-----------------------------------------------|
| Parameter         | Summary    | Period 1 (N=11) without concomitant itraconazole | Period 3 (N=11) with concomitant itraconazole |
| Cmax (ng/mL)      | gMean      | 121.1                                            | 206.0                                         |
| Cmax (ng/mL)      | (gCV%)     | (34.62)                                          | (31.46)                                       |
| AUCinf (h*ng/mL)  | gMean      | 597.6                                            | 1167                                          |
| AUCinf (h*ng/mL)  | (gCV%)     | (26.92)                                          | (21.92)                                       |
| AUClast (h*ng/mL) | gMean      | 573.8                                            | 1135                                          |
| AUClast (h*ng/mL) | (gCV%)     | (28.52)                                          | (21.56)                                       |
| tmax (h)          | Median     | 1.50                                             | 1.50                                          |
| tmax (h)          | (Min, Max) | (0.50-3.50)                                      | (0.50-2.52)                                   |
| t1/2λz (h)        | Mean       | 7.390                                            | 10.28                                         |
| t1/2λz (h)        | (SD)       | (1.383)                                          | (1.105)                                       |
| tlast (h)         | Median     | 24.05                                            | 47.95                                         |
| tlast (h)         | (Min, Max) | (23.97-47.52)                                    | (47.78-48.07)                                 |
| CL/F (L/h)        | gMean      | 133.9                                            | 68.57                                         |
| CL/F (L/h)        | (gCV%)     | (26.92)                                          | (21.92)                                       |
| Vz/F (L)          | gMean      | 1407                                             | 1012                                          |
| Vz/F (L)          | (gCV%)     | (22.44)                                          | (21.09)                                       |
| M:P [AUCinf]      | gMean      | NA                                               | NA                                            |
| M:P [AUCinf]      | (gCV%)     | (NC)                                             | (NC)                                          |

Period 1 = 80 mg capivasertib; Period 3 = 80 mg capivasertib and 200 mg itraconazole gCV% = geometric coefficient of variation; gMean = geometric mean; Max = maximum; min = minimum; NA = Not applicable; NC = Not calculated; M:P = ratio of metabolite

<div style=\"page-break-after: always\"></div>

Table 27 Statistical comparison of key PK parameters: DDI assessment (PK set)

|           |    |    |    | Geometric   |                | Pairwise comparisons   | Pairwise comparisons            | Pairwise comparisons   |
|-----------|----|----|----|-------------|----------------|------------------------|---------------------------------|------------------------|
|           |    |    | n  | mean        | 95% CI         | Pair                   | Ratio of LS geometric means (%) | 90% CI                 |
| Cmax      | A  | 11 |    | 121.1       | (97.88, 149.8) |                        |                                 |                        |
| (ng/mL)   | C  | 11 | 11 | 206.0       | (166.5, 254.9) | C/A                    | 170.1                           | (155.6, 186.0)         |
| AUCinf    | A  | 11 |    | 597.6       | (509.5, 701.0) |                        |                                 |                        |
| (h*ng/mL) | C  | 11 | 11 | 1167        | (994.6, 1368)  | C/A                    | 195.2                           | (181.8, 209.6)         |
| AUClast   | A  | 11 |    | 573.8       | (487.1, 676.0) |                        |                                 |                        |
| (h*ng/mL) | C  | 11 | 11 | 1135        | (963.2, 1337)  | C/A                    | 197.7                           | (183.3, 213.3)         |

Treatment A = Period 1, 80 mg capivasertib; Treatment C = Period 3, 80 mg capivasertib and 200 mg itraconazole

## CYP3A4 inducers (capivasertib=victim)

Study results of the RE-AKT study have been published by M. P. Kolinsky et al. 3 . As summarised by the applicant, the RE-AKT study comprised a Phase I safety run-in, followed by a randomised Phase II study of  capivasertib + enzalutamide versus placebo + enzalutamide, with a Phase II expansion cohort of capivasertib + enzalutamide, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

The effect of enzalutamide on the PK of capivasertib was assessed as a secondary objective. Patients in all parts of the study received enzalutamide 160 mg OD. Capivasertib was administered 4 days on, 3 days off at doses of 320, 400, or 480 mg BD in the safety run-in, and at 400 mg BD in the Phase II parts.

Capivasertib AUC was 40% lower on Cycle 2, Day 1 (capivasertib + enzalutamide) than on Cycle 0, Day 1 (capivasertib) (GMR for AUC of 0.60).

After accounting for the predicted accumulation between Cycle 0 Day 1 and Cycle 2 Day 1 (ratio 1.08) based  on  the  population  PK  model,  the  estimated  decrease  in  capivasertib  AUC  by  enzalutamide  is approximately 40% to 50%.

## Inhibitors/inducers of UGT2B7 (capivasertib=victim)

The  potential  of  DDIs  based  on  interactions  with  UGT2B7  (capivasertib  as  a  victim)  have  not  been investigated in clinical studies.

## Inhibitors of transporters (capivasertib=victim)

The potential of DDIs based on interactions of inhibitors of transporters (capivasertib as a victim) have not been investigated in clinical studies.

## Antacids, H2 antagonists, and proton pump inhibitors (PPI)

Study  D3614C00005  was  a  Phase  I,  2-part,  adaptive,  open-label,  randomised,  crossover  study  to evaluate the effect of food and acid-reducing agents on the PK of capivasertib in healthy subjects.

3 Kolinsk et al.; A phase I dose -escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castrationresistant prostate cancer; Ann Oncol 2020;31:619 -625

<div style=\"page-break-after: always\"></div>

Table 28 Statistical comparison of key pharmacokinetic parameters - Part 1 (pharmacokinetic analysis set)

|                   |                      |          |                   |                                  | Comparison of treatment groups   | Comparison of treatment groups   |
|-------------------|----------------------|----------|-------------------|----------------------------------|----------------------------------|----------------------------------|
| Parameter a       | Treatment Comparison | n        | Geometric LS mean | 95% CI                           | GMR                              | GMR90% CI                        |
| Cmax (ng/mL)      | B versus A           | 22 vs 22 | 757.1 vs 614.0    | (671.1, 854.1) vs (544.4, 692.6) | 1.233                            | (1.078, 1.410)                   |
| Cmax (ng/mL)      | C versus A           | 21 vs 22 | 449.7 vs 614.0    | (397.6, 508.5) vs (544.4, 692.6) | 0.7323                           | (0.6393, 0.8389)                 |
| AUCinf (h*ng/mL)  | B versus A           | 22 vs 22 | 4341 vs 3282      | (3932, 4793) vs (2973, 3623)     | 1.323                            | (1.223, 1.431)                   |
| AUCinf (h*ng/mL)  | C versus A           | 21 vs 22 | 3078 vs 3282      | (2784, 3402) vs (2973, 3623)     | 0.9378                           | (0.8658, 1.016)                  |
| AUClast (h*ng/mL) | B versus A           | 22 vs 22 | 4250 vs 3203      | (3851, 4689) vs (2903, 3534)     | 1.327                            | (1.226, 1.436)                   |
| AUClast (h*ng/mL) | C versus A           | 21 vs 22 | 2984 vs 3203      | (2701, 3297) vs (2903, 3534)     | 0.9316                           | (0.8597, 1.010 )                 |

a For definitions of pharmacokinetic parameters see Section 4.

CI Confidence interval; GMR Geometric mean ratio; LS Least-squares; n Number of subjects in analysis.

Treatment A: Single oral dose of 400 mg capivasertib, fasted state (reference treatment).

Treatment B: Single oral dose of 400 mg capivasertib, fed state (after a high-fat, high-calorie meal).

Treatment C: Twice daily oral doses of 20 mg rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 + a single oral dose of 400 mg capivasertib under fasted conditions on Day 1.

Result based on a mixed effects model of log transformed PK parameter with treatment, sequence, period as fixed effects  and  subject  within  sequence  as  random  effect.  Geometric  LS  mean  and  corresponding  95%  CI  are back -transformed. Geometric mean ratio and corresponding CI are back-transformed. Treatment comparison B vs A and C vs A refers to Treatment A as the reference and thus the GMR refers to the ratio B/A and C/A respectively.

## Interaction of capivasertib and fulvestrant (capivasertib=victim or perpetrator)

In a publication by Jones et al. 4  cited by the applicant, a comparison of trough fulvestrant concentrations between the capivasertib + fulvestrant arm and the placebo + fulvestrant arm in the FAKTION study in patients  with  advanced  HR+/HER2-  breast  cancer  showed  no  relevant  effect  of  capivasertib  on  the plasma levels of fulvestrant.

4 R H Jones et al.; Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial; Vol Lancet Onco logy 2020:21:345-357

<div style=\"page-break-after: always\"></div>

Table 29 FAKTION: PK analysis of mean minimum fulvestrant concentration

|           |       | Placebo                          | Placebo    | Placebo   | Placebo   | Placebo        | Capivasertib   | Capivasertib                 | Capivasertib                 | Capivasertib   |
|-----------|-------|----------------------------------|------------|-----------|-----------|----------------|----------------|------------------------------|------------------------------|----------------|
| Cycle Day | and   | Geometric mean Cmin 95% CI Cmin) | (Geometric | mean n    |           | Geometric Cmin |                | 95% CI (Geometric mean Cmin) | 95% CI (Geometric mean Cmin) | n              |
| C1 D15    | 9.64  | 8.87                             | 10.46      |           | 60        | 9.47           |                | 8.54                         | 10.49                        | 56             |
| C2 D1     | 13.26 | 12.08                            | 14.48      |           | 57        | 14.57          |                | 13.34                        | 15.92                        | 56             |
| C3 D1     | 10.34 | 9.60                             | 11.13      |           | 48        | 10.46          |                | 9.63                         | 11.36                        | 46             |

Source: Table 5 of Jones et al 2020 (supplementary information) taken from the submitted CS 2.7.2

In the FTIH study (D3610C00001), no effect of fulvestrant on the plasma levels of capivasertib was observed (Parts E and F). Plasma levels of capivasertib following the administration of capivasertib + fulvestrant were similar to those after administration of capivasertib monotherapy.

Table  30 FTIH  Study  (D3610C00001):  Dose-normalised  (to  400  mg)  capivasertib  plasma concentrations in patients with (parts E and F) and without (parts C and D) concomitant fulvestrant

| Concentration (ng/mL)   | Pre-dose   | Pre-dose   | 2 hours   | 2 hours    | 4 hours   | 4 hours   |
|-------------------------|------------|------------|-----------|------------|-----------|-----------|
| Study parts a           | C and D b  | E and F c  | C and D b | E and F c  | C and D b | E and F c |
| N                       | 103        | 59         | 100       | 56         | 100       | 55        |
| Geometric mean          | 272        | 249        | 1085      | 1270       | 773       | 835       |
| 95% CI                  | 238, 309   | 207, 301   | 942, 1250 | 1119, 1441 | 678, 883  | 732, 952  |

a FTIH Study (D3610C00001) Visit 5 (Day 11).

b Parts C and D: capivasertib 480 mg without concomitant fulvestrant.

c Parts E and F: capivasertib 400 mg with concomitant fulvestrant.

In the population PK analysis, in patients treated with concomitant fulvestrant, the ratios for AUCss and Cmax,ss were 1.05 (95% CI: 1.01, 1.09) and 1.06 (95% CI: 1.02, 1.10) compared to patients who did not receive concomitant fulvestrant. These results indicate that fulvestrant has no relevant impact on the PK of capivasertib.

A PBPK model for capivasertib was developed based on internally generated physicochemical data and the clinical studies of capivasertib alone after single dose oral or intravenous administration in healthy subjects (food/PPI study (D3614C00005) and ADME study (D3614C00007)) and/or cancer patients (FTIH study (D3610C00001)). The CYP3A4 Km and Vmax of capivasertib were optimised using the clinical PK data of capivasertib after single dose of 80, 400, and 800 mg oral administration in cancer patients in the  FTIH  study  (D3610C00001)  and  renal  excretion  data  in  healthy  subjects  in  the  ADME  study (D3614C00007). Also, the kinact for CYP3A4 time-dependent inhibition of capivasertib was optimised to match with the observed clinical DDI between midazolam and capivasertib in the midazolam DDI study (D3614C00003). The advanced dissolution, absorption and metabolism (ADAM) model, which describes the  drug  absorption  from  each  gut  segment  as  a  function  of  dissolution,  precipitation,  luminal degradation, permeability, metabolism, transport, and transit from one segment to another, was utilised to  describe  capivasertib  oral  absorption.  A full  PBPK  model  assuming all  tissues/organs  as perfusion limited compartments was applied.

<div style=\"page-break-after: always\"></div>

Figure 5 Modelling workflow overview

<!-- image -->

ADMEAbsorption,metabolism,distribution,andexcretion;CLutIntrinsicclearance;CLivIntravenousclearance;DDI Drug-druginteraction;fFraction ofrenal excretion;KmMichaelisconstant;VmaxMaximumrateofmetabolism.

According to the applicant, the developed model was validated using the clinical studies of capivasertib alone after single or multiple dose administration in cancer patients in the FTIH study (D3610C00001) or  in  healthy  subjects  in  the  food/PPI  study  (D3614C00005)  and  ADME  study  (D3614C00007).  The itraconazole DDI study (D3614C00004) was used to validate the fraction of metabolism by CYP3A4. In addition, the model was validated with a study in which capivasertib was combined with a strong CYP3A4 inducer, enzalutamide (Kolinsky et al 2020), to confirm capivasertib's drug interaction potential as a CYP3A4 substrate.  Finally,  the  validated  PBPK  model  was  applied  to  predict  the  potential  impact  of coadministration of capivasertib at intermittent dosing schedule with other CYP3A4  inhibitors (erythromycin,  verapamil,  and  cimetidine),  CYP3A4  inducer  (rifampicin),  sensitive  CYP2D6  substrate (desipramine), UGT1A1 substrate (raltegravir), and transporter substrates (atorvastatin (for OATP1B1), rosuvastatin (for OATP1B1 and OATP1B3 and BCRP), and metformin (for MATE1 and OCT2)).

## Pharmacokinetics using human biomaterials

Metabolic profiling in plasma and urine of patients and reaction phenotyping

Study DMPKTrax\\_079 quantified metabolites of capivasertib in human plasma using NMR spectroscopy and characterised capivasertib metabolites in plasma and urine with UHPLC-UV-MS. The samples used were  from  the  first-in-human  multiple-ascending-dose  (MAD)  study  D3610C00001.  NMR  analysis detected  two  plasma  metabolites,  ether  glucuronide  M2  present  at  82.7%  of  total  parent-related material, and a minor metabolite (+ 3[O], M1) at 1.9% of total parent-related material. The only other quantifiable  substance  was  capivasertib  itself,  present  at  15.4%  of  total  circulating  parent-related material.  The  complementary  UHPLC-UV  data  were  in  line  with  these  findings  showing  the  two metabolites (M2, M1) and capivasertib present at 78.0, 1.2 and 17.0% of total parent-related material, respectively.

Study  BE002560-11 used the original  LC-UV-MS  data  from  study  DMPKTrax\\_079  to  reveal  that  the quantity of M2 (ether glucuronide metabolite of capivasertib) in human urine was 4.9-fold higher than the parent compound (83 vs. 17%, respectively).

<div style=\"page-break-after: always\"></div>

## Interplay of transport and metabolism in human hepatocytes

In  vitro concentration-time  profiles  of  capivasertib  in  absence  and  presence  of  rifamycin  SV  (OATP inhibitor) and 1-aminobenzotriazole (broad range CYP inhibitor) were analysed in study BE000901-57. The  results  showed  that  the  contribution  of  active  transport  comprises  45%  of  the  total  uptake  of capivasertib in human hepatocytes in vitro . In this system, the unbound intracellular concentration of the compound was 1.8-fold higher compared to that in the extracellular medium.

Potential for drug interactions: in vitro studies with metabolic enzymes

In vitro studies assessing possible relevance of CYP (cytochrome P450) and UGT (UDPglucuronosyltransferase)  enzymes  for  drug  interactions  of  capivasertib  are  summarised  in  the  table below. Studies for the ether glucuronide AZ14102143 are summarised in the table thereafter.

Table  31 Overview of in vitro  studies  assessing  relevance  of  metabolic  enzymes  for  drug interactions of capivasertib

| Study nr.           | Capivasertib:   | Study system                                           | Enzymes Receptors   | / Results /                                                                   | Implications                       |
|---------------------|-----------------|--------------------------------------------------------|---------------------|-------------------------------------------------------------------------------|------------------------------------|
| AZM100108- 02       | activator       | PXR- transfectedHe pG2 cells                           | PXR                 | unbound IC 50 or K i 50 µ M: no activation                                    | -                                  |
| 301078331 (KMX018)  | inducer         | human hepatocytes NB: 64-86% viability at 5 and 15 µ M | CYP1A2              | ↑ mRNA not dose-dep. <2× at 15×C max,u ↑ activity dose-dep. <2× at 15×C max,u | in vivo relevance unlikely*        |
| 301078331 (KMX018)  | inducer         | human hepatocytes NB: 64-86% viability at 5 and 15 µ M | CYP2B6              | ↓ activity dose-dep. only in 1/3 donors                                       | in vivo relevance unlikely*        |
| 301078331 (KMX018)  | inducer         | human hepatocytes NB: 64-86% viability at 5 and 15 µ M | CYP3A4              | ↑ mRNA dose-dep. >2× at 15×C max,u                                            | in vivo relevance likely*          |
| ONC5363- 0001PK_CYP | inducer         | human hepatocytes RIS-qualified donor                  | CYP3A4              | ↑ mRNA dose-dep. RIS = 0.349 R 3 = 0.274                                      | in vivo relevance likely**         |
| BS001265-62         | inhibitor       | human liver microsomes                                 | UGT1A1              | IC 50 = 84.9 µ M                                                              | in vivo study warranted ***        |
| BS001265-62         | inhibitor       | human liver microsomes                                 | UGT2B7              | IC 50 > 300 µ M                                                               | no in vivo study needed ***        |
| BS001705-69         | inhibitor       | human liver microsomes                                 | UGT1A9              | 1 mM: no inhibition                                                           | no in vivo study needed ***        |
| BS003400-56         | inhibitor       | human liver microsomes                                 | UGT1A4              | 300 µ M: 45.5% inhibition (IC 50 300 µ Massumed)                              | clinical DDI cannot be excluded*** |
| KMX009              |                 |                                                        | CYP1A2              | 50 µ M: no inhibition                                                         | further studies needed             |
| KMX009              |                 |                                                        | CYP2A6              | 50 µ M: no inhibition                                                         | further studies needed             |
| KMX009              |                 |                                                        | CYP2B6              | 50 µ M: 58.4% inhibition                                                      | further studies needed             |
| KMX009              | inhibitor       | human liver                                            | CYP2C8              | 50 µ M: no inhibition                                                         | further studies needed             |
| KMX009              |                 | microsomes                                             | CYP2C9              | IC 50 > 16.7 µ M                                                              | further studies needed             |
| KMX009              |                 |                                                        | CYP2C19             | 50 µ M: 67.0% inhibition                                                      | further studies needed             |
| KMX009              |                 |                                                        | CYP2E1              | 50 µ M: no inhibition                                                         | further studies needed             |
| KMX009              |                 |                                                        | CYP2D6              | K i = 2.7 µ M                                                                 | in vivo study warranted ***        |
| KMX009              |                 |                                                        | CYP3A4/5            | IC 50 > 16.7 µ M TDI                                                          | further studies needed             |
| BS001265-84         |                 | human liver                                            | CYP2A6              | 150 µ M: no inhibition                                                        | no in vivo study needed ***        |
| BS001265-84         |                 | human liver                                            | CYP2B6              | IC 50 = 134 µ M                                                               | no in vivo study needed ***        |
| BS001265-84         | inhibitor       | human liver                                            | CYP2C8              | IC 50 > 150 µ M                                                               | no in vivo study needed ***        |
| BS001265-84         |                 | microsomes                                             | CYP2E1              | IC 50 > 150 µ M                                                               | no in vivo study needed ***        |
|                     |                 |                                                        | (nifedipine)        |                                                                               |                                    |
| BS001265-85         | inhibitor       | human liver microsomes                                 | CYP1A2              | 150 µ M: no inhibition                                                        | no in vivo study needed ***        |
| BS001265-85         | inhibitor       | human liver microsomes                                 | CYP2C9              | IC 50 = 75.7 µ M                                                              | clinical DDI cannot be excluded*** |
| BS001265-85         | inhibitor       | human liver microsomes                                 | CYP2C19             | IC 50 ∼ 119-125 µ M                                                           | no in vivo study needed ***        |
| BS001265-85         |                 |                                                        | CYP2D6              | IC 50 = 15.2 µ M                                                              |                                    |

<div style=\"page-break-after: always\"></div>

|        |                |                        | CYP3A4/5 (midazolam)   | IC 50 = 54.7 µ M               | in vivo study warranted ***   |
|--------|----------------|------------------------|------------------------|--------------------------------|-------------------------------|
| KMX004 | inhibitor, TDI | human liver microsomes | CYP3A4/5               | k inact = 0.040 1/min 10.5 µ M | time-dependent inhibitor      |
| KMX014 | inhibitor, TDI | human hepatocytes      | CYP3A4/5               | k inact = 0.027 1/min 24 µ M   | time-dependent inhibitor      |

Need for in vivo study as estimated by the assessor according to the EMA guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2**) and draft ICH M12 guideline on drug interactions:

in vivo evaluation is warranted if

* at least in one donor a drug increases mRNA expression of a CYP enzyme in a concentration-dependent manner and the foldchange of CYP mRNA expression is ≥ 2 -fold at 15×Cmax,u,

** RIS / R &lt; 0.8,

***[I]/Ki ≥ 0.02 where [I] is the unbound mean Cmax obtained during treatment with the highest recommended dose ([I] = 0.717 µM), for intestinal enzymes [I]/Ki ≥ 10 where [I] is max. dose taken one occasion/ 250 ml, Ki is estimated as IC50/2

Table  32  Overview  of  in  vitro  studies  assessing  relevance  of  metabolic  enzymes  for  drug interactions of AZ14102143

| Study nr.    | AZ14102143:   | Study system           | Enzymes Receptors     | / Results / or K i                            | IC 50                                                | Implications                      |
|--------------|---------------|------------------------|-----------------------|-----------------------------------------------|------------------------------------------------------|-----------------------------------|
| BS001884- 52 | inhibitor     | human liver microsomes | CYP2A6                | 300 µ M: 10.2% inhibition                     | inconclusive*                                        |                                   |
| BS001884- 52 | inhibitor     | human liver microsomes | CYP2B6                | 300 µ M: 18.2% inhibition                     | inconclusive*                                        |                                   |
| BS001884- 52 | inhibitor     | human liver microsomes | CYP2C8                | 300 µ M: no inhibition                        | inconclusive*                                        |                                   |
| BS001884- 52 | inhibitor     | human liver microsomes | CYP2E1                | 300 µ M: 11.4% inhibition                     | inconclusive*                                        |                                   |
| BS001884- 52 | inhibitor     | human liver microsomes | CYP3A4/5 (nifedipine) | 300 µ M: no inhibition                        | inconclusive*                                        |                                   |
| BS001884- 58 | inhibitor     | human liver microsomes | CYP1A2                | 300 µ M: 22% inhibition                       | inconclusive*                                        |                                   |
| BS001884- 58 | inhibitor     | human liver microsomes | CYP2C9                | 300 µ M: no inhibition                        | inconclusive*                                        |                                   |
| BS001884- 58 | inhibitor     | human liver microsomes | CYP2C19               | 300 µ M: 13.1% inhibition                     | inconclusive*                                        |                                   |
| BS001884- 58 | inhibitor     | human liver microsomes | CYP2D6                | 300 µ M: 9.13% inhibition                     | inconclusive*                                        |                                   |
| BS001884- 58 | inhibitor     | human liver microsomes | CYP3A4/5 (midazolam)  | 300 µ M: no inhibition                        | inconclusive*                                        |                                   |
| BS004445- 50 | inhibitor     | human liver microsomes | UGT1A1                | IC 50 = 843 µ M                               | no in vivo needed *                                  | study                             |
| BS004445- 50 | inhibitor     | human liver microsomes | UGT2B7                | 1 mM: no inhibition                           | no in vivo needed *                                  | study                             |
| BS004445- 51 | inhibitor     | human liver microsomes | CYP1A2                | IC 50 = 898 µ M                               | no in vivo needed *                                  | study                             |
| BS004445- 51 | inhibitor     | human liver microsomes | CYP2C9                | 1 mM: no inhibition                           | no in vivo needed *                                  | study                             |
| BS004445- 51 | inhibitor     | human liver microsomes | CYP2C19               | 1 mM: 19.2% inhibition                        | no in vivo needed *                                  | study                             |
| BS004445- 51 | inhibitor     | human liver microsomes | CYP2D6                | 1 mM: 35.3% inhibition                        | no in vivo needed *                                  | study                             |
| BS004445- 51 | inhibitor     | human liver microsomes | CYP3A4                | 1 mM: 23.9% inhibition                        | no in vivo needed *                                  | study                             |
| BS004445- 52 | inhibitor     | human liver microsomes | CYP2A6 CYP2B6         | 1 mM: 12.1% inhibition 1 mM: 49.5% inhibition | no in vivo needed *                                  | study                             |
| BS004445- 52 | inhibitor     | human liver microsomes | CYP2C8                | 1 mM: 19.1% inhibition                        | no in vivo needed *                                  | study                             |
| BS004445- 52 | inhibitor     | human liver microsomes | CYP2E1                | IC 50 = 193 µ M                               | in vivo warranted needed lack of relevant substrates | study * but not due to clinically |

CYP3A4

1 mM: 31.6% inhibition

*Need for in vivo study as estimated by the assessor according to the EMA guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2**) and draft ICH M12 guideline on drug interactions: in vivo evaluation is warranted if

[I]/Ki ≥ 0.02 where [I] is the unbound mean C max obtained during treatment with the highest recommended dose ([I] = 18.54 × 0.368 = 6.82 µ M)

Potential for drug interactions: in vitro studies with transporters

In vitro studies assessing possible relevance of transport proteins for drug interactions of capivasertib are summarised in the table below. The results for the metabolite AZ14102143 are presented in the table thereafter.

<div style=\"page-break-after: always\"></div>

Table 33 Overview of in vitro studies assessing relevance of transporters for drug interactions of capivasertib

| Study nr.    | Capivasertib:   | Study system                             | Transporters   | Results / unbound IC 50 or K i                         | Implications                |
|--------------|-----------------|------------------------------------------|----------------|--------------------------------------------------------|-----------------------------|
| 19AZTrP7     | substrate       | HEK293 cells overexpressing transporters | OATP1B1        | efflux ratio OATP1B cells vs. ctrl < 2 =with inhibitor | not a transporter substrate |
| 19AZTrP7     | substrate       | HEK293 cells overexpressing transporters | OATP1B3        | efflux ratio OATP1B cells vs. ctrl < 2 =with inhibitor | not a transporter substrate |
| BE000458- 19 | inhibitor       | Caco-2 cells                             | BCRP           | IC 50 = 100.1 µ M                                      | in vivo study warranted *   |
| Pgp_inhib    | inhibitor       | MDCKII-MDR1 cells                        | P-gp           | no inhibition up to 300 µ M                            | no in vivo study needed *   |
| 05102012     | inhibitor       | HEK293 cells overexpressing OATP1B1      | OATP1B1        | IC 50 = 15 µ M                                         | in vivo study warranted *   |
| 16AZTrP3     | substrate       | MDCK cells overexpressing transporters   | P-gp           | efflux ratio MDR1 cells vs. ctrl > 2 ↓ with inhibitor  | transporter substrate       |
| 16AZTrP3     | substrate       | MDCK cells overexpressing transporters   | BCRP           | efflux ratio BCRP cells vs. ctrl < 2 =with inhibitor   | not a transporter substrate |
| 16AZTrP3     |                 |                                          | MATE1          | IC 50 = 1.79 µ M                                       | in vivo study warranted *   |
| 16AZTrP3     | inhibitor       | HEK293 cells overexpressing transporters | MATE2-K        | IC 50 = 14.0 µ M                                       | in vivo study warranted *   |
| 16AZTrP3     | inhibitor       | HEK293 cells overexpressing transporters | OATP1B3        | IC 50 = 25.2 µ M                                       | in vivo study warranted *   |
| 16AZTrP3     | inhibitor       | HEK293 cells overexpressing transporters | OAT1           | 13.9% inhibition at 100 µ M                            | no in vivo study *          |
| 16AZTrP3     | inhibitor       | HEK293 cells overexpressing transporters | OAT3           | ↑ uptake at <10 µ M IC 50 ∼ 28 µ M                     | needed                      |
|              | inhibitor       | HEK293 cells overexpressing OCT2         | OCT2           | IC 50 = 1.34 µ M                                       | in vivo study warranted *   |
| KMN025       | substrate       | HEK293 cells overexpressing OCT2         | OCT2           | uptake ratio OCT2 cells vs. ctrl < 2 + inhibitor ↓ 22% | minor OCT2- mediated uptake |

study as estimated by the assessor according to the ICH M12 draft guideline on drug interactions:

** need for in vivo in vivo evaluation is warranted if Ki ≤

- for BCRP and P-gp: 0.1-fold the maximum dose on one occasion/250 ml

-  for OATP1B1 and OATP1B3: 10-fold the unbound hepatic inlet concentration (9.888 µ M)
-  for OCT2, OAT1 and OAT3: 10-fold unbound Cmax (0.717 µ M)

-  for MATE1 and MATE2-K: 50-fold unbound Cmax (0.717 µ M)

<div style=\"page-break-after: always\"></div>

Table 34 Overview of in vitro studies assessing relevance of transporters for drug interactions of AZ14102143.

| Study nr.   | AZ14102143:   | Study system                        | Transporters   | Results / unbound IC 50 or K i   | Implications                |
|-------------|---------------|-------------------------------------|----------------|----------------------------------|-----------------------------|
| BS001884-49 | inhibitor     | MDCKII-MDR1 cells                   | P-gp           | no inhibition up to 300 µ M      | no in vivo study needed *   |
| BS001884-49 | inhibitor     | Caco-2 cells                        | BCRP           | no inhibition up to 300 µ M      | no in vivo study needed *   |
| BS001884-51 | inhibitor     | HEK293 cells overexpressing OATP1B1 | OATP1B1        | IC 50 = 65.8 µ M                 | in vivo study warranted *   |
| BS004445-53 | inhibitor     | MDCKII-MDR1 cells                   | P-gp           | 20% inhibition at mM             | 1 no in vivo study needed * |
| BS004445-54 | inhibitor     | Caco-2 cells                        | BCRP           | IC 50 = 613 µ M IC 50 K i        | ≈ no in vivo study needed * |

* need for in vivo study as estimated by the assessor according to the ICH M12 draft guideline on drug interactions: in vivo evaluation is warranted if Ki ≤

- for BCRP and P-gp: 0.1-fold the maximum dose on one occasion/250 ml

-  for OATP1B1: 10-fold the unbound hepatic inlet concentration (6.845 µ M)

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Capivasertib is a potent, selective inhibitor of the kinase activity of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3). AKT is a pivotal node in the phosphatidylinositol 3-kinase (PI3K) signalling  cascade  regulating  multiple  cellular  processes  including  cellular  survival,  proliferation,  cell cycle,  metabolism,  gene  transcription  and  cell  migration.  AKT  activation  in  tumours  is  a  result  of upstream activation from other signalling pathways, mutations of AKT, loss of phosphatase and tensin homolog (PTEN) function and mutations in the catalytic subunit of PI3K (PIK3CA).

Capivasertib  inhibits  the  phosphorylation  of  AKT  substrates  such  as  glycogen  synthase  kinase  3β (GSK3β) and proline rich AKT substrate of 40 kilodaltons (PRAS40). Capivasertib reduces growth of a range of cell lines derived from solid tumours and haematological disease. Multiple breast cancer cell lines  were  sensitive  to  capivasertib  monotherapy.  Within  cell  lines  showing  greater  sensitivity  to capivasertib there was an enrichment of PIK3CA or AKT1 mutations, or loss of PTEN. Some cell lines lacking such mutations were also sensitive to capivasertib.

In vivo , monotherapy, capivasertib inhibits growth of human cancer xenograft models representative of different  tumour  types  including  ER+  and  triple  negative  breast  cancer  models  with  PIK3CA,  AKT1 mutations, PTEN loss and HER2 amplification, mutant xenograft models and triple negative breast cancer xenograft models. Combined treatment with capivasertib and fulvestrant demonstrated a greater antitumour response in a range of human breast cancer PDX models representative of different breast cancer subsets. This included models without detectable mutations or alterations in PIK3CA, PTEN or AKT, as well as models with mutations or alterations in PIK3CA, PTEN or AKT.

## Primary and secondary pharmacology

Primary Pharmacology

<div style=\"page-break-after: always\"></div>

## FTIH study D3610C00001

Optional paired biopsies were collected and analysed for phospho-proline-rich serine/threonine specific protein kinase (AKT) substrate of 40 kilo Daltons (pPRAS40), phospho-glycogen synthase kinase-3-beta (pGSK3β),  phospho -AKT  (pAKT),  phosphatidylethanolamine  bonding  protein  1  (pEBP1)  and  Foxo3a nuclear translocation.

## · Platelet rich plasma

## pGSK3β / pPRAS40

The mean percentage decrease from baseline in phosphorylation of PRAS40 ranged from 9% to 34%, one hour to12 hours after a single 80 mg to 800 mg dose of AZD5363. The maximal mean decrease of pPRAS40 at the Phase II RD (480 mg), was 33.9% four hours after a single dose of 480 mg AZD5363, and was 28.4% at steady state (C1D8, continuous dosing) and 31.0% at steady state (C4D1, intermittent dosing). The mean percentage decrease from baseline in phosphorylation of GSK3β ranged from 6% to 47%, four hours after a single 80 mg to 800 mg AZD5363. The maximal mean decrease of pGSK3β at the Phase II RD (480 mg) was 36.1% four hours after dosing a single dose of 480 mg AZD5363, and was 37.3% at steady state (C1D8, continuous dosing), and 23.9% at steady state (C4D1, intermittent dosing).  In  summary,  there  was  a  slight  trend  towards  reduced  pGSK3b  with  increasing  AZD5363 concentrations  observed,  as  was  a  slight  trend  towards  reduced  pPRAS40  with  increasing  AZD5363 concentrations.  Although  a  reduction  of  pGSK3β  and  pPRAS4 0  was  the  expected  response  to  the pharmacological  activity  of  AZD5363,  increased  phosphorylation  of  these  substrates  compared  to baseline  was  observed  at  some  time  points  at  all  doses.  These  increases  showed  no  consistent relationship with dose or time after dosing and was discussed to be most likely attributable to assay variability.

## pAKT

The  phosphorylation  status  of  AKT  Ser473  was  generally  increased  in  response  to  AZD5363.  The maximum mean percentage increase from baseline in pAKT occurred within the first 24 hours after a single dose, and the maximum mean increase in pAKT after a single 80 mg to 800 mg dose of AZD5363 was 185%. Generally, the mean percentage increase from baseline for pAKT at steady state was larger than that achieved after a single dose. However, there was a mean percentage decrease from baseline in pAKT after both single dose and at steady state in the 480 mg bd (continuous) cohort. Also, at 600 mg bd (continuous) and 640 mg bd intermittent 2 on/5 off doses, the mean percentage increase from baseline in pAKT was lower at steady state than that observed after a single dose. In summary, the expected  increase  in  pAKT  change  from  baseline  with  increasing  AZD5363  concentrations  was  not apparent in the platelet rich plasma data:

## · Plasma glucose levels

The PDc activity of AZD5363 was supported by the observed increase in plasma glucose levels, which can be attributed to the role of AKT in the physiological regulation of glucose transport and uptake.

In summary, it was concluded that PD data indicated AZD5363 exerting a biologically relevant effect both on target and downstream of the target at the recommended dose.

## Banerji et al. 2018

Combined data for paired tumour biopsies were collected from patients with advanced solid malignancies across a range of capivasertib doses and schedules following at least 7 days of treatment in the FTIH study (D3610C00001) and the Japanese safety/PK study (D3610C00004).

Data from these studies demonstrate inhibition of AKT after administration of capivasertib. Paired tumour biopsies from 12 patients with advanced solid malignancies (9 from the FTIH study [D3610C00001: Parts

<div style=\"page-break-after: always\"></div>

A  to  C]  and  3  from  the  Japanese  safety/PK  study  [D3610C00004])  receiving  a  range  of  doses  and schedules were evaluated to assess target engagement.

Changes in AKT pathway effectors, including pAKT, pPRAS40, pGSK3β and FOXO1/3a nuclear staining, were assessed using immunohistochemistry (IHC). Preclinical PK, PD and efficacy data were used to define  'proof  of  mechanism  (PoM)  thresholds'  for  modulation  in  phosphorylation  of  the  proximal biomarkers pPRAS40 and pGSK3β to provide confidence that on -target PoM was achieved: a greater than 50% inhibition in mean pPRAS40 or a greater than 30% inhibition in mean pGSK3β.

After treatment with capivasertib, downregulation of PD biomarkers was observed following at least 7 days of treatment. Greater than 50% inhibition of pPRAS40 was observed in 4 of 12 paired biopsies, with greater than 30% decrease in pGSK3β in 6 of 11 pair ed biopsies. Four of 11 samples met both endpoints, see figure below.

Figure 6 FTIH study (D3610C00001) part A and Japanese safety/PK study (D3610C00004): Effect on pGSK3 β and pPRAS40 H scores from paired tumour biopsies

<!-- image -->

Cont = Continuous; 4/7 = 4 days on, 3 days off; 2/7 = 2 days on, 5 days off. Percentage change is based on the average H score for individual biomarkers in baseline and on-treatment biopsies from 3 non-consecutive tissue sections. Each pair of bars represents data from an individual patient. X indicates missing data.

Tumour types:  1:  clear-cell  renal  carcinoma;  2:  colorectal  adenocarcinoma  (KRAS-mutant  colorectal  cancer);  3: hypopharyngeal cancer; 4: breast cancer; 5: mesothelioma; 6: mesothelioma; 7: colorectal adenocarcinoma; 8: medullary thyroid cancer; 9: liver metastasis from colorectal adenocarcinoma; 10: adenosquamous cervical carcinoma (PIK3CA  E545K  mutant  cervical  cancer;  patient  enrolled  in  Study  D3610C00001  Part  C),  11:  adenocarcinoma, intestinal type; 12: melanoma.

Source: Figure 3B from Banerji et al 2018; cited as figure 9 in the CS 2.7.2 pg. 55

In the 5 patients treated with the 'recommended phase 2 dose' (RP2D) and schedule (480 mg, 4 days on, 3 days off intermittent), there was an average decrease of 59% from baseline for pPRAS40, and 67% for pGSK3β.  The magnitudes of these decreases were cons istent with the PD responses required for preclinical efficacy and target inhibition with 480 mg BD 4 days on, 3 days off was stronger than with the 320 mg BD continuous dose.

Treatment with capivasertib also increased pAKT (consistent with ATP competitive mechanism of action), inhibited phosphorylation of 4EBP1, and resulted in an increase of FOXO nuclear translocation.

<div style=\"page-break-after: always\"></div>

## Robertson et al. 2020: STAKT

STAKT ('Short Term Effects of an AKT Inhibitor [AZD5363] on Biomarkers of the AKT Pathway and Antitumour Activity in a Breast Cancer Paired Biopsy') was a 2-stage, double-blind, randomised, placebocontrolled, 'window-of-opportunity' (pre-surgical paired biopsy) study in patients with newly diagnosed ER+ invasive breast cancer 5 .

The primary objective was to compare the AKT pathway biomarker and anti-proliferative effect of 4.5 days' treatment with 3 dose levels of capivasertib monotherapy. Patients were randomised (1:1) in Stage 1 to either capivasertib 480 mg BD or placebo, and in Stage 2 to capivasertib 360 mg BD or 240 mg BD.

Tumour core biopsies were taken prior to the first dose and after 4.5 days of dosing (within 12 hours after the last dose), and levels of pPRAS40, pGSK3 β, and Ki67 were measured using immunohistochemistry (IHC).

Treatment with capivasertib monotherapy at 480 mg BD for 4.5 days led to significant decreases from baseline in the H-score for the primary biomarkers, pPRAS40 and pGSK3 β, compared to placebo.

As outlined in the methods part of the study, the H-score was calculated as the sum (% weak [1+]) + (% moderate [2+] x 2) + (% strong [3+] x 3), of staining localised in the cytoplasm and/or nucleus. Ki67 was evaluated by percentage nuclear positivity only.

A decrease of -39.0% (p = 0.006) for pGSK3 β and -50.2% (p &lt; 0.0001) for pPRAS40 (n = 17 samples for both) was observed.

Capivasertib treatment induced a reduction in cell proliferation as measured by Ki67 staining (-23.4%, p = 0.052).

Significant changes also occurred in secondary signalling biomarker pS6 (-30.0%, p = 0.003), while pAKT and nuclear  FOXO3a  increased  in  accordance  with  capivasertib's  mechanism  of  action  (pAKT: 117%, p = 0.011; FOXO3a nuclear: 844%, p = 0.018).

For the lower doses of capivasertib studied (360 mg BD and 240 mg BD), reductions in absolute and percentage  pPRAS40  and  pGSK3 β were  also  observed,  which  were  smaller  in  magnitude  than  the changes observed at 480 mg BD; although the number of samples analy sed was small (n = 5 and n = 6, respectively).

According to Robertson et al. 2020, biomarker modulation was dose and concentration dependent. The dose-response relationship for percentage change from baseline could be described by a nonlinear (Emax) model for all primary biomarkers in the figure below.

Similar correlations were observed for the change in the biomarkers and PK exposure (Cmax on day 1 or concentration at the time of biopsy on day 5).

5 John F.R. Robertson et al.; Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363)

Treatment of Patients with ERþ Invasive Breast Cancer (STAKT); Clin Cancer Res 2020;26:1574 -85

<div style=\"page-break-after: always\"></div>

Figure 7 STAKT:  Observed  and  Model-predicted Doseand Concentrationresponse Relationships  for  (A)  pGSK3 β,  ( B)  pPRAS40,  and  (C)  Ki67  as  Percentage  Change  From Baseline

A

<!-- image -->

## Secondary Pharmacology

## Cardiac Electrophysiology

Based  on  an  exposure-response  analysis  of  centrally  evaluated  digital  ECG  data  for  patients  with advanced solid malignancies who received capivasertib doses from 80 to 800 mg, the predicted mean QTcF prolongation was 3.87 ms (90% CI: 2.77, 4.97) at the mean steady state Cmax following 400 mg BD. See exposure/response analysis below.

## Hyperglycaemia

Hyperglycaemia is an on-target adverse effect of inhibition of the PI3K/AKT/PTEN signalling pathway. Rash

<div style=\"page-break-after: always\"></div>

Rash was also discussed to be an adverse effect related to the inhibition of PI3K/AKT/PTEN signalling pathway.

## Exposure-response analyses of efficacy following combination treatment with capivasertib + fulvestrant

To explore the relationship between capivasertib exposure parameters and the efficacy endpoints, PFS, ORR  and  OS,  in  patients  with  locally  advanced  or  metastatic  HR+/HER2-breast  cancer  following recurrence  or  progression  on  or  after  treatment  with  an  AI  who  were  treated  with  capivasertib  + fulvestrant, exposure-response analyses of efficacy were performed using data for patients treated with capivasertib + fulvestrant in the pivotal CAPItello-291 study.

In  the  CAPItello-291  study,  the  PFS  Kaplan-Meier  curves  for  the  Overall  Population  and  the  Altered Population showed no statistically significant differences between the quartiles of the exposure metrics (using the Benjamini-Hochberg method) at the dose level of 400 mg BD [4 days treatment/3 days off].

Cox proportional hazards models were developed and a stepwise covariate performed on the capivasertib arm in the Overall Population and the Altered Population. Capivasertib exposure was not a significant predictor of PFS at the dose level of 400 mg BD [4/3].

Exposure-response relationships between the exposure metrics and ORR did not show any statistically significant differences for the exposure metrics as quartiles or continuous, or for any covariate, in the Overall Population or in the Altered Population at the dose level of 400 mg BD [4/3].

It was concluded that there was no relationship between capivasertib PK exposure at the range observed from the dose and regimen that was studied in CAPItello-291 (400 mg BD [4/3]) and PFS or ORR in the Overall Population and the Altered Population.

## Exposure-response analysis of safety following capivasertib monotherapy

Pooled pharmacokinetic and safety data from 277 patients who participated in three Phase I trials: First time in human (FTIH) (D3610C00001), Japanese safety/PK study (D3610C00004) and Formulation/food study (OAK, D3610C00007) were evaluated.

Patients received doses of 80 to 800 mg twice daily (BD), either with a continuous (daily) schedule, or with one of two intermittent schedules; 4 days on/3 days off ([4/3]) or 2 days on/5 days off ([2/5]).

The objectives of this analysis were to explore the relationship between exposure to capivasertib and incidence of AE leading to dose discontinuation, AE leading to dose modification (interruption and/or reduction), serious adverse event (SAE), AE grade ≥ 3, AE grade ≥ 1, diarrhoea AE grade ≥ 2, rash AE grade ≥ 2, hyperglycaemia AE grade ≥ 3 and increased blood glucose &gt; 13.9 mmol/L in patients with solid tumours who were administered capivasertib as monotherapy.

Significant relationships were identified between the weekly dose (PWD) and/or weekly AUC (AUCPWD) and all  safety  endpoints  evaluated,  except  for  AEs  of  any  grade  which  were  observed  in  almost  all patients.

## Exposure-response analysis of safety following combination treatment with capivasertib + fulvestrant

Exposure-response  analyses  of  safety  were  performed  using  data  from  414  patients  treated  with capivasertib (400 mg BD 4 days on, 3 days off) + fulvestrant (500 mg IM on Days 1, 15 and 29 and once monthly thereafter) from the FTIH study (D3610C00001: 74 patients) and the CAPItello-291 study (340 patients).

The provided report concluded that based on the pooled data, the exposure-safety modelling predicted no  clinically  relevant  relationship  between  capivasertib  PK  exposure  and  the  investigated  safety endpoints over the range of exposure observed in CAPItello-291 and these analyses do not indicate a need for a priori dose adjustments in any subgroup of patients.

<div style=\"page-break-after: always\"></div>

Exposure-response analysis to evaluate QT/QTc interval prolongation for capivasertib

An  exposure-response  analysis  of  baseline-adjusted  QTc  interval  was  performed  in  patients  with advanced or metastatic solid malignancies enrolled in the FTIH study (D3610C00001) (Parts A, B, C and D). Of 208 patients, 22 patients with no time-matched QT-PK measurements and 6 patients with no single dose data were excluded. As a result, in total, 503 measurements from 180 individuals, collected following single capivasertib administration of 80 to 800 mg, were used for the analysis.

Table 35 Predictions based on a prespecified concentration-QTcF model

| Dose regimen                    |   Cmax (ng/mL) |   Mean △QTcF (ms) |   Lower limit of △QTcF ID %06 (ms) |   Upper limit of △QTcF 90% CI, (ms) |
|---------------------------------|----------------|-------------------|------------------------------------|-------------------------------------|
| Continuous, 80 mg BD            |            172 |              0.34 |                              -0.64 |                                1.32 |
| Continuous, 160 mg BD           |            653 |              1.95 |                               1.04 |                                2.87 |
| Continuous, 240 mg BD           |            666 |              2    |                               1.08 |                                2.91 |
| Continuous, 320 mg BD           |            982 |              3.06 |                               2.07 |                                4.05 |
| Continuous, 400 mg BD           |           1223 |              3.87 |                               2.77 |                                4.97 |
| Continuous, 480 mg BD           |           2030 |              6.58 |                               4.92 |                                8.24 |
| Continuous, 600 mg BD           |           2936 |              9.62 |                               7.2  |                               12.04 |
| 4 days on/3 days off, 480 mg BD |           1426 |              4.55 |                               3.33 |                                5.77 |
| 4 days on/3 days off, 640 mg BD |           2721 |              8.9  |                               6.66 |                               11.13 |
| 2 days on/5 days off, 640 mg BD |           2484 |              8.1  |                               6.07 |                               10.14 |
| 2 days on/5 days off, 800 mg BD |           3856 |             12.71 |                               9.46 |                               15.95 |

1: Geometric mean of observed Cmax on day 8, Day 4, and Day 2 for continuous, 4 days on/3 days off and 2 days on/5 days off schedules, respectively.

Source: Exposure-Response Analysis Report; Population C-QT/QTc relationship analysis, table 8; pg. 26

As outlined above, observed Cmax at 400 mg BD continuous dosing on Day 8 was selected as an estimate of  the  therapeutic  Css,max.  Based  on  the  model,  mean  QTcF  increased  with  increasing  Cmax.  The predicted mean QTcF change from baseline is 3.87 ms (90% CI 2.77 ms -4.97 ms) at the estimated steady state at day 8 of Cmax 1223 ng/mL at the therapeutic dose (400 mg b.i.d. continuous dosing).

## 2.6.3. Discussion on clinical pharmacology

## Pharmacokinetics

Capivasertib (AZD5636) has been studied in healthy subjects and in participants with advanced solid malignancies with oral doses ranging from 80 mg to 600 mg twice daily [BD] (up to 800 mg BD for intermittent schedule).

The basic PK of capivasertib has been characterised using non-compartmental analysis in the Phase I ADME study (D3614C00007) in healthy subjects, and in Part A and Part B of the Phase I FTIH study (D3610C00001) of single and multiple doses of capivasertib in patients with advanced solid malignancies.

The potential effect of intrinsic and extrinsic factors on capivasertib PK has been quantitatively assessed in  the  Japanese  safety/PK  study  (D3610C00004),  formulation/food  study  (D3610C00007),  food/PPI

<div style=\"page-break-after: always\"></div>

study (D3614C00005), itraconazole DDI study (D3614C00004), midazolam DDI study (D3614C00003),

RE-AKT (a study of capivasertib + enzalutamide in mCRPC), and using population PK analysis. Population PK parameters for capivasertib have been estimated based on population PK analysis of data from a pool of Phase I, II, and III studies of capivasertib monotherapy, capivasertib + fulvestrant, and capivasertib + paclitaxel in patients with advanced solid malignancies, including the pivotal phase III CAPItello-291 study. DDI predictions have been made using a PBPK model developed using both in vitro data and PK data from Phase I studies of capivasertib. During the course of the development program, three different immediate release formulations were used: a drug in capsule formulation used in Phase 1 clinical studies, a Phase 2 film-coated tablet and an optimised  film-coated  tablet  formulation  used  in  Phase  3  studies.  The  commercial  capivasertib  filmcoated tablets are qualitatively and quantitatively identical to the Phase 3 clinical film-coated tablets, but are differentiated through use of debossing. Bridging between the Phase 1 capsule and the Phase 2 film-coated  tablet  formulations  was  to  be  demonstrated  via  an in  viv o  relative  bioavailability  study (D3610C00007). Subsequent bridging between Phase 2 tablets and Phase 3 tablets was performed. Study D3610C00007 was performed with multiple dosings, which is acceptable for an application with an oncology indication, but adds another source of variability in the study. Of note, the results are also outside of the 0.8-1.25 acceptance range, therefore not completely in line with the Guideline on the investigation of bioequivalence (BE). Conclusion on BE from this study was regarded tenuous at best and during the evaluation the applicant was requested to justify the bridging of the formulation. The applicant pointed out to similar PK (not BE but not expected significant differences in PD) between Phase I, Phase II and Phase III formulations. The quality assessment was acknowledged to go in the same direction. The CHMP in the end concluded that no additional bridging between formulations will be required. Capivasertib has been assigned a BCS 4 classification (low solubility, low permeability) based on available solubility, permeability, and absolute bioavailability data which is considered acceptable. Pharmacokinetic data from study D3614C00007 (ADME) in healthy volunteers (n=5 completers) showed that capivasertib is readily absorbed following a single oral dose of 400 mg capivasertib tablets with median tmax for Capivasertib was 1.74 h post-dose. The geometric mean apparent terminal plasma halflife  for  capivasertib  was  12.9  h  and  the  absolute  bioavailability  of  Capivasertib  following  a  400  mg Capivasertib oral dose was 29%. In subjects with advanced solid malignancies in study D3610C00001 (FTIH), following single oral doses of capivasertib, median tmax values ranged from 1.00 to 2.17 hours. The apparent terminal half-life was approximately  10  hours  (range:  6.85  to  15.0  hours)  and  was  independent  of  dose.  Taking  into consideration the small cohort sizes and the data variability, the geometric mean Cmax and AUC data from patients that had received 80 mg, 160 mg, 240 mg, 320 mg, 400 mg, 480 mg, 600 mg, 640 mg, or 800 mg AZD5363 appeared to be generally dose-proportional. Following  multiple  bd  oral  doses,  the  plasma  concentration-time  profiles  measured  over  the  dosing interval, quantified from samples collected on Day 8 (continuous dosing), Day 4 (4 days on, 3 days off) and Day 2 (2 days on, 5 days off) of dosing, were generally consistent with the first 12 hours of the single dose profiles. The exposure (area under the plasma concentration-time curve from 0 hours to 12 hours) after multiple dosing was approximately 2 times the exposure reported after the first dose. The systemic exposure (AUC and Cmax) increased proportionally over the dose range of 80 to 800 mg range after single dose administration in patients. After multiple-dose administration of 80 to 600 mg twice daily, the AUC increased slightly more than dose proportional. Following intermittent dosing of capivasertib  400 mg  twice  daily,  4  days  on,  3  days  off,  the  capivasertib  steady-state  AUC  is

<div style=\"page-break-after: always\"></div>

8 069 h ng/mL (37%) and Cmax is 1 371 ng/mL (30%). Concentrations are predicted to be attained on the 3rd and 4th dosing day of each week, starting from week 2. During the off-dosing days, the plasma concentrations are low (approximately 0.5% to 15% of the steady state Cmax). Food  effects  were  investigated  in  studies  D3610C00007  and  D3614C00005.  The  results  of  study D3610C00007 indicate that food reduced the rate and/or amount of AZD5363 absorption from the tablet formulation (Phase II tablet) and that the extent of exposure is only modestly decreased after fed and fasted administrations of the tablet. In the cross-over  with the phase  III  formulation  study D3614C00005, the comparison of high-fat, high-calorie breakfast to partially fasted conditions in line with the pivotal study showed an overall similar exposure (AUCinf 90% CI 0.99-1.29). This is also true for the comparison of low-fat, low-calorie breakfast to partially fasted conditions (AUCinf 90% CI 0.881.05). The effect of a high-fat, high-calorie breakfast when compared to overnight fasting was modest (AUCinf  90%  CI  1.22-1.43).  When  capivasertib  was  administered  after  a  high-fat,  high-calorie  meal (approximately 1000 kcal), the fed to fasted ratio was 1.32 and 1.23, for AUC and Cmax, respectively, compared to when given after an overnight fast. When capivasertib was administered after a low-fat, low-calorie meal (approximately 400 kcal), the exposure was similar to that after fasted administration with fed to fasted ratios of 1.14 and 1.21, for AUC and Cmax, respectively. Co-administration with food did not result in clinically relevant changes to the exposure. Based  on  non-clinical  data,  capivasertib  is  not  extensively  bound  to  plasma  proteins  (percentage unbound 22.3%). The plasma to blood ratio was 0.714. The mean volume of distribution was 2.6 L/Kg after intravenous administration to healthy subjects. The results of mass balance study D3614C00007 indicate that faecal excretion is the major route of elimination,  while  urinary  excretion  is  the  minor  elimination  pathway.  An  average  of  95.1%  of  the radioactivity administered was recovered in excreta over the 168 h sampling period. The effective half life after multiple dosing in patients was 8.3 h. The mean total plasma clearance was 38 L/h after a single IV administration to healthy subjects. The mean total oral plasma clearance was 60 L/h after single oral administration and decreased by 8% after repeated dosing of 400 mg twice daily. Following single oral dose of 400 mg, the mean total recovery of radioactive dose was 45% from urine and 50% from faeces. Renal clearance was 21% of total clearance. Capivasertib is primarily eliminated by metabolism. The value of the effective half-life of 8.34 L is derived from population PK analysis based only on Phase 1 and Phase 2 data and not the final model including Phase 3 data. This is also the half-life reported in the SmPC (8.3 h). Since all studies have been conducted in patients and the model did not reveal a difference between study phases it is considered acceptable to base estimation of effective half-life only on the studies with rich sampling. Results from in vitro studies suggest that capivasertib is primarily metabolised by CYP3A4 and UGT2B7 enzymes. Human metabolites of capivasertib were detected and quantified in Day 8 AUC pooled plasma samples from patients receiving 400 mg BD from the FTIH study D3610C00001.The major metabolite in human plasma was identified as an ether glucuronide (AZ14102143) that accounted for 83% of total drug-related material using nuclear magnetic resonance spectroscopy, and was inactive against AKT. A minor oxidative metabolite ('+3[O]') was detected and quantified at much lower levels (2%), while capivasertib accounted for 15% of total circulating drug-related material. No active metabolites have been identified. In urine, the major response was characterised as the ether glucuronide, and it was estimated that it represented 19% to 37% of the dose in urine. As stated above, capivasertib is primarily metabolised by CYP3A4 and UGT2B7 enzymes. UGT2B7 was

discussed to be an enzyme rich in single nucleotide polymorphisms (SNPs). There are currently no data that indicate that genetic polymorphism of UGT2B7 would have a clinically relevant impact on the PK of capivasertib. With  regard  to  special  populations,  clinical  pharmacology  studies  to  specifically  evaluate  the  role  of impaired renal function, impaired hepatic function, age and gender have not been conducted. Based on population pharmacokinetic analyses, AUC and Cmax were 1% higher in patients with mild renal  impairment  (creatinine  clearance  60  to  89 mL/min),  compared  to  patients  with  normal  renal function.  AUC  and  Cmax  were  16%  higher  in  patients  with  moderate  renal  impairment  (creatinine clearance 30 to 59 mL/min), compared to patients with normal renal function. There is no data in severe renal impairment or end-stage renal disease (creatinine clearance &lt; 30 ml/min). No dose adjustment is required for patients with mild or moderate renal impairment. Based on population pharmacokinetic analyses, AUC and Cmax were 5% higher in patients with mild hepatic impairment (bilirubin ≤ ULN and AST &gt; ULN, or bilirubin &gt; 1 ULN to ≤ 1.5 ULN), compared to patients with normal hepatic function (bilirubin ≤ ULN and AST ≤ ULN). AUC was 17% and Cmax was 13% higher in patients with moderate hepatic impairment (bilirubin &gt; 1.5 ULN to ≤ 3 ULN), compared to  patients  with  normal  hepatic  function.  There  is  limited  data  in  patients  with  moderate  hepatic impairment and no data in severe hepatic impairment. No dose adjustment is required for patients with mild hepatic impairment. Based on population pharmacokinetic analysis, AUC and Cmax showed that race (including White and Japanese patients), gender or age did not significantly impact the capivasertib exposure. There was a statistically significant correlation of apparent oral clearance of capivasertib to body weight. Compared to a patient with a body weight of 66 kg, a 47 kg patient is predicted to have 12% higher AUC. There is no basis for dose modification based on body weight as the predicted effect on capivasertib exposure was small. Drug-drug interactions (DDI) have been discussed based on the provided results of in vitro studies using human biomaterial, the applicant´s own and published clinical studies ( in vivo ) in healthy volunteers and patients  as  well  as  PBPK  modelling  ( in  silico ).  The  PBPK  model  cannot  be  accepted  to  predict  drug interactions and potential dose adjustments. According to the EMA guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2**) and draft ICH M12 guideline on drug interactions, when t he candidate enzymes have been identified in vitro, the main metabolic pathways (≥25% of total elimination) generally require additional clinical characterisation to determine and quantify the risk of interaction with the investigational drug as a victim. Based on the shortcomings of the PBPK model, potential DDIs identified in in vitro investigation which have not yet been investigated in vivo have been identified to require additional clinical characterisation to determine and quantify the risk of interaction. During the evaluation, the applicant was asked to comment and outline how DDI risk as discovered in the in vitro studies can be further investigated in vivo and propose adequate amendments for the product information based on the currently available data. Section 4.5 of the SmPC has been revised accordingly and the applicant is strongly encouraged to further investigate potential DDIs with UGT1A1, CYP2D6 and CYP2B6 metabolizing enzymes (capivasertib as a perpetrator) (REC). Co-administration of a single dose of capivasertib 400 mg after repeated dosing of acid-reducing agent rabeprazole 20 mg BID for 3 days in healthy subjects did not result in clinically relevant changes of the capivasertib exposure. In vitro studies have demonstrated that capivasertib is primarily metabolised by CYP3A4 and UGT2B7 enzymes. In vivo, capivasertib is a weak, time-dependent inhibitor of CYP3A. Results of clinical drugdrug interaction (DDI) studies investigating potential DDI based on CYP3A4 interactions (itraconazole and enzalutamide) are cited below, clinical DDI studies investigating potential DDIs based on UGT2B7 interactions have not been performed.

<div style=\"page-break-after: always\"></div>

## Medicinal products that may increase capivasertib plasma concentrations

## Strong CYP3A4 inhibitors

Coadministration of TRUQAP with strong CYP3A4 inhibitors increases capivasertib concentration, which may increase the risk of TRUQAP toxicity. Avoid coadministration with strong CYP3A4 inhibitors (e.g. boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, ensitrelvir, idelalisib, indinavir, itraconazole, josamycin,  ketoconazole,  lonafarnib,  mibefradil,  mifepristone,  nefazodone,  nelfinavir,  posaconazole, ribociclib,  ritonavir,  saquinavir,  telaprevir,  telithromycin,  troleandomycin,  tucatinib,  voriconazole, grapefruit or grapefruit juice). If coadministration cannot be avoided, reduce the dose of TRUQAP. Coadministration  of  multiple  200 mg  doses  of  the  strong  CYP3A4  inhibitor  itraconazole  increased capivasertib total exposure (AUCinf) and the peak concentration (Cmax) by 95% and 70%, respectively, relative to capivasertib given alone.

## Moderate CYP3A4 inhibitors

Coadministration  of  TRUQAP  with  moderate  CYP3A4  inhibitors  increases  capivasertib  concentration, which may increase the risk of TRUQAP toxicity. Reduce the dose of TRUQAP when coadministered with moderate  CYP3A4  inhibitor  (e.g.  aprepitant,  ciprofloxacin,  cyclosporine,  diltiazem,  erythromycin, fluconazole, fluvoxamine, tofisopam, verapamil).

## Medicinal products that may decrease capivasertib plasma concentrations

## Strong CYP3A4 inducers

Coadministration of TRUQAP with strong CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, St.  John's  wort)  should  be  avoided.  Coadministration  of  capivasertib  with  strong  CYP3A4  inducer enzalutamide decreased the capivasertib AUC by approximately 40% to 50%.

## Moderate CYP3A4 inducers

Coadministration  of  capivasertib  with  moderate  CYP3A4  inducer  has  the  potential  to  decrease  the concentration of capivasertib. This may reduce the efficacy of TRUQAP. Coadministration of moderate CYP3A4  inducers  should  be  avoided  (e.g.  bosentan,  cenobamate,  dabrafenib,  elagolix,  etravirine, lersivirine,  lesinurad,  lopinavir,  lorlatinib,  metamizole,  mitapivat,  modafinil,  nafcillin,  pexidartinib, phenobarbital, rifabutin, semagacestat, sotorasib, talviraline, telotristat ethyl, thioridazine).

## Medicinal products whose plasma concentrations may be altered by capivasertib

## Substrates of CYP3A

Concentration of medicinal products that are primarily eliminated via CYP3A metabolism may increase when  coadministered  with  TRUQAP  which  may  then  lead  to  increased  toxicity  depending  on  their therapeutic window. Capivasertib increased the midazolam AUC by 15% to 77% and is therefore a weak CYP3A inhibitor (see section 5.2). Dose adjustment may be required for medicinal products that are primarily eliminated via CYP3A metabolism and have narrow therapeutic window (e.g. carbamazepine, cyclosporine, fentanyl, pimozide, simvastatin, tacrolimus).

## CYP2D6 substrates with a narrow therapeutic index

In vitro evaluations indicated that capivasertib has a potential to inhibit the activities of CYP2D6 enzymes. Capivasertib should be used with caution in combination with sensitive substrates of CYP2D6 enzymes which exhibit a narrow therapeutic index because capivasertib may increase the systemic exposure of these substrates.

## CYP2B6 substrates with a narrow therapeutic index

<div style=\"page-break-after: always\"></div>

In  vitro  evaluations  indicated  that  capivasertib  has  a  potential  to  induce  the  activities  of  CYP2B6 enzymes. Capivasertib should be used with caution in combination with sensitive substrates of CYP2B6 enzymes which exhibit a narrow therapeutic index (e.g. bupropion) because capivasertib may decrease the systemic exposure of these substrates.

## UGT1A1 substrates with a narrow therapeutic index

In  vitro  evaluations  indicated  that  capivasertib  has  a  potential  to  inhibit  the  activities  of  UGT1A1 enzymes. Capivasertib should be used with caution in combination with sensitive substrates of UGT1A1 enzymes which exhibit a narrow therapeutic index (e.g. irinotecan) because capivasertib may increase the systemic exposure of these substrates.

## Interactions with hepatic transporters (BCRP, OATP1B1, OATP1B3)

The exposure of medicinal products that are sensitive to inhibition of BCRP, OATP1B1 and/or OATP1B3 if they are metabolised by CYP3A4, may increase by co-administration with TRUQAP. This may lead to increased  toxicity.  Depending  on  their  therapeutic  window,  dose  adjustment  may  be  required  for medicinal  products  that  are  sensitive  to  inhibition  of  BCRP,  OATP1B1  and/or  OATP1B3  if  they  are metabolised by CYP3A4 (e.g. simvastatin).

## Interactions with renal transporters (MATE1, MATE2K, OCT2)

The exposure of medicinal products that are sensitive to inhibition of MATE1, MATE2K and/or OCT2 may increase  by  coadministration  with  TRUQAP.  This  may  lead  to  increased  toxicity.  Depending  on  their therapeutic  window,  dose  adjustment  may  be  needed  for  medicinal  products  that  are  sensitive  to inhibition of MATE1, MATE2K and OCT2 (e.g. dofetilide, procainamide). The SmPC of the other medicinal products should be consulted for the recommendations regarding coadministration with MATE1, MATE2K and/or OCT2 inhibitors. Transient serum creatinine increases may be observed during treatment with TRUQAP due to inhibition of OCT2, MATE1 and MATE2K by capivasertib.

Capivasertib inhibited CYP2C9, CYP2D6, CYP3A4 and UGT1A1 and induced CYP1A2, CYP2B6 and CYP3A4 metabolising  enzymes  in  in  vitro  studies.  It  also  inhibited  BCRP,  OATP1B1,  OATP1B3,  OAT3,  OCT2, MATE1 and MATE2K drug transporters in vitro.

Clinical DDI studies investigating potential DDIs based on CYP1A2, CYP2B6, CYP2C9, CYP2D6, UGT1A1, BCRP, OATP1B1, OATP1B3, OAT3, OCT2, MATE1 and MATE2K interactions have not been performed.

## Pharmacodynamics

## Hyperglycaemia

Hyperglycaemia is an on-target adverse effect of inhibition of the PI3K/AKT/PTEN signalling pathway. Frequency and severity of adverse events related to hyperglycaemia and the possibility to manage these AEs with supportive treatments and/or capivasertib dose modification are discussed below in clinical efficacy and clinical safety sections.

## Rash

Rash was also discussed to be an adverse effect related to the inhibition of PI3K/AKT/PTEN signalling pathway. Frequency and severity of adverse events related to 'rash' and the possibility to manage these AEs with supportive treatments and/or capivasertib dose modification are discussed below in the clinical efficacy and clinical safety sections.

Exposure-response modelling of efficacy data has been performed on data from the pivotal CAPItello291 study.

<div style=\"page-break-after: always\"></div>

The relationship between capivasertib exposure and safety outcomes has been assessed using exposureresponse modelling of data from a pool of Phase I studies of capivasertib monotherapy conducted in patients with advanced solid malignancies.

Exposure-response safety modelling has also been conducted on data from a pool of Phase I studies and the  Phase  III  pivotal  CAPItello-291  study  in  patients  with  advanced  breast  cancer  who  received capivasertib  +  fulvestrant.  QT/QTc  interval  prolongation  for  capivasertib  has  been  evaluated  using exposure-response modelling of centrally evaluated digital ECG data from the FTIH study (D3610C00001).

During the evaluation it was concluded that the pharmacodynamic rationale for the treatment in the PIK3CA/AKT1/PTEN alteration negative population lacks further justification. It was finally concluded that due  to  the  very  limited  efficacy  in  terms  of  PFS  in  the  'Known  non-altered  population'  and  the considerable  toxicity  for  the  combination  treatment,  the  indication  should  be  restricted  to  the PIK3CA/AKT1/PTEN altered population (see Clinical efficacy section).

## 2.6.4. Conclusions on clinical pharmacology

The  pharmacokinetics,  pharmacodynamic  and  interaction  potential  of  capivasertib  are  considered sufficiently characterised and the relevant information has been included in sections 4.5 and 5.2 of the SmPC.

## 2.6.5. Clinical efficacy

## 2.6.5.1. Dose response study(ies)

The  dosing  regimen  selection  for  the  combination  of  capivasertib  and  fulvestrant  was  preceded  by selection of the dosing regimen for capivasertib monotherapy.

In the FTIH study (D3610C00001) of capivasertib, a continuous and two intermittent dosing schedules were  evaluated  (all  BD).  The  continuous  schedule  doses  ranged  from  80  mg  to  600  mg,  while  the intermittent schedules tested 480 mg and 640 mg given 4 days on, 3 days off, or 640 mg and 800 mg, given 2 days on, 5 days off. The RP2Ds were 320 mg, 480 mg, and 640 mg for the 'continuous', '4 days on - 3 days off', and '2 days on - 5 days off' schedules, respectively. In each case, the number of DLTs observed at the next dose levels above in each schedule did not meet the threshold for a non-tolerated dose as defined in the clinical study protocol. However, based on the totality of the data, including chronic tolerability, the lower doses were selected as the RP2Ds.

Table 36 FTIH study (D3610C00001): Summary of dosing schedules studied and results

| Study part                                                                                  | Dosing schedule        | Dose and frequency a   | NumberofDLTs (number of evaluable patients)   | Tolerability/ RP2D b,c    |
|---------------------------------------------------------------------------------------------|------------------------|------------------------|-----------------------------------------------|---------------------------|
| A (dose-escalation): capivasertib administered to patients with advanced solid malignancies | Schedule 1, continuous | Capi 80 mg BD          | 0 (5)                                         | -                         |
| A (dose-escalation): capivasertib administered to patients with advanced solid malignancies | Schedule 1, continuous | Capi 160 mg BD         | 0 (5)                                         | -                         |
| A (dose-escalation): capivasertib administered to patients with advanced solid malignancies | Schedule 1, continuous | Capi 240 mg BD         | 0 (6)                                         | -                         |
| A (dose-escalation): capivasertib administered to patients with advanced solid malignancies | Schedule 1, continuous | Capi 320 mg BD         | 0 (12)                                        | MWTD/RP2D                 |
| A (dose-escalation): capivasertib administered to patients with advanced solid malignancies | Schedule 1, continuous | Capi 400 mg BD         | 1 (11)                                        | Not chronically tolerated |
| A (dose-escalation): capivasertib administered to patients with advanced solid malignancies | Schedule 1, continuous | Capi 480 mg BD         | 4 (6)                                         | NTD                       |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                   |                                                | Capi 600 mg BD                                                                        | 2 (2)   | NTD                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------|---------|---------------------------|
|                                                                                                                                                                                                                                                                                                   | Schedule 2, intermittent                       | Capi 480 mg BD                                                                        | 0 (11)  | MWTD/RP2D                 |
|                                                                                                                                                                                                                                                                                                   | 4 days on, 3 days off                          | Capi 640 mg BD                                                                        | 0 (10)  | Not chronically tolerated |
|                                                                                                                                                                                                                                                                                                   | Schedule 2, intermittent                       | Capi 640 mg BD                                                                        | 1 (8)   | MWTD/RP2D                 |
|                                                                                                                                                                                                                                                                                                   | 2 days on, 5 days off                          | Capi 800 mg BD                                                                        | 3 (14)  | Not chronically tolerated |
| B (dose-expansion): capivasertib administered to patients with advanced solid malignancies                                                                                                                                                                                                        | Schedule 1, continuous                         | Capi 320 mg BD                                                                        | -       | -                         |
| B (dose-expansion): capivasertib administered to patients with advanced solid malignancies                                                                                                                                                                                                        | Schedule 2, intermittent 4 days on, 3 days off | Capi 480 mg BD                                                                        | -       | -                         |
| C: capivasertib administered to patients with advanced or metastatic ER+ or HER2+ breast cancer or gynaecological (ovarian, cervical or endometrial) cancer, or other advanced solid cancer, that had a PIK3CA mutation                                                                           | Intermittent 4 days on, 3 days off             | Capi 480 mg BD                                                                        | -       | -                         |
| D: capivasertib administered to patients with advanced or metastatic ER+ or HER2+ breast cancer, gynaecological (ovarian, cervical or endometrial) cancer or other advanced solid cancer that had an AKT1 mutation or other molecular aberration leading to dysregulation of the PI3K/AKT pathway | Intermittent 4 days on, 3 days off             | Capi 480 mg BD                                                                        | -       | -                         |
| E: capivasertib in combination with background fulvestrant administered to patients with advanced or metastatic ER+ breast cancer that had an AKT1 mutation                                                                                                                                       | Intermittent 4 days on, 3 days off             | Capi 400 mg BD + fulvestrant 500 mg on Days 1, 15 and 29, and once monthly thereafter | -       | -                         |
| F: capivasertib in combination with background fulvestrant administered to patients with advanced or metastatic ER+ breast cancer that had a PTEN mutation                                                                                                                                        | Intermittent 4 days on, 3 days off             | Capi 400 mg BD + fulvestrant 500 mg on Days 1, 15 and 29, and once monthly thereafter | -       | -                         |

a Doses are presented in ascending order, which may differ from the order in which they were studied. Some doses/schedules were studied in parallel.

b According to the protocol: If 2 or more patients report a DLT in a group of up to 6 evaluable patients, the dose will be considered not tolerated.

c According to the protocol: Once the NTD is defined the MTD will be confirmed at the dose-level below the NTD or a dose between the NTD and the last tolerated dose will be investigated.

No further evaluation of capivasertib monotherapy was performed.

The  recommended  dose  and  dosing  regimen  of  capivasertib  in  combination  with  fulvestrant  was determined to be 400 mg BD, 4 days on, 3 days off for the Phase Ib part of FAKTION study (see section 3.8 Supportive study). Although no DLTs were observed at 400 mg, 480 mg was not explored in the interests of maintaining appropriate tolerability. The dose and schedule selected (400 mg BD, 4 days on,

<div style=\"page-break-after: always\"></div>

3 days off) achieved exposure levels in a similar range to that required to achieve efficacy in ER+ breast cancer non-clinical models.

## 2.6.5.2. Main study(ies)

Study D3615C0000 (CAPItello-291): a Phase III Double-blind Randomised Study Assessing the  Efficacy  and  Safety  of  Capivasertib  +  Fulvestrant  Versus  Placebo  +  Fulvestrant  as Treatment  for  Locally  Advanced  (Inoperable)  or  Metastatic  Hormone  Receptor-Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+, HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor

EudraCT number: 2019-003629-78

## Methods

CAPItello-291 is the Phase III, double-blind, placebo-controlled, parallel-group, randomised, multicentre study to investigate the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant for the treatment of patients with HR+, HER2- locally advanced or metastatic breast cancer following disease recurrence or progression on or after aromatase inhibitor therapy, with or without a CDK4/6 inhibitor.

The study was powered to show a statistically significant difference between capivasertib + fulvestrant and placebo + fulvestrant in PFS in the overall  population and the altered  population (dual primary endpoints) and OS (key secondary endpoint) in the Overall Population; OS in the altered population was also assessed (see Protocol Version 4.0)

Clinical  outcome  was  examined  in  the overall  population of  patients  (i.e.  regardless  of  tumour PIK3CA/AKT1/PTEN alteration status) as well as in a patient subgroup with tumours carrying at least one PIK3CA/AKT1/PTEN alteration (altered population).

<div style=\"page-break-after: always\"></div>

## Figure 8 Flow chart of study design

<!-- image -->

## · Study Participants

## Key inclusion criteria:

For inclusion in the study, patients had to fulfil the following criteria amongst others:

## · Informed consent

- 1 For inclusion in the optional exploratory genetic and/or biomarker research, provision of signed and dated written genetic and/or biomarker informed consents, respectively, prior to collection of sample(s)
- Age
- 2 Patients aged ≥ 18 years (aged ≥ 20 years in Japan) at the time of signing the ICF
- Type of patient and disease characteristics
- 3 Adult females, pre- and/or post-menopausal, and adult males
- -Pre-menopausal (and peri-menopausal, i.e., those that did not meet the criteria for postmenopausal defined below) women could be enrolled if amenable to treatment with an LHRH agonist. Patients were to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and had to be willing to continue on it for the duration of the study.
- -Post-menopausal women were defined as:
- o aged ≥ 60 years of age, or
- o aged &lt; 60 years of age and amenorrhoeic for at least 12 months following cessation of all  exogenous  hormonal  treatments/chemotherapy/ovarian  suppression/tamoxifen  or similar.  These patients should also have had serum oestradiol and follicle stimulating hormone (FSH) levels confirmed as being within the standard laboratory reference range for post-menopausal females, OR
- o documented bilateral oophorectomy.
- 4 Histologically  confirmed  HR+/HER2-  breast  cancer  determined  from  the  most  recent tumour sample (primary or metastatic), as per the American Society of Clinical Oncology and College of American Pathologists guideline recommendations (Hammond et al 2010, Wolff et al 2018). To fulfil  the  requirement  of  HR+  disease,  a  breast  cancer  had  to  express  ER  with  or  without  coexpression of progesterone receptor. Therefore, tumours had to be:
- -ER+ defined as ≥ 1% of tumour cells stain positive for ER on immunohistochemistry (IHC) or, if no percentage was available, then an Allred IHC score of ≥ 3/8,
- -PR+ defined as ≥ 1% of tumour cells stain positive for progesterone receptor on IHC or, if no percentage was available, then an Allred IHC score of ≥ 3/8; or PR - defined as &lt; 1% of tumour cells stain positive for progesterone receptor on IHC or, if no percentage was available, then an Allred IHC score of ≤ 2/8; or progesterone receptor unknown, and
- -HER2- defined  as  0  or  1+  intensity  on  IHC,  or  2+  intensity  on  IHC  and  no  evidence  of amplification on ISH, or if IHC not done, no evidence of amplification on ISH.
- 5 Metastatic  or  locally  advanced  disease  with  radiological  or  objective  evidence  of  recurrence  or progression (the cancer should have shown progression during or after most recent therapy); locally advanced disease must not have been amenable to resection with curative intent (patients who were considered suitable for surgical or ablative techniques following potential down-staging with study treatment were not eligible).
- 6 Patients  were  to  have  received  treatment  with  an  AI-containing  regimen  (single  agent  or  in combination) and have:
- (a) Radiological evidence of breast cancer recurrence or progression while on, or within 12 months of the end of (neo)adjuvant treatment with an AI, OR
- (b) Radiological evidence of progression while on prior AI administered as a treatment line for locally advanced or metastatic breast cancer (this did not need to be the most recent therapy)
- 7 Patients had to have:
- -at least 1 lesion, not previously irradiated, that could be measured accurately at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which had to have short axis ≥ 15 mm) with CT or MRI which was suitable for accurate repeated measurements, OR
- -in absence of measurable disease as defined above, at least 1 lytic or mixed (lytic + sclerotic) bone lesion that could be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease were not eligible.
- 8 Patients had to be eligible for fulvestrant therapy as per local investigator assessment.
- 9 Consented to submit and provide a mandatory FFPE tumour sample for central testing.
- 10 Eastern  Cooperative  Oncology  Group  (ECOG)/World  Health  Organization  (WHO)  performance status 0 or 1 with no deterioration over the previous 2 weeks and life expectancy of ≥ 12 weeks .

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## · Reproduction

- 11 Pre-menopausal patients with ovarian suppression induced by LHRH agonist should have agreed to use 2 forms of highly effective methods of accepted contraception  to prevent pregnancy during the study and for 2 years after the last dose of fulvestrant, or until 16 weeks after discontinuing capivasertib/placebo whichever occurred later.
- 12 Male patients should have used barrier contraception (i.e., condoms) from the time of screening until  2  years  after  the  last  dose  of  fulvestrant  or  until  16  weeks  after  discontinuation  of capivasertib/placebo, whichever occurred later.

## Main exclusion criteria:

## · Medical conditions

- 1 A disease burden that made the patient ineligible for endocrine therapy per the investigator's best judgement (e.g., symptomatic visceral disease that was potentially life-threatening in the shortterm).
- 2 Malignancies other than breast cancer within 5 years prior to study treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma or Stage I endometrioid uterine cancer).
- 3 Radiotherapy  with  a  wide  field  of  radiation  within  4  weeks  prior  to  study  treatment  initiation (capivasertib/placebo) and/or radiotherapy with a limited field of radiation for palliation within 2 weeks prior to study treatment initiation (capivasertib/placebo).
- 4 Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- 5 Any of the following cardiac criteria:
- -Mean resting QT interval corrected by Fridericia's formula (QTcF) &gt; 470 msec obtained from 3 consecutive ECGs
- -Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
- -Any  factors  that  increased  the  risk  of  corrected  QT  interval  (QTc)  prolongation  or  risk  of arrhythmic  events  such  as  heart  failure,  hypokalaemia,  potential  for  torsades  de  pointes, congenital  long  QT  syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
- -Experience  of  any  of  the  following  procedures  or  conditions  in  the  preceding  6  months: coronary  artery  bypass  graft,  angioplasty,  vascular  stent,  myocardial  infarction,  angina pectoris, congestive heart failure NYHA grade ≥ 2
- -Uncontrolled  hypotension  -  systolic  blood  pressure  &lt;  90  mmHg  and/or  diastolic  blood pressure &lt; 50 mmHg
- -Cardiac  ejection  fraction  outside  institutional  range  of  normal  or  &lt;  50%  (whichever  was higher) as measured by ECHO (or MUGA scan if an ECHO could not be performed or was inconclusive).
- 6 Clinically significant abnormalities of glucose metabolism as defined by any of the following:
- -Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment
- -HbA1C ≥ 8.0% (63.9 mmol/mol) .
- 7 Inadequate  bone  marrow  reserve  or  organ  function  as  demonstrated  by  any  of  the  following laboratory values:
- -Absolute neutrophil count &lt; 1.5 × 10 9 /L
- -Platelet count &lt; 100 × 10 9 /L
- -Haemoglobin &lt; 9 g/dL (&lt; 5.59 mmol/L). [ NOTE: any blood transfusion had to be &gt; 14 days prior to the determination of a haemoglobin ≥ 9 g/dL (≥ 5.59 mmol/L)]
- -Alanine aminotransferase (ALT) and AST &gt; 2.5 times ULN if no demonstrable liver metastases or &gt; 5 × ULN in the presence of liver metastases
- -Total bilirubin &gt; 1.5 × ULN (Patients with confirmed Gilbert's syndrome could be included in the study)
- -Creatinine  &gt;  1.5  ×  ULN  concurrent  with  creatinine  clearance  &lt;  50  mL/min  (measured  or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance was only required when creatinine was &gt; 1.5 × ULN.
- 8 As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled  hypertension,  or  active  infection  including  hepatitis  B,  hepatitis  C  and  human immunodeficiency virus (HIV), including those who had confirmed COVID-19. Screening for chronic conditions was not required. Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant or LHRH agonist (if applicable).
- 9 Previous allogenic bone marrow or solid organ transplant.
- 10 Known immunodeficiency syndrome.
- 11 History of hypersensitivity to active or inactive excipients of capivasertib, fulvestrant and LHRH agonists (if applicable, i.e., concomitant LHRH agonist required in this study) or drugs with a similar chemical  structure  or  class  to  capivasertib,  fulvestrant  or  LHRH  agonists  (if  applicable,  i.e., concomitant LHRH agonist required in this study).

<div style=\"page-break-after: always\"></div>

## · Prior/concomitant therapy

- 12 More than 2 lines of endocrine therapy for inoperable locally advanced or metastatic disease.
- 13 More than 1 line of chemotherapy for inoperable locally advanced or metastatic disease. Adjuvant and neoadjuvant chemotherapy were not classed as lines of chemotherapy for ABC.
- 14 Prior treatment with any of the following:
- -AKT, PI3K and mTOR inhibitors
- -Fulvestrant, and other SERDs
- -Potent  inhibitors  or  inducers  of  CYP3A4  within  2  weeks  prior  to  the  first  dose  of  study treatment (3 weeks for St John's wort) or drugs that are sensitive to CYP3A4 inhibition within 1 week prior to study treatment initiation.
- -Any concomitant medication that may have interfered with fulvestrant safety and efficacy based on the prescribing information of fulvestrant and local clinical guidelines.

<div style=\"page-break-after: always\"></div>

## · Other exclusions

15 Pregnant women (confirmed with positive pregnancy test) or breast-feeding women.

## · Treatments

Patients received capivasertib 400 mg BD (2 tablets of 200 mg taken BD; total daily dose 800 mg) given on an intermittent weekly dosing schedule 4 days on, 3 days off or placebo. Where possible, doses were to be taken in a fasted state from at least 2 hours prior to the dose to at least 1-hour post-dose 12 hours apart at approximately the same time each day, and fulvestrant (at the approved dose regimen of 500 mg intramuscular injections on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter).

Study treatment was continued until disease progression unless there was evidence of unacceptable toxicity, or if the patient requested to stop the study treatment.

Pre- or peri-menopausal patients were to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and had to be willing to continue LHRH agonist treatment for the duration of  the  study.  Male  patients  could  receive  concomitant  LHRH  agonist  if  deemed  appropriate  by  the investigator.

LHRH analogues were not considered as IMP.

For  capivasertib  dose  reductions  (level  1:  320  mg  BD  and  level  2  200  mg  BD)  were  permitted,  reescalation was not allowed. For general capivasertib-related toxicities any intolerable AE or AE grade G ≥3 led to dose reduction, for specific AE -  hyperglycaemia, maculo-papular rash and other skin reactions, and diarrhoea- the protocol provided specific advice.

Dose interruptions were recommended for substantial acute toxicities as medically indicated.

A  maximum break  of  28  consecutive  days  for  capivasertib/placebo  dosing  was  allowed  within  each treatment  cycle  or  between  two  consecutive  cycles.  A  maximum  delay  of  35  days  since  a  planned injection of fulvestrant was allowed.

Patients were required to return all bottles of study medication, and the number of tablets remaining was counted by the research nurse/pharmacist/investigator. Data regarding capivasertib/placebo dosing were collected.

## · Objectives

The primary objective was to show superiority on the effect of capivasertib + fulvestrant vs placebo + fulvestrant  by  assessment  of  PFS  in  the overall  population and  in  the  PIK3CA/AKT1/PTEN-altered subgroup.

<div style=\"page-break-after: always\"></div>

## · Outcomes/endpoints

## Table 37 Objectives and endpoints

| Objectives a                                                                                                                                                                                                                 | Endpoints                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                        |
| • To compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by assessment of PFS in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3).  | • PFS is defined as the time from randomisation until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.                                                                                                                       |
| Secondary                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                        |
| • To compare the effect of capivasertib +fulvestrant relative to placebo + fulvestrant by assessment of OS in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3).    | • OS is length of time from randomisation until the date of death due to any cause.                                                                                                                                                                                                    |
| • To compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by assessment of PFS2 in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3). | • PFS2 is defined as the time from randomisation until second progression on next-line treatment, as assessed by the investigator at the local site, or death due to any cause.                                                                                                        |
| • To compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by assessment of ORR in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3).  | • ORR is defined as the percentage of patients with at least one CR or PR per RECIST v1.1, as assessed by the investigator at the local site.                                                                                                                                          |
| • To compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by assessment of DoR in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3).  | • DoR is defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.                                                                                                                           |
| • To compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by assessment of CBR in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3).  | • CBR is defined as the percentage of patients who have a CR, PR or stable disease per RECIST v1.1 (without subsequent cancer therapy) maintained ≥ 24 weeks after randomisation.                                                                                                      |
| • To assess the safety and tolerability of capivasertib + fulvestrant as compared to placebo + fulvestrant in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup.                                          | • Safety and tolerability will be evaluated in terms of AEs/SAEs, vital signs, clinical chemistry/haematology/ glucose metabolism parameters, and ECG parameters. For full details of the assessments, refer to Protocol Version 4.0, Table 3).                                        |
| • To evaluate the PK of capivasertib when given in combination with fulvestrant.                                                                                                                                             | • Plasma concentration of capivasertib pre-dose (C trough ) and post-dose (C 1h and C 4h ) in the overall population (patients randomised to capivasertib + fulvestrant). • AUC 0-12h , C max and t max in a subpopulation of approximately 6 Japanese patients with rich PK sampling. |

<div style=\"page-break-after: always\"></div>

| • To assess the impact of capivasertib + fulvestrant vs placebo + fulvestrant on patients' disease- related symptoms, function and HRQoL in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup where applicable (see Protocol Version 4.0, Section 3).                          | • Evaluation of EORTC QLQ-C30, EORTC QLQ-BR23, scale/item scores including change from baseline and time to deterioration.                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • To compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by assessment of time to definitive deterioration of ECOG performance status from baseline in the overall population and in the PIK3CA/AKT1/PTEN -altered subgroup (see Protocol Version 4.0, Section 3). | • Time to definitive deterioration of ECOG performance status is defined as time from randomisation to the earlier of the date of the first definitive deterioration or death due to any cause. |

a The PIK3CA/AKT1/PTEN -altered subgroup is referred to as the 'Altered Population' in this CSR. Exploratory objectives are not included in the CSR Synopsis, but can be found in the CSR.

Imaging for PFS was performed using CT or MRI scans of the chest, abdomen and pelvis (with additional anatomy as clinically indicated by extent of disease) at baseline and every 8 weeks (±7 days) for the first 18 months and every 12 weeks thereafter, from randomisation to radiological progression. Patients who discontinue treatment prior to progression should continue to be scanned until progression.

Bone scans were performed at baseline and further if clinically indicated.

If the patient progressed or died immediately after two or more consecutive missed visits, the patient was to be censored at the time of the latest evaluable RECIST v1.1 assessment prior to the two missed visits.

## · Sample size

The  study  was  powered  to  show  a  statistically  significant  difference  in  OS  between  capivasertib  + fulvestrant and placebo + fulvestrant in the Overall Population. It was also sufficiently powered to assess PFS in the PIK3CA/AKT1/PTEN-altered population (Altered Population) and overpowered to assess PFS in the Overall Population.

Assuming a significance level of 5%, a total of 492 OS events will be required to achieve 90% power to detect a treatment effect of an average hazard ratio of 0.74 in the Overall Population, assuming a 12month delay to a treatment effect and a hazard ratio of 0.64 after the delay. Assuming 70% maturity at the time of the final analysis, approximately 700 patients were planned to be randomised to receive either capivasertib + fulvestrant or placebo + fulvestrant. Of these 700 randomised patients, it was expected that a minimum of 280 patients would have a tumour harbouring an eligible PIK3CA/AKT1/PTEN alteration, based on a prevalence of approximately 40% to 45%.

The PFS primary analysis took place after PFS reached approximately 77% maturity (542 events) in the Overall  Population  and  approximately  77%  maturity  in  patients  whose  tumours  harbour  an  eligible PIK3CA/AKT1/PTEN alteration, based on a prevalence of ~ 40% to 45% (and 174 events will have been observed if a test failure rate is 20%). Assuming a significance level of 3.5%, a total of 542 PFS events would provide &gt; 99% power to detect a treatment effect of hazard ratio 0.64 in the overall population. Given the estimated sample size of the Altered Population and assuming a significance level of 5% following recycling of the remaining 3.5% alpha, a total of 217 PFS events (approximately 77% maturity) would provide 90.8% power to detect a treatment effect of hazard ratio 0.64 in the Altered Population. A median PFS of 5.5 months was assumed for the placebo + fulvestrant arm. At DCO1 (15 August 2022) the actual maturity was 77.8% (551 events) in the overall population, and 81.7% (236 events) in the altered population.

<div style=\"page-break-after: always\"></div>

## · Randomisation and blinding (masking)

Eligible patients were randomised in a 1:1 ratio to each arm of the global cohort in a blinded manner. Randomisation was stratified on the following factors:

- Liver metastases (yes vs no)
- Prior use of CDK4/6 inhibitors (yes vs no)
- Geographic location:
- -Region 1: United States, Canada, Western Europe, Australia, and Israel
- -Region 2: Latin America, Eastern Europe and Russia
- -Region 3: Asia.

Randomisation continued in China after randomisation of the global cohort was complete, and data from the China cohort was to be reported separately. Chinese patients randomised prior to the last patient first visit of the global cohort were also included in the global cohort (n = 8).

Capivasertib and placebo film-coated tablets were identical in appearance and presented in the same packaging to ensure blinding of the capivasertib.

## · Statistical methods

## Analysis sets

Full  Analysis  Set  (FAS)  (Overall  Population):  This  comprised  all  patients  randomised  into  the  study, excluding patients randomised in China after the global cohort last patient first visit (LPFV). The FAS was analysed according to randomised treatment regardless of the treatment received (ITT principle). The FAS was used as the primary population for reporting efficacy data (including PROs) and to summarise baseline characteristics.

Altered  Subgroup  FAS  (Altered  Population):  This  comprised  all  patients  included  in  the  FAS  with  a PIK3CA/AKT1/PTEN altered tumour determined by central testing.

Safety Analysis Set (SAS): The SAS comprised all patients included in the FAS, who received at least one dose of study drug (fulvestrant, capivasertib, placebo) and were analysed according to the treatment received.

Progression-free survival is defined as the time from the date of randomisation until the date of objective disease progression, as defined by RECIST v1.1, or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy  prior  to  progression  (i.e.  date  of  PFS  event  or  censoring  -  date  of  randomisation  +  1). Progression-free survival was assessed by investigator assessment. A sensitivity analysis of PFS by BICR is also reported.

If the patient progressed or died immediately after two or more consecutive missed visits, the patient was censored at the time of the latest evaluable RECIST v1.1 assessment prior to the two missed visits. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment.

The intention of the study was to demonstrate the superiority of capivasertib + fulvestrant over placebo + fulvestrant in either or both of the Overall Population and the Altered Population.

The dual primary endpoint PFS in the Overall Population based on the investigator RECIST v1.1 was analysed using a log-rank test stratified by randomisation stratification factors. To estimate the effect of treatment, the HR together with its 95% CI and CI adjusted for multiplicity were estimated from a stratified Cox proportional hazards model. Kaplan-Meier plots of PFS were presented by treatment group.

<div style=\"page-break-after: always\"></div>

Summaries of the number and percentage of patients experiencing a PFS event and the type of event (RECIST v1.1 progression or death) over time at 6, 9 and 12 months were provided along with the median PFS for each treatment group.

The  dual  primary  endpoint  of  PFS  in  the  Altered  Population  was  analysed  in  the  same  way.  In  an exploratory analysis, progression-free survival in the Non-altered Population, including the Known Nonaltered Population and the No Result Population, was analysed as described for the PFS in the Overall Population.

Overall survival is defined as the time from the date of randomisation until death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomisation + 1). Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.

The secondary endpoint OS was analysed using similar methodology as described for the primary PFS endpoint (hypothesis testing was not planned at data cut-off 1).

PFS2 was analysed using the same methodology as described for the primary PFS endpoint.

Objective response rate was analysed for both the Overall Population and the Altered Population. The ORR was compared between capivasertib + fulvestrant vs placebo + fulvestrant using logistic regression models adjusting for the stratification factors.

Descriptive data were provided for the duration of response (DoR) and clinical benefit rate (CBR).

## Adjustment for multiplicity

To control the family-wise error rate in the strong sense at 5% for the treatment comparisons in OS and PFS, a predefined multiple testing procedure (MTP) with an alpha-exhaustive recycling strategy (Burman et al. 2009) taking into account intrinsic correlation between test statistics (Spiessens and Debois 2010), was applied. The MTP is outlined in the figure below. According to alpha (test mass) splitting and alpha recycling, if the higher-level hypothesis in the MTP is rejected for superiority, then the next lower level hypothesis will be tested.

<div style=\"page-break-after: always\"></div>

## Figure 9 Illustration of DCOs and associated treatment comparisons

<!-- image -->

Following FDA's advice, a small alpha spend was applied to the assessment of no OS detriment at the time  of  the  PFS  primary  analysis.  This  used  a  bespoke  alpha  spending  function  with  0.0001  alpha assigned  to  DCO1  in  each  of  the  Overall  Population  and  the  Altered  Population.  The  remaining  OS analyses will use the planned cumulative alpha at DCO2 and DCO3 from the 2-look O'Brien &amp; Fleming method. The OS Interim Analysis is expected to occur when approximately 394 OS events have been observed in the Overall Population (56% maturity, 80% information fraction). The OS Final Analysis will take place when approximately 70% maturity has been observed in both the Overall Population and the Altered Population.

## Results

## · Participant flow

A total of 901 patients were enrolled in 181 centres in 19 countries worldwide, of which193 patients were screen  failures.  A  total  of  708  patients  were  randomised  to  receive  treatment  with  capivasertib  + fulvestrant (n = 355) or placebo + fulvestrant (n = 353).

Three patients in the placebo + fulvestrant arm did not receive treatment: one died before its first dose, one withdrew consent, and the reason for the other was unknown.

At the time of DCO1, a higher proportion of patients continued to receive treatment in the capivasertib + fulvestrant arm compared with the placebo + fulvestrant arm (20.0% vs 12.3%). The most common reasons  for  discontinuing  capivasertib/placebo  (≥  5%  of patients)  were  breast  cancer  progression (58.9%) and adverse event (AE) (12.4%) in the capivasertib  +  fulvestrant  arm,  and  breast  cancer progression (78.0%) in the placebo + fulvestrant arm.

<div style=\"page-break-after: always\"></div>

## Figure 10 Patient disposition (all patients)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11 Patient disposition (altered population)

<!-- image -->

Source: Table 14.1.1.2 and Listing 16.2.1.1.

## · Recruitment

The first patient was randomised on 02 June 2020 and the last patient was randomised into the Global cohort on 13 October 2021.

## Patients were enrolled as follows:

- Region 1 (112 centres in United States, Canada, Western Europe, Australia, and Israel: 395 patients)
- Region 2 (23 centres in Latin America, Eastern Europe and Russia: 136 patients)
- Region 3 (46 centres in Asia, 177 patients).

The first DCO date for the study that is the basis for the submitted study report is 15 August 2022 (DCO1). At DCO1, the median duration of follow-up (defined as time to censoring or death) in all patients in the capivasertib + fulvestrant and placebo + fulvestrant arms was 14.9 and 14.3 months, respectively.

Recruitment continued in China after the Global cohort last patient first visit (LPFV) (13 October 2021) until approximately 134 Chinese patients had been randomised into the China cohort. Patients recruited in China prior to the Global cohort LPFV were included in both the Global and China cohorts. The results from the China cohort are presented in a separate clinical study report.

## · Conduct of the study

The original study protocol (Version 1.0, dated 04 November 2019) was amended 3 times.

<div style=\"page-break-after: always\"></div>

Table 38 Main protocol amendments

| Amendment Number/Date                                       | Main key details of amendment                                                                                                                            | Main reason(s) for amendment                                                                 |
|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Amendments made before the start of participant recruitment | Amendments made before the start of participant recruitment                                                                                              | Amendments made before the start of participant recruitment                                  |
| None                                                        |                                                                                                                                                          |                                                                                              |
| Amendments made after the start of participant recruitment  | Amendments made after the start of participant recruitment                                                                                               | Amendments made after the start of participant recruitment                                   |
|                                                             | Key secondary endpoints were updated.                                                                                                                    | To elevate ORR and CBR in the overall population to key secondary endpoints.                 |
|                                                             | Changes to wording of inclusion criterion 5, inclusion of females                                                                                        | To clarify details of menopausal status.                                                     |
|                                                             | Changes to wording of inclusion criterion 6, confirmation of breast cancer                                                                               | To clarify definition of HER2-                                                               |
|                                                             | Changes to wording of inclusion criterion 7, metastatic or locally advanced disease with radiological or objective evidence of recurrence or progression | To clarify that the cancer should have shown progression during or after most recent therapy |

| Amendment Number/Date         | Key details of amendment                                                                                                                                                                                                                                                                                                                                                                        | Main reason(s) for amendment                                                   |
|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                               | Clarified wording regarding the China cohort, and removed inclusion of patients from Taiwan in the China cohort. Removed the restriction on the biomarker test result for China patients to join global cohort FAS.                                                                                                                                                                             | For clarification.                                                             |
|                               | Clarified FAS to comprise patients randomised into the study prior to global cohort LPFV; clarified the SASwould also include patients who received only fulvestrant and these patients would be included in the treatment arm to which they were randomised; clarified the Altered Subgroup FAS would include patients with a result from a valid biomarker test as pre- specified in the SAP. | For clarification.                                                             |
|                               | Added text to state that the remaining alpha will be recycled to test the study secondary endpoints if the OS endpoint is successful, and to specify the hierarchical testing order.                                                                                                                                                                                                            | To specify the hierarchical testing order to test secondary endpoints after OS |
| CSP Version 3.0/ 29 June 2021 | Clarified the FAS is to comprise patients randomised into the study, excluding patients randomised in China after the global cohort LPFV                                                                                                                                                                                                                                                        | For clarification of the cut-off for the definition of global cohort FAS.      |
| CSP Version 3.0/ 29 June 2021 | Removed reference to Asian population analyses                                                                                                                                                                                                                                                                                                                                                  | For simplification.                                                            |

<div style=\"page-break-after: always\"></div>

| Amendment Number/Date             | Key details of amendment                                                                                                                                                                                                                                                                                                                                                           | Main reason(s) for amendment                                                                                                                                                                                                                                                                                                                |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CSP Version 4.0/ 08 February 2022 | Clarification of primary objectives. The primary objective was renamed as dual primary: PFS in the overall population and PFS in the PIK3CA/AKT1/PTEN -altered subgroup                                                                                                                                                                                                            | The study was designed with an alpha split between the overall population and the PIK3CA/AKT1/PTEN -altered subgroup; however, only the overall population was defined as the primary endpoint. To render the nomenclature consistent with the intent of the multiple testing procedure, the primary objective was renamed as dual primary. |
| CSP Version 4.0/ 08 February 2022 | Removed the interim PFS analysis for the Overall Population                                                                                                                                                                                                                                                                                                                        | To align with the change to the dual primary endpoints of PFS in the overall population and PIK3CA/AKT1/PTEN -altered subgroup.                                                                                                                                                                                                             |
| CSP Version 4.0/ 08 February 2022 | Duplication of all secondary objectives (except PK), so they are assessed in both the overall population and the PIK3CA/AKT1/PTEN - altered subgroup                                                                                                                                                                                                                               | To align with the dual primary endpoints.                                                                                                                                                                                                                                                                                                   |
| CSP Version 4.0/ 08 February 2022 | Clarification of the data cut-off trigger for primary PFS analysis as well as OS interim and final analysis                                                                                                                                                                                                                                                                        | To align with the dual primary endpoints, the triggers of these DCOs were to be based on reaching the prespecified maturity both in the overall population and the PIK3CA/AKT1/PTEN -altered subgroup                                                                                                                                       |
| CSP Version 4.0/ 08 February 2022 | ORR added to exploratory objective and definition added to endpoint                                                                                                                                                                                                                                                                                                                | To support the PFS analysis in various biomarker subgroups                                                                                                                                                                                                                                                                                  |
| CSP Version 4.0/ 08 February 2022 | Updates to the MTP. With the removal of the PFS interim analysis, the 0.1% alpha originally reserved for the interim PFS analysis was allocated to test PFS in the Overall Population. The MTP was updated to allow alpha recycling from PFS in the overall population to the PIK3CA/AKT1/PTEN -altered subgroup. The testing sequence of the key secondary endpoints was amended. | To maximise the chance of success in PFS in the PIK3CA/AKT1/PTEN -altered subgroup.                                                                                                                                                                                                                                                         |
| CSP Version 4.0/ 08 February 2022 | Definition of altered subgroup China FAS and China altered subgroup safety analysis set added, along with an updated timing for the China efficacy analysis                                                                                                                                                                                                                        | Toalign with the updated planned analysis for the global cohort.                                                                                                                                                                                                                                                                            |

a The changes in CSP Version 2.0 (03 June 2021) came into effect with CSP Version 3.0 (29 June 2021). Important protocol violation were reported for 8.8% of patients, the majority concerned use of prior medication, for details see below.

<div style=\"page-break-after: always\"></div>

Table 39 Important protocol deviations (overall population)

|                                                                                                                                                                                                                  | Number (%) of patients               | Number (%) of patients          | Number (%) of patients   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------|--------------------------|
| Important protocol deviation a                                                                                                                                                                                   | Capivasertib + Fulvestrant (N = 355) | Placebo + Fulvestrant (N = 353) | Total (N = 708)          |
| Number of patients with at least 1 important deviation                                                                                                                                                           | 38 (10.7)                            | 24 (6.8)                        | 62 (8.8)                 |
| Patients who deviate from key entry criteria per the Clinical Study Protocol b                                                                                                                                   | 17 (4.8)                             | 9 (2.5)                         | 26 (3.7)                 |
| Inclusion Criterion 6 (histologically confirmed HR+/HER2- breast cancer)                                                                                                                                         | 1 (0.3)                              | 0                               | 1 (0.1)                  |
| Inclusion Criterion 9 (criterion for measurable lesion)                                                                                                                                                          | 1 (0.3)                              | 0                               | 1 (0.1)                  |
| Inclusion Criterion 11 (consent to FFPE tumor sample for central testing)                                                                                                                                        | 1 (0.3)                              | 0                               | 1 (0.1)                  |
| Exclusion Criterion 21 (more than 1 line of chemotherapy for inoperable locally advanced or metastatic disease)                                                                                                  | 1 (0.3)                              | 0                               | 1 (0.1)                  |
| Exclusion Criterion 22 (prior medication use)                                                                                                                                                                    | 12 (3.4)                             | 9 (2.5)                         | 21 (3.0)                 |
| Missing                                                                                                                                                                                                          | 1 (0.3)                              | 0                               | 1 (0.1)                  |
| Randomised patients received capivasertib/placebo at incorrect dose for more than 4 days during any treatment cycle                                                                                              | 13 (3.7)                             | 3 (0.8)                         | 16 (2.3)                 |
| Fulvestrant administered 4 or more days prior planned per protocol/label date (D28 or D14 depending on cycle)                                                                                                    | 9 (2.5)                              | 3 (0.8)                         | 12 (1.7)                 |
| Non-compliance with screening procedure protocol requirements (RECIST v1.1 tumor assessment not performed or not performed within screening period of 28 days)                                                   | 0                                    | 4 (1.1)                         | 4 (0.6)                  |
| Patient randomised but did not receive study treatment                                                                                                                                                           | 0                                    | 3 (0.8)                         | 3 (0.4)                  |
| Failure to complete or comply with inclusion/exclusion criteria (IC#2; IC#6; IC#7; IC#8; IC#9; IC#11; IC#13; EC#2; EC#5; EC#10; EC#14; EC#20; EC#21; EC#22) for cases not covered by program protocol deviations | 0                                    | 1 (0.3)                         | 1 (0.1)                  |
| Non-compliance with protocol restrictions (e.g., use of prohibited medication or prohibited anti-cancer treatment therapy or wash out periods not respected [including St John's Wort])                          | 0                                    | 1 (0.3)                         | 1 (0.1)                  |

a Important deviations before the start of treatment and during treatment, as per SAP, are reported in this table.

b Patients allocated to treatment who were subsequently discovered to fail the eligibility criteria.

Specific inclusion/exclusion criteria defined as IPD are listed in the PDMP.

The same patient may have had more than 1 important protocol deviation.

Impact of COVID-19 pandemic

All patients were randomised into the study after the start of the COVID-19 pandemic. The proportion of patients in the FAS with 1 or more disruptions due to the pandemic was low (37 patients, 5.2%), and was  similar  between  treatment  arms.  The  majority  of  disruptions  were  impacts  on  study  visits  (32 patients, 4.5%). Six patients (0.8%) had study drug impacted, and 1 patient (0.1%) withdrew from the study due to COVID-19.

<div style=\"page-break-after: always\"></div>

## Biomarker test and assignment to populations

PIK3CA/AKT1/PTEN alterations were identified by FoundationOne ® CDx (F1CDx) and classified as altered or non-altered, as per the biomarker rules described in CSR Appendix 16.1.13. According to the CSR the samples were analysed retrospectively.

## · Baseline data

The overall study population had a median age of 58.0 years including 30.7% patients &gt; 65 years. Most patients were women (99.0%), most patients were White (57.5%) followed by Asian (26.7%). Median weight was 65.5 kg with a very wide range (34-150 kg), in line with the inclusion criteria 99.7% of patients presented with ECOG 0-1. The majority of patients was in postmenopausal state (77.3%).

Metastatic disease state was predominant (98.2%), most commonly located in bone and locomotor sites (73.0%), liver (43.9%) and lung (27.4%). At initial diagnosis the most common histology was invasive ductal carcinoma, 33.1 % presented with American Joint Committee on Cancer (AJCC) stage IV.

All tumours were tested ER positive, the majority developed secondary endocrine resistance.

All patients enrolled in the study were treated with previous endocrine therapy and, i.e. an AI, 44.6 % had also received tamoxifen. 76.1% had been treated with 1 line of endocrine treatment in the locally advanced/metastatic setting. The majority had received CDK 4/6 inhibitors (70.1 %).

49.4% had been treated with chemotherapy in the (neo)adjuvant setting and 18.2 % had received chemotherapy in the locally advanced/metastatic setting.

Details on patient characteristics, disease characteristics and prior treatment are given in the following tables.

<div style=\"page-break-after: always\"></div>

## Table 40 Patient and disease characteristics

|                                                  | Overall Population                    | Overall Population             | Overall Population   | Altered Population                    | Altered Population              | Altered Population   |
|--------------------------------------------------|---------------------------------------|--------------------------------|----------------------|---------------------------------------|---------------------------------|----------------------|
|                                                  | Capivaserti b + fulvestrant (N = 355) | Placebo + fulvestrant (N= 353) | Total (N = 708)      | Capivaserti b + fulvestrant (N = 155) | Placebo + fulvestrant (N = 134) | Total (N = 289)      |
| Median age, years (range)                        | 59.0 (26, 84)                         | 58.0 (26, 90)                  | 58.0 (26, 90)        | 58.0 (36, 84)                         | 60.0 (34, 90)                   | 59.0 (34, 90)        |
| Age group, n (%)                                 |                                       |                                |                      |                                       |                                 |                      |
| < 50 years                                       | 76 (21.4)                             | 99 (28.0)                      | 175 (24.7)           | 27 (17.4)                             | 29 (21.6)                       | 56 (19.4)            |
| ≥ 50 to < 65 years                               | 164 (46.2)                            | 152 (43.1)                     | 316 (44.6)           | 83 (53.5)                             | 60 (44.8)                       | 143 (49.5)           |
| ≥ 65 to < 75 years                               | 91 (25.6)                             | 76 (21.5)                      | 167 (23.6)           | 37 (23.9)                             | 28 (20.9)                       | 65 (22.5)            |
| ≥ 75 years                                       | 24 (6.8)                              | 26 (7.4)                       | 50 (7.1)             | 8 (5.2)                               | 17 (12.7)                       | 25 (8.7)             |
| Sex, n (%)                                       |                                       |                                |                      |                                       |                                 |                      |
| Male                                             | 3 (0.8)                               | 4 (1.1)                        | 7 (1.0)              | 2 (1.3)                               | 0                               | 2 (0.7)              |
| Female                                           | 352 (99.2)                            | 349 (98.9)                     | 701 (99.0)           | 153 (98.7)                            | 134 (100)                       | 287 (99.3)           |
| Race, n (%)                                      |                                       |                                |                      |                                       |                                 |                      |
| Black or African American                        | 4 (1.1)                               | 4 (1.1)                        | 8 (1.1)              | 2 (1.3)                               | 1 (0.7)                         | 3 (1.0)              |
| White                                            | 201 (56.6)                            | 206 (58.4)                     | 407 (57.5)           | 75 (48.4)                             | 76 (56.7)                       | 151 (52.2)           |
| Other a                                          | 52 (14.6)                             | 47 (13.3)                      | 99 (14.0)            | 29 (18.7)                             | 21 (15.7)                       | 50 (17.3)            |
| WHO/ ECOG PS, n (%)                              | WHO/ ECOG PS, n (%)                   | WHO/ ECOG PS, n (%)            |                      |                                       |                                 |                      |
| (0) Normal activity                              | 224 (63.1)                            | 241 (68.3)                     | 465 (65.7)           | 93 (60.0)                             | 97 (72.4)                       | 190 (65.7)           |
| (1) Restricted activity                          | 131 (36.9)                            | 111 (31.4)                     | 242 (34.2)           | 62 (40.0)                             | 36 (26.9)                       | 98 (33.9)            |
| (2) In bed less than or equal to 50% of the time | 0                                     | 1 (0.3)                        | 1 (0.1)              | 0                                     | 1 (0.7)                         | 1 (0.3)              |
| Weight (kg)                                      |                                       |                                |                      |                                       |                                 |                      |
| Mean (SD)                                        | 67.7 (16.19)                          | 68.8 (16.90)                   | 68.3 (16.55)         | 67.9 (14.63)                          | 69.1 (16.81)                    | 68.4 (15.66)         |
| Median                                           | 65.0                                  | 66.5                           | 65.7                 | 65.8                                  | 66.7                            | 66.0                 |
| Range                                            | 34-150                                | 37-147                         | 34-150               | 44-115                                | 37-124                          | 37-124               |
| Diabetic status                                  |                                       |                                |                      |                                       |                                 |                      |
| Diabetes                                         | 34 (9.6)                              | 20 (5.7)                       | 54 (7.6)             | 18 (11.6)                             | 8 (6.0)                         | 26 (9.0)             |
| No Diabetes                                      | 321 (90.4)                            | 333 (94.3)                     | 654 (92.4)           | 137 (88.4)                            | 126 (94.0)                      | 263 (91.0)           |

<div style=\"page-break-after: always\"></div>

## Table 41 Illness characteristics

|                                         | Overall Population                      | Overall Population                      | Overall Population                      | Altered Population                      | Altered Population                      | Altered Population                      |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| b                                       | Capivaserti + fulvestrant (N = 355)     | Placebo + fulvestrant (N= 353)          | Total (N = 708)                         | Capivaserti b + fulvestrant (N = 155)   | Placebo + fulvestrant (N = 134)         | Total (N = 289)                         |
| Overall disease classification, n (%)   | Overall disease classification, n (%)   | Overall disease classification, n (%)   | Overall disease classification, n (%)   | Overall disease classification, n (%)   | Overall disease classification, n (%)   | Overall disease classification, n (%)   |
| Locally advanced c                      | 6 (1.7)                                 | 6 (1.7)                                 | 12 (1.7)                                | 0                                       | 2 (1.5)                                 | 2 (0.7)                                 |
| Missing d                               | 0                                       | 1 (0.3)                                 | 1 (0.1)                                 | 0                                       | 0                                       | 0                                       |
| Metastatic b                            | 349 (98.3)                              | 346 (98.0)                              | 695 (98.2)                              | 155 (100)                               | 132 (98.5)                              | 287 (99.3)                              |
| Bone and locomotor                      | 261 (73.5)                              | 256 (72.5)                              | 517 (73.0)                              | 123 (79.4)                              | 99 (73.9)                               | 222 (76.8)                              |
| Liver                                   | 156 (43.9)                              | 155 (43.9)                              | 311 (43.9)                              | 72 (46.5)                               | 52 (38.8)                               | 124 (42.9)                              |
| Lung                                    | 109 (30.7)                              | 85 (24.1)                               | 194 (27.4)                              | 53 (34.2)                               | 37 (27.6)                               | 90 (31.1)                               |
| Distant lymph nodes                     | 57 (16.1)                               | 65 (18.4)                               | 122 (17.2)                              | 24 (15.5)                               | 30 (22.4)                               | 54 (18.7)                               |
| AJCC Stage IV                           | 116 (32.7)                              | 118 (33.4)                              | 234 (33.1)                              | 50 (32.3)                               | 44 (32.8)                               | 94 (32.5)                               |
| Menopausal status (females only), n (%) | Menopausal status (females only), n (%) | Menopausal status (females only), n (%) | Menopausal status (females only), n (%) | Menopausal status (females only), n (%) | Menopausal status (females only), n (%) | Menopausal status (females only), n (%) |
| Pre/peri- menopausal                    | 65 (18.3)                               | 89 (25.2)                               | 154 (21.8)                              | 23 (14.8)                               | 29 (21.6)                               | 52 (18.0)                               |
| Post-menopausal                         | 287 (80.8)                              | 260 (73.7)                              | 547 (77.3)                              | 130 ( 83.9)                             | 105 ( 78.4)                             | 235 (81.3)                              |
| Receptor status                         | Receptor status                         | Receptor status                         | Receptor status                         | Receptor status                         | Receptor status                         | Receptor status                         |
| ER+/PR+                                 | 255 (71.8)                              | 246 (69.7)                              | 501 (70.8)                              | 116 (74.8)                              | 101 (75.4)                              | 217 (75.1)                              |
| ER+/PR-                                 | 94 (26.5)                               | 103 (29.2)                              | 197 (27.8)                              | 35 (22.6)                               | 31 (23.1)                               | 66 (22.8)                               |
| ER+/PR unknown                          | 5 (1.4)                                 | 4 (1.1)                                 | 9 (1.3)                                 | 4 (2.6)                                 | 2 (1.5)                                 | 6 (2.1)                                 |
| ER- d                                   | 1 (0.3)                                 | 0                                       | 1 (0.1)                                 | 0                                       | 0                                       | 0                                       |
| Type of endocrine resistance, n (%)     | Type of endocrine resistance, n (%)     | Type of endocrine resistance, n (%)     | Type of endocrine resistance, n (%)     | Type of endocrine resistance, n (%)     | Type of endocrine resistance, n (%)     | Type of endocrine resistance, n (%)     |
| Primary                                 | 127 (35.8)                              | 135 (38.2)                              | 262 (37.0)                              | 60 (38.7)                               | 55 (41.0)                               | 115 (39.8)                              |
| Secondary                               | 228 (64.2)                              | 218 (61.8)                              | 446 (63.0)                              | 95 (61.3)                               | 79 (59.0)                               | 174 (60.2)                              |

d One patient did not have any site of disease as during the treatment phase it was discovered that the lung lesion with which patient was randomised was not metastasis but primary lung cancer.

## Table 42 Prior treatments

|                               | Overall Population                    | Overall Population             | Overall Population            | Altered Population                    | Altered Population              | Altered Population            |
|-------------------------------|---------------------------------------|--------------------------------|-------------------------------|---------------------------------------|---------------------------------|-------------------------------|
|                               | Capivaserti b + fulvestrant (N = 355) | Placebo + fulvestrant (N= 353) | Total (N = 708)               | Capivaserti b + fulvestrant (N = 155) | Placebo + fulvestrant (N = 134) | Total (N = 289)               |
| Prior hormonal therapy, n (%) | Prior hormonal therapy, n (%)         | Prior hormonal therapy, n (%)  | Prior hormonal therapy, n (%) | Prior hormonal therapy, n (%)         | Prior hormonal therapy, n (%)   | Prior hormonal therapy, n (%) |
| Aromatase inhibitor           | 355 (100)                             | 353 (100)                      | 708 (100)                     | 155 (100)                             | 134 (100)                       | 289 (100)                     |
| Tamoxifen                     | 157 (44.2)                            | 155 (43.9)                     | 312 (44.1)                    | 69 (44.5)                             | 57 (42.5)                       | 126 (43.6)                    |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                          | Overall Population                                                                                                                       | Overall Population                                                                                                                       | Overall Population                                                                                                                       | Altered Population                                                                                                                       | Altered Population                                                                                                                       | Altered Population                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| b                                                                                                                                        | Capivaserti + fulvestrant (N = 355)                                                                                                      | Placebo + fulvestrant (N= 353)                                                                                                           | Total (N = 708)                                                                                                                          | Capivaserti b + fulvestrant (N = 155)                                                                                                    | Placebo + fulvestrant (N = 134)                                                                                                          | Total (N = 289)                                                                                                                          |
| Prior CDK4/6 inhibitors, n (%)                                                                                                           | Prior CDK4/6 inhibitors, n (%)                                                                                                           | Prior CDK4/6 inhibitors, n (%)                                                                                                           | Prior CDK4/6 inhibitors, n (%)                                                                                                           | Prior CDK4/6 inhibitors, n (%)                                                                                                           | Prior CDK4/6 inhibitors, n (%)                                                                                                           | Prior CDK4/6 inhibitors, n (%)                                                                                                           |
| Yes                                                                                                                                      | 247 (69.6)                                                                                                                               | 249 (70.5)                                                                                                                               | 496 (70.1)                                                                                                                               | 113 (72.9)                                                                                                                               | 93 (69.4)                                                                                                                                | 206 (71.3)                                                                                                                               |
| No                                                                                                                                       | 108 (30.4)                                                                                                                               | 104 (29.5)                                                                                                                               | 212 (29.9)                                                                                                                               | 42 (27.1)                                                                                                                                | 41 (30.6)                                                                                                                                | 83 (28.7)                                                                                                                                |
| Treatment not approved                                                                                                                   | 23 (21.3)                                                                                                                                | 25 (24.0)                                                                                                                                | 48 (22.6)                                                                                                                                | 10 (23.8)                                                                                                                                | 11 (26.8)                                                                                                                                | 21 (25.3)                                                                                                                                |
| Treatment not affordable or not reimbursed                                                                                               | 26 (24.1)                                                                                                                                | 19 (18.3)                                                                                                                                | 45 (21.2)                                                                                                                                | 10 (23.8)                                                                                                                                | 5 (12.2)                                                                                                                                 | 15 (18.1)                                                                                                                                |
| Tolerability concerns                                                                                                                    | Tolerability concerns                                                                                                                    | Tolerability concerns                                                                                                                    | Tolerability concerns                                                                                                                    | Tolerability concerns                                                                                                                    | Tolerability concerns                                                                                                                    | Tolerability concerns                                                                                                                    |
| Haematologi c                                                                                                                            | 1 (0.9)                                                                                                                                  | 1 (1.0)                                                                                                                                  | 2 (0.9)                                                                                                                                  | 1 (2.4)                                                                                                                                  | 1 (2.4)                                                                                                                                  | 2 (2.4)                                                                                                                                  |
| Non- haematologic                                                                                                                        | 1 (0.9)                                                                                                                                  | 0                                                                                                                                        | 1 (0.5)                                                                                                                                  |                                                                                                                                          |                                                                                                                                          |                                                                                                                                          |
| Patient's preference                                                                                                                     | 15 (13.9)                                                                                                                                | 18 (17.3)                                                                                                                                | 33 (15.6)                                                                                                                                | 7 (16.7)                                                                                                                                 | 7 (17.1)                                                                                                                                 | 14 (16.9)                                                                                                                                |
| Healthcare provider's preference                                                                                                         | 39 (36.1)                                                                                                                                | 40 (38.5)                                                                                                                                | 79 (37.3)                                                                                                                                | 13 (31.0)                                                                                                                                | 17 (41.5)                                                                                                                                | 30 (36.1)                                                                                                                                |
| Prior chemotherapy, n (%)                                                                                                                | Prior chemotherapy, n (%)                                                                                                                | Prior chemotherapy, n (%)                                                                                                                | Prior chemotherapy, n (%)                                                                                                                | Prior chemotherapy, n (%)                                                                                                                | Prior chemotherapy, n (%)                                                                                                                | Prior chemotherapy, n (%)                                                                                                                |
| (Neo)adjuvant treatment only                                                                                                             | 145 (40.8)                                                                                                                               | 148 (41.9)                                                                                                                               | 293 (41.4)                                                                                                                               | 62 (40.0)                                                                                                                                | 61 (45.5)                                                                                                                                | 123 (42.6)                                                                                                                               |
| Locally advanced (inoperable) / metastatic treatment                                                                                     | 65 (18.3)                                                                                                                                | 64 (18.1)                                                                                                                                | 129 (18.2)                                                                                                                               | 30 (19.4)                                                                                                                                | 23 (17.2)                                                                                                                                | 53 (18.3)                                                                                                                                |
| Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  | Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  | Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  | Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  | Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  | Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  | Prior (neo)adjuvant chemotherapy, n (%)                                                                                                  |
| Yes                                                                                                                                      | 180 (50.7)                                                                                                                               | 170 (48.2)                                                                                                                               | 350 (49.4)                                                                                                                               | 79 (51.0)                                                                                                                                | 67 (50.0)                                                                                                                                | 146 (50.5)                                                                                                                               |
| No                                                                                                                                       | 175 (49.3)                                                                                                                               | 183 (51.8)                                                                                                                               | 358 (50.6)                                                                                                                               | 76 (49.0)                                                                                                                                | 67 (50.0)                                                                                                                                | 143 (49.5)                                                                                                                               |
| Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease e                                         |
| 0                                                                                                                                        | 39 (11.0)                                                                                                                                | 54 (15.3)                                                                                                                                | 93 (13.1)                                                                                                                                | 13 (8.4)                                                                                                                                 | 20 (14.9)                                                                                                                                | 33 (11.4)                                                                                                                                |
| 1                                                                                                                                        | 287 (80.8)                                                                                                                               | 252 (71.4)                                                                                                                               | 539 (76.1)                                                                                                                               | 131 (84.5)                                                                                                                               | 96 (71.6)                                                                                                                                | 227 (78.5)                                                                                                                               |
| 2                                                                                                                                        | 29 (8.2)                                                                                                                                 | 47 (13.3)                                                                                                                                | 76 (10.7)                                                                                                                                | 11 (7.1)                                                                                                                                 | 18 (13.4)                                                                                                                                | 29 (10.0)                                                                                                                                |
| Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens | Prior lines of endocrine-based therapy for locally advanced (inoperable) or metastatic disease - aromatase inhibitor containing regimens |
| 0                                                                                                                                        | 42 (11.8)                                                                                                                                | 56 (15.9)                                                                                                                                | 98 (13.8)                                                                                                                                | 15 (9.7)                                                                                                                                 | 21 (15.7)                                                                                                                                | 36 (12.5)                                                                                                                                |
| 1                                                                                                                                        | 301 (84.8)                                                                                                                               | 275 (77.9)                                                                                                                               | 576 (81.4)                                                                                                                               | 136 (87.7)                                                                                                                               | 103 (76.9)                                                                                                                               | 239 (82.7)                                                                                                                               |
| 2                                                                                                                                        | 12 (3.4)                                                                                                                                 | 22 (6.2)                                                                                                                                 | 34 (4.8)                                                                                                                                 | 4 (2.6)                                                                                                                                  | 10 (7.5)                                                                                                                                 | 14 (4.8)                                                                                                                                 |
| Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      | Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      | Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      | Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      | Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      | Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      | Prior lines of therapy for locally advanced (inoperable) or metastatic disease (includes endocrine or chemotherapy)                      |
| 0                                                                                                                                        | 37 (10.4)                                                                                                                                | 52 (14.7)                                                                                                                                | 89 (12.6)                                                                                                                                | 12 (7.7)                                                                                                                                 | 20 (14.9)                                                                                                                                | 32 (11.1)                                                                                                                                |
| 1                                                                                                                                        | 235 (66.2)                                                                                                                               | 208 (58.9)                                                                                                                               | 443 (62.6)                                                                                                                               | 107 (69.0)                                                                                                                               | 79 (59.0)                                                                                                                                | 186 (64.4)                                                                                                                               |
| 2                                                                                                                                        | 73 (20.6)                                                                                                                                | 77 (21.8)                                                                                                                                | 150 (21.2)                                                                                                                               | 31 (20.0)                                                                                                                                | 29 (21.6)                                                                                                                                | 60 (20.8)                                                                                                                                |
| 3                                                                                                                                        | 10 (2.8)                                                                                                                                 | 16 (4.5)                                                                                                                                 | 26 (3.7)                                                                                                                                 | 5 (3.2)                                                                                                                                  | 6 (4.5)                                                                                                                                  | 11 (3.8)                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

- e Race data for France, Hungary, Belgium were not allowed to be collected per local regulations and were recorded as 'other.'
- f Metastatic disease - patient has any metastatic site of disease.
- g Locally advanced - patient has only locally advanced sites of disease.
- h One patient did not have any site of disease as during the treatment phase it was discovered that the lung lesion with which patient was randomised was not metastasis but primary lung cancer.
- i Endocrine maintenance therapy was counted as a separate line.

The number of patients with data was used as the denominator for calculating percentages.

Details on type of the PIK3CA/AKT1/PTEN alteration status are that 44.2 % of the ITT belong to the confirmed non-altered subgroup, 40.8 % to the confirmed altered subgroup and 15.0 % to the unknown, i.e. no-result subgroup. More patients with confirmed PIK3CA/AKT1/PTEN alteration were randomised to the capivasertib+fulvestrant treatment group (43.7% vs 38.0%). Approximately 70% of PIK3CA/AKT1/PTEN alterations were alterations of PIK3CA only.

Table 43 Summary of PIK3CA/AKT1/PTEN alteration status (overall population)

|                                            | Number (%) of patients               | Number (%) of patients          | Number (%) of patients   |
|--------------------------------------------|--------------------------------------|---------------------------------|--------------------------|
| PIK3CA/AKT1/PTEN alteration status         | Capivasertib + Fulvestrant (N = 355) | Placebo + Fulvestrant (N = 353) | Total (N =708)           |
| Altered                                    | 155 (43.7)                           | 134 (38.0)                      | 289 (40.8)               |
| PIK3CA only a, b                           | 110 (31.0)                           | 92 (26.1)                       | 202 (28.5)               |
| AKT1 only a, b                             | 18 (5.1)                             | 15 (4.2)                        | 33 (4.7)                 |
| PTEN only a, b                             | 21 (5.9)                             | 16 (4.5)                        | 37 (5.2)                 |
| PIK3CA and AKT1 a                          | 2 (0.6)                              | 2 (0.6)                         | 4 (0.6)                  |
| PIK3CA and PTEN a                          | 4 (1.1)                              | 9 (2.5)                         | 13 (1.8)                 |
| Non-altered                                | 200 (56.3)                           | 219 (62.0)                      | 419 (59.2)               |
| Knownnon-altered (confirmed non-altered) c | 142 (40.0)                           | 171 (48.4)                      | 313 (44.2)               |
| No result (unknown)                        | 58 (16.3)                            | 48 (13.6)                       | 106 (15.0)               |
| FFPE not provided                          | 10 (2.8)                             | 4 (1.1)                         | 14 (2.0)                 |
| Not done (preanalytical failure)           | 39 (11.0)                            | 34 (9.6)                        | 73 (10.3)                |
| Not evaluable (post analytical failure)    | 9 (2.5)                              | 10 (2.8)                        | 19 (2.7)                 |

a Mutually exclusive groups.

b Patients with co-occurring mutations are excluded from single gene count.

c All patients included in the overall population with no qualifying alterations in PIK3CA, AKT1 and PTEN in their tumour, as determined by central testing. Patients with unknown PIK3CA/AKT1/PTEN alteration status were excluded from this subgroup.

Source: Table 14.1.14.

The following 2 below tables provide details on the type of previous treatment classes prior to study and post-study. Post-study 49.4 % of patients received further treatment, the majority being chemotherapy (43.2%),  much  less  patients  received  further  hormonal  treatment  (11.7  %)  or  targeted  treatment (9.0 %).

Table 44 Previous disease-related treatment classes (overall population)

|                            | Number (%) of patients               | Number (%) of patients          | Number (%) of patients   |
|----------------------------|--------------------------------------|---------------------------------|--------------------------|
| Previous treatment classes | Capivasertib + Fulvestrant (N = 355) | Placebo + Fulvestrant (N = 353) | Total (N 708)            |
| Immunotherapy              | 3 (0.8)                              | 1 (0.3)                         | 4 (0.6)                  |

<div style=\"page-break-after: always\"></div>

| Hormonal therapy 355   | Hormonal therapy 355   | (100)      | 353 (100)   | 708 (100)   |
|------------------------|------------------------|------------|-------------|-------------|
| Aromatase inhibitor    | Aromatase inhibitor    | 355 (100)  | 353 (100)   | 708 (100)   |
| Tamoxifen              | Tamoxifen              | 157 (44.2) | 155 (43.9)  | 312 (44.1)  |
| Cytotoxic chemotherapy | Cytotoxic chemotherapy | 210 (59.2) | 212 (60.1)  | 422 (59.6)  |
| Targeted therapy       | Targeted therapy       | 247 (69.6) | 249 (70.5)  | 496 (70.1)  |
| CDK4/6 inhibitor 247   | CDK4/6 inhibitor 247   | (69.6)     | 249 (70.5)  | 496 (70.1)  |
| Antiangiogenic therapy | Antiangiogenic therapy | 11 (3.1)   | 9 (2.5)     | 20 (2.8)    |
| Radiopharmaceuticals   | 0                      |            | 0           |             |
| PARPinhibitor          | PARPinhibitor          | 5 (1.4)    | 0           | 5 (0.7)     |
| Biologic therapy       | Biologic therapy       | 5 (1.4)    | 8 (2.3)     | 13 (1.8)    |
| Experimental therapy   | 0                      |            | 2 (0.6)     | 2 (0.3)     |
| Other                  | Other                  | 25 (7.0)   | 33 (9.3)    | 58 (8.2)    |

Other category includes other not experimental anti-cancer therapies, past LHRH analogue, prior denosumab or bisphosphonate if it was considered as anti-cancer by investigator.

Patients may appear under more than one previous therapy class, if they have received more than one treatment.

Table 45 Post-discontinuation disease-related anti-cancer therapy (overall population)

|                          | Number (%) of patients               | Number (%) of patients        | Number (%) of patients   |
|--------------------------|--------------------------------------|-------------------------------|--------------------------|
| Anti-cancer therapy a    | Capivasertib + Fulvestrant (N = 355) | Placebo Fulvestrant (N = 353) | Total (N=708)            |
| Total number of patients | 238 (67.0)                           | 264 (74.8)                    | 502 (70.9)               |
| Immunotherapy            | 9 (2.5)                              | 3 (0.8)                       | 12 (1.7)                 |
| Hormonal therapy         | 98 (27.6)                            | 107 (30.3)                    | 205 (29.0)               |
| Cytotoxic chemotherapy   | 199 (56.1)                           | 216 (61.2)                    | 415 (58.6)               |
| Targeted therapy         | 67 (18.9)                            | 91 (25.8)                     | 158 (22.3)               |
| Antiangiogenic therapy   | 22 (6.2)                             | 29 (8.2)                      | 51 (7.2)                 |
| PARP inhibitor           | 3 (0.8)                              | 8 (2.3)                       | 11 (1.6)                 |
| Biologic therapy         | 4 (1.1)                              | 4 (1.1)                       | 8 (1.1)                  |
| Experimental therapy     | 2 (0.6)                              | 1 (0.3)                       | 3 (0.4)                  |
| Other                    | 4 (1.1)                              | 3 (0.8)                       | 7 (1.0)                  |

a Therapies post-discontinuation of study treatment.

Patients may have more than one cancer therapy.

Source: Table 14.1.19.1.

The applicant also provided baseline patient and disease characteristics by either menopausal status, by prior treatment with CDK 4/6 inhibitors and PIK3CA/AKT1/PTEN alteration status, i.e. confirmed nonaltered, unknown.

Prior CDK 4/6 inhibitor use was specifically addressed. Reasons not to use were predominantly health care providers preference, CDK 4/6 inhibitors not affordable or reimbursed, and CDK 4/6 inhibitors not approved.

In comparison to the CDK 4/6 inhibitors treated subgroup, the CDK 4/6 inhibitors naïve subgroup had a higher median age, less patients with pre/peri menopausal status, less AJCC stage IV at diagnosis, more (neo)adjuvant chemotherapy and substantially more patients with no prior endocrine based therapy for locally advanced or metastatic breast cancer (40.6% vs 1.4%). The proportion of CDK 4/6 inhibitors naïve patients was higher in region 3 and 2 than in 1 (46.2% vs 31.6 % vs 22.2% of the CDK 4/6 inhibitors naïve population originated from the respective region). Thus, 47/395 patients (11.9%) in region 1 (including Western Europe, North America) and 98/177 patients (55.4%) in region 3 (Asia) were naïve to CDK 4/6 inhibitors.

<div style=\"page-break-after: always\"></div>

In  comparison  to  the  postmenopausal  subgroup,  the  pre/peri  menopausal  subgroup  included  more patients  with  AJCC  stage  IV  at  diagnosis  and  liver  metastases,  more  patients  treated  with  CDK  4/6 inhibitors and less patients with PIK3CA/AKT1/PTEN alterations.

## · Numbers analysed

The primary analysis populations for reporting efficacy data and to summarise baseline characteristics were as follows:

- o The overall population (FAS) was analysed according to randomised treatment regardless of the treatment received (ITT principle).
- o The altered population (Altered Subgroup FAS).

In addition, exploratory analyses for the complementary non-altered population are provided and the non-altered  population is  further  divided  in  the Known  Non-altered  Population ,  and  the No  Result Population .

## Figure 12 Efficacy population terminology

## Overall Population

(FAS)

All patients randomised into the study, excluding patients randomised in China after the global cohort last patient  first  visit.  Analysed  according  to  randomised  treatment  regardless  of  the  treatment  received (ITT principle)

N = 708

## Altered Population

(Altered Subgroup FAS) Patients with a PIK3CA/AKT1/PTEN altered tumour determined by central testing

N = 289

## Non-altered Population

(Non-altered Subgroup FAS)  a

Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN altered tumour determined by central testing

N = 419

Known Non-altered Population (Confirmed  Nonaltered Subgroup FAS)  a Patients in the Nonaltered Population excluding those without a valid central test result N = 313

## No Result Population (Unknown FAS)  b Patients in the Nonaltered Population  without  a valid central test result

N = 106

<div style=\"page-break-after: always\"></div>

- a Pre-specified exploratory population.
- b Post hoc exploratory population.

Three DCOs (PFS primary [DCO1], OS interim and OS final) are planned for the pivotal CAPItello-291 study. Results for DCO1 (15 August 2022) are submitted in this marketing authorisation application.

## Table 46 CAPItello-291 Planned DCOs

|      |                                                |                    | Number of Events (Maturity of Data) a   | Number of Events (Maturity of Data) a   |
|------|------------------------------------------------|--------------------|-----------------------------------------|-----------------------------------------|
| DCO  | Analysis                                       | (Estimated) Date b | Overall Population                      | altered population c                    |
| DCO1 | PFS primary                                    | 15 August 2022     | 542 (77%)                               | 217 (77%)                               |
| DCO2 | OS interim (assuming 80% information fraction) | March 2024         | 394 (56%)                               | 158 (56%)                               |
| DCO3 | OS final                                       | May 2025           | 492 (70%)                               | 197 (70%)                               |

For each specified analysis, the planned analysis DCO is expected to occur when the required number of events have been observed in the overall population and similar maturity has been reached in the Altered Population.

Estimated date for DCO2 and DCO3.

a Assuming N = 280 for the Altered Population.

## · Outcomes and estimation

## Primary endpoint: Progression-free survival PFS (investigator assessment)

Table  47  Progression-free  survival  based  on  investigator  assessments,  per  RECIST  1.1  at DCO1 15 August 2022, primary analysis - pivotal CAPItello-291 study (overall population and altered population)

|                                               | Overall Population                   | Overall Population              | Altered Population                   | Altered Population              |
|-----------------------------------------------|--------------------------------------|---------------------------------|--------------------------------------|---------------------------------|
|                                               | Capivasertib + Fulvestrant (N = 355) | Placebo + Fulvestrant (N = 353) | Capivasertib + Fulvestrant (N = 155) | Placebo + Fulvestrant (N = 134) |
| Total number of patients with events, n (%) a | 258 (72.7)                           | 293 (83.0)                      | 121 (78.1)                           | 115 (85.8)                      |
| RECIST progression                            | 249 (70.1)                           | 281 (79.6)                      | 115 (74.2)                           | 108 (80.6)                      |
| Target lesions b                              | 104 (29.3)                           | 142 (40.2)                      | 45 (29.0)                            | 59 (44.0)                       |
| Non-target lesions b                          | 73 (20.6)                            | 107 (30.3)                      | 31 (20.0)                            | 42 (31.3)                       |
| New lesions b                                 | 156 (43.9)                           | 188 (53.3)                      | 76 (49.0)                            | 63 (47.0)                       |
| Death in the absence of progression           | 9 (2.5)                              | 12 (3.4)                        | 6 (3.9)                              | 7 (5.2)                         |
| Median PFS (months) c                         | 7.2                                  | 3.6                             | 7.3                                  | 3.1                             |
| 95% CI for median PFS c                       | 5.5, 7.4                             | 2.8, 3.7                        | 5.5, 9.0                             | 2.0, 3.7                        |
| PFS rate at 6 months (%) c                    | 51.8                                 | 32.0                            | 53.4                                 | 29.6                            |
| 95% CI for PFS rate at 6 months c             | 46.4, 57.0                           | 27.0, 37.0                      | 45.1, 60.9                           | 21.9, 37.7                      |
| PFS rate at 9 months (%) c                    | 40.9                                 | 24.4                            | 42.0                                 | 21.6                            |
| 95% CI for PFS rate at 9 months c             | 35.6, 46.1                           | 19.9, 29.1                      | 34.0, 49.7                           | 14.9, 29.1                      |
| PFS rate at 12 months (%) c                   | 28.5                                 | 18.4                            | 28.2                                 | 15.8                            |
| 95% CI for PFS rate at 12 months c            | 23.7, 33.5                           | 14.4, 22.8                      | 21.2, 35.6                           | 10.0, 22.7                      |
| Comparison between groups                     |                                      |                                 |                                      |                                 |
| 2-sided p-value d                             | < 0.001                              | < 0.001                         | < 0.001                              | < 0.001                         |

<div style=\"page-break-after: always\"></div>

|                              | Overall Population                   | Overall Population              | Altered Population                   | Altered Population              |
|------------------------------|--------------------------------------|---------------------------------|--------------------------------------|---------------------------------|
|                              | Capivasertib + Fulvestrant (N = 355) | Placebo + Fulvestrant (N = 353) | Capivasertib + Fulvestrant (N = 155) | Placebo + Fulvestrant (N = 134) |
| Hazard ratio e               | 0.60                                 |                                 | 0.50                                 |                                 |
| 95% CI for hazard ratio e    | 0.51, 0.71                           |                                 | 0.38, 0.65                           |                                 |
| 96.50% CI for hazard ratio e | 0.50, 0.72                           |                                 | -                                    |                                 |

To the 551 PFS events contributed 530 progression events, most of them new lesions, and 21 deaths without documented progression. In the capivasertib + fulvestrant arm and the placebo + fulvestrant arm 97 (27.3%) and 60 (17.0 %) patients were censored, respectively.

Figure 13 Kaplan-Meier plot of progression-free survival based on investigator assessments, per  RECIST  1.1  at  DCO1  15  August  2022,  primary  analysis  -  pivotal  CAPItello-291  study (overall population)

<!-- image -->

Time from randomization (months)

133

86

78

64

55

44

81

115

66

59

51

41

33

24

43

23

Number of randomized patients/number ofevents

355/258

353/293

Number of patients at risk

Capivasertib+Fuvestrant 355330

266

252

Placebo + Fulvestrant

353329

207

182

+ indicates a censored observation.

Note: Progression determined by RECIST 1.1. Does not include RECIST progression events that occur after 2 or more missed visits or death after 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment. 2-sided p-value. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no), and geographic region (Region 1: United States, Canada, Western Europe, Australia, and Israel, Region 2: Latin America, Eastern Europe, and Russia vs Region 3: Asia). A hazard ratio &lt; 1 favours capivasertib + fulvestrant.

HR = hazard ratio.

207

142

199

136

172

106

166

100

138

83

25

12

25

11

21

10

8

4

8

4

5

3

2

1

2

1

1

0

0

0

<div style=\"page-break-after: always\"></div>

Figure 14 Kaplan-Meier plot of progression-free survival based on investigator assessments, per  RECIST  1.1  at  DCO1  15  August  2022,  primary  analysis  -  pivotal  CAPItello-291  study (altered population)

<!-- image -->

Time from randomization (months)

<!-- image -->

Note: Progression determined by RECIST 1.1. Does not include RECIST progression events that occur after 2 or more missed visits or within 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment. 2-sided p-value. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), and prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant.

HR = hazard ratio.

## Key secondary endpoint: Overall survival

According to the multiple testing procedure, only a small alpha was spent for the OS analysis at this data cut-off and the null hypothesis could not be rejected (spending small alpha was advised by the FDA, while originally no alpha was planned to be spent at all). Therefore, the results are exploratory only.

Table 48 Overall survival at DCO1 15 August 2022, secondary analysis - pivotal CAPItello-291 study (overall population)

|                                                                         | Capivasertib Fulvestrant (N = 355)   | +   | Placebo Fulvestrant (N = 353)   | +   |
|-------------------------------------------------------------------------|--------------------------------------|-----|---------------------------------|-----|
| Death, n (%)                                                            | 87 (24.5)                            |     | 108 (30.6)                      |     |
| Censored patients, n (%)                                                | 268 (75.5)                           |     | 245 (69.4)                      |     |
| Still in survival follow-up a                                           | 249 (70.1)                           |     | 215 (60.9)                      |     |
| Terminated prior to death b                                             | 19 (5.4)                             |     | 30 (8.5)                        |     |
| Lost to follow-up                                                       | 4 (1.1)                              |     | 3 (0.8)                         |     |
| Withdrawn consent                                                       | 15 (4.2)                             |     | 25 (7.1)                        |     |
| Discontinued study (any other specified reason for discontinuing study) | 0                                    |     | 2 (0.6)                         |     |
| Death with no recorded death date                                       | 0                                    |     | 0                               |     |
| Median overall survival (months) c                                      | NC                                   |     | NC                              |     |
| 95% CI for median overall survival c                                    | NC, NC                               |     | 21.7, NC                        |     |
| Overall survival rate at 18 months (%) c                                | 73.9                                 |     | 65.0                            |     |

<div style=\"page-break-after: always\"></div>

|                                                                    | Capivasertib + Fulvestrant (N = 355)   | Placebo Fulvestrant (N = 353)   | +   |
|--------------------------------------------------------------------|----------------------------------------|---------------------------------|-----|
| 95% CI for overall survival rate at 18 months c                    | 68.3, 78.7                             | 58.7, 70.6                      |     |
| Overall survival rate at 24 months (%) c                           | 64.3                                   | 56.5                            |     |
| 95% CI for overall survival rate at 24 months c                    | 55.5, 71.8                             | 48.3, 63.9                      |     |
| 2-sided p-value d                                                  | Not applicable                         | Not applicable                  |     |
| Hazard ratio e                                                     | 0.74                                   |                                 |     |
| 95% CI for hazard ratio e                                          | 0.56, 0.98                             |                                 |     |
| Median (range) duration of follow-up in censored patients (months) | 15.9 (0.5, 26.4)                       | 15.4 (0.5, 26.0)                |     |

Includes patients known to be alive at data cut-off date.

Includes patients with unknown survival status or patients who were lost to follow-up.

Kaplan-Meier estimate. CI for median overall survival is derived based on Brookmeyer-Crowley method.

Stratified log-rank test.

Stratified Cox proportional hazards model. A hazard ratio &lt; 1 favours capivasertib + fulvestrant.

Log-rank test and Cox model stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no).

0.01% alpha penalty assigned to the assessment of no OS detriment. Formal analysis not prespecified.

Figure 15 Kaplan-Meier plot of overall survival at DCO1 15 August 2022, secondary analysis pivotal CAPItello-291 study (overall population)

<!-- image -->

Capivesetib+ Fulvestrant 355351343335 327 321 318315306304295283 258

Plecebo + Fulvest rant

+ indicates a censored observation.

Note: 0.01% alpha penalty assigned to the assessment of no OS detriment. Formal analysis not prespecified. Patients not known to have died at the time of analysis are censored at the last recorded date on which the patient was last known to be alive. 2-sided p-value. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant. HR = hazard ratio.

237

224

211

198

181

170

154

144

134

119

106

95

90

81

76

63

59

44

45

33

30

19

15

9

11

5

5

2

0

0

0

355/87

353/108

<div style=\"page-break-after: always\"></div>

Figure 16 Kaplan-Meier plot of overall survival at DCO1 15 August 2022, secondary analysis pivotal CAPItello-291 study (altered population)

<!-- image -->

+ indicates a censored observation. Note: 0.01% alpha penalty assigned to the assessment of no OS detriment. Formal analysis not prespecified. Patients not known to have died at the time of analysis are censored at the last recorded date on which the patient was last known to be alive. 2-sided p-value. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant. HR = hazard ratio.

## Figure 17 Kaplan-Meier plot of overall survival at DCO1 15 August 2022, exploratory analysis - pivotal CAPItello-291 study (non-altered population)

<!-- image -->

+ indicates a censored observation. Note: Patients not known to have died at the time of analysis are censored at the last recorded date on which the patient was last known to be alive. 2sided p-value. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant. HR = hazard ratio.

## Other secondary endpoints

Overall response rate

<div style=\"page-break-after: always\"></div>

Formal tests for the objective response rates is planned for future analyses. Exploratory analyses for both primary populations were presented and best objective response rate by INV are reported for the overall population and for the PIK3CA/AKT1/PTEN altered population .

## Table 49 Overall response rate

| Descriptive statistics and estimate variability (ORR) Treatment   | Overall Population   | Overall Population   | Altered Population   | Altered Population   |
|-------------------------------------------------------------------|----------------------|----------------------|----------------------|----------------------|
| Descriptive statistics and estimate variability (ORR) Treatment   | C+F                  | P+F                  | C+F                  | P+F                  |
| Number of subjects g                                              | N=310                | N=320                | N=132                | N=124                |
| Number (%) patients response                                      | of with 71 (22.9)    | 39 (12.2)            | 38 (28.8)            | 12 9.7)              |

In the Known non altered population ,  ORR was 17.1 % for capivasertib+fulvestrant and 14.5 % for placebo+fulvestrant.

Duration of response - based on small numbers - was similar in both arms (9.8 vs 8.4 months and 9.4 vs  8.6  months  for  capivasertib+fulvestrant  and  placebo+fulvestrant  in  the  Overall  population  and PIK3CA/AKT1/PTEN altered population, respectively).

## PFS2

Table 50 Time from randomisation to second progression or death at DCO1 15 August 2022, secondary analysis - pivotal CAPItello-291 study (overall population and altered population)

|                                                                    | Overall Population               | Overall Population                | Altered Population                 | Altered Population                  |
|--------------------------------------------------------------------|----------------------------------|-----------------------------------|------------------------------------|-------------------------------------|
|                                                                    | Capivasertib Fulvestrant (N 355) | + = Placebo Fulvestrant (N = 353) | + Capivasertib Fulvestrant (N 155) | + = Placebo + Fulvestrant (N = 134) |
| Total number of patients with events, n (%) a                      | 176 (49.6)                       | 207 (58.6)                        | 79 (51.0)                          | 87 (64.9)                           |
| Second progression                                                 | 132 (37.2)                       | 155 (43.9)                        | 57 (36.8)                          | 62 (46.3)                           |
| Death in the absence of second progression                         | 44 (12.4)                        | 52 (14.7)                         | 22 (14.2)                          | 25 (18.7)                           |
| Censored patients, n (%) b                                         | 179 (50.4)                       | 146 (41.4)                        | 76 (49.0)                          | 47 (35.1)                           |
| Median PFS2 (months) c                                             | 14.7                             | 12.5                              | 15.5                               | 10.8                                |
| 95% CI for median PFS 2 c                                          | 13.6, 16.4                       | 11.3, 13.4                        | 13.2, 17.6                         | 8.1, 12.7                           |
| PFS2 rate at 6 months (%) c                                        | 85.3                             | 77.8                              | 86.7                               | 72.2                                |
| 95% CI for PFS2 rate at 6 months c                                 | 81.1, 88.7                       | 72.9, 82.0                        | 80.2, 91.2                         | 63.5, 79.2                          |
| PFS2 rate at 9 months (%) c                                        | 73.4                             | 63.5                              | 76.6                               | 55.1                                |
| 95% CI for PFS2 rate at 9 months c                                 | 68.3, 77.9                       | 58.0, 68.5                        | 68.9, 82.6                         | 45.9, 63.3                          |
| PFS2 rate at 12 months (%) c                                       | 62.8                             | 52.2                              | 64.4                               | 44.6                                |
| 95% CI for PFS 2 rate at 12 months c                               | 57.2, 67.9                       | 46.5, 57.6                        | 56.0, 71.6                         | 35.6, 53.2                          |
| 2-sided p-value d                                                  | < 0.001                          | < 0.001                           | < 0.001                            | < 0.001                             |
| Hazard ratio e                                                     | 0.70                             | 0.70                              | 0.52                               | 0.52                                |
| 95% CI for hazard ratio e                                          | 0.57, 0.86                       | 0.57, 0.86                        | 0.38, 0.71                         | 0.38, 0.71                          |
| Median (range) duration of follow-up in censored patients (months) | 13.1 (0.0, 25.0)                 | 12.9 (0.0, 24.9)                  | 13.8 (0.0, 24.9)                   | 13.0 (0.0, 24.0)                    |

Progression events determined by investigator assessment subsequent to the first subsequent therapy or death.

Patients alive and for whom a second disease progression has not been observed censored at the date last and without a second disease progression.

Calculated using the Kaplan-Meier technique.

known alive

<div style=\"page-break-after: always\"></div>

Calculated using stratified log-rank test.

Calculated using stratified Cox proportional hazards model. A hazard ratio &lt; 1 favours capivasertib + fulvestrant. Log-rank test and Cox model stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no).

For the 'Known Nonaltered Population' median PFS2 is reported with 13.9 vs 13.1 months (HR 0.95; 95% CI: 0.70, 1.29) for capivasertib+fulvestrant and placebo+fulvestrant, respectively.

## Patient-reported Outcomes / Health-related Quality of Life (HRQoL)

EORTC QLQ-C30, EORTC QLQ-BR23 and EQ-5D PRO questionnaires were used for the evaluation of HRQoL. Overall, presented data (data not shown) show no clinically relevant changes in quality of life between the control  and  the  experimental  arm  (neither  in  the  overall  population  nor  in  the  altered population).

## · Ancillary analyses

## Sensitivity analyses of PFS

Several sensitivity analyses were provided. Importantly, a BICR assessment was performed for the full population.

Further  sensitivity  analyses  for  evaluation  time  bias  and  for  attrition  bias  were  performed:  In  the sensitivity  analysis  for  evaluation  time  bias,  the  midpoint  between  the  time  of  progression  and  the previous evaluable RECIST v1.1 assessment was analysed. In the sensitivity analysis for attrition bias, patients who progressed or died in the absence of progression immediately following 2 or more missed assessments were included. Patients who took subsequent therapy prior to progression or death were censored at their last evaluable assessment prior to taking the subsequent therapy.

A further sensitivity analysis was conducted to assess for the potential impact of COVID-19 deaths on PFS. There was no impact of COVID-19 deaths on PFS. One patient in the placebo + fulvestrant arm died due to COVID-19.

Table 51 Progression-free survival sensitivity analyses ( overall population and PIK3CA/AKT1/PTEN altered population)

|                             |                    | Number (%) of patients with   | Median (months)    | Comparison between groups   | Comparison between groups   | Comparison between groups   |
|-----------------------------|--------------------|-------------------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|
| Group                       | N                  | events                        | a                  | Hazard ratio b, c           | 95% CI b, c                 | 2-sided p-value c, d        |
| Overall Population          | Overall Population | Overall Population            | Overall Population | Overall Population          | Overall Population          | Overall Population          |
| Evaluation-time bias e      |                    |                               |                    |                             |                             |                             |
| Capivasertib + fulvestrant  | 355                | 258 (72.7)                    | 6.3                | 0.60                        | 0.51, 0.71                  | < 0.001                     |
| Placebo + fulvestrant       | 353                | 293 (83.0)                    | 2.7                |                             |                             |                             |
| Attrition bias f            |                    |                               |                    |                             |                             |                             |
| Capivasertib + fulvestrant  | 355                | 265 (74.6)                    | 7.2                | 0.61                        | 0.52, 0.72                  | < 0.001                     |
| Placebo + fulvestrant       | 353                | 296 (83.9)                    | 3.6                |                             |                             |                             |
| Ascertainment bias (BICR) g |                    |                               |                    |                             |                             |                             |
| Capivasertib + fulvestrant  | 355                | 215 (60.6)                    | 7.3                | 0.61                        | 0.50, 0.73                  | < 0.001                     |
| Placebo + fulvestrant       | 353                | 238 (67.4)                    | 3.7                |                             |                             |                             |
| Altered Population          |                    |                               |                    |                             |                             |                             |
| Evaluation-time bias e      |                    |                               |                    |                             |                             |                             |
| Capivasertib + fulvestrant  | 155                | 121 (78.1)                    | 6.4                | 0.50                        | 0.39, 0.66                  | < 0.001                     |
| Placebo + fulvestrant       | 134                | 115 (85.8)                    | 2.4                |                             |                             |                             |

<div style=\"page-break-after: always\"></div>

| Attrition bias f            |     |            |     |      |            |         |
|-----------------------------|-----|------------|-----|------|------------|---------|
| Capivasertib + fulvestrant  | 155 | 121 (78.1) | 7.3 | 0.51 | 0.39, 0.66 | < 0.001 |
| Placebo + fulvestrant       | 134 | 117 (87.3) | 3.3 |      |            |         |
| Ascertainment bias (BICR) g |     |            |     |      |            |         |
| Capivasertib + fulvestrant  | 155 | 98 (63.2)  | 7.3 | 0.51 | 0.38, 0.68 | < 0.001 |
| Placebo + fulvestrant       | 134 | 88 (65.7)  | 3.3 |      |            |         |

a

b

c

d

e

Kaplan-Meier estimate.

Cox proportional hazards model.

Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no). Stratified log-rank test.

The midpoint between the time of progression and the previous evaluable RECIST v1.1 assessment was analysed.

f Patients who progressed or died in the absence of progression immediately following 2 or more missed assessments were included. Patients who took subsequent therapy prior to progression or death were censored at their last evaluable assessment prior to taking the subsequent therapy.

g Blinded Independent Central Review data based upon RECIST v1.1 was used. Source: Table 14.2.1.5 and Table 14.2.1.18.

## Concordance rates for PFS between investigator and central review

Disagreements between investigator and central reviews of RECIST v1.1 progression were presented for each treatment group (data not shown).

Exploratory analyses: PFS in the non-altered Population

Figure 18 Kaplan-Meier plot of progression-free survival based on investigator assessments, per RECIST 1.1 at DCO1 15 August 2022, exploratory analysis - pivotal CAPItello-291 study (non-altered population)

<!-- image -->

Time from randomization (months)

61

49

40

33

29

22

42

39

34

27

22

18

22

17

Numberof patients/number

randomized ofevents

200/137

219/178

Number of patients at risk

Capivasertib+Fulvestrant 200

180

139

131

Placebo+Fulvestrant

219

205

130

118

+ indicates a censored observation.

Note: Progression determined by RECIST 1.1. Does not include RECIST progression events that occur after 2 or more missed visits or within 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), and prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant. Non-altered Population includes patients with unknown biomarker results. HR = hazard ratio.

Source: Figure 14.2.1.24, CAPItello-291 CSR, Module 5.3.5.1.

Exploratory analysis further divided the Non-altered Population into the Known Non-altered Population and the No Result Population depending on the fact if non-alteration status was confirmed by a valuable laboratory finding.

108

6

102

68

92

69

06

65

73

55

71

54

13

10

13

9

12

8

5

3

5

3

2

1

1

1

1

0

0

0

<div style=\"page-break-after: always\"></div>

Figure 19 Kaplan-Meier plot of progression-free survival based on investigator assessments, per RECIST 1.1 at DCO1 15 August 2022, exploratory analysis - pivotal CAPItello-291 study (known non-altered population)

<!-- image -->

Numberof patients/number

randomized of events

142/103

171/141

Time from randomization(months)

45

32

28

22

18

15

41

8

30

27

26

21

17

15

15

14

Number of patients at risk

Capivasertib+Fulvestrant142

128

95

88

Placebo+Fulvestrant

171

163

109

98

+ indicates a censored observation.

Note: Progression determined by RECIST 1.1. Does not include RECIST progression events that occur after 2 or more missed visits or within 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by presence of liver metastases (yes vs no), and prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant.

HR = hazard ratio.

Source: Figure 14.2.1.23, CAPItello-291 CSR, Module 5.3.5.1.

Median  PFS  by  BICR  is  reported  with  3.9  vs  3.7  months  (HR  0.85,  95%  CI  0.65,  1.12)  for capivasertib+fulvestrant and placebo+fulvestrant, respectively.

In the No Result Population , a reduction in the risk of progression in favour of capivasertib + fulvestrant was reported with a hazard ratio of 0.52; 95% CI: 0.32, 0.83.

72

75

68

70

58

52

58

49

47

42

9

7

9

6

9

5

4

2

4

2

3

1

1

0

1

0

1

0

0

0

<div style=\"page-break-after: always\"></div>

Figure 20 Kaplan-Meier plot of progression-free survival based on investigator assessments, per RECIST 1.1 at DCO1 15 August 2022, post hoc exploratory analysis - pivotal CAPItello291 study (no result population)

<!-- image -->

Note: Progression determined by RECIST 1.1. Does not include RECIST progression events that occur after 2 or more missed visits or death after 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment. Hazard ratio calculated using stratified Cox proportional hazards model. Hazard ratio &lt; 1 favours capivasertib + fulvestrant. Cox model stratified by prior use of CDK4/6 inhibitors (yes vs no). HR = hazard ratio.

Source: IEMT083 HLR0024.1, CAPItello-291 CSR, Module 5.3.5.1.

## Exploratory analyses Overall Survival by subgroup

The risk of death in favour of capivasertib + fulvestrant was in the entire Non-altered Population (hazard ratio: 0.76; 95% CI: 0.52, 1.11).

<div style=\"page-break-after: always\"></div>

Figure 21 Kaplan-Meier plot of overall survival at DCO1 15 August 2022, exploratory analysis - pivotal CAPItello-291 study (known non-altered population)

<!-- image -->

+ indicates a censored observation. Note: Patients not known to have died at the time of analysis are censored at the last recorded date on which the patient was last known to be alive. 2sided p-value. Hazard ratio calculated using stratified Cox proportional hazards model. Log-rank test and Cox model were stratified by prior use of CDK4/6 inhibitors (yes vs no). A hazard ratio &lt; 1 favours capivasertib + fulvestrant. HR = hazard ratio.

<div style=\"page-break-after: always\"></div>

Figure 22 Kaplan-Meier plot of overall survival at DCO1 15 August 2022, post hoc exploratory analysis - pivotal CAPItello-291 study (no result population)

<!-- image -->

Note: Patients not known to have died at the time of analysis are censored at the last recorded date on which the patient was last known to be alive. A hazard ratio &lt; 1 favours capivasertib + fulvestrant. Hazard ratio calculated using stratified Cox proportional hazards model. Cox model unstratified following the pooling strategy.

HR = hazard ratio.

Source: IEMT083 HLR0024.2, Appendix 2.7.3.6.1, Module 5.3.5.3.

## Subgroup analysis by prior use of CDK4/6 inhibitors

In patients with prior CDK4/6 inhibitor use, median PFS was 5.5 months in the capivasertib + fulvestrant arm, compared to 2.6 months in the placebo + fulvestrant arm (hazard ratio: was 0.59; 95% CI: 0.48, 0.72).

In  patients  with  no  prior  CDK4/6  inhibitor  use,  median  PFS  was  10.9  months  in  the  capivasertib  + fulvestrant arm, compared to 7.2 months in the placebo + fulvestrant arm (hazard ratio was 0.64; 95% CI: 0.45, 0.90).

## Strata and further subgroups

Subgroup analyses addressed the homogeneity of treatment effects for the strata - regions, prior use of CDK 4/6 inhibitors and presence of liver metastases - and for relevant subgroups, under which are menopausal status, type of metastases or prior use of chemotherapy, number of treatment lines, and importantly for different types of mutational status. Forest plots were provided for the overall population as well as the PIK3CA/AKT1/PTEN altered population.

It is observed that the point estimate is uniformly in favour of capivasertib+fulvestrant. In the overall population, effect sizes are smaller and 95%  CI  cross  the 1 for the subgroups  region 2, pre/perimenopausal state, and smoking history 'yes'. All these subgroups are small (below 100 patients per arm) and CI are wide.

Effect size is larger in subgroups of patients without visceral metastases and no prior endocrine based treatment. The same observations were made for the PIK3CA/AKT1/PTEN altered population.

<div style=\"page-break-after: always\"></div>

Figure 23 Forest plot of progression-free survival based on investigator assessments, per RECIST  1.1  at  DCO1  15 August  2022,  by  subgroup  -  pivotal  CAPItello-291  study  (altered population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Size of circle is proportional to the number of events. Grey band represents the 95% confidence interval for the overall (all patients) hazard ratio. Note: Progression determined by RECIST 1.1. Hazard ratio &lt; 1 implies a lower risk of progression on capivasertib + fulvestrant. Cox proportional hazards model including treatment term only was fitted for each subgroup level as factor. 'All patients' analysis present primary analysis results for the Altered Population. Progression includes deaths in the absence of RECIST progression. Does not include RECIST progression events baseline that occur after 2 or more missed visits or death after 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment. Race 'other' includes Black or African American, and Israel; Native Hawaiian or Other Pacific Islander and American Indian or Alaska Native. Region 1: United States, Canada, Western Europe, Australia, and Israel; Region 2: Latin America, Eastern Europe, and Russia; Region 3: Asia. * Hazard ratio and CI not calculated due to insufficient number of events.

## PIK3CA/AKT1/PTEN altered population further by-gene analysis

For the PIK3CA/AKT1/PTEN altered population, further by-gene analysis of PFS by AKT1, PIK3CA and/or PTEN alteration status was also conducted post hoc. In respect to the evaluation of the clinical validity of  the  biomarker  these  by-gene  analyses  are  important  to  address  at  least  the  effects  of  the  more frequent gene alterations.

The following by-gene analyses were performed and the Kaplan-Meier plots were presented:

- AKT1 only (hazard ratio: 0.51, 95% CI: 0.22, 1.12).
- PIK3CA only (hazard ratio: 0.51, 95% CI: 0.37, 0.70).
- PTEN only (hazard ratio: 0.43; 95% CI, 0.21, 0.88).
- AKT1 independent (i.e., irrespective of the presence) of PIK3CA / PTEN (hazard ratio: 0.55, 95% CI: 0.26, 1.17).
- PIK3CA independent of AKT1 / PTEN (hazard ratio: 0.51, 95% CI: 0.37, 0.69).
- PTEN independent of AKT1 / PIK3CA (hazard ratio: 0.45, 95% CI: 0.24, 0.84).
- PIK3A and/or AKT1 independent of PTEN (hazard ratio: 0.50, 95% CI: 0.38, 0.66).
- PIK3CA and/or AKT1 without (i.e., in the absence of) PTEN (hazard ratio: 0.50, 95% CI: 0.38, 0.67).

Results (HR) for these by-gene analyses of PFS for AKT1, PIK3CA and/or PTEN alteration status are consistent with the result for the PIK3CA/AKT1/PTEN altered population. The subgroups of AKT1 mutation only and PTEN mutation only are very small.

<div style=\"page-break-after: always\"></div>

## · Summary of main efficacy results.

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 52 Summary of efficacy for trial D3615C00001 (CAPItello-291)

| Title: A Phase III double-blind randomised study assessing the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant as treatment for locally advanced (inoperable) or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor   | Title: A Phase III double-blind randomised study assessing the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant as treatment for locally advanced (inoperable) or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor   | Title: A Phase III double-blind randomised study assessing the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant as treatment for locally advanced (inoperable) or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                                          | Study code: D3615C00001 EudraCT number: 2019-003629-78                                                                                                                                                                                                                                                                                                                                                    | Study code: D3615C00001 EudraCT number: 2019-003629-78                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                                                                                                                                                                    | Phase III, double-blind, placebo-controlled, parallel-group, randomised, multicentre study.                                                                                                                                                                                                                                                                                                               | Phase III, double-blind, placebo-controlled, parallel-group, randomised, multicentre study.                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                            | Ongoing Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                     |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                | Superiority                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                               |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                         | Capivasertib + Fulvestrant (C+F)                                                                                                                                                                                                                                                                                                                                                                          | 355 patients were randomised to receive: • 400 mg capivasertib (2 tablets of 200 mg) orally, twice daily (BD) (total daily dose 800 mg) on Days 1 to 4 in each week of a 28-day treatment cycle, and • 500 mg fulvestrant via intramuscular injection on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter.                                                           |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                         | Placebo + Fulvestrant (P+F)                                                                                                                                                                                                                                                                                                                                                                               | 353 patients were randomised to receive: • Placebo (2 tablets) orally, BD on Days 1 to 4 in each week of a 28-day treatment cycle, and • 500 mg fulvestrant via intramuscular injection on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter.                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                                         | Study treatment was continued until disease progression unless there was evidence of unacceptable toxicity, or if the patient requested to stop the study treatment.                                                                                                                                                                                                                                      | Study treatment was continued until disease progression unless there was evidence of unacceptable toxicity, or if the patient requested to stop the study treatment.                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                 | Dual primary endpoint PFS                                                                                                                                                                                                                                                                                                                                                                                 | Progression-free survival (PFS) in the capivasertib + fulvestrant arm relative to the placebo + fulvestrant arm in the ' Overall population' and in the ' Altered Population' . PFS is defined as the time from randomisation until progression per RECIST v1.1, as assessed by the investigator at the local site, or death due to any cause.                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                                                 | Key secondary endpoint OS                                                                                                                                                                                                                                                                                                                                                                                 | Overall survival (OS) in the capivasertib + fulvestrant arm relative to the placebo + fulvestrant arm in the 'O verall population' and in the ' Altered Population '. OS is length of time from randomisation until the date of death due to any cause.                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Overall response rate (ORR) in the capivasertib + fulvestrant arm relative to the placebo + fulvestrant arm in the overall population and in the Altered Population. ORR is defined as the percentage of patients with at least one complete response or partial response per RECIST v1.1, as assessed by the investigator at the                                                                                                                                           | Overall response rate (ORR) in the capivasertib + fulvestrant arm relative to the placebo + fulvestrant arm in the overall population and in the Altered Population. ORR is defined as the percentage of patients with at least one complete response or partial response per RECIST v1.1, as assessed by the investigator at the                                                                                                                                           | Overall response rate (ORR) in the capivasertib + fulvestrant arm relative to the placebo + fulvestrant arm in the overall population and in the Altered Population. ORR is defined as the percentage of patients with at least one complete response or partial response per RECIST v1.1, as assessed by the investigator at the                                                                                                                                           | Overall response rate (ORR) in the capivasertib + fulvestrant arm relative to the placebo + fulvestrant arm in the overall population and in the Altered Population. ORR is defined as the percentage of patients with at least one complete response or partial response per RECIST v1.1, as assessed by the investigator at the                                                                                                                                           |
|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database                                              | 03 October 2022                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | lock                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Results and Analysis                                  | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description                                  | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Analysis population and time point description        | Overall Population : All patients randomised into the study, excluding patients randomised in China after the global cohort last patient first visit. Altered Population : Patients in the overall population with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing. At the data cut-off, the median duration of follow-up in the overall population (defined as time to censoring or death) was 14.9 months in the C+F arm and 14.3 months in the P+F arm. | Overall Population : All patients randomised into the study, excluding patients randomised in China after the global cohort last patient first visit. Altered Population : Patients in the overall population with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing. At the data cut-off, the median duration of follow-up in the overall population (defined as time to censoring or death) was 14.9 months in the C+F arm and 14.3 months in the P+F arm. | Overall Population : All patients randomised into the study, excluding patients randomised in China after the global cohort last patient first visit. Altered Population : Patients in the overall population with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing. At the data cut-off, the median duration of follow-up in the overall population (defined as time to censoring or death) was 14.9 months in the C+F arm and 14.3 months in the P+F arm. | Overall Population : All patients randomised into the study, excluding patients randomised in China after the global cohort last patient first visit. Altered Population : Patients in the overall population with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing. At the data cut-off, the median duration of follow-up in the overall population (defined as time to censoring or death) was 14.9 months in the C+F arm and 14.3 months in the P+F arm. | Overall Population : All patients randomised into the study, excluding patients randomised in China after the global cohort last patient first visit. Altered Population : Patients in the overall population with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing. At the data cut-off, the median duration of follow-up in the overall population (defined as time to censoring or death) was 14.9 months in the C+F arm and 14.3 months in the P+F arm. | Overall Population : All patients randomised into the study, excluding patients randomised in China after the global cohort last patient first visit. Altered Population : Patients in the overall population with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing. At the data cut-off, the median duration of follow-up in the overall population (defined as time to censoring or death) was 14.9 months in the C+F arm and 14.3 months in the P+F arm. |
| Descriptive statistics and estimate variability (PFS) | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Overall Population                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Overall Population                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Overall Population                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Altered Population                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Altered Population                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability (PFS) | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                             | C+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | C+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability (PFS) | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                          | N=355                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=353                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=353                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=155                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | N=134                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability (PFS) | Total number of patients with PFS events, n (%) a                                                                                                                                                                                                                                                                                                                                                                                                                           | 258 (72.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 293 (83.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 293 (83.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 121 (78.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 115 (85.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability (PFS) | Median PFS (months) b                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 7.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 3.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 3.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 7.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 3.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability (PFS) | 95% CI for median PFS b                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5.5, 7.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.8, 3.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.8, 3.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 5.5, 9.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.0, 3.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison (PFS)                  | Dual Primary Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                       | Dual Primary Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2-sided p-value c                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2-sided p-value c                                                                                                                                                                                                                                                                                                                                                                                                                                                           | < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                       | Dual Primary Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                                                                                                                                           | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.60                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.60                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.60                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.51, 0.71                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.51, 0.71                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.51, 0.71                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                       | Dual Primary Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                       | ' Altered Population'                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2-sided p-value c                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 2-sided p-value c                                                                                                                                                                                                                                                                                                                                                                                                                                                           | < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.50                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.50                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.50                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.38, 0.65                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.38, 0.65                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.38, 0.65                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis description                                  | Subgroup Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description        | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   | ' Non-altered Population ': Patients in the overall population excluding patients with a PIK3CA/AKT1/PTEN -altered tumour determined by central testing (pre-specified exploratory population). Known Non-altered Population ': Patients in the Non altered Population excluding those without a valid central test result (pre-specified exploratory population).   |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability (PFS) | Treatment group                                                                                                                                                                                                                                                                                                                                                      | Non-altered Population                                                                                                                                                                                                                                                                                                                                               | Non-altered Population                                                                                                                                                                                                                                                                                                                                               | Known Non-altered Population                                                                                                                                                                                                                                                                                                                                         | Known Non-altered Population                                                                                                                                                                                                                                                                                                                                         | No Result Population                                                                                                                                                                                                                                                                                                                                                 | No Result Population                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability (PFS) | Treatment group                                                                                                                                                                                                                                                                                                                                                      | C+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  | C+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  | C+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability (PFS) | No of subjects                                                                                                                                                                                                                                                                                                                                                       | N=200                                                                                                                                                                                                                                                                                                                                                                | N=219                                                                                                                                                                                                                                                                                                                                                                | N=142                                                                                                                                                                                                                                                                                                                                                                | N=171                                                                                                                                                                                                                                                                                                                                                                | N=58                                                                                                                                                                                                                                                                                                                                                                 | N=48                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability (PFS) | Median PFS (months) b                                                                                                                                                                                                                                                                                                                                                | 7.2                                                                                                                                                                                                                                                                                                                                                                  | 3.7                                                                                                                                                                                                                                                                                                                                                                  | 5.3                                                                                                                                                                                                                                                                                                                                                                  | 3.7                                                                                                                                                                                                                                                                                                                                                                  | 10.0                                                                                                                                                                                                                                                                                                                                                                 | 1.9                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability (PFS) | 95% CI for median PFS b                                                                                                                                                                                                                                                                                                                                              | 4.5, 7.4                                                                                                                                                                                                                                                                                                                                                             | 3.0, 5.0                                                                                                                                                                                                                                                                                                                                                             | 3.6, 7.3                                                                                                                                                                                                                                                                                                                                                             | 3.5, 5.1                                                                                                                                                                                                                                                                                                                                                             | 7.3, 11.1                                                                                                                                                                                                                                                                                                                                                            | 1.8, 7.3                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimate per comparison (PFS)                  | Prespecified Exploratory Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison (PFS)                  | Prespecified Exploratory Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                        | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                       | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                       | 0.70                                                                                                                                                                                                                                                                                                                                                                 | 0.70                                                                                                                                                                                                                                                                                                                                                                 | 0.70                                                                                                                                                                                                                                                                                                                                                                 | 0.70                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison (PFS)                  | Prespecified Exploratory Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                        | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                            | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                            | 0.56, 0.88                                                                                                                                                                                                                                                                                                                                                           | 0.56, 0.88                                                                                                                                                                                                                                                                                                                                                           | 0.56, 0.88                                                                                                                                                                                                                                                                                                                                                           | 0.56, 0.88                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison (PFS)                  | Prespecified Exploratory Endpoint: PFS in the Known Non-altered Population                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison (PFS)                  |                                                                                                                                                                                                                                                                                                                                                                      | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                       | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                       | 0.79                                                                                                                                                                                                                                                                                                                                                                 | 0.79                                                                                                                                                                                                                                                                                                                                                                 | 0.79                                                                                                                                                                                                                                                                                                                                                                 | 0.79                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison (PFS)                  |                                                                                                                                                                                                                                                                                                                                                                      | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                            | 95% CI for hazard ratio d                                                                                                                                                                                                                                                                                                                                            | 0.61, 1.02                                                                                                                                                                                                                                                                                                                                                           | 0.61, 1.02                                                                                                                                                                                                                                                                                                                                                           | 0.61, 1.02                                                                                                                                                                                                                                                                                                                                                           | 0.61, 1.02                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison (PFS)                  | Posthoc Exploratory Endpoint: PFS in the                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison (PFS)                  | No Result Population                                                                                                                                                                                                                                                                                                                                                 | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                       | Hazard ratio d                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison (PFS)                  |                                                                                                                                                                                                                                                                                                                                                                      | 95% CI for hazard d                                                                                                                                                                                                                                                                                                                                                  | 95% CI for hazard d                                                                                                                                                                                                                                                                                                                                                  | 0.52 0.32, 0.83                                                                                                                                                                                                                                                                                                                                                      | 0.52 0.32, 0.83                                                                                                                                                                                                                                                                                                                                                      | 0.52 0.32, 0.83                                                                                                                                                                                                                                                                                                                                                      | 0.52 0.32, 0.83                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison (PFS)                  |                                                                                                                                                                                                                                                                                                                                                                      | ratio                                                                                                                                                                                                                                                                                                                                                                | ratio                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description                                  | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   | Secondary Analysis                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability (OS)  | Treatment group                                                                                                                                                                                                                                                                                                                                                      | Overall Population                                                                                                                                                                                                                                                                                                                                                   | Overall Population                                                                                                                                                                                                                                                                                                                                                   | Overall Population                                                                                                                                                                                                                                                                                                                                                   | Altered Population                                                                                                                                                                                                                                                                                                                                                   | Altered Population                                                                                                                                                                                                                                                                                                                                                   | Altered Population                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability (OS)  | Treatment group                                                                                                                                                                                                                                                                                                                                                      | C+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  | C+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  | P+F                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability (OS)  | Number of subjects                                                                                                                                                                                                                                                                                                                                                   | N=355                                                                                                                                                                                                                                                                                                                                                                | N=353                                                                                                                                                                                                                                                                                                                                                                | N=353                                                                                                                                                                                                                                                                                                                                                                | N=155                                                                                                                                                                                                                                                                                                                                                                | N=134                                                                                                                                                                                                                                                                                                                                                                | N=134                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability (OS)  | Death, n (%)                                                                                                                                                                                                                                                                                                                                                         | 87 (24.5)                                                                                                                                                                                                                                                                                                                                                            | 108 (30.6)                                                                                                                                                                                                                                                                                                                                                           | 108 (30.6)                                                                                                                                                                                                                                                                                                                                                           | 41 (26.5)                                                                                                                                                                                                                                                                                                                                                            | 46 (34.3)                                                                                                                                                                                                                                                                                                                                                            | 46 (34.3)                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison (OS)                   | Secondary Endpoint: OS in the overall population e                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                    | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           | C+F vs P+F                                                                                                                                                                                                                                                                                                                                                           |

Hazard ratio  f

0.74

95% CI for hazard ratio

f

0.56, 0.98

Secondary Endpoint: OS in the altered population e

Comparison groups

C+F vs P+F

Hazard ratio  f

0.69

95% CI for hazard ratio

f

0.45, 1.05

Descriptive  statistics  and estimate variability (ORR)

Treatment group

Overall Population

Altered Population

C+F

P+F

C+F

P+F

Number of subjects  g   N=310

N=320

N=132

N=124

Number (%) of patients with response

71 (22.9)

39 (12.2)

38 (28.8)

12 (9.7)

Notes

- a Does not include RECIST progression events that occur after 2 or more missed visits or death after 2 visits of baseline where the patient has no evaluable visits or does not have a baseline assessment.

- b Kaplan-Meier estimate.

- c Stratified log-rank test.

- d Stratified Cox proportional hazards model. A hazard ratio &lt; 1 favours capivasertib + fulvestrant. For the Overall Population, the log-rank test and Cox model are stratified by presence of liver metastases (yes vs no), prior use of CDK4/6 inhibitors (yes vs no)  and  geographic  region  (Region  1:  United  States,  Canada,  Western  Europe, Australia, and Israel, Region 2: Latin America, Eastern Europe, and Russia vs Region 3: Asia). For the Altered Population, Non-altered Population, and Known Non-altered Population,  the  log  rank  test  and  Cox  model  are  stratified  by  presence  of  liver metastases (yes vs no), and prior use of CDK4/6 inhibitors (yes vs no). For the No Result Population, the Cox model is stratified by prior use of CDK4/6 inhibitors (yes vs no).

- e 0.01% alpha penalty assigned to the assessment of no OS detriment. Formal analysis not prespecified.

- f Stratified Cox proportional hazards model. A hazard ratio &lt; 1 favours capivasertib + fulvestrant.

- g Number of patients with measurable disease at baseline in treatment group.

<div style=\"page-break-after: always\"></div>

## 2.6.5.3. Clinical studies in special populations

According to the CAPITELLO 291 baseline characteristics &gt;30% of patients were 65 years and older.

## Table 53 Age distribution for older subjects (safety population)

|                         | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Phase III    | 91/355                                            | 24/355                                            | 0/355                                           |
| Non-controlled trials b | 114/597                                           | 30/597                                            | 1/597                                           |

<div style=\"page-break-after: always\"></div>

- b CAPItello-291 study.
- c Single-arm uncontrolled studies: D3610C00001; D3610C00002; D3610C00003; D3610C00004; D3610C00007; D3614C00002;  D3614C00005;  D3614C00007;  D3618C00002;  D361DC00001  (open -label  Phase  Ib  part). D3610C00002 (BEECH) was included as a non-controlled trial as Part A was not a randomised controlled trial.

Patients exposed to capivasertib are presented. Ongoing blinded studies are not included.

DCO of 01 March 2023 for the Investigator's Brochure.

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

## Scientific rationale for testing of the PIK3CA/AKT1/PTEN alteration status

## Mechanism of action:

Capivasertib is a potent, selective inhibitor of the kinase activity of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3). AKT is a pivotal node in the phosphatidylinositol 3-kinase (PI3K) signalling  cascade  regulating  multiple  cellular  processes  including  cellular  survival,  proliferation,  cell cycle,  metabolism,  gene  transcription  and  cell  migration.  AKT  activation  in  tumours  is  a  result  of upstream activation from other signalling pathways, mutations of AKT, loss of phosphatase and tensin homolog (PTEN) function and mutations in the catalytic subunit of PI3K (PIK3CA).

In vivo, monotherapy, capivasertib inhibits growth of human cancer xenograft models representative of different  tumour  types  including  ER+  and  triple  negative  breast  cancer  models  with  PIK3CA,  AKT1 mutations and PTEN loss, mutant xenograft models and triple negative breast cancer xenograft models. Combined treatment with capivasertib and fulvestrant demonstrated a greater anti-tumour response in a  range  of  human breast cancer PDX models representative of different breast cancer subsets. This included models without detectable mutations or alterations in PIK3CA, PTEN or AKT, as well as models with mutations or alterations in PIK3CA, PTEN or AKT.

## Biomarker definition / definition of biomarker positivity:

Patients  that  fulfilled  the  eligibility  criteria  and  consented  to  join  the  CAPItello-291  study  were randomised irrespective  of  their  'tumour  PIK3CA/AKT1/PTEN  alteration  status'.  However,  mandatory baseline tissue samples (newly collected or archival formalin-fixed, paraffin-embedded tissue block or tumour  slides  from  the  most  recently  collected  tumour  tissue  sample,  derived  from  the  primary  or recurrent cancer site) were required from all patients at screening and were analysed retrospectively, post randomisation, to assess the PIK3CA/AKT1/PTEN alteration status.

As  to  the  following  definition  patients  were  assigned  to  the  PIK3CA/AKT1/PTEN-altered  analysis population:

' Patients with breast cancer tumours harbouring at least one alteration in the PIK3CA, AKT1 or PTEN genes as detected  by  the  FoundationOne ® CDx  (F1CDx)  test  and  classified  as  per  the  CAPItello-291 biomarker rules (see table on 'Biomarker Rules for CAPItello-291' below) '.

## Table 54 Biomarker rules for CAPItello-291

| Gene (Transcript)   | Variant Class              | Biomarker Rules                                                                                                               |
|---------------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| PIK3CA (NM_006218)  | Short Variant a            | C420R, E542K, E545A, E545D, E545G , E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations                               |
| PIK3CA (NM_006218)  | Short Variant (AZ defined) | R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, and G1049R                                                                  |
| AKT1 (NM_001014431) | Short Variant (AZ defined) | Any short variant with protein effect E17K                                                                                    |
| PTEN (NM_000314)    | Short Variant (AZ defined) | Any short variants listed below: C124R, C124S, G129E, G129V, G129R, R130Q, R130G, R130L, R130P, C136R, C136Y, S170R and R173C |

<div style=\"page-break-after: always\"></div>

|                                     | Any nonsense (including stop codons), frameshift, or splice site alteration, including those that affect the start codon (i.e. M1?, M1T, M1fs*23).                                                                                                                                                                 |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Copy Number Alteration (AZ defined) | Anyhomozygous deletion of one or more exons, regardless of transcript                                                                                                                                                                                                                                              |
| Rearrangement b (AZ defined)        | Anyrearrangement that disrupts protein function, regardless of transcript. Intragenic events including duplications of only part of the gene, deletions, or inversions. Translocations, deletions, or inversions where one breakpoint is in PTEN and the other breakpoint is in another gene or intergenic region. |

a Variants previously FDA-approved per P170019/S006. AZ defined variants are not currently FDA approved

b PTEN Rearrangement not included in OncoScreen Plus TM  biomarker rules

Source: Appendix 16.1.13 ,PIK3CA/AKT1/PTEN Diagnostic Testing'(table 1, page 8/28)

## Overall, the CAPItello-291 biomarker rules included:

- 19 PI3KCA short variants:
- -11 short variants previously (FDA approved for alpelisib in the treatment of breast cancer)
- -8 additional short variants (sponsor-defined)
- any AKT1 short variant with protein effect E17K (sponsor-defined)
- 13 PTEN short variants (sponsor-defined)
- PTEN copy number alteration and rearrangements (sponsor-defined).

As an exception for patients enrolled into study CAPItello-291 from mainland China the 'Burning Rock OncoScreen Plus TM' ' test was used instead of the F1CDx test. The biomarker rules employed were the same, with the exception that 'PTEN intragenic rearrangement' was not included due to limited analytical validation of OncoScreen Plus TM  for these intragenic rearrangements. 8 Patients with valid 'OncoScreen Plus TM '  results  were  enrolled  in  study  CAPItello-291, two of these 8 patients were tested biomarkerpositive as defined above (both patients had PIK3CA alteration variant E545K).

During  the  evaluation  it  was  clarified  by  the  applicant  that  study  specific  documents  on  biomarker definitions and the type of test to be used were not yet in place during the first 7 months of enrolment. The relevant documents on biomarker definitions used during the study was provided by the applicant during the procedure. In Capitello-291 the first patient was enrolled on 16/04/2020, and the last patient was  randomised  on  13/10/2021.  Tissue  testing  was  performed  between  22 August 2020  and 28 October 2021, apparently partly retrospective, partly real time. DCO was in August 2022.

The applicant clarified that biomarker rules defining biomarker positive status and used for F1CDx testing on CAPItello-291 were finalised with FMI on 30 November 2020 prior to the first data transfer on 21 December 2020 and that they did not change throughout the rest of the study.

The  applicant  clarified  that  the  same  biomarker  definition  was  used  for  NGS-identified  subgroup  in FAKTION as in the CAPitello-291 study. In FAKTION, tissue for NGS analysis was available only for a subset of patients due to the retrospective approach for the updated analyses. With the intent to include the  information  for  more  patients,  NGS  analysis  for  detection  of  ctDNA  in  plasma  was  performed (Guardant Health OMNI). Apart from PTEN homozygous deletions which could not be detected in plasma (found in 2.4% of patients in CAPitello-291), the same biomarker definition was used as in CAPitello291.  Following  this  approach,  NGS  results  became  available  for  80%  (n=112)  of  the  FAKTIONpopulation.

## Justification / validation of biomarker definition

As to the information applied, the justification for the definition of biomarker-positivity (i.e. PIK3CA/AKT1/PTEN alterations as specified above) is following a scientific rationale being mainly based on preclinical data. Regarding clinical validation see below.

<div style=\"page-break-after: always\"></div>

## Tests used

FoundationOne ® CDx (F1CDx) (Foundation Medicine Inc., Cambridge, Massachusetts, USA), a tissuebased test, was used to determine the PIK3CA/AKT1/PTEN alteration status in the single pivotal study CAPItello-291. As an exception for patients enrolled into study CAPItello-291 from mainland China the 'Burning Rock OncoScreen Plus TM ' test was used instead of the F1CDx test. No local tests investigating the PIK3CA/AKT1/PTEN alteration status were performed.

## Analytical method including assay platform, specimen, pre-analytical processing requirements and read-out method

F1CDx is an NGS-based in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations (indels) and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), homologous recombination deficiency, and tumour mutational burden (TMB) using DNA isolated from FFPE tumour tissue specimens.

F1CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, Massachusetts, USA. The assay includes reagents, software, instruments and procedures for testing DNA extracted from FFPE tumour tissue samples.

The assay employs a single DNA extraction method from routine FFPE tumour biopsy or surgical resection specimens, 50-1000 ng of which undergoes whole-genome  shotgun library construction and hybridisation-based  capture  of  a  total  of  324  genes  (mostly  targeting  exons,  for  some  genes  also promotor regions, select intronic regions or noncoding RNAs). Using the Illumina ®  HiSeq 4000 platform, hybrid-capture-selected libraries will be sequenced to high uniform depth (targeting &gt; 500x median coverage with &gt;99% of exons at coverage &gt;100x). Sequence data is processed using a customised analysis  pipeline  designed  to  detect  all  classes  of  genomic  alterations,  including  base  substitutions, indels,  copy  number  alterations  (amplifications  and  homozygous  deletions),  and  selected  genomic rearrangements (e.g. gene fusions).

## Analytical validation strategy

Analytical  validation  of  FoundationOne ® CDx  (F1CDx)  with  regard  to  accuracy,  sensitivity,  specificity, precision and robustness was demonstrated.

## Clinical validation strategy

Treatment with capivasertib + fulvestrant resulted in an improvement in investigator-assessed PFS by RECIST 1.1  compared with placebo + fulvestrant  in  the  Altered  (i.e.  biomarker-positive)  Population (hazard ratio: 0.50; 95% CI: 0.38, 0.65).

A by-gene analysis of PFS for AKT1, PIK3CA and/or PTEN alteration status demonstrated efficacy that was consistent with the PIK3CA/AKT1/PTEN altered subpopulation in study CAPItello-291:

- AKT1 only (hazard ratio: 0.51, 95% CI: 0.22, 1.12)
- PIK3CA only (hazard ratio: 0.51, 95% CI: 0.37, 0.70)
- PTEN only (hazard ratio: 0.43; 95% CI, 0.21, 0.88)
- AKT1 independent (i.e., irrespective of the presence) of PIK3CA/PTEN (hazard ratio: 0.55, 95% CI: 0.26, 1.17)
- PIK3CA independent of AKT1/PTEN (hazard ratio: 0.51, 95% CI: 0.37, 0.69)
- PTEN independent of AKT1/PIK3CA (hazard ratio: 0.45, 95% CI: 0.24, 0.84)
- PIK3CA and/or AKT1 independent of PTEN (hazard ratio: 0.50, 95% CI: 0.38, 0.66)
- PIK3CA and/or AKT1 without (i.e., in the absence of) PTEN (hazard ratio: 0.50, 95% CI: 0.38, 0.67).

<div style=\"page-break-after: always\"></div>

Table 55 Prevalence of individual PIK3CA/AKT1/PTEN gene alterations in CAPItello-291

| Variant                                                          | Patients with valid result (N = 602), n (%)   |
|------------------------------------------------------------------|-----------------------------------------------|
| PIK3CA alterations (included in FDAapproved F1CDx)               | 205 (34.1%)                                   |
| C420R                                                            | 6 (1.0%)                                      |
| E542K                                                            | 36 (6.0%)                                     |
| E545A                                                            | 3 (0.5%)                                      |
| E545G                                                            | 2 (0.3%)                                      |
| E545K                                                            | 56 (9.3%)                                     |
| Q546E                                                            | 1 (0.2%)                                      |
| Q546R                                                            | 1 (0.2%)                                      |
| H1047Y                                                           | 1 (0.2%)                                      |
| H1047R                                                           | 89 (14.8%)                                    |
| H1047L                                                           | 14 (2.3%)                                     |
| PIK3CA alterations (sponsor-defined)                             | 18 (3.0%)                                     |
| N345K                                                            | 6 (1.0%)                                      |
| E545Q                                                            | 1 (0.2%)                                      |
| Q546P                                                            | 3 (0.5%)                                      |
| Q546K                                                            | 2 (0.3%)                                      |
| R88Q                                                             | 2 (0.3%)                                      |
| G1049R                                                           | 4 (0.7%)                                      |
| AKT1 alterations short variant: missense E17K (sponsor-defined)  | 37 (6.1%)                                     |
| PTEN short variants: missense (sponsor-defined)                  | 3 (0.5%)                                      |
| R130Q                                                            | 1 (0.2%)                                      |
| R130G                                                            | 1 (0.2%)                                      |
| R130P                                                            | 1 (0.2%)                                      |
| PTEN short variants: protein truncating (sponsor-defined)        | 31 (5.1%)                                     |
| Frameshift                                                       | 20 (3.3%)                                     |
| Nonsense                                                         | 9 (1.5%)                                      |
| Splice site                                                      | 3 (0.5%)                                      |
| PTEN large structural variants leading to loss (sponsor-defined) | 16 (2.7%)                                     |
| Rearrangement                                                    | 2 (0.3%)                                      |
| Copy number alterations                                          | 14 (2.3%)                                     |

Source: Appendix 16.1.13 ,PIK3CA/AKT1/PTEN Diagnostic Testing'(table 8, page 17/28)

## Cut-point selection

No information on cut-point selection (i.e. the threshold (i.e. cut-point) defining a patient as biomarker positive) was provided. The applicant clarified that unlike tests that measure protein expression levels (e.g. IHC), molecular tests are typically binary, based on limit of detection/limit of blank, determined as part of the analytical validation for performance characteristics. The detection and reporting of variants by  the  FMI  analysis  pipeline  are  not  determined  by  a  singular  threshold,  but  rather,  a  number  of thresholds and quality metrics that are set by the variant class (i.e. short variants, rearrangements, copy number amplifications and losses).

<div style=\"page-break-after: always\"></div>

Discussion of other possible cut point definitions that could have an impact on the benefit-risk ratio of capivasertib was requested during the evaluation. Cut-points used for the respective genetic alteration defining  'PIK3CA/AKT1/PTEN  alteration-positivity'  were  provided  for  the  central  confirmation  test 'F1CDx'. However, no clinical thresholding was performed. Albeit not ideal the applicant's clarifications are noted and this issue is considered as closed.

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## 2.6.5.6. Supportive study

FAKTION -A Phase Ib/II Randomised Placebo-controlled Trial of Fulvestrant +/- Capivasertib in  Post-menopausal Women with Advanced Breast Cancer Previously Treated with a Third Generation Aromatase Inhibitor (Jones, Casbard et al. 2020)

As no CSR was submitted for the FAKTION study, this below section is based on the primary analysis published by Jones et al. 2020 (DCO: 30 January 2019) as well as discussions provided by the applicant in the dossier. Of note in July 2022 Howell et al. (Howell, Casbard et al. 2022) published an update of results  on  OS,  PFS  and  expanded  biomarker  analyses  (DCO:  25  November  2021)  which  are  also discussed below.

## Methods

The FAKTION study is a Phase Ib/II study funded by the applicant and Cancer Research UK as co-founder. According to the publication by Jones et al 2020 (Jones, Casbard et al. 2020), the applicant provided study medicinal products, contributed to study design and reviewed the draft analysis plan and the draft report.

## · Study participants

Postmenopausal  women  with  ER+  HER2-  locally  advanced  or  metastatic  breast  cancer,  which  had relapsed or progressed on an aromatase inhibitor with an ECOG status 0-2 were included.

## · Treatments

Enrolled patients were to receive intramuscular fulvestrant 500 mg (day 1) every 28 days (plus a loading dose on day 15 of cycle 1) with either capivasertib 400 mg or matching placebo, orally twice daily on an intermittent weekly schedule of 4 days on and 3 days off (starting on cycle 1 day 15) until disease progression, unacceptable toxicity.

## · Objectives

The primary objective for the Phase 2 part was to assess the relative anti-tumour activity of capivasertib + fulvestrant vs placebo + fulvestrant in terms of PFS in women with ER+ advanced breast cancer.

## · Outcomes/endpoints

PFS was defined as the time from randomisation to either the first documented progression confirmed by RECIST criteria (regardless of whether the patient withdrew from study therapy or received another anti-cancer therapy before progression or death from any cause) assessed by the investigator.

Secondary endpoints included overall survival and ORR.

<div style=\"page-break-after: always\"></div>

Analysis of the effect of PI3K pathway alteration on these outcomes was planned prospectively and subgroup analyses of progression-free survival, overall survival, and objective response by PI3K pathway alteration were additional secondary outcomes.

## · Randomisation and blinding (masking)

Treatment allocation was done using an interactive web-response system using a minimisation method (with a 20% random element) and the following minimisation factors: measurable or non-measurable disease, primary or secondary aromatase inhibitor resistance, PIK3CA status, and PTEN status.

Blood  and  tissue  samples  were  centrally  tested  for  PIK3CA  and  PTEN  alteration  status  before randomisation. Pathway alteration was protocol defined as either a hotspot mutation detected by digital droplet PCR (ddPCR) on PIK3CA exons 9 or 20 in tumour tissue or blood or an immunohistochemistry null status for PTEN in tumour tissue (primary tumour or metastatic biopsy). The method of mutational analysis  changed  from  pyrosequencing  to  ddPCR  during  the  trial  (from  9  November  2016),  which provided greater sensitivity to detect mutations. For 14 patients who were categorised as non-altered on the basis of initial pyrosequencing analysis had insufficient material to carry out a repeat ddPCR analysis.

## Results

## · Baseline data

Between 16 March 2015 and 06 March 2018, 183 patients were screened and 140 randomly assigned to receive capivasertib + fulvestrant (n = 69) or placebo + fulvestrant (n = 71).

Table 56 Baseline characteristics - Supportive FAKTION study (ITT population)

|                                                            | Capivasertib + fulvestrant (n = 69)                        | Placebo + fulvestrant (n = 71)                             |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Median age, years (IQR); range                             | 62 (55, 68); 42, 81                                        | 61 (53, 68); 40, 82                                        |
| ECOG PS, n (%)                                             | ECOG PS, n (%)                                             | ECOG PS, n (%)                                             |
| 0                                                          | 42 (61%)                                                   | 49 (69%)                                                   |
| 1                                                          | 25 (36%)                                                   | 17 (24%)                                                   |
| 2                                                          | 1 (1%)                                                     | 2 (3%)                                                     |
| Missing                                                    | 1 (1%)                                                     | 3 (4%)                                                     |
| Stage, n (%)                                               | Stage, n (%)                                               | Stage, n (%)                                               |
| III inoperable                                             | 0 (0%)                                                     | 1 (1%)                                                     |
| IV                                                         | 68 (99%)                                                   | 68 (96%)                                                   |
| Missing                                                    | 1 (1%)                                                     | 2 (3%)                                                     |
| Visceral disease, n (%)                                    | 49 (71%)                                                   | 47 (66%)                                                   |
| Liver metastases, n (%)                                    | 32 (46%)                                                   | 29 (41%)                                                   |
| Bone only disease, n (%)                                   | 10 (14%)                                                   | 8 (11%)                                                    |
| Measurable disease, n (%)                                  | 49 (71%)                                                   | 50 (70%)                                                   |
| Primary or secondary aromatase inhibitor resistance, n (%) | Primary or secondary aromatase inhibitor resistance, n (%) | Primary or secondary aromatase inhibitor resistance, n (%) |
| Primary                                                    | 25 (36%)                                                   | 26 (37%)                                                   |
| Secondary                                                  | 44 (64%)                                                   | 45 (63%)                                                   |

<div style=\"page-break-after: always\"></div>

|                                                                              | Capivasertib + fulvestrant (n = 69)                                          | Placebo + fulvestrant (n = 71)                                               |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Aromatase inhibitor given as last treatment before registration, n (%)       | 57 (83%)                                                                     | 52 (73%)                                                                     |
| Previous adjuvant endocrine therapy, n (%)                                   | 60 (87%)                                                                     | 65 (92%)                                                                     |
| Any tamoxifen                                                                | 41 (68%)                                                                     | 43 (66%)                                                                     |
| Any aromatase inhibitor                                                      | 40 (67%)                                                                     | 36 (55%)                                                                     |
| Any gonadotropin-releasing hormone                                           | 2 (3%)                                                                       | 1 (2%)                                                                       |
| Other                                                                        | 1 (2%)                                                                       | 1 (2%)                                                                       |
| Missing                                                                      | 0                                                                            | 1 (2%)                                                                       |
| Previous endocrine treatment (metastatic or locally advanced setting), n (%) | Previous endocrine treatment (metastatic or locally advanced setting), n (%) | Previous endocrine treatment (metastatic or locally advanced setting), n (%) |
| Median lines, (IQR); range                                                   | 1 (1, 2); 0, 3                                                               | 1 (1, 2); 0, 3                                                               |
| 0 lines                                                                      | 9 (13%)                                                                      | 6 (8%)                                                                       |
| 1 line                                                                       | 39 (57%)                                                                     | 45 (63%)                                                                     |
| ≥ 2 lines                                                                    | 20 (29%)                                                                     | 20 (28%)                                                                     |
| Missing                                                                      | 1 (1%)                                                                       | 0                                                                            |
| Previous adjuvant chemotherapy, n (%)                                        | 36 (52%)                                                                     | 42 (59%)                                                                     |
| Metastatic chemotherapy for advanced breast cancer, n (%)                    | 17 (25%)                                                                     | 20 (28%)                                                                     |
| Previous CDK 4/6 inhibitor, n (%)                                            | 0                                                                            | 0                                                                            |
| PIK3CA results -blood or tissue, n (%)                                       | PIK3CA results -blood or tissue, n (%)                                       | PIK3CA results -blood or tissue, n (%)                                       |
| Wild type                                                                    | 42 (61%)                                                                     | 47 (66%)                                                                     |
| Mutation                                                                     | 27 (39%)                                                                     | 24 (34%)                                                                     |
| Missing                                                                      | 0                                                                            | 0                                                                            |
| PTEN results, n (%)                                                          | PTEN results, n (%)                                                          | PTEN results, n (%)                                                          |
| 0                                                                            | 4 (6%)                                                                       | 4 (6%)                                                                       |
| 1                                                                            | 9 (13%)                                                                      | 8 (11%)                                                                      |
| 2                                                                            | 13 (19%)                                                                     | 23 (32%)                                                                     |
| 3                                                                            | 34 (49%)                                                                     | 28 (39%)                                                                     |
| Missing                                                                      | 9 (13%)                                                                      | 8 (11%)                                                                      |

Adapted from Jones et al 2020

The analysis sets and the number of patients in each analysis set are summarised in the below table.

Table 57 Analysis populations 2020- Supportive FAKTION study

| Population                    |   Capivasertib + fulvestrant (n) |   Placebo + fulvestrant (n) |
|-------------------------------|----------------------------------|-----------------------------|
| ITT                           |                               69 |                          71 |
| PI3K/PTEN Pathway Altered     |                               31 |                          28 |
| PI3K/PTEN Pathway Non-altered |                               38 |                          43 |

<div style=\"page-break-after: always\"></div>

Figure 24 Participant flow

<!-- image -->

From Jones et al 2020

In total, 183 patients were screened for eligibility, of whom 140 (77%) were eligible. A total of 69 and 71  patients  were  randomised  to  the  capivasertib  +  fulvestrant  and  placebo  +  fulvestrant  arms, respectively. Treatment groups were well balanced for baseline characteristics.

## · Outcomes and estimation

Overall, in the ITT analysis by Jones et al 2020, PFS was significantly longer in patients who received capivasertib + fulvestrant than in those who received placebo + fulvestrant.

<div style=\"page-break-after: always\"></div>

Table 58 FAKTION analyses 2020: Progression-free survival and overall survival

|                           | ITT Population            | ITT Population            | PI3K/PTEN Pathway Altered Subgroup   | PI3K/PTEN Pathway Altered Subgroup   | PI3K/PTEN Pathway Non-altered Subgroup   | PI3K/PTEN Pathway Non-altered Subgroup   |
|---------------------------|---------------------------|---------------------------|--------------------------------------|--------------------------------------|------------------------------------------|------------------------------------------|
|                           | C + F (N = 69)            | P + F (N = 71)            | C + F (N = 31)                       | P + F (N = 28)                       | C + F (N = 38)                           | P + F (N = 43)                           |
| Progression-free survival | Progression-free survival | Progression-free survival | Progression-free survival            | Progression-free survival            | Progression-free survival                | Progression-free survival                |
| Number of events (%)      | 49 (71)                   | 63 (89)                   | NR                                   | NR                                   | NR                                       | NR                                       |
| Median (months)           | 10.3                      | 4.8                       | 9.5                                  | 5.2                                  | 10.3                                     | 4.8                                      |
| Adjusted HR (95% CI)      | 0.58 (0.39, 0.85)         | 0.58 (0.39, 0.85)         | 0.59 (0.34, 1.03)                    | 0.59 (0.34, 1.03)                    | 0.56 (0.33, 0.96)                        | 0.56 (0.33, 0.96)                        |
| 2-sided p-value           | 0.0049                    | 0.0049                    | 0.064                                | 0.064                                | 0.035                                    | 0.035                                    |
| Overall survival          | Overall survival          | Overall survival          | Overall survival                     | Overall survival                     | Overall survival                         | Overall survival                         |
| Number of events (%)      | 21 (30)                   | 31 (44)                   | NR                                   | NR                                   | NR                                       | NR                                       |
| Median (months)           | 26.0                      | 20.0                      | 30.5                                 | 18.7                                 | 23.7                                     | 20.3                                     |
| Adjusted HR (95% CI)      | 0.59 (0.34, 1.05)         | 0.59 (0.34, 1.05)         | 0.53 (0.21, 1.33)                    | 0.53 (0.21, 1.33)                    | 0.62 (0.30, 1.28)                        | 0.62 (0.30, 1.28)                        |
| 2-sided p-value           | 0.071                     | 0.071                     | 0.17                                 | 0.17                                 | 0.20                                     | 0.20                                     |

C, capivasertib; F, fulvestrant; P, placebo.

Source:

Jones et al 2020

OS data reported by Jones et al. were immature with a median follow-up for survival of 12 months.

A recent publication by Howell et al 2022 - reported updated PFS and OS analyses from FAKTION and moreover expanded biomarker analyses.

For OS, mature results were reported for the ITT population with median OS of 29.3 months (95% CI 23.7-39.0)  versus  23.4  months  (18.732.7;  adjusted  HR  0.66  [95%  CI  0.45 -0.97];  two -sided p=0.035).

Updated PFS results for the ITT population were reported with median PFS of 10.3 months (95% CI 5.013.4) versus 4.8 months (3.17.9; adjusted HR 0.56 [95% CI 0.38 -0.81]; two -sided p=0.023).

For expanded biomarker analyses, tissue and blood samples were re-analysed retrospectively in 2 steps. In the first step AKT mutation was included, in the second step of -expanded biomarker analyses NGS methods were included: FoundationOne for tissue (similar to CAPITELLO-291) and GuardantOMNI RUO for cfDNA. NGS results became available for 80% (n=112) of the FAKTION-population. Apart from PTEN homozygous deletions which could not be detected in plasma (found in 2.4% of patients in CAPitello291), the same biomarker definition was used as in CAPitello-291.

This led to newly defined pathway altered and non-altered subgroups. The publication included a table with results for PFS and OS for the pathway altered and non-altered subgroups as originally identified, according  to  an  expanded  definition  and  a  definition  in  which  only  NGS  results  are  the  basis  for determination of the biomarker (see below).

<div style=\"page-break-after: always\"></div>

Table 59 Progression free survival and overall survival in the intention to treat population and the  PI3K/AKT/PTEN  pathway-altered  and  pathway  non-altered  subgroups  identified  by original, expanded, and NGS testing

<!-- image -->

|                                                                    | Fulvestrant plus caplvasertlb group                              | Fulvestrant plus caplvasertlb group                        | Fulvestrant plus placebo group                             | Fulvestrant plus placebo group                             | UnadJusted HR (95% CI);  two-slded pvalue                  | AdJusted HR (95% CI); two-slded pvalue                     |
|--------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
|                                                                    | Number of events/ number of patients (%)                         | Median (95% CI), months                                    | Numberofevents/ numberof patients (%)                      | Median (95% CI), months                                    |                                                            |                                                            |
| Progression-free suvival in intention- to-treat population, months | 54/69 (78%)                                                      | 10-3 (5.0-13-4)                                            | 64/71(90%)                                                 | 4·8 (3·1-7·9)                                              |                                                            | 0.55 (0-38-0-80); p=0-0019 0-56 (0-38-0-81); p=0-0023      |
| Overall survivalinintention-to-treat population, months            | 49/69 (71%)                                                      | 29·3 (23.7-39·0)                                           | 59/71 (83%)                                                | 23·4 (18.7-32.7)                                           | 0.66 (0-45-0.96); p=0·030                                  | 0.66 (0-45-0-97); p=0·035                                  |
| Progression-free suvival in pathway-altered subgroups              | Progression-free suvival in pathway-altered subgroups            | Progression-free suvival in pathway-altered subgroups      | Progression-free suvival in pathway-altered subgroups      | Progression-free suvival in pathway-altered subgroups      | Progression-free suvival in pathway-altered subgroups      | Progression-free suvival in pathway-altered subgroups      |
| Original pathway-altered subgroup                                  | 26/31(83%)                                                       | 10.5 (6.6-18.7)                                            | 28/28 (100%)                                               | 5.2 (3.1-8-4)                                              | 0.51(0-30-0.89); p=0·018 0.46 (0-28-0.75); p=0-0021        | 0·47 (0-26-0.84); p=0.011 0-44 (0-26-0.72); p=0-0014       |
| (% //) e/oe  dnosbqns paalje-(emyed papuedx                        |                                                                  | 12.8 (6-6-18.8)                                            | 36/37 (97%)                                                | 4·6 (2.8-7.9)                                              |                                                            |                                                            |
| NGS-identifed pathway-altered subgroup                             | 25/34 (74%)                                                      | 13·4 (6-6-20.7)                                            | 29/29 (100%)                                               | 3.1 (2-8-7.7)                                              | 0.35 (0-20-0.63); p=0.0004                                 | 0.36(0.20-0.65);p=0-0007                                   |
| Progression-free survival in pathway non-altered subgroups         | Progression-free survival in pathway non-altered subgroups       | Progression-free survival in pathway non-altered subgroups | Progression-free survival in pathway non-altered subgroups | Progression-free survival in pathway non-altered subgroups | Progression-free survival in pathway non-altered subgroups | Progression-free survival in pathway non-altered subgroups |
| Original pathway non-altered subgroup                              | 28/38 (74%)                                                      | 10-3 (3·2-13·5)                                            | 36/43 (84%)                                                | 4·8 (3·0-10-3)                                             | 0.59 (0·35-0-99); p=0·044                                  | 0.59 (0-35-0-98);p=0·042                                   |
| Expanded pathway non-altered subgroup                              | 24/30 (80%)                                                      | 7.7 (3.1-13-2)                                             | 28/34 (82%)                                                | 4·9 (3·2-10.5)                                             | 0.72 (0-41-1.27); p=0-25                                   | 0.70 (0-40-1.25); p=0.23                                   |
| NGS-identified pathway non-altered 18/22(82%) subgroup             |                                                                  | 4·8 (1-3-10·3)                                             | 22/27 (81%)                                                | 5·2 (2.2-10-5)                                             | 0.95 (0-50-1.81); p=0-88                                   | 0.95 (0-49-1.82); p=0-87                                   |
| Overall survival in pathway-altered subgroups                      | Overall survival in pathway-altered subgroups                    | Overall survival in pathway-altered subgroups              | Overall survival in pathway-altered subgroups              | Overall survival in pathway-altered subgroups              | Overall survival in pathway-altered subgroups              | Overall survival in pathway-altered subgroups              |
| Original pathway-altered subgroup                                  | 20/31 (64%)                                                      | 33·5 (22.3-50-7)                                           | 24/28 (86%)                                                | 20·9 (15.5-36·1)                                           | 0-51(0.28-0-94);p=0-030                                    | 0.50 (0-27-0.92); p=0.025                                  |
| (%) be/sdnosbanspaane-emedpapuedxg                                 |                                                                  | 38.9 (23·3-50.7)                                           | 32/37 (86%)                                                | 20·0 (14·8-31·4)                                           | 0-49 (0-29-0·84);p=0.0091                                  | 0-46 (0-27-0.79); p=0.0047                                 |
| NGS-identified pathway-altered subgroup                            | 21/34 (61%)                                                      | 39·0 (22.3-50.7)                                           | 25/29 (86%)                                                | 20·9 (14-1-35-4)                                           | 0-43 (0.24-0.78);p=0-0056                                  | 0-44(0-24-0-81);p=0-0076                                   |
| Overall survival in pathway non-altered subgroups                  | Overall survival in pathway non-altered subgroups                | Overall survival in pathway non-altered subgroups          | Overall survival in pathway non-altered subgroups          | Overall survival in pathway non-altered subgroups          | Overall survival in pathway non-altered subgroups          | Overall survival in pathway non-altered subgroups          |
| Original pathway non-altered subgroup                              | 29/38 (76%)                                                      | 26-2 (20.7-38.5)                                           | 35/43 (81%)                                                |                                                            | E-0=d:(00-1-/-0)08:0(5-20--91)6-EZ                         | 0.80 (0-49-1.32); p=0-39                                   |
| Expanded pathway non-altered  subgroup                             | 24/30 (80%)                                                      | 26·0 (18-4-33·8)                                           | 27/34 (79%)                                                |                                                            | 25.2 (20.3-36·2)0.95 (0.55-1.64); p=0.85                   | 0.86 (0-49-1.52);p=0.60                                    |
| NGS-identified pathway non-altered  17/22 (77%) subgroup           |                                                                  | 23.7 (16.7-38-5)                                           | 22/27 (81%)                                                |                                                            | 25-2 (15-3-38.8)0.87 (0-46-1.64); p=0.66                   | 0.86 (0-45-1.63); p=0-64                                   |
| HR=hazard ratio. NGS=next-generation sequencing. NR=not reached.   | HR=hazard ratio. NGS=next-generation sequencing. NR=not reached. |                                                            |                                                            |                                                            |                                                            |                                                            |

By the NGS method two distinctly different populations with different treatment outcome were identified, while  in  the  initial  publication  the  treatment  outcome  was  not  influenced  by  biomarker  status.  The treatment effect in the non-altered subgroup which was reported by Jones et al. 2020 diminishes when the new definitions for biomarker positivity are used. For the non-altered subgroup, adjusted HR was 0.95 [95% CI 0.49, 1.82]. For the pathway altered population, adjusted HR was 0.35 [95% CI 0.20, 0.63]. The  authors´  interpretation of the results is that in the original tests, patients with PIK3CA/AKT1/PTEN  altered  tumours  were  erroneously  placed  in  the  non-altered  population  and concluded that their analyses suggest 'that NGS testing is needed to accurately identify patients who might  not  benefit  from  capivasertib'  and  the  'expanded  pathway  non-altered  subgroup  analysis suggests, but does not prove, that capivasertib predominantly benefits patients with PIK3CA/AKT1/PTEN pathway alterations'.

## 2.6.6. Discussion on clinical efficacy

As part of this MAA, the applicant submitted clinical study results in support of the following indication (wording amended during the evaluation):

' TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER) positive, HER2 negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen (see section 5.1 ).

In  pre-  or  perimenopausal  women,  TRUQAP  plus  fulvestrant  should  be  combined  with  a luteinising hormone releasing hormone (LHRH) agonist.

<div style=\"page-break-after: always\"></div>

For men, administration of LHRH agonist according to current clinical practice standards should be considered.'

The clinical development programme in support of the claimed indication consists of 2 clinical trials: one supportive phase 1b/2 study (FAKTION; performed in an academic context, funded by Cancer Research UK, with involvement of the applicant in funding, planning and reviewing) and the pivotal phase 3 study CAPItello-291.

## Dose finding and dose recommendation

The recommended capivasertib dose is 800 mg daily (400 mg BD with or without food) for 4 days followed by 3 days off treatment, based on PK, PD, safety and efficacy data.

The recommended dosage of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter as approved in the EU. In pre/perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

Because of the choice of dosage regimen for the fulvestrant combination, the usual approach to dose finding was not followed and the dosing regimen selection for the fulvestrant combination was mostly based on the selection of the dosing regimen for the capivasertib monotherapy.

As to the data provided, dose finding did not lead to an explicit recommended phase 2 dosing study. The decision to use the dosing regimen described above in the pivotal study CAPItello-291 was based on the FTIH study and consecutive clinical experience from the supportive phase 1b/2 FAKTION study. Although this dosing regimen is overall acceptable, based on the data provided it cannot be concluded whether the dosing regimen is optimal.

In terms of dose adjustment, a first dose reduction from 400 mg to 320 mg twice daily for 4 days followed by 3 days off treatment is proposed followed by a second dose reduction to 200 mg twice daily for 4 days followed by 3 days off treatment  to manage adverse reactions. In order to further justify the proposed 2 nd  dose reduction scheme for Capivasertib rather than immediate discontinuation of treatment for all relevant  populations,  a  post-hoc  analysis  was  conducted  to  explore  efficacy  in  patients  with  a  dose reduction to capivasertib 200 mg in the pivotal CAPItello-291 study. These analyses showed no evidence of less benefit in patients with dose reductions to capivasertib 200 mg BD (versus placebo+fulvestrant and versus capivasertib+fulvestrant) hence supporting the proposed 2 nd  dose reduction.

## Design and conduct of clinical studies

## Pivotal study: CAPItello-291

The general design as a randomised, double-blind, placebo-controlled multicentre trial is endorsed. CHMP scientific advice (SA) on the design of the proposed pivotal phase 3 study (D3615C00001; CAPItello -291) was obtained in October 2019 (ref. EMEA/H/SA/3985/2/2019/III).

## · Inclusion and exclusion criteria

The  overall  population  includes  several  very  relevant  subgroups,  e.g.  pre/perimenopausal  patients, postmenopausal patients, patients with prior CDK4/6i treatment, and CDK4/6I naïve patients, tumours with PIK3CA/AKT1/PTEN alteration, confirmed non-altered tumours and tumours for which biomarker test on PIK3CA/AKT1/PTEN was not successful.

In the CHMP scientific advice ,aspects of the inclusion and exclusion criteria were discussed, e.g. inclusion of  pre-  and  post-menopausal  patients,  patients  progressing  after  adjuvant  therapy  and  on  1 st   line advanced therapy, respectively, and with or without previous chemotherapy exposure in the same study was agreed for HR+/HER2- breast cancer patients. Furthermore, the impact of inclusion of CDK 4/6 inhibitors naïve patients on heterogeneity and the appropriateness of the comparator was addressed. CHMP highlighted the expectation of adequately interpretable data for all subgroups of interest.

<div style=\"page-break-after: always\"></div>

The inclusion  and  exclusion  criteria  largely  reflect  the  large  and  heterogeneous  target  population  in endocrine (i.e. AI-) resistant advanced and metastatic breast cancer. It is agreed that patients with rapidly progressive disease are excluded in order to avoid complications of treatments that may induce tumour response in short time, e.g. chemo- or radiotherapy are preferred.

As CDK 4/6 inhibitors combined with endocrine treatment are recommended as first-line treatment in HR+/HER2- advanced breast cancer, it would have been expected that all patients previously treated in the metastatic setting would all have received CDK 4/6 inhibitors. The applicant's intention was to include both, CDK 4/6 inhibitors pretreated (&gt;50%) and CDK 4/6 inhibitors naïve patients. This increases the heterogeneity,  which  is  already  apparent,  as  pre/peri-  and  postmenopausal  women  and  men  with metastatic breast cancer (mBC) and patients with different lines of prior treatment are included in the single pivotal trial.

Inclusion of pre/peri- and postmenopausal women and men with mBC is acceptable in line with recent guidelines,  provided  that  premenopausal  women  receive  LHRH  analogues  for  continuous  ovarian suppression. The combination with LHRH analogues in pre- or perimenopausal women has been included in section 4.1 of the SmPC.

Patients with diabetes mellitus were excluded from the pivotal trial and additional data on the efficacy and also the safety in these patients are needed to give evidence-based recommendations to prescribers, when patients with concomitant diabetes mellitus should be part of the target population (see also section 2.6.8. ). In the context of the capivasertib Phase IIIb programme (including studies CAPItana, CAPItrue and CAPIcorn) enrolment of patients with clinically stable diabetes mellitus (complying with eligibility criteria defined as HbA1c ≤8.0% (63.9 mmol/mol) at scre ening) should be encouraged and subgroup analyses on efficacy (ORR, PFS, OS) in diabetic patients in the individual studies and in the combined analyses  should  be  planned.  Results  of  such  studies  (CAPItana,  CAPItrue  and  CAPIcorn)  should  be submitted once available (REC).

## · Biomarker PIK3CA/AKT1/PTEN alteration

For investigation of PIK3CA/AKT1/PTEN alteration status a tumor sample - preferably FFPE or freshlycut unstained serial tumor slides - was mandatory for central testing by FoundationOne ® CDx (with the exception of 8 patients from mainland China due to restrictions in shipping tissue from China). For the definition  of  biomarker-positivity,  several  PIK3CA/AKT1/PTEN  alterations  were  added  to  the  PIK3CA alterations that were already FDA approved for the FoundationOne ® CDx.

Clarification on the definitions of biomarker rules and timelines for implementation were requested during the evaluation. In Capitello-291 the first patient was enrolled on 16/04/2020 and the last patient on 13/10/2021. Tissue testing was performed between 22 August 2020 and 28 October 2021, apparently partly retrospective, partly in real time. DCO was in August 2022. The applicant clarified that biomarker rules defining biomarker positive status and used for F1CDx testing on CAPItello291 were finalised with FMI on 30 November 2020 prior to the first data transfer on 21 December 2020 and that they did not change throughout the rest of the study. In view of the role of the biomarker positive treatment group as primary analysis population, documentation in an appendix to the protocol prior to first patient first visit (FPFV) would have been expected.

CHMP scientific advice indicated that prospective NGS testing for PIK3CA/AKT1/PTEN alterations would have allowed stratification by PIK3CA/AKT1/PTEN alteration status. However, prospective NGS testing for PIK3CA mutations was not considered feasible by the applicant due to the delay of start of treatment by ≥30 days. While this argument was accepted, CHMP highlighted the importance of the ability to assess consistency between the mutated and the non-mutated subgroups.

<div style=\"page-break-after: always\"></div>

Furthermore,  CHMP  scientific  advice  requested  subgroup  analyses  with  regard  to  PI3K/AKT/PTEN pathway activation status (with the need to demonstrate and confirm the benefit regardless of biomarker status), and prior exposure to CDK 4/6 inhibitors (with the need to show the benefit in CDK 4/6 inhibitors pre-treated patients even in relation with biomarker status) was considered particularly relevant.

Next to the overall population , the PI3K/AKT/PTEN altered population is a primary population. For the non-altered population exploratory analyses were presented. For the benefit-risk, separate discussions for the PI3K/AKT/PTEN altered and for the non-altered population / known non-altered population were deemed necessary.

## · Randomisation

The stratification factors: presence of liver metastases, prior use of CDK4/6 inhibitors and geographic location are endorsed. PI3K/AKT/PTEN alteration status would have been highly welcomed also as a stratification factor in view of the importance of the PI3K/AKT/PTEN altered population as a primary population.

## · Comparator placebo + fulvestrant

Placebo + fulvestrant was chosen as comparator. Fulvestrant is included in current treatment guidelines for patients with no risk of organ failure. However, based on a substantial PFS benefit over endocrine monotherapy, CDK4/6I are recommended in combination with an AI or fulvestrant for first-line or second line endocrine treatment, respectively. Therefore, fulvestrant monotherapy is not considered as the best available treatment option in CDK 4/6 inhibitors naïve patients. This shortcoming was addressed as part of the CHMP Scientific advice. CHMP requested contextualisation of the results and a discussion on their clinical relevance in light of the best available alternative treatment options was expected to support the B/R assessment. In principal allowing fulvestrant + CDK4/6I to CDK4/6I naïve patients would have been a valuable option for the reference treatment arm, still allowing to assess the contribution of capivasertib in the doublet regimen under study, given that a large majority of the patients was intended to be pretreated with CDK4/6I.

## · Endpoints

Dual primary endpoints were planned for the study, PFS (by investigator assessment) in the overall population and the PIK3CA/AKT1/PTEN altered population . PFS assessment by investigator is considered appropriate in view of the blinded placebo-controlled design. It is acknowledged that sensitivity analyses for  PFS  include  full  BICR  assessment  which  is  considered  important  as  blinding  might  have  been compromised by capivasertib-associated adverse drug reactions.

Overall survival is a key secondary endpoint and analysed for both primary populations.

Overall response rate (best overall response rate), duration of response and PFS2 are relevant secondary endpoints, which are endorsed. All these clinical endpoints are planned for the overall population and the PIK3CA/AKT1/PTEN altered population .  For the non-altered population exploratory analyses were planned for the same endpoints.

A number of further exploratory endpoints address different aspects of the biomarker role, including comparisons of PIK3CA/AKT1/PTEN alterations in ctDNA and tissue samples and comparisons of samples taken pre-treatment and on-treatment.

<div style=\"page-break-after: always\"></div>

Standard safety endpoints to assess the safety and tolerability are endorsed. Patient reported outcomes include EORTC-QLQ-C30 and EORTC-BR23, PRO-CTCAE, and EQ-5D-5L health state utility index. These are standardised measures appropriate for the target population.

In the target population of patients with locally advanced or metastatic HR positive, HER2 negative breast cancer, PFS is the appropriate time-to-event endpoint for evaluation of the direct treatment effect. It is acceptable for the pivotal study provided the effect is homogeneous across important subpopulations, and PFS is sufficiently large to outweigh added toxicity, and that mature OS data at least exclude any detriment.  The  plan  for  two  primary  populations  is  agreed  to  allow  a  separate  evaluation  in  the PIK3CA/AKT1/PTEN altered population next to the overall population . The complementary non-altered population is important for the assessment of homogeneity of subgroups.

## · Statistical methods

The analyses were generally pre-specified in SAP 4.0 that was finalised before the primary PFS analysis database lock, however, the multiplicity procedure was changed to include spending small alpha for the first OS analysis after unblinding which was not ideal but not considered critical as the change did not result in confirmatory claims.

The FAS excludes patients randomised in China after the global cohort last patient first visit (LPFV), as pre-specified  in  the  protocol.  Analyses  based  on  Chinese  patients  randomised  before  and  after  are described in a separate 'China SAP', reported in a separate CSR and are exploratory according to study protocol. No results from this cohort are provided in this application.

The primary PFS analysis was based on investigator's assessment, while an analysis using BICR was provided as sensitivity analysis. This is appropriate for a blinded study.

While  defining  time  to  PFS  regardless  of  whether  the  patient  withdrew  from  randomised  therapy  or received another anti-cancer therapy prior to progression (i.e. patients were not censored in case of these events) is in accordance with the relevant EMA guidance on PFS, censoring patients in case of progression or death immediately after two consecutively missed visits is not. It is acknowledged that a sensitivity analysis reverting these two censoring rules was provided.

Standard  methods  for  time  to  event  analysis  (log-rank  test  and  Cox  regression)  were  applied  for hypothesis  testing  and  treatment  effect  estimation  for  PFS  and  OS.  The  randomisation  stratification factors were appropriately taken into account by a correspondingly stratified analysis.

In accordance with the pre-specified multiplicity procedure, confirmatory hypotheses tests were possible for PFS and OS in the overall population and the PIK3CA/AKT1/PTEN altered population , respectively. The multiple testing strategy was appropriate to ensure control of the family-wise type 1 error rate. The multiplicity strategy including alpha splitting would have allowed confirmatory conclusions for PFS for the overall and the altered population even if the null hypothesis for the overall population could not have been rejected and vice versa; consequently, considering the PFS analyses in these populations as dual primary was appropriate. The originally planned interim analysis for the overall  population was removed in a protocol amendment (CSP V4.0) while the study was blinded, which is appreciated.

Although the testing strategy allows confirmatory conclusions for the overall population and the altered population , a positive result in the overall population could be driven by an effect in the altered population such  that  the  exploratory  analysis  in  the Non-altered  population (including  the Known  non-altered population and the No Result Population) is particularly relevant.

No confirmatory conclusions can be drawn for OS. The nominal 95% confidence interval for the HR that was provided for OS is not consistent with the confirmatory testing strategy. In particular, an effect on OS based on the 95% CI excluding 1 cannot be claimed.

<div style=\"page-break-after: always\"></div>

During the study conduct, 3 amendments were issued, the most fundamental ones concern the definition of the primary endpoint as dual primary endpoints in the overall and the PIK3CA/AKT1/PTEN altered population and the separation of the Chinese patients from the Global cohort. In June 2021, when the majority of patients was enrolled, the inclusion criteria were amended so that progression or recurrence on the most recent treatment was required.

A total of 62 patients were known for at least one important deviation (8.8%; 62/708). One of the most frequent protocol deviation (25%; 16/62) was patients receiving capivasertib/placebo at incorrect dose, mostly reduced dose for a given period of time. This could have possibly impacted the observed safety results  by  minimizing  them.  It  seems  that  the  wording  of  the  posology  may  have  lead  to  posology mistakes. The proposed SmPC section 4.2 is considered clear and understandable regarding posology, which is reassuring.

The  applicant  stated  that  8  audits  at  investigator  sites  were  performed  and  provided  the  audits certificates.

## Efficacy data and additional analyses

## Baseline characteristics

In the overall population, the median age was 58 years (range from 26 to 90 including 30.7% of patients over 65 years of age). Most patients were female (99.0%) and White (57.5%) followed by Asian (26.7%) and Black (1.1%). While the proportion of men in the study program is very low, it is still considered possible to extrapolate results to men, based on the common biological and pharmacological rationale. Most patients had Eastern Cooperative Oncology Group (ECOG) performance status 0 and the majority of patients was in postmenopausal state (77.3%). All patients received prior endocrine-based therapy (100% AI-based treatment and 44.1% received tamoxifen). Prior treatment with CDK4/6 inhibitor was reported in 70.1% of patients. Chemotherapy for locally advanced (inoperable) or metastatic disease was reported in 18.2% of patients.

Patient demographics for those in the PIK3CA/AKT1/PTEN-altered population were generally representative of the overall study population with some differences between arms. There  were less patients with a pre/perimenopausal status, less in the youngest and oldest age cohorts and more patients with lung and/or liver metastases in the capivasertib arm.

In the 'Known non-altered population' capivasertib treatment group, slightly more patients presented with locally advanced disease, in postmenopausal state and without CDK 4/6I pre-treatment and with diabetes. There is no indicator for a more unfavourable prognosis in this treatment group.

In terms of subgroups, the pre-/perimenopausal subgroup presented with somewhat more advanced disease, more liver metastases and had less likely PIK3CA/AKT1/PTEN alterations. The CDK 4/6 inhibitors naïve subgroup included more patients from Asia, more in p ostmenopausal status, more (neo)adjuvant chemotherapy and substantially more patients with no prior endocrine based therapy for locally advanced or metastatic breast cancer.

Only patients with ER+ disease as per ASCO recommendation were in fact included in the study, in line with the mode of action for fulvestrant. The initially proposed indication wording was therefore changed from 'hormone receptor positive breast cancer' to 'oestrogen receptor (ER) positive ' .

## Dual primary endpoints PFS in the overall and PIK3CA/AKT1/PTEN altered populations

Based on approximately 77% of events both primary endpoints of PFS (by investigator assessment ) in the overall and in the PIK3CA/AKT1/PTEN altered populations were met. In both primary populations the effect on PFS is statistically significant and in its reported size clinically relevant with doubling of the median PFS time i.e. 3-4 months.

<div style=\"page-break-after: always\"></div>

In the PIK3CA/AKT1/PTEN altered population (40.8 % of the overall population ), a reduction in the risk of progression in favour of capivasertib + fulvestrant was observed with a HR 0.50 (95% CI: 0.38 0.65; p &lt; 0.001). The median PFS was 7.3 months in the capivasertib + fulvestrant arm compared with 3.1 months in the placebo + fulvestrant arm.

The  effect  on  PFS  is  considered  robust  regarding  the  results  of  several  sensitivity  analyses  (on ascertainment bias, evaluation time bias and attrition bias) which are consistent with the results for the primary  analyses  for  both  primary  populations.  The  effect  in  the  overall  population  was  primarily attributed to the results seen in the PIK3CA/AKT1/PTEN altered population .

## PFS in the non-altered population

Importantly, for the understanding of the treatment effect in the biomarker PIK3CA/AKT1/PTEN negative population, exploratory PFS analyses were submitted for the non-altered population (59.2 % of overall population ) and its subgroups known non-altered subgroup (44.2% of overall population ) and no-result subgroup (15.0 % of overall population ).

Although for the entire non-altered population the absolute effect size was similar to that in the overall and  the PIK3CA/AKT1/PTEN  altered  populations ,  this  is  mainly  due  to  the  effect  in  the  no-result population (HR 0.52 (95% CI: 0.32, 0.83)). The effect in the documented biomarker negative, i.e. known non-altered population was very limited with PFS by investigator HR 0.79 (95% CI: 0.61, 1.02) and PFS by BICR HR 0.85, (95% CI 0.65, 1.12).

Overall survival is  a  key  secondary  endpoint  for  both  primary  populations.  After  approximately  16 months of follow-up, data are still immature. For both the overall population and the PIK3CA/AKT1/PTEN altered  population ,  the  analyses  on  OS  at  the  time  of  the  primary  PFS  analysis  did  not  suggest  a detrimental effect on survival of treatment with capivasertib + fulvestrant compared with placebo + fulvestrant.

Further interim and final OS analyses will be provided with more mature data (scheduled DCO March 2024 and May 2025). The applicant indicated the interim and final analyses on OS should be available approximately in Q3 2024 and Q4 2025, respectively. The applicant agreed to provide both OS analyses as soon as they become available (REC).

Results  of PFS2 events  need  to  be  interpreted  with  caution,  as  standardised  uniform  tumour assessments cannot be assumed. Results showing a numerical trend in favour of capivasertib+fulvestrant for the overall population and the PIK3CA/AKT1/PTEN altered population go in the same direction as the primary results, whereas for the known non-altered population no relevant difference  was  reported.  It  is  considered  reassuring  that  there  is  no  sign  of  detriment  with capivasertib+fulvestrant.

Exploratory analyses on objective response rates for both primary populations by INV and BICR showed higher  ORR  for  capivasertib+fulvestrant  than  for  placebo+fulvestrant  in  both  primary  populations. Duration of response - based on small numbers - appeared similar in both arms.

## Supportive study FAKTION

Results of the phase 2 part of the FAKTION study which investigated the combination capivasertib+fulvestrant  vs  placebo+fulvestrant  in  140  patients  with  endocrine  resistant  HR  positive locally advanced and metastatic breast cancer were reported by Jones et al 2020 and updated PFS and OS analyses and further biomarker analyses were reported by Howell et al 2022.

<div style=\"page-break-after: always\"></div>

The study is relevant because the design as a placebo-controlled RCT is widely comparable to CAPITELLO291, the dose and dose regimen are the same and there was a wide overlap in terms of the study populations. Both studies CAPITELLO-291 and FAKTION included HR+ HER2- advanced breast cancer patients following progression on AI. In comparison to CAPITELLO-291, the population in FAKTION is slightly  older  and  postmenopausal,  more  in  metastatic  stage,  and  more  patients  had  not  received previous  CDK  4/6  inhibitors,  previous  endocrine  treatment  appears  slightly  different,  patients  had received more tamoxifen, and more chemotherapy.

In FAKTION, blood and tissue samples were centrally tested for PIK3CA and PTEN alteration status before randomisation. As methods for detection of the biomarker 'pathway' alteration evolved, the second publication reported results for newly defined pathway altered and pathway non altered populations, based on NGS methods that are comparable to those used in CAPItello-291 (only PTEN homozygous deletions could not be detected in plasma).

While the original analyses - using ddPCR and IHC for a limited set of alterations - found no impact of the biomarker status on the PFS and OS results, the updated results - using NGS and a wider set of alterations - found two distinctly different populations with different treatment outcome. The treatment effect in the non-altered subgroup which was reported by Jones et al 2020 diminished when the new definitions for biomarker positivity are used: for the non-altered subgroup the adjusted HR is 0.95 [95% CI 0.49, 1.82]. For the pathway altered population, the adjusted HR is 0.35 [95% CI 0.20, 0.63] is reported. The authors' interpret indicated 'that NGS testing is needed to accurately identify patients who might  not  benefit  from  capivasertib'  and  the  'expanded  pathway  non-altered  subgroup  analysis suggests, but does not prove, that capivasertib predominantly benefits patients with PIK3CA/AKT1/PTEN pathway alterations'.

CHMP scientific advice highlighted the heterogeneity of the broad target population and requested adequately interpretable data for all subgroups of interest and indicated the need to demonstrate and confirm the benefit regardless of biomarker status, and prior exposure to CDK 4/6 inhibitors.

## PFS analyses by further important subgroups

CHMP scientific advice highlighted the heterogeneity of the target population and requested adequately interpretable data for all subgroups of interest, this included prior exposure to CDK 4/6 inhibitors.

- Efficacy by previous CDK4/6i treatment

A majority of patients (70.1%) had received a prior CDK4/6i. For the remaining 29.9%, the reference treatment with fulvestrant monotherapy is not in line with recent clinical guidelines (Gennari, André et al. 2021). It is apparent that the proportion of CDK 4/6 inhibitor naïve patients varies within region, with the highest proportion in region 3 (Asia) and the lowest in region 1 (including North America and Western Europe, 12%). The applicant provided details for not being treated with a CDK4/6I. The main reasons were Health Care Providers preference (37.3%), followed by treatment not approved (25.3%), treatment not reimbursed (18.1%). Thus, for the latter two, CDK4/6 treatment was objectively not available.

A similar relative benefit in PFS was observed independent of prior exposure to CDK4/6 inhibitors (HR of 0.59 and 0.64 respectively). A shorter absolute PFS in both treatment arms was associated with prior use of CDK4/6 inhibitors. Although small, the absolute size of median PFS in the placebo + fulvestrant arm in patients  pre-treated  with  CDK  4/6  inhibitors  (2.6  months)  is  in  line  with  recent  publications (Lindeman, Bowen et al. 2021, Bidard, Kaklamani et al. 2022) and therefore considered acceptable.

- Efficacy in premenopausal women

Pre/perimenopausal patients are an important subgroup of the target population for which conclusions on efficacy are considered important. It was clarified that nearly all pre-/perimenopausal women actually received  LHRH  analogues  throughout  the  study.  According  to  the  baseline  characteristics,  pre-

<div style=\"page-break-after: always\"></div>

/perimenopausal  patients  appeared  to  have  somewhat  more  advanced  disease,  and  had  less  likely PIK3CA/AKT1/PTEN  alterations.  In  the  subgroup  of  pre/perimenopausal  women  the  effect  size  was smaller and the 95% CI crossed 1 (HR of 0.86, 95% CI 0.60-1.20). As the FAKTION study did not include pre-/perimenopausal women, there are no supportive data. The applicant indicated that further studies are investigating capivasertib in combination with other medicinal products (CAPItello-292 and CAPItello290)  and  will  provide  further  efficacy  data  for  capivasertib  in  women  in  premenopausal  state.  The applicant agreed to provide results of CAPItello-292 and CAPItello-290 once available to address the efficacy in pre-menopausal women (REC).

It is reassuring that for patients with prior chemotherapy in the locally advanced/metastatic setting, an important subgroup with possibly poorer prognosis, results did not indicate impaired efficacy.

## 2.6.7. Conclusions on the clinical efficacy

The dual primary endpoint PFS (by investigator assessment) showed a statistically significant effect in favour of capivasertib + fulvestrant compared to placebo + fulvestrant both in the overall population and the PIK3CA/AKT1/PTEN altered population .  In  both primary populations, the size of the PFS effect is considered clinically relevant with doubling of the median PFS time i.e. 3-4 months.

In the entire non-altered population the absolute effect size was similar to that in the overall population and the PIK3CA/AKT1/PTEN altered population however this is mainly due to the PFS effect observed in the no-result part of the non-altered population. Therefore, the indication was restricted to patients with a PIK3CA/AKT1/PTEN tumour alteration.

Data for the key secondary endpoint OS are still immature after approximately 16 months of follow-up but for both the overall population and the PIK3CA/AKT1/PTEN altered population , the analyses on OS at the time of the primary PFS analysis did not suggest a detrimental effect on survival of treatment with capivasertib + fulvestrant compared with placebo + fulvestrant. Kaplan-Meier plots appearing to diverge early. Further interim and final OS analyses will be provided with more mature data (scheduled DCO March 2024 and May 2025).

In conclusion, the efficacy of capivasertib in combination with fulvestrant is considered established for the treatment of adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alterations following recurrence or progression on or after endocrine-based therapy.

## 2.6.8. Clinical safety

## Table 60 Safety analysis sets

| Analysis set      | Number of patients                                                 | Definition                                                                                                                                                                          | Purpose                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CAPItello-291 SAS | Capivasertib + fulvestrant: N = 355 Placebo + fulvestrant: N = 350 | All patients in the CAPItello-291 Overall Population who received at least 1 dose of study drug (fulvestrant, capivasertib, placebo), analysed according to the treatment received. | Provide the pivotal safety data to evaluate the safety and tolerability of capivasertib + fulvestrant in the intended patient population. The capivasertib + fulvestrant arm is the basis for identifying common ADRs and their frequency. The placebo control provides the basis for evaluating the contribution of capivasertib to the safety profile of the combination therapy with fulvestrant. |

<div style=\"page-break-after: always\"></div>

| FTIH Study Pool   | Capivasertib fulvestrant: N = 75                             | +   | All patients from the FTIH study (D3610C00001), Parts E and F, who received at least 1 dose of capivasertib.                                                                                                                                                  | Understand any differences in safety data between the CAPItello-291 SAS and the Combined Pool.                        |
|-------------------|--------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Combined Pool     | Capivasertib fulvestrant: N = 430                            | +   | All patients in the capivasertib + fulvestrant arm of the CAPItello-291 SAS and all patients in the FTIH Study Pool.                                                                                                                                          | Support evaluation and characterisation of common AEs.                                                                |
| Monotherapy Pool  | Capivasertib: N = 165                                        |     | All patients from the FTIH study (D3610C00001), Parts A to D, the Japanese safety/PK study (D3610C00004), and the formulation/food study (D3610C00007) who received at least 1 dose of capivasertib monotherapy at a dose of 480 mg BD 4 days on, 3 days off. | Indicate the potential contribution of capivasertib monotherapy to the safety profile when combined with fulvestrant. |
| FAKTION study     | Capivasertib fulvestrant: N = 69 Placebo fulvestrant: N = 71 | + + | Phase II part                                                                                                                                                                                                                                                 | Supportive data                                                                                                       |

## 2.6.8.1. Patient exposure

## CAPItello-291 study

As  of  the  data  cut-off  (15  August  2022),  median  duration  of  follow-up  was  14.9  months  in  the capivasertib + fulvestrant arm and 14.3 months in the placebo + fulvestrant arm.

<div style=\"page-break-after: always\"></div>

Table 61 Duration of treatment (CAPItello-291 SASDCO: 15-08-2022)

|                                                                       |                       | Capivasertib+ Fulvestrant (N = 355)   | Placebo + Fulvestran t (N =350)   |
|-----------------------------------------------------------------------|-----------------------|---------------------------------------|-----------------------------------|
| Total (intended) treatment duration (months) - capivasertib/placebo a | Median                | 5.42                                  | 3.58                              |
| Total (intended) treatment duration (months) - capivasertib/placebo a | Range                 | 0.1-26.3                              | 0.1-25.0                          |
| Total (intended) treatment duration (months) - capivasertib/placebo a | Total treatment years | 211.0                                 | 164.2                             |
| Total (intended) treatment duration (months) - fulvestrant b          | Median                | 5.75                                  | 3.68                              |
| Total (intended) treatment duration (months) - fulvestrant b          | Range                 | 0.5-26.3                              | 0.5-25.1                          |
| Total (intended) treatment duration (months) - fulvestrant b          | Total treatment years | 233.5                                 | 172.0                             |
| Actual treatment duration (months) - capivasertib/placebo c           | Median                | 5.29                                  | 3.52                              |
| Actual treatment duration (months) - capivasertib/placebo c           | Range                 | 0.1-26.0                              | 0.1-23.6                          |
| Actual treatment duration (months) - capivasertib/placebo c           | Total treatment years | 206.7                                 | 162.2                             |

a     Total treatment duration = (date of last dose date where dose &gt; 0 - first dose date + 1)/(365.25/12).

b Total treatment duration = (min (date of last dose where dose &gt; 0 + D, date of death, date of DCO) first dose date + 1)/(365.25/12), where D is equal to the scheduled number of days between doses minus one.

c Actual treatment duration = total treatment duration minus the total duration of dose interruptions. Total treatment years is calculated as total treatment duration in months summed over patients divided by 12.

The median relative dose intensities of capivasertib and placebo were 93.8% and 99.5%, respectively.

The median percentage of the actual dose delivered relative to the intended dose (relative dose intensity) was  95.3%  (78.0%,  100.0%)  for  capivasertib,  99.7%  (96.6%,  100.0%)  for  placebo,  and  100% (100.0%, 100.0%) for fulvestrant in both treatment groups.

The exposures and relative dose intensities in the altered subgroup safety analysis set were similar to those of the overall safety population.

In the confirmed non-altered subgroup the median total and actual duration of exposure to capivasertib were shorter (3.6. and 3.2 months, respectively) than in the overall population, and were comparable to placebo + fulvestrant arm.

The  safety  data  update  included  data  for  all  patients  who  received  the  study  drug  in  the  Overall Population of CAPItello-291 with DCO 27 March 2023. The median total treatment duration remained the same, 5.4 months vs 3.6 months for capivasertib and placebo, respectively, and total treatment duration increased by 29.1 total treatment years for capivasertib (211.0 and 240.1 total treatment years at DCO1 and 27 March 2023 DCO, respectively) and by 21.9 total treatment years for placebo (164.2 and 186.1 total treatment years, respectively).

## FAKTION study

As  of  the  DCO  of  30  January  2019,  the  median  duration  of  capivasertib  treatment  (capivasertib  + fulvestrant arm) was 7.7 (1.5 to 13.5) months. The median duration of fulvestrant treatment was 9.2 (3.0 to 14.1) months in the capivasertib + fulvestrant arm and 4.6 (2.8 to 10.5) months in the placebo + fulvestrant arm. The median duration of placebo treatment (placebo + fulvestrant arm) was 4.9 (2.3 to 10.6) months.

<div style=\"page-break-after: always\"></div>

## 2.6.8.2. Adverse events

Table 62 Adverse events in any category - study CAPItello-291 (SAS and altered subgroup SAS) at DCO: 15 August 2022

| Any AE                                                                           | Number (%) of patients a              | Number (%) of patients a        | Number (%) of patients a             | Number (%) of patients a        |
|----------------------------------------------------------------------------------|---------------------------------------|---------------------------------|--------------------------------------|---------------------------------|
|                                                                                  | Overall population                    | Overall population              | Altered subgroup                     | Altered subgroup                |
|                                                                                  | Capivasertib + Fulvestran t (N = 355) | Placebo + Fulvestrant (N = 350) | Capivasertib + Fulvestrant (N = 155) | Placebo + Fulvestrant (N = 133) |
|                                                                                  | 343 (96.6)                            | 288 (82.3)                      | 151 (97.4)                           | 112 (84.2)                      |
| Any AE possibly related to capivasertib/placebo                                  | 318 (89.6)                            | 166 (47.4)                      | 139 (89.7)                           | 67 (50.4)                       |
| Any AE possibly related to capivasertib/placebo only b                           | 308 (86.8)                            | 129 (36.9)                      | 137 (88.4)                           | 53 (39.8)                       |
| Any AE possibly related to both capivasertib/placebo and fulvestrant b           | 91 (25.6)                             | 66 (18.9)                       | 40 (25.8)                            | 27 (20.3)                       |
| Any AE possibly related to fulvestrant only b                                    | 65 (18.3)                             | 65 (18.6)                       | 33 (21.3)                            | 23 (17.3)                       |
| Any AE of CTCAE Grade 3 or higher                                                | 152 (42.8)                            | 55 (15.7)                       | 65 (41.9)                            | 21 (15.8)                       |
| Any SAE with outcome of death                                                    | 4 (1.1)                               | 1 (0.3)                         | 2 (1.3)                              | 1 (0.8)                         |
| Any SAE (including events with outcome of death)                                 | 57 (16.1)                             | 28 (8.0)                        | 28 (18.1)                            | 14 (10.5)                       |
| Any AE leading to discontinuation of capivasertib/placebo                        | 46 (13.0)                             | 8 (2.3)                         | 16 (10.3)                            | 3 (2.3)                         |
| Any AE leading to discontinuation of capivasertib/placebo only                   | 33 (9.3)                              | 2 (0.6)                         | 10 (6.5)                             | 1 (0.8)                         |
| Any AE leading to discontinuation of both capivasertib/placebo and fulvestrant   | 13 (3.7)                              | 6 (1.7)                         | 6 (3.9)                              | 2 (1.5)                         |
| Any AE leading to discontinuation of fulvestrant only                            | 1 (0.3)                               | 0                               | 0                                    | 0                               |
| Any AE leading to dose modification of capivasertib/placebo                      | 156 (43.9)                            | 43 (12.3)                       | 70 (45.2)                            | 18 (13.5)                       |
| Any AE leading to dose interruption of capivasertib/placebo c                    | 138 (38.9)                            | 43 (12.3)                       | 60 (38.7)                            | 18 (13.5)                       |
| Any AE leading to dose interruption of capivasertib/placebo only                 | 124 (34.9)                            | 36 (10.3)                       | 55 (35.5)                            | 14 (10.5)                       |
| Any AE leading to dose interruption of both capivasertib/placebo and fulvestrant | 22 (6.2)                              | 9 (2.6)                         | 9 (5.8)                              | 4 (3.0)                         |
| Any AE leading to dose interruption of fulvestrant only                          | 6 (1.7)                               | 2 (0.6)                         | 3 (1.9)                              | 0                               |
| Any AE leading to dose reduction of capivasertib/placebo only c                  | 70 (19.7)                             | 6 (1.7)                         | 33 (21.3)                            | 1 (0.8)                         |

a Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories.

b As assessed by the investigator.

c       The number of dose modifications due to AEs in the exposure summary (capivasertib + fulvestrant arm: 73 patients with dose reductions due to AEs and 137 patients with interruptions due to AEs; placebo + fulvestrant arm: 6 patients with dose reductions due to AEs and 38 patients with interruptions due to AEs; see Section 12.1) differs from the number of AEs resulting in a dose modification in this table (capivasertib + fulvestrant arm: 70 patients with AE leading to dose reduction and 138 patients with AEs leading to interruption; placebo + fulvestrant arm: 6 patients with AEs leading to dose reduction and 43 patients with AEs leading to interruption) due to the differences in data capture between the exposure and AE eCRFs.

Adverse events with an onset date on/after date of first dose; AEs with onset date prior to dosing which worsen after dosing; AEs occurring up to 30 days (+ 7 days) following date of last dose are reported.

CTCAE version 5 (23 September 2018).

<div style=\"page-break-after: always\"></div>

MedDRA version 25.0.

Common AEs

Table 63 CAPItello-291, FTIH study pool, and combined pool: most common AEs (Frequency &gt; 5% in any treatment group) (SAS), DCO: 15 August 2022

| MedDRA PT                            | Number (%) of patients a             | Number (%) of patients a        | Number (%) of patients a            | Number (%) of patients a             |
|--------------------------------------|--------------------------------------|---------------------------------|-------------------------------------|--------------------------------------|
| MedDRA PT                            | CAPItello-291                        | CAPItello-291                   | FTIH Study Pool                     | Combined Pool                        |
| MedDRA PT                            | Capivasertib + fulvestrant (N = 355) | Placebo+ fulvestran t (N = 350) | Capivasertib + fulvestrant (N = 75) | Capivasertib + fulvestrant (N = 430) |
| Patients with any AE                 | 343 (96.6)                           | 288 (82.3)                      | 74 (98.7)                           | 417 (97.0)                           |
| Diarrhoea                            | 257 (72.4)                           | 70 (20.0)                       | 49 (65.3)                           | 306 (71.2)                           |
| Nausea                               | 123 (34.6)                           | 54 (15.4)                       | 37 (49.3)                           | 160 (37.2)                           |
| Rash b                               | 78 (22.0)                            | 15 (4.3)                        | 7 (9.3)                             | 85 (19.8)                            |
| Fatigue                              | 74 (20.8)                            | 45 (12.9)                       | 17 (22.7)                           | 91 (21.2)                            |
| Vomiting                             | 73 (20.6)                            | 17 (4.9)                        | 20 (26.7)                           | 93 (21.6)                            |
| Headache                             | 60 (16.9)                            | 43 (12.3)                       | 13 (17.3)                           | 73 (17.0)                            |
| Decreased appetite                   | 59 (16.6)                            | 22 (6.3)                        | 18 (24.0)                           | 77 (17.9)                            |
| Hyperglycaemia                       | 58 (16.3)                            | 13 (3.7)                        | 14 (18.7)                           | 72 (16.7)                            |
| Rash maculo-papular b                | 57 (16.1)                            | 9 (2.6)                         | 15 (20.0)                           | 72 (16.7)                            |
| Stomatitis                           | 52 (14.6)                            | 17 (4.9)                        | 11 (14.7)                           | 63 (14.7)                            |
| Asthenia                             | 47 (13.2)                            | 36 (10.3)                       | 7 (9.3)                             | 54 (12.6)                            |
| Pruritus                             | 44 (12.4)                            | 23 (6.6)                        | 10 (13.3)                           | 54 (12.6)                            |
| Anaemia                              | 37 (10.4)                            | 17 (4.9)                        | 10 (13.3)                           | 47 (10.9)                            |
| Urinary tract infection              | 36 (10.1)                            | 23 (6.6)                        | 6 (8.0)                             | 42 (9.8)                             |
| Arthralgia                           | 33 (9.3)                             | 38 (10.9)                       | 8 (10.7)                            | 41 (9.5)                             |
| Aspartate aminotransferase increased | 33 (9.3)                             | 34 (9.7)                        | 10 (13.3)                           | 43 (10.0)                            |
| Alanine aminotransferase increased   | 32 (9.0)                             | 30 (8.6)                        | 7 (9.3)                             | 39 (9.1)                             |
| Back pain                            | 32 (9.0)                             | 24 (6.9)                        | 12 (16.0)                           | 44 (10.2)                            |
| Pyrexia                              | 32 (9.0)                             | 14 (4.0)                        | 9 (12.0)                            | 41 (9.5)                             |
| Constipation                         | 28 (7.9)                             | 29 (8.3)                        | 8 (10.7)                            | 36 (8.4)                             |
| Dry skin                             | 25 (7.0)                             | 15 (4.3)                        | 5 (6.7)                             | 30 (7.0)                             |
| Dyspnoea                             | 25 (7.0)                             | 23 (6.6)                        | 4 (5.3)                             | 29 (6.7)                             |
| Pain in extremity                    | 23 (6.5)                             | 23 (6.6)                        | 3 (4.0)                             | 26 (6.0)                             |
| COVID-19                             | 22 (6.2)                             | 11 (3.1)                        | 0                                   | 22 (5.1)                             |
| Insomnia                             | 22 (6.2)                             | 21 (6.0)                        | 4 (5.3)                             | 26 (6.0)                             |
| Abdominal pain                       | 21 (5.9)                             | 10 (2.9)                        | 12 (16.0)                           | 33 (7.7)                             |
| Dysgeusia                            | 21 (5.9)                             | 4 (1.1)                         | 3 (4.0)                             | 24 (5.6)                             |
| Dry mouth                            | 19 (5.4)                             | 9 (2.6)                         | 2 (2.7)                             | 21 (4.9)                             |
| Dyspepsia                            | 18 (5.1)                             | 7 (2.0)                         | 1 (1.3)                             | 19 (4.4)                             |

<div style=\"page-break-after: always\"></div>

| Hot flush                            | 18 (5.1)   | 19 (5.4)   | 5 (6.7)   | 23 (5.3)   |
|--------------------------------------|------------|------------|-----------|------------|
| Hypertension                         | 18 (5.1)   | 13 (3.7)   | 5 (6.7)   | 23 (5.3)   |
| Cough                                | 17 (4.8)   | 13 (3.7)   | 7 (9.3)   | 24 (5.6)   |
| Blood creatinine increased           | 16 (4.5)   | 2 (0.6)    | 4 (5.3)   | 20 (4.7)   |
| Dizziness                            | 16 (4.5)   | 12 (3.4)   | 12 (16.0) | 28 (6.5)   |
| Myalgia                              | 16 (4.5)   | 18 (5.1)   | 3 (4.0)   | 19 (4.4)   |
| Abdominal pain upper                 | 13 (3.7)   | 11 (3.1)   | 4 (5.3)   | 17 (4.0)   |
| Blood alkaline phosphatase increased | 13 (3.7)   | 12 (3.4)   | 6 (8.0)   | 19 (4.4)   |
| Weight decreased                     | 12 (3.4)   | 8 (2.3)    | 8 (10.7)  | 20 (4.7)   |
| Neutrophil count decreased           | 9 (2.5)    | 8 (2.3)    | 6 (8.0)   | 15 (3.5)   |
| Oedema peripheral                    | 7 (2.0)    | 9 (2.6)    | 4 (5.3)   | 11 (2.6)   |
| Erythema                             | 6 (1.7)    | 2 (0.6)    | 4 (5.3)   | 10 (2.3)   |
| Hypomagnesaemia                      | 5 (1.4)    | 2 (0.6)    | 4 (5.3)   | 9 (2.1)    |
| Peripheral sensory neuropathy        | 4 (1.1)    | 6 (1.7)    | 5 (6.7)   | 9 (2.1)    |
| Upper respiratory tract infection    | 4 (1.1)    | 2 (0.6)    | 6 (8.0)   | 10 (2.3)   |
| Electrocardiogram QT prolonged       | 3 (0.8)    | 0          | 4 (5.3)   | 7 (1.6)    |
| Flatulence                           | 1 (0.3)    | 3 (0.9)    | 4 (5.3)   | 5 (1.2)    |
| Nasal congestion                     | 1 (0.3)    | 0          | 6 (8.0)   | 7 (1.6)    |

a Number (%) of patients with AEs, sorted in descending frequency of PT in the capivasertib + fulvestrant arm of CAPItello-291. Patients with multiple AEs are counted once for each PT.

b These PTs are included in the AESI grouped term of rash. MedDRA Version 25.0.

## Monotherapy Pool

In the Monotherapy Pool, the most frequently reported AEs were diarrhoea (79.4%), nausea (52.7%), hyperglycaemia (43.6%), fatigue (41.2) and vomiting (40.6).

## Grade 3 or higher AEs

Table 64 CAPItello-291, FTIH study pool, and combined pool: AEs of CTCAE grade 3 or higher (frequency &gt; 2% in any treatment group) (SAS)

|                                      | Number (%) of patients a             | Number (%) of patients a        | Number (%) of patients a            | Number (%) of patients a             |
|--------------------------------------|--------------------------------------|---------------------------------|-------------------------------------|--------------------------------------|
| MedDRA PT                            | CAPItello-291                        | CAPItello-291                   | FTIH Study Pool                     | Combined Pool                        |
|                                      | Capivasertib + fulvestrant (N = 355) | Placebo + fulvestrant (N = 350) | Capivasertib + fulvestrant (N = 75) | Capivasertib + fulvestrant (N = 430) |
| Patients with any CTCAE ≥ Grade 3 AE | 152 (42.8)                           | 55 (15.7)                       | 40 (53.3)                           | 192 (44.7)                           |
| Diarrhoea                            | 33 (9.3)                             | 1 (0.3)                         | 4 (5.3)                             | 37 (8.6)                             |
| Rash maculo-papular b                | 22 (6.2)                             | 0                               | 8 (10.7)                            | 30 (7.0)                             |
| Rash b                               | 19 (5.4)                             | 1 (0.3)                         | 0                                   | 19 (4.4)                             |
| Hyperglycaemia                       | 8 (2.3)                              | 1 (0.3)                         | 4 (5.3)                             | 12 (2.8)                             |
| Hypokalaemia                         | 8 (2.3)                              | 0                               | 1 (1.3)                             | 9 (2.1)                              |
| Alanine aminotransferase increased   | 7 (2.0)                              | 3 (0.9)                         | 3 (4.0)                             | 10 (2.3)                             |
| Aspartate aminotransferase increased | 7 (2.0)                              | 7 (2.0)                         | 3 (4.0)                             | 10 (2.3)                             |

<div style=\"page-break-after: always\"></div>

| Vomiting    | 6 (1.7)   | 2 (0.6)   | 2 (2.7)   | 8 (1.9)   |
|-------------|-----------|-----------|-----------|-----------|
| Nausea      | 3 (0.8)   | 2 (0.6)   | 3 (4.0)   | 6 (1.4)   |
| Dehydration | 2 (0.6)   | 0         | 2 (2.7)   | 4 (0.9)   |
| Back pain   | 1 (0.3)   | 3 (0.9)   | 3 (4.0)   | 4 (0.9)   |

| Electrocardiogram QT prolonged   | 1 (0.3)   | 0       | 2 (2.7)   | 3 (0.7)   |
|----------------------------------|-----------|---------|-----------|-----------|
| Hypercalcaemia                   | 1 (0.3)   | 2 (0.6) | 2 (2.7)   | 3 (0.7)   |
| Hypertransaminasaemia            | 0         | 0       | 2 (2.7)   | 2 (0.5)   |

- a Number (%) of patients with AEs of CTCAE Grade 3 or higher, sorted in descending frequency of PT in the capivasertib + fulvestrant arm of CAPItello-291. Patients with multiple AEs are counted once for each PT.

b     These PTs are included in the AESI grouped term of rash.

CTCAE Version 4.0 was used in the FTIH study (D3610C00001) and Version 5.0 in CAPItello-

291. MedDRA Version 25.0.

## FAKTION STUDY

As of the DCO of 30 January 2019, AEs of CTCAE Grade 3 or higher were reported in 45 (65.2%) patients in  the  capivasertib  +  fulvestrant  arm  and  35  (49.3%)  patients  in  the  placebo  +  fulvestrant  arm  in FAKTION (Jones et al 2020). The most common AEs of CTCAE Grade 3 to 4 were hypertension (22 [32%] patients in the capivasertib + fulvestrant arm and 17 [24%] patients in the placebo + fulvestrant arm), rash (grouped term; note, the PTs in this grouped term were not specified and may or may not align with the rash grouped term in CAPItello-291 (14 [20%] and 0 patients, respectively), diarrhoea (10 [14%]  and  3  [4%]  patients,  respectively),  infection  (including  UTI)  (4  [6%]  and  2  [3%]  patients, respectively), and fatigue (one [1%] and 3 [4%] patients, respectively).

## Adverse events of special interest

The AESIs for capivasertib include hyperglycaemia, diarrhoea (termed non-infectious diarrhoea in the CSP), rash, QT prolongation, infective pneumonia, stomatitis and UTI.

## Hyperglycaemia

Patients with type 2 diabetes were eligible for CAPItello-291 if HbA1C at screening was less than 8.0% (63.9 mmol/mol), and if they did not require insulin treatment. Patients with type 1 diabetes were not eligible.

At a population level, median fasted glucose in both treatment arms was within the normal range at baseline (capivasertib + fulvestrant arm, 5.39 mmol/L; placebo + fulvestrant arm, 5.33 mmol/L), and for the duration of the on-treatment period, except for Cycle 2 Week 3 Day 1 in the placebo + fulvestrant arm (6.68 mmol/L).

At baseline, 34 (9.6%) patients in the capivasertib + fulvestrant arm and 20 (5.7%) patients in the placebo + fulvestrant arm had diabetes mellitus. Of the patients who had a hyperglycaemia event, 10 patients in the capivasertib + fulvestrant arm and 4 patients in the placebo + fulvestrant arm had a history of diabetes mellitus.

The  incidence  of  hyperglycaemia  AESIs  (which  included  the  PTs  hyperglycaemia  and  blood  glucose increased) was higher in the capivasertib + fulvestrant arm (16.9% of patients vs 4.0% of patients in the placebo + fulvestrant arm).

In patients where hyperglycaemia was reported as an AE, the first event typically occurred within the initial few weeks of treatment. Most of these AEs were CTCAE Grade 1 or 2.

<div style=\"page-break-after: always\"></div>

Hyperglycaemia  AESIs  of  CTCAE  Grade  3  were  reported  in  7  patients  (2.0%)  in  the  capivasertib  + fulvestrant arm and 1 patient (0.3%) in the placebo + fulvestrant arm. A hyperglycaemia AESI of CTCAE Grade 4 was reported for 1 patient (0.3%) in the capivasert ib + fulvestrant arm; this patient had an ongoing medical history of obesity. The patient developed grade 4 hyperglycaemia 5 days after the most recent dose of capivasertib, and presented with altered sensorium. The patient had an additional SAE of sepsis 2 days later with an outcome of death the following day (see also section SAEs and deaths).

Of  those  patients  in  the  capivasertib  +  fulvestrant  arm  with  hyperglycaemia  AESIs  that  required treatment (28 of 60 patients), the most common anti-diabetic agent received was metformin but 10 patients required also insulin therapy. Few patients required capivasertib dose interruptions (9 patients) or reductions (2 patients), and only one AESI of hyperglycaemia led to discontinuation of capivasertib.

At the time of DCO1, the events were recovered or recovering in the 37 out of 60 patients experiencing hyperglycaemia, and had not recovered in 28 of the 60 patients.

Table 65 Other AEs related to hyperglycaemia (SAS)

|                                    | Number (%) of patients              | Number (%) of patients              | Number (%) of patients              | Number (%) of patients          |
|------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|---------------------------------|
|                                    | Capivasertib+ Fulvestrant (N = 355) | Capivasertib+ Fulvestrant (N = 355) | Capivasertib+ Fulvestrant (N = 355) | Placebo + Fulvestran t (N =350) |
|                                    | Total                               | Grade 3                             | Grade 4                             | Total                           |
| Glycosylated haemoglobin increased | 5 (1.4)                             | 0                                   | 0                                   | 0                               |
| Diabetes mellitus                  | 1 (0.3)                             | 0                                   | 0                                   | 0                               |
| Diabetic ketoacidosis              | 1 (0.3)                             | 0                                   | 1 (0.3)                             | 0                               |
| Diabetic metabolic decompensation  | 2 (0.6)                             | 1 (0.3)                             | 0                                   | 0                               |

The AE of Grade 4 diabetic ketoacidosis was reported in a patient with pre-existing type 2 diabetes mellitus  and  baseline  HbA1C  of  7.6%  and  fasting  blood  glucose  of  9.546  mmol/L.  The  patient  had intercurrent UTI which may have contributed to this complication of the patient's diabetes. The diabetic ketoacidosis led to discontinuation of capivasertib.

There were 2 AEs of diabetic metabolic decompensation. One (CTCAE Grade 3) occurred in a patient who took capivasertib for 14 consecutive days prior to the event and who had concomitant SAEs of diarrhoea, described  as  intense  diarrhoea  with  weight  loss  and  signs  and  symptoms  of  dehydration,  and  renal failure. The other was Grade 2 and occurred in a patient concomitantly receiving 3 antidiabetic agents (dapaglifozin, pioglitazone, alogliptin). No action was taken with the study treatments and the patient recovered.

## Diarrhoea

The incidence of diarrhoea AESIs was higher in the capivasertib + fulvestrant arm (72.4% vs 20.3% in placebo + fulvestrant arm). Patients experiencing diarrhoea had a median of 1 diarrhoea AESI, most events occurred during the first cycle of treatment, and were mostly CTCAE Grade 1. Few patients (2%) discontinued treatment with capivasertib due to AESIs of diarrhoea. Most events were managed with treatment such as loperamide. Capivasertib interruptions and reductions were reported in 35 and 28 patients, respectively.

In the capivasertib + fulvestrant arm, 33 patients (9.3%) had diarrhoea events of CTCAE Grade 3, and 6 (1.7%) patients had SAEs of diarrhoea.

The following AEs were reported with a close temporal relationship (during or within 7 days of a diarrhoea AE)  in  a  small  number  of  patients  in  the  capivasertib  +  fulvestrant  arm:  dehydration  (4  patients), hyponatremia  (3  patients),  hypokalaemia  (8  patients),  creatinine  increase  (10  patients),  and  acute kidney injury (5 patients).

<div style=\"page-break-after: always\"></div>

In general, diarrhoea events occurred early on, with few patients experiencing their first diarrhoea AESI after 4 months of treatment.

## Rash

The incidence of rash AESIs was higher in the capivasertib + fulvestrant arm then in placebo+ fulvestrant arm (38.0% vs 7.1%, respectively), and occurred with greater severity (CTCAE Grade 3: 12.1% vs 0.3%, respectively). Patients experiencing rash had a median of 1 rash event, with most events starting already during the first cycle of treatment. Of those patients with rash AESIs that required treatment (109  of  135  patients),  most  were  managed  with  topical  corticosteroids  or  antihistamine  treatment. Systemic corticosteroids were used in 28 of 109 patients.

Capivasertib interruptions and reductions were reported in 42 and 16 patients, respectively, and events were mostly resolved or recovering at the time of DCO1. 16 patients (4.5%) discontinued treatment with capivasertib due to AESIs of rash.

Seven patients (2.0%) in the capivasertib + fulvestrant arm had serious AESIs of rash. Rash AESIs of CTCAE Grade 3 were reported as follows in the capivasertib + fulvestrant arm: rash maculo-papular (22 patients, 6.2%), rash (19 patients, 5.4%), and rash papular (2 patients, 0.6%).

Other selected AEs observed during CAPItello-291 within the Skin and subcutaneous tissue disorders SOC, but not captured by this AESI category include following:

Table 66 CAPItello-291: Other selected skin AEs (SAS), DCO: 15 August 2022

|                                                       | Number (%) of patients              | Number (%) of patients              | Number (%) of patients         | Number (%) of patients         |
|-------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|
|                                                       | Capivasertib +fulvestrant (N = 355) | Capivasertib +fulvestrant (N = 355) | Placebo +fulvestrant (N = 350) | Placebo +fulvestrant (N = 350) |
|                                                       | Total                               | Grade 3                             | Total                          | Grade 3                        |
| Dermatitis                                            | 3 (0.8)                             | 0                                   | 1 (0.3)                        | 0                              |
| Dermatitis exfoliative generalised                    | 2 (0.6)                             | 2 (0.6)                             | 0                              | 0                              |
| Drug eruption                                         | 4 (1.1)                             | 4 (1.1)                             | 0                              | 0                              |
| Drug reaction with eosinophilia and systemic symptoms | 1 (0.3)                             | 0                                   | 0                              | 0                              |
| Erythema                                              | 6 (1.7)                             | 0                                   | 2 (0.6)                        | 0                              |
| Erythema multiforme                                   | 6 (1.7)                             | 3 (0.8)                             | 0                              | 0                              |
| Palmar-plantar erythrodysaesthesia syndrome           | 3 (0.8)                             | 0                                   | 1 (0.3)                        | 0                              |
| Rash erythematous                                     | 4 (1.1)                             | 1 (0.3)                             | 2 (0.6)                        | 0                              |
| Rash follicular                                       | 1 (0.3)                             | 0                                   | 0                              | 0                              |
| Rash pustular                                         | 2 (0.6)                             | 2 (0.6)                             | 1 (0.3)                        | 0                              |
| Toxic skin eruption                                   | 1 (0.3)                             | 0                                   | 0                              | 0                              |

CTCAE Version 5.0.

MedDRA Version 25.0.

Source: Table 2.7.4.3.3, Appendix 2.7.4.7.2 in Module 5.3.5.3.

## Urinary Tract Infection

The incidence of UTI AESIs was higher in the capivasertib + fulvestrant arm. Patients experiencing a UTI had a median of 1 UTI event; most were CTCAE Grade 1 or 2 and occurred during the first 4 cycles of treatment. Most events were managed with appropriate medication. One patient in the capivasertib + fulvestrant arm discontinued treatment. Most events were recovered or recovering at the time of DCO1.

<div style=\"page-break-after: always\"></div>

Seven patients (2.0%) in the capivasertib + fulvestrant arm had UTI AESIs of CTCAE Grade 3; in 2 patients, the UTI was reported as an SAE.

## Infective Pneumonia

There was a low incidence of infective pneumonia events, and the incidence and characterisation of the events was similar in both treatment arms (2.3% vs 2.6%).

## Stomatitis

The  incidence  of  stomatitis  AESIs  (including  PTs:  aphthous  ulcer,  lip  ulceration,  mouth  ulceration, mucosal  inflammation,  and  stomatitis)  was  higher  in  the  capivasertib  +  fulvestrant  arm  (20.0%  vs 5.7%). Patients experiencing stomatitis had a median of 1 stomatitis event; most occurred during the first cycle of treatment, and were CTCAE Grade 1. Only few patients had dose modifications due to AESIs of stomatitis. One patient in the capivasertib + fulvestrant arm discontinued treatment due to an AESI of stomatitis. In the capivasertib + fulvestrant arm, approximately half of the patients with stomatitis required treatment. The majority of events were recovered or recovering at the time of DCO1

Stomatitis  AESIs  of  CTCAE  Grade  3  were  reported  in  the  capivasertib  +  fulvestrant  arm  as  follows: stomatitis (7 patients, 2.0%) and mucosal inflammation (1 patient, 0.3%). For 1 patient (0.3%), the stomatitis was reported as a SAE.

QT Prolongation

## Table 67 Characterisation of QT prolongation events (DCO: 15 August 2022)

|                                                             | Number (%) of patients a             | Number (%) of patients a        | Number (%) of patients a          | Number (%) of patients a               |
|-------------------------------------------------------------|--------------------------------------|---------------------------------|-----------------------------------|----------------------------------------|
|                                                             | CAPItello-291                        | CAPItello-291                   | FTIH Study Pool                   | Combined Pool                          |
|                                                             | Capivasertib + fulvestrant (N = 355) | Placebo + fulvestrant (N = 350) | Capivasertib fulvestrant (N = 75) | + Capivasertib + fulvestrant (N = 430) |
| Patients experiencing QT prolongation a                     | 11 (3.1)                             | 0                               | 5 (6.7)                           | 16 (3.7)                               |
| Syncope                                                     | 6 (1.7)                              | 0                               | 1 (1.3)                           | 7 (1.6)                                |
| Electrocardiogram QT prolonged                              | 3 (0.8)                              | 0                               | 4 (5.3)                           | 7 (1.6)                                |
| Seizure                                                     | 1 (0.3)                              | 0                               | 0                                 | 1 (0.2)                                |
| Ventricular arrhythmia                                      | 1 (0.3)                              | 0                               | 0                                 | 1 (0.2)                                |
| Torsade de pointes                                          | 0                                    | 0                               | 0                                 | 0                                      |
| SAEs                                                        | 1 (0.3)                              | 0                               | 0                                 | 1 (0.2)                                |
| Maximum AE severity b                                       |                                      |                                 |                                   |                                        |
| CTCAE Grade 1                                               | 2 (0.6)                              | 0                               | 3 (4.0)                           | 5 (1.2)                                |
| CTCAE Grade 2                                               | 1 (0.3)                              | 0                               | 0                                 | 1 (0.2)                                |
| CTCAE Grade 3                                               | 8 (2.3)                              | 0                               | 1 (1.3)                           | 9 (2.1)                                |
| CTCAE Grade 4                                               | 0                                    | 0                               | 1 (1.3)                           | 1 (0.2)                                |
| CTCAE Grade 5                                               | 0                                    | 0                               | 0                                 | 0                                      |
| Median number of AEs of QT prolongation a per patient (IQR) | 1.0 (1.0-1.0)                        | NC                              | 1.0 (1.0-1.0)                     | 1.0 (1.0-1.0)                          |

<div style=\"page-break-after: always\"></div>

| Median time to onset in days of first AE of QT prolongation a per patient (IQR)   | 16.0 (13.0- 98.0)   | NC   | 22.0 (4.0-22.0)   | 17.0 (13.0-61.0)   |
|-----------------------------------------------------------------------------------|---------------------|------|-------------------|--------------------|
| AESI leading to capivasertib/placebo dose modification or discontinuation         |                     |      |                   |                    |
| AESI leading to capivasertib/placebo dose reduction for QT prolongation a 0       |                     | 0    | 0                 | 0                  |
| AESI leading to capivasertib/placebo dose interruption for QT prolongation a      | 2 (0.6)             | 0    | 2 (2.7)           | 4 (0.9)            |
| AESI leading to capivasertib/placebo discontinuation forQT prolongation a         | 0                   | 0    | 0                 | 0                  |
| Treatment required for QT prolongation a,c                                        | 2 (0.6)             | 0    | 0                 | 2 (0.5)            |
| Outcome of QT prolongation a : recovered/recovering d                             | 10 (2.8)            | 0    | 4 (5.3)           | 14 (3.3)           |
| Outcome of QT prolongation a : not recovered                                      | 1 (0.3)             | 0    | 1 (1.3)           | 2 (0.5)            |

a The QT prolongation medical concept search included the MedDRA SMQ (broad) of Torsade de pointes/QT prolongation plus the MedDRA PT of Seizure.

b       In patients where more than one episode of event occurred, the severity represented above is on a patientlevel using the highest CTCAE grade episode of event reported.

c     According to yes/no tick box on Adverse Event CRF page.

d Includes terms of recovered, recovered with sequelae, and recovering. Each patient will only be counted once per category, a patient will be counted in more than one category if the outcomes are different.

Percentages are based on the total number of patients in the treatment group (N).

CTCAE Version 4.0 was used in the FTIH study (D3610C00001) and Version 5.0 in CAPItello-

291. MedDRA Version 25.0.

## Other AEs of potential interest

Renal Function-related Adverse Events

Table 68 Renal function-related adverse events (SAS), DCO: 15 August 2022

|                            | Number (%) of patients              | Number (%) of patients              | Number (%) of patients          | Number (%) of patients          |
|----------------------------|-------------------------------------|-------------------------------------|---------------------------------|---------------------------------|
|                            | Capivasertib+ Fulvestrant (N = 355) | Capivasertib+ Fulvestrant (N = 355) | Placebo + Fulvestran t (N =350) | Placebo + Fulvestran t (N =350) |
|                            | Total                               | Grade 3                             | Total                           | Grade 3                         |
| Acute kidney injury        | 5 (1.4)                             | 3 (0.8)                             | 0                               | 0                               |
| Renal failure              | 2 (0.6)                             | 1 (0.3)                             | 1 (0.3)                         | 0                               |
| Renal impairment           | 4 (1.1)                             | 0                                   | 1 (0.3)                         | 1 (0.3)                         |
| Blood creatinine increased | 16 (4.5)                            | 1 (0.3)                             | 2 (0.6)                         | 0                               |

<div style=\"page-break-after: always\"></div>

Grade 3 hepatic AEs were reported as follows: AST increased (7 patients in each treatment arm), ALT increased (capivasertib + fulvestrant, 7 patients; placebo + fulvestrant, 3 patients), blood ALP increased (capivasertib  +  fulvestrant,  2  patients), γ -glutamyl  transferase  (GGT)  increased  (1  patient  in  each treatment arm), hepatic enzyme increased (placebo + fulvestrant, 1 patient), and drug-induced liver injury (1 patient in each treatment arm).

## Adverse drug reactions

The primary safety population from the pivotal placebo-controlled CAPItello-291 study was considered the most appropriate basis for identification of ADRs. Objective criteria were applied to the data for AEs to screen for potential ADRs, which were then subject to clinical review. Based on the analysis, the ADRs, as  summarised  in  the  ADR  Table  were  identified  for  capivasertib  in  the  CAPItello-291  study.  This approach however was modified/updated to include data from patients treated with capivasertib plus fulvestrant in clinical studies at the recommended dose (including FTIH Study Pool and FAKTION study). Furthermore, all AEs for which a causal relationship to the capivasertib treatment has been established are now included in ADR table.

Table 69 ADRs, by system organ class and ADR grouped term; DCO: 15-08-2022

|                                                   | Capillo-201                                    | Capillo-201                                    | Capillo-201             | Capillo-201             |                                 |              |                                                            |              |
|---------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------|-------------------------|---------------------------------|--------------|------------------------------------------------------------|--------------|
| Byaten Orgun Clun ADR gooupd tor..                | Capiasrrab + Fuhreshrant N.b.r (w) ef Cious mI | Capiasrrab + Fuhreshrant N.b.r (w) ef Cious mI | Pbcsbo +Fuubraat (=550) | Pbcsbo +Fuubraat (=550) | Capieuwertib + Fuhwstrast (GL=N | D3610C00001  | Totl Capiouwrtib + Fuhlrast (=450) Numb.r (lh)of Ciours mI | cale-err lb1 |
|                                                   | patinh [al                                     | caleyerrb1                                     | palinh [bl              | Nu.br (W)of Ciousm      | Numb.r (w)ef ciousin            |              |                                                            |              |
| Puienk wih uny ADR                                | 325 (91.5)                                     |                                                | 189 (54.0)              |                         | 72(96.0)                        |              |                                                            |              |
| BLOODANDLYMPHATIC SYSTEM DISORDERS                | 37(10.4)                                       |                                                | 17(4.9)                 |                         | 10(13.3)                        |              | 47(10.9)                                                   |              |
| Anienin                                           | 37 (10.4)                                      | Vey Comon                                      | 17(49)                  | Comnon                  | 10(13.3)                        | Very Comnion | 47(10.9)                                                   | Very Common  |
| GASTROINTESTINAL DISORDERS                        | 288 (81.1)                                     |                                                | 123 (35.1)              |                         | 67(89.3)                        |              | 355 (82.6)                                                 |              |
| Dlnhoei                                           | 257(72.4)                                      | Vey Comon                                      | 70(20.0)                | Very Comnon             | (E5916)                         | Very Common  | 306 (71.2)                                                 | Very Commn   |
|                                                   | 123 (34.6)                                     | Vey Common                                     | 54(15.4)                | Vey Common              | 37(493)                         | Very Common  | 160(37.2)                                                  | Very Common  |
| Vomilin                                           | 73 (20.6)                                      | Vey Conmn                                      | 17(49)                  | Common                  | 192102                          | Very Common  | 9921.6)                                                    | Very Common  |
| Somuik                                            | 61(17.2)                                       | Vey Comon                                      | 19(54)                  | Comnon                  | 12(16.0)                        | Very Common  | 73(17.0)                                                   | Very Common  |
| Drppin                                            | 18( 5.1)                                       | Common                                         | 7120                    | Common                  | 1(13)                           | Commion      | 19(4.4)                                                    | Conmion      |
| GENERAL.DISORDERSAND ADMINISTRATIONSTE CONDITIONS | 81 (22.8)                                      |                                                | 46(13.1)                |                         | 17 (22.7)                       |              | 98(22.8)                                                   |              |
| Fallue                                            | 74 (20.8)                                      | Vey Comon                                      | 45(12.9)                | Ver Comnon              | 72121                           | Very Common  | 91(21.2)                                                   | Very Common  |
| Mucoal innummwtion                                | 11(3.1)                                        | Common                                         | 1(03)                   | Uncommon                | 0                               |              | 11(2.6)                                                    | Conmon       |
| IMMUNESYSTEMDISORDERH                             | 3(0.8)                                         |                                                | D                       |                         | 1(13)                           |              | 4(0.9)                                                     |              |
| Hypersensitivily                                  | 3108                                           | Uhcimmon                                       |                         |                         | 1(13)                           |              | 4(09)                                                      | Uheamon      |
| INFECTIONS AND INFESTATIONS                       | 48 (13.5)                                      |                                                | 24(69)                  |                         | 9(12.0)                         |              | 57 (13.3)                                                  |              |
|                                                   |                                                | Vay Commn                                      | 24(6.9)                 | Comnon                  | 9(12.0)                         | Very Common  | 57 (13.3)                                                  | Very Commion |
| INVESTIGATIONS                                    | 21(59)                                         |                                                | 2(06)                   |                         | 11915                           |              | 26(6.0)                                                    |              |
| Blod Creatinineinerensed                          | 16(45)                                         | Common                                         | 2106                    | Uncomnon                | 4(53)]                          | Chmmon       | 20(4.7)                                                    | Common       |
| Glyeosylaied hremoglobn icreased                  | 5(14)                                          | Common                                         |                         |                         | 1(13)                           |              | 6(14)                                                      | Common       |
| METABOLISMANDNUTRITION DISORDERS                  | 113 (31.8)                                     |                                                | 33[94)                  |                         | 27 (36.0)                       |              | 140 (326)                                                  |              |
| Dereud apktile                                    | 59(16.6]                                       | Vay Common                                     | 2[6])                   | Comnon                  | 18 (24.0)                       | Very Common  | 77(17.9)                                                   | Very Commion |
| Hypergheienln                                     | 60 (16.9)                                      | Vey Common                                     | 14(4.0)                 | Comnon                  | 16(21.3)                        | Very Common  | 76(17.7)                                                   | Very Common  |
| NERVOUSSYSTEMDISORDERS                            | 21(39)                                         |                                                | 4(11)                   |                         | 3(40)                           |              | 24(5.6)                                                    |              |
| Dyavsln                                           | 21(59)                                         | Common                                         | 4(11)                   | Comnon                  | 3(40)                           |              | 24(5.6)                                                    | Common       |
| SKINANDSUBCUTANEOUS TISSUEDISORDERS               | 183 (51.5)                                     |                                                | 55(15.7)                |                         | EIDIE                           |              | 214 (49.8)                                                 |              |
| Rnh                                               |                                                | 143 (403)Vey Common                            | 2183)                   | Comnon                  | 28(37.3)                        | Very Common  | 171(39.8)                                                  | Very Common  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Pnurilus                       | 44(12.4)   | Vey Conmmon   | 2(6.6)   | Comnon   | 10 (13.3)   | Very Common   | 54(12.6)   | Very Common   |
|--------------------------------|------------|---------------|----------|----------|-------------|---------------|------------|---------------|
| Dn din                         | 2(7.0)     | Comon         | 15(4.3)  | Common   | 5(6.7)      | Common        | 30(7.0)    | Common        |
| Enhennmulifome                 | 6(1.7)     | Comon         | D        |          | D           |               | 6(1.4)     | Common        |
| Dmg Enuplion                   | 4(1.1)     | Commion       |          |          | D           |               | (60)+      | Uneommon      |
| Demnlilla                      | 3(0.8)     | Lhcommon      | 1(0.3)   | Uneommon | D           |               |            | Uheommon      |
| Demutiia exoliative genemlised | 2(0.6)     | Lheommon      | 口        |          | D           |               | 2(0.5)     | Uheommon      |
| ToxieSkin Enuption             | 1(0.3)     | Lheommon      |          |          |             |               | 1(0.2)     | Uheommon      |

Table 70 ADRs CTCAE grade 3 or higher, by system organ class and ADR grouped term; DCO: 15 August 2022

|                                                   |                         |                      |                      | Number(H)ofpatiah [l   | Number(H)ofpatiah [l   | Number(H)ofpatiah [l   |                   |                      |
|---------------------------------------------------|-------------------------|----------------------|----------------------|------------------------|------------------------|------------------------|-------------------|----------------------|
|                                                   |                         | Capielle-101 Pleibo+ | Capielle-101 Pleibo+ |                        | DS610C00001            | DS610C00001            | Total Capimwrib + | Total Capimwrib +    |
| Bylm Orgua Cll                                    | Gapinamrib + Tuhosiraot | CIONSOI              |                      | CIONSm                 | Capimsrih+ Tuhoirast   | CIOMSIO                | Fulrutrant        | CIOMSmI calegerr lb1 |
| ADR greuprd tero                                  | 0=155)                  | caleerrb1            | (=150)               |                        | (=15)                  | earb]                  | 0=490)            |                      |
| INFECTIONSAND INFESTATIONS                        | 6(1.7)                  |                      |                      |                        | 1(13)                  |                        | 7(16)             |                      |
|                                                   | 6(1.7)                  | Common               |                      |                        | 1(13)                  | Commion                | 7(1.6)            | Conmion              |
| INVESTIGATIONS                                    | 1(03)                   |                      |                      |                        | 0                      |                        | 1(02)             |                      |
| Bhood Creatinine nereised                         | 1(03)                   | Theommon             |                      |                        | 0                      |                        | 1(02)             | Lheommon             |
| METABOLISMANDNUTRITION DISORDERS                  | 8(23)                   |                      | 3(09)                |                        | 4(53)                  |                        | 12(28)            |                      |
| Hiperdheremla                                     | 8(23)                   | Comsn                | 1(03)                | Unconnon               | les)t                  |                        | 12(28)            | Conmoa               |
| Decreised aptie                                   | 1(03)                   | Uhcommion            | 2(06)                | Uncommon               | 1(13)                  | Common                 | 2(0.51            | Uhcomon              |
| SKINANDSUBCUTANEOUS TISSUEDISORDERS               | 54(15.2)                |                      | 2(06)                |                        | 8(10.7)                |                        | 62(14.4)          |                      |
| Dr dkin                                           | D                       |                      | 1(03)                | Unconnon               | D                      |                        | 0                 |                      |
| Rh                                                |                         | Vey Commn            | 1(03)                | Unconmon               | 8(10.7)                | Very Common            | 52(12.1)          | Very Common          |
| Dmg Enuplion                                      |                         | Commion              |                      |                        | D                      |                        | 4(09)             | Lheomon              |
| Puiens wih ADR ofuy CTCAE gede3 or higher         | 100 (28.2) 7(20)        |                      | 11(3.1) 4(L1)        |                        | 1(13)                  |                        | 120 (27.9)        |                      |
| BLOODANDLYMPHATIC SYSTEMDISORDERS                 |                         |                      |                      |                        |                        |                        | 8(19)             |                      |
| Aniemin                                           | 7(2.0)                  | Comon                | 4(1.1)               | Comnon                 | 1(1.3)                 |                        | 8(1.9)            | Conmion              |
| GASTROINTESTINAL DISORDERS                        | 45 (12.7)               |                      | 3(09)                |                        |                        |                        | 53(12.3)          |                      |
| Dinhoca                                           | 1e616E                  | Coimon               | 1(0.3)               | Uhcommon               | 4(53]                  | Common                 | 37(8.6)           | Conmon               |
| Vomiling                                          | 6(1.7)                  | Commion              | 2(06)                | Uhconmon               |                        |                        | 8(1.9)            | Conmion              |
| Somulla                                           | 7120                    | Common               |                      |                        | 0                      |                        | 7(1.6)            | Conmon               |
| Nmsen                                             | 3(08)                   | Uhcommon             | 2(0.6)               | Uncommon               | 3(4.0)                 | Common                 | 6(14)             | Conmon               |
| GENERALDISORDERSAND ADMINISTRATIONSITE CONDITIONS | 3(08)                   |                      | 2(06)                |                        | 1(13)                  |                        | 4(09)             |                      |
| Fillgue                                           | 2(06)                   | Uheommon             | 2(06)                | Uhcomnon               | 1(13)                  | Common                 |                   | Uhwommon             |
| Mueosalinfmmwtion                                 | 1(03)                   | Uhcommon             |                      |                        |                        |                        | 1(02)             | Uhcomon              |
| Erthennmulifome                                   | 3(0.8)                  | Uneommion            | D                    |                        | D                      |                        |                   |                      |
| Demutitila exfoliatie geienliaed                  | 2(0.6)                  | Uhcommon             | D                    |                        | D                      |                        | 2(05)             | Lheomon              |
| Prurilns                                          | 2(0.6)                  | Theommon             |                      |                        | D                      |                        |                   | Uheommon             |

<div style=\"page-break-after: always\"></div>

Table 71 Serious adverse drug reactions, by system organ class and ADR grouped term DCO: 15 August 2022

|                                                  | Capille-201                                      | Capille-201                                      | Capille-201                                  | Capille-201                                  | DN610C00001                                      |                                                  | Total                                              |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Byaten Orgu Clml                                 | Capiramrtb + Tuhesirant (Y=555) N.br(h)of CiousI | Capiramrtb + Tuhesirant (Y=555) N.br(h)of CiousI | Placsbe + Fulwiraat (=150) Nubr (wjof Ciousm | Placsbe + Fulwiraat (=150) Nubr (wjof Ciousm | Capianertib + Fuhostrast (=75) Numbr(jof Ciousin | Capianertib + Fuhostrast (=75) Numbr(jof Ciousin | Capiarib + Fuhetrast (=450) Number (Nn)of Cious mI |
| AoRerouprdtero                                   | painh[]                                          | cale-er [b]                                      | pinh[]                                       |                                              | pahinah [al                                      |                                                  | palirab [a] cale-err [b]                           |
| Puients with y Sedona ADR                        | 23(6.5)                                          | 23(6.5)                                          | 4(1.1)                                       | 4(1.1)                                       | 8(10.7)                                          | 8(10.7)                                          | 31(72)                                             |
| BLOODANDLYMPHATIC SYSTEM DISORDERS               |                                                  |                                                  | 1(0.3)                                       | 1(0.3)                                       | D                                                | D                                                |                                                    |
| Aniemin                                          | 0                                                | 0                                                | 1(03) Uncxmon                                | 1(03) Uncxmon                                | 0                                                | 0                                                | 0                                                  |
| GASTROINTESTINAL DISORDERS                       | 11(3.1)                                          | 11(3.1)                                          | 3(09)                                        | 3(09)                                        | 4(53)                                            | 4(53)                                            | 15(35)                                             |
| Vomiing                                          | 4(1.1)                                           | Common                                           | 2(06)                                        | Uncommon                                     | lotle                                            | Chmmon                                           | 7(1.6) Common                                      |
| Dilnhoea                                         | 6(1.7)                                           | Comimon                                          | 1(03)                                        | Uncommon                                     | 0                                                | 0                                                | 6(14) Common                                       |
|                                                  | 1(03)                                            | Uhcommon                                         | 2(06)                                        | Uhcmnon                                      |                                                  | Chmmon                                           | Uhwommon                                           |
| Somutilk                                         | 1(0.3)                                           | Theommon                                         |                                              |                                              | 0                                                | 0                                                | 1(02) Uheammion                                    |
| GENERALDISORDERSAND ADMINISTRATIONSITE CONDTIONS | 1(0.3)                                           | 1(0.3)                                           |                                              |                                              |                                                  |                                                  | 1(02)                                              |
| Fillge                                           | 1(03)                                            | Uhcommon                                         |                                              |                                              |                                                  |                                                  | 1(02) Uheommon                                     |
| IMMUNESYSTEMDISORDERS                            | 1(0.3)                                           | 1(0.3)                                           |                                              |                                              |                                                  |                                                  | 1(0.2)                                             |
| Hyrersensitivily                                 | 1(03)                                            | Lhcommon                                         |                                              |                                              | 0                                                | 0                                                | 1(02) Lhconmon                                     |
| INFECTIONSAND INFESTATIONS                       | 1(03)                                            | 1(03)                                            |                                              |                                              |                                                  |                                                  |                                                    |
|                                                  | 1(03)                                            | Thcommon                                         |                                              |                                              | Common                                           | Common                                           | 3(07 Uhcomon                                       |
| METABOLISMANDNUTRITION DISORDERS                 | 3(0.8)                                           |                                                  |                                              |                                              | 1(13)                                            | 1(13)                                            | 4(09)                                              |
| Hyperglreienia                                   | 3(08)                                            | Thcommion                                        |                                              |                                              | 1(1.3) Chmmon                                    | 1(1.3) Chmmon                                    | 4(09) Thwommon                                     |
| SKINANDSUBCUTANEOUS TISSUEDISORDERS              | 11 (3.1)                                         | 11 (3.1)                                         |                                              |                                              | 1(1.3)                                           | 1(1.3)                                           | 12(28)                                             |
| Rndh                                             | 8(23)                                            | Corimon                                          |                                              |                                              |                                                  |                                                  | 9(2.1) Comon                                       |
| Demtitiaexfoliathe genemlised                    | 1(03)                                            | Thcommon                                         |                                              |                                              | D                                                | D                                                | 1(02) Uheamon                                      |
| Dng Enuptlon                                     | 1(03)                                            | Theommon                                         |                                              |                                              | D                                                | D                                                | 1(02) Uheonmon                                     |
| Erthemnmulifome                                  | (60)1                                            | Uhcommon                                         |                                              |                                              | 0                                                | 0                                                | 1(02) Theammon                                     |

[a Nunber (Hjd pdiata with Saiow ADs, sated by sqycemorgan caad dexedirg iaqerey (brADR oped temIChpinsth + Fuhelml groupitheep-2ll stuh)

Nrle Iudeafor CArieb-291 - Beriow ADRawihsnonsclbleorhlendeeof finddse ADlawihcusd dae pirbdhcing which worensledsig sd ADRacecuing p lo30 dpa(u7dhy) blwing dhteof lde.

[6 c1oms ml conwelon sd ia defned m: (0)vey cmon p= W10g(2)cemmenpo=1m00 to c 1/10y(9)urcommwn(o= 11,000 to c 1m00y, (4)e(= 1/0ym to c 1/1 p00,(5)vey mre(c 1/1o.po01. sd(ojNk (na lnown -caret be edinated fem awibhkdta)

Hetc Indludea for DosioCoooi - ADRa with orsst hle on or sflethe ie of fina dosc ard uptn 2i dapa follwing dhteof bet dhee. AF wonering(CTCAE gndle chmgsl damlcollected inthia slrdy. Potelyoaebueedonheloalnunrofpaliabintheloanelmup(N).

Saiow ADR= Seriow Adhenedhuaroctio. ModDRA manion 250.

Upon CHMP request, the following ADRs were included in section 4.8 of the SmPC: asthenia (in the footnote,  as  part  of  fatigue),  pyrexia  (common),  headache  (very  common),  dry  mouth  (common), abdominal  pain  (common),  hypokalaemia  (common),  dizziness  (common),  acute  kidney  injury (common), and syncope (common).

<div style=\"page-break-after: always\"></div>

## 2.6.8.1. Serious adverse event/deaths/other significant events

Deaths Table 72 Summary of deaths (SAS)

|                                                                                                                     | Number (%) of patients             | Number (%) of patients          | Number (%) of patients            | Number (%) of patients                 |
|---------------------------------------------------------------------------------------------------------------------|------------------------------------|---------------------------------|-----------------------------------|----------------------------------------|
| Category                                                                                                            | CAPItello-291                      | CAPItello-291                   | FTIH Study Pool                   | Combined Pool                          |
| +                                                                                                                   | Capivasertib fulvestrant (N = 355) | Placebo + fulvestrant (N = 350) | Capivasertib fulvestrant (N = 75) | + Capivasertib + fulvestrant (N = 430) |
| Total number of deaths                                                                                              | 87 (24.5)                          | 107 (30.6)                      | 48 (64.0)                         | 135 (31.4)                             |
| Death related to disease under investigation only a                                                                 | 79 (22.3)                          | 101 (28.9)                      | 43 (57.3)                         | 122 (28.4)                             |
| AE with outcome of death only b                                                                                     | 4 (1.1)                            | 1 (0.3)                         | 0                                 | 4 (0.9)                                |
| AE with outcome of death and death related to disease under investigation b 0                                       |                                    | 0                               | 0                                 | 0                                      |
| AE with outcome of death and AE onset date falling after 30 (+ 7) days following the last dose of study treatment c | 1 (0.3)                            | 0                               | 0                                 | 1 (0.2)                                |
| Other deaths d                                                                                                      | 3 (0.8)                            | 5 (1.4)                         | 5 (6.7)                           | 8 (1.9)                                |

a     Death related to disease under investigation as determined by the investigator.

b       AEs with an onset date on/after date of first dose; AEs with onset date prior to dosing which worsen after dosing; AEs occurring up to 30 days (+ 7 days) following date of last dose are reported.

- c       Investigators were not obligated to actively seek AEs in patients who had already completed follow-up. The AE reported in this category had the PT General physical health deterioration and was not considered related to treatment.
- d       Patients who died and are not captured in the earlier categories. Investigators were not obligated to actively seek AEs in patients who had already completed follow-up. This category includes deaths that occurred after follow-up had been completed, were not reported as AEs, and were not only related to the disease under investigation.

At the DCO 27 March 2023, one additional death was reported in the category 'AE with outcome of death only' in the capivasertib + fulvestrant arm. The event of Liver abscess was assessed by the investigator as possibly related to capivasertib.

Table 73 Adverse events with an outcome of death by PT (CAPItello 291-SAS)

|                                        | Number (%) of patients              | Number (%) of patients          |
|----------------------------------------|-------------------------------------|---------------------------------|
| MedDRA preferred term                  | Capivasertib+ Fulvestrant (N = 355) | Placebo + Fulvestran t (N =350) |
| Patients with AE with outcome of death | 4 (1.1)                             | 1 (0.3)                         |
| Acute myocardial infarction            | 1 (0.3)                             | 0                               |
| Cerebral haemorrhage                   | 1 (0.3)                             | 0                               |
| Liver abscess                          | 1 (0.3)                             | 0                               |
| Pneumonia aspiration                   | 1 (0.3)                             | 0                               |
| Sepsis                                 | 1 (0.3)                             | 0                               |
| COVID-19                               | 0                                   | 1 (0.3)                         |

Patients with multiple events in the same preferred term are counted only once in that preferred term.

<div style=\"page-break-after: always\"></div>

Note: AEs with an onset date on/after date of first dose; AEs with onset date prior to dosing which worsen after dosing; AEs occurring up to 30 days (+ 7 days) following date of last dose are reported.

Percentages are based on the total number of patients in the treatment arm

(N). MedDRA version 25.0

## Serious Adverse Events

Table 74 SAEs ( reported in ≥ 2 capivasertib -treated patients in CAPItello-291) by PT (SAS)

|                         | Number (%) of patients a             | Number (%) of patients a        | Number (%) of patients a            | Number (%) of patients a             |
|-------------------------|--------------------------------------|---------------------------------|-------------------------------------|--------------------------------------|
| MedDRA PT               | CAPItello-291                        | CAPItello-291                   | FTIH Study Pool                     | Combined Pool                        |
|                         | Capivasertib + fulvestrant (N = 355) | Placebo+ fulvestran t (N = 350) | Capivasertib + fulvestrant (N = 75) | Capivasertib + fulvestrant (N = 430) |
| Patients with any SAE c | 62 (17.5)                            | 28 (8.0)                        | 24 (32.0)                           | 86 (20.0)                            |
| Diarrhoea c             | 9 (2.5)                              | 1 (0.3)                         | 0                                   | 9 (2.1)                              |
| Rash maculo-papular b   | 5 (1.4)                              | 0                               | 1 (1.3)                             | 6 (1.4)                              |
| Vomiting                | 4 (1.1)                              | 2 (0.6)                         | 3 (4.0)                             | 7 (1.6)                              |
| Acute kidney injury c   | 4 (1.1)                              | 0                               | 0                                   | 4 (1.0)                              |
| Hyperglycaemia          | 3 (0.8)                              | 0                               | 1 (1.3)                             | 4 (0.9)                              |
| Asthenia                | 2 (0.6)                              | 0                               | 0                                   | 2 (0.5)                              |
| Pneumonia aspiration    | 2 (0.6)                              | 0                               | 0                                   | 2 (0.5)                              |
| Sepsis                  | 2 (0.6)                              | 1 (0.3)                         | 0                                   | 2 (0.5)                              |
| COVID-19 c              | 2 (0.6)                              | 1 (0.3)                         |                                     |                                      |
| Pyelonephritis c        | 2 (0.6)                              | 0                               |                                     |                                      |
| Stomatitis c            | 2 (0.6)                              | 0                               |                                     |                                      |

a Number (%) of patients with SAEs, sorted in descending frequency of PT in the capivasertib + fulvestrant arm of CAPItello-291.

b This PT is included in the AESI grouped term of rash. MedDRA Version 25.0.

c Update of the table with SAEs reported at the 27 March 2023 DCO

## 2.6.8.2. Laboratory findings

## Haematology

In CAPItello-291, there were more clinically relevant decreases in haemoglobin and lymphocytes in the capivasertib + fulvestrant arm than in the placebo + fulvestrant arm.

For haemoglobin, there was a higher proportion of patients with a CTCAE grade shift (decrease) in the capivasertib + fulvestrant arm (44.9%) than in the placebo + fulvestrant arm (21.0%); most had a maximum increase of one grade (41.2% and 17.5%, respectively), and most shifts were from CTCAE Grade 0 to Grade 1.

For lymphocytes, there was a higher proportion of patients with a CTCAE grade shift (decrease) in the capivasertib + fulvestrant arm (46.3%) than in the placebo + fulvestrant arm (18.1%); almost half of those in the capivasertib + fulvestrant arm had a maximum decrease of more than one grade.

## Clinical Chemistry

<div style=\"page-break-after: always\"></div>

In  CAPItello-291,  for  sodium,  there  was  a  higher  proportion  of  patients  with  a  CTCAE  grade  shift (increase) in the capivasertib + fulvestrant arm (7.9%) than in the placebo + fulvestrant arm (4.3%). There were no high sodium results above CTCAE Grade 1. There was no significant impact on patients. In CAPItello-291, for potassium, there was a higher proportion of patients with a CTCAE grade shift (decrease) in the capivasertib + fulvestrant arm (16.7%) than in the placebo + fulvestrant arm (4.9%); most had a maximum increase of one grade (13.3% and 4.6%, respectively). Decreased potassium is possibly a secondary consequence of diarrhoea. There was a higher proportion of patients with a grade shift in calcium (corrected for albumin) (increase) in the capivasertib + fulvestrant arm (15.6%) compared with the placebo + fulvestrant arm (7.8%); most had a maximum decrease of 1 grade (13.3% and 7.8%, respectively) There were shifts in urea from normal at baseline to above the ULN during the study in 33.5% of patients in the capivasertib + fulvestrant arm compared with 15.5% of patients in the placebo + fulvestrant arm. There was a higher proportion of patients with a grade shift in magnesium (decrease) in the capivasertib + fulvestrant arm (5.7%) compared with the placebo + fulvestrant arm (1.2%); most had a maximum decrease of 1 grade (5.1% and 1.2%, respectively). Lipids Similar proportions of patients in the capivasertib + fulvestrant arm and the placebo + fulvestrant arm had a shift in total cholesterol and LDL cholesterol from within the normal range at baseline to above the ULN during treatment (total cholesterol: 27.1 % and 27.3%, respectively; LDL cholesterol: 22.1% and 24.2%, respectively). There was a slightly higher proportion of patients in the capivasertib + fulvestrant arm with a shift in triglycerides from within the normal range at baseline to above the ULN during treatment, compared with the placebo + fulvestrant arm (27.8% vs 20.5%) Renal Biochemistry In  CAPItello-291,  there  was  a  higher  proportion  of  patients  with  a  CTCAE  grade  shift  (increase)  in creatinine in the capivasertib + fulvestrant arm (21.8%) than in the placebo + fulvestrant arm (6.3%). In CAPItello-291 in the capivasertib + fulvestrant arm, there was a small increase in median creatinine at Cycle 1 (66.3 μmol/L versus 63.6 μmol/L at baseline), though it remained stable and well within the normal range for the duration of the on-treatment period. Hepatic Biochemistry In CAPItello-291, there were lower proportions of patients with CTCAE grade shifts (increases) in AST and alkaline phosphatase in the capivasertib + fulvestrant arm than in the placebo + fulvestrant arm; maximum grade shifts in ALT and bilirubin were similar between the 2 arms. There were cases of potential Hy's Law (10 in the capivasertib + fulvestrant arm and 14 in the placebo + fulvestrant arm) reported but all had alternative explanation for the elevation in liver biochemistry other than study treatment (i.e. progression of disease). Urinalysis There were more shifts from negative at baseline to trace or positive urine glucose results on treatment in the capivasertib + fulvestrant arm compared with the placebo + fulvestrant arm, which was expected. Vital Signs

<div style=\"page-break-after: always\"></div>

There were no unexpected or clinically meaningful trends or changes from baseline in vital signs over time.

## ECG

In the CAPitello 291 study, most of the ECGs recorded during the study were 'normal' or 'abnormal but not clinically significant' as reported by the investigator. However, there were slightly more 'abnormal clinically significant' observations in the capivasertib + fulvestrant arm than in placebo + fulvestrant arm (1.9% vs 0.3%).

Overall, reported changes from baseline in the mean or median QTc interval were small; and both very small increases and decreases were observed, and were similar in both treatment arms. The mean and median increase in QTc interval from baseline at 1 hour post-dose (Cycle 1, Week 1, Day 1), close to the time of expected peak concentration for capivasertib, were less than 1 msec.

The proportion of patients with QTcF increases of &gt; 30 msec from baseline at any time during treatment was 7.9% in the capivasertib + fulvestrant arm and 5.7% in the placebo + fulvestrant arm. Few patients had a change from baseline of &gt; 60 msec and this was balanced between the arms (2 patients [0.6%] in the capivasertib + fulvestrant arm, 3 patients [0.9%] in the placebo + fulvestrant arm). One patient in the capivasertib + fulvestrant arm had a QTcF value above 500 msec whilst on treatment. Adverse events related to QT prolongation were discussed previously.

## 2.6.8.3. In vitro biomarker test for patient selection for safety

Not applicable.

## 2.6.8.4. Safety in special populations

## Intrinsic factors

Effect of Age

<div style=\"page-break-after: always\"></div>

Table 75 Key safety parameters by age group (CAPItello-291-SAS)

|                                                                                           | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   | Number (%) of Patients a   |                       |                          |                          |                       |
|-------------------------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-----------------------|--------------------------|--------------------------|-----------------------|
|                                                                                           | Capivasertib + Fulvestrant | Capivasertib + Fulvestrant | Capivasertib + Fulvestrant | Capivasertib + Fulvestrant | Placebo + Fulvestrant | Placebo + Fulvestrant    | Placebo + Fulvestrant    | Placebo + Fulvestrant |
|                                                                                           | < 65 Years (N = 240 )      | 65 to 74 Years (N = 91 )   | 75 to 84 Years (N = 24 )   | ≥ 85 Years (N = 0 )        | < 65 Years (N = 249 ) | 65 to 74 Years (N = 76 ) | 75 to 84 Years (N = 23 ) | ≥ 85 Years (N = 2 )   |
| Total AEs                                                                                 | 231 (96.3)                 | 89 (97.8)                  | 23 (95.8)                  | 0                          | 202 (81.1)            | 66 (86.8)                | 18 (78.3)                | 2 (100)               |
| Serious AEs - total                                                                       | 35 (14.6)                  | 18 (19.8)                  | 4 (16.7)                   | 0                          | 20 (8.0)              | 7 (9.2)                  | 0                        | 1 (50.0)              |
| Fatal                                                                                     | 3 (1.3)                    | 0                          | 1 (4.2)                    | 0                          | 1 (0.4)               | 0                        | 0                        | 0                     |
| Hospitalisation/prolo ng existing hospitalisation                                         | 31 (12.9)                  | 18 (19.8)                  | 4 (16.7)                   | 0                          | 15 (6.0)              | 6 (7.9)                  | 0                        | 1 (50.0)              |
| Life-threatening                                                                          | 3 (1.3)                    | 2 (2.2)                    | 0                          | 0                          | 4 (1.6)               | 1 (1.3)                  | 0                        | 0                     |
| Disability/incapacity                                                                     | 1 (0.4)                    | 1 (1.1)                    | 0                          | 0                          | 2 (0.8)               | 1 (1.3)                  | 0                        | 1 (50.0)              |
| Other (medically significant)                                                             | 8 (3.3)                    | 6 (6.6)                    | 0                          | 0                          | 5 (2.0)               | 1 (1.3)                  | 0                        | 0                     |
| AE leading to discontinuation of capivasertib/placebo                                     | 20 (8.3)                   | 20 (22.0)                  | 6 (25.0)                   | 0                          | 7 (2.8)               | 0                        | 0                        | 1 (50.0)              |
| Psychiatric disorders (SOC)                                                               | 22 (9.2)                   | 8 (8.8)                    | 3 (12.5)                   | 0                          | 21 (8.4)              | 8 (10.5)                 | 3 (13.0)                 | 1 (50.0)              |
| Nervous system disorders (SOC)                                                            | 73 (30.4)                  | 31 (34.1)                  | 8 (33.3)                   | 0                          | 61 (24.5)             | 15 (19.7)                | 3 (13.0)                 | 0                     |
| Injury, poisoning and procedural complications (SOC)                                      | 12 (5.0)                   | 7 (7.7)                    | 3 (12.5)                   | 0                          | 8 (3.2)               | 4 (5.3)                  | 2 (8.7)                  | 0                     |
| Cardiac disorders (SOC)                                                                   | 13 (5.4)                   | 8 (8.8)                    | 3 (12.5)                   | 0                          | 5 (2.0)               | 3 (3.9)                  | 1 (4.3)                  | 1 (50.0)              |
| Vascular disorders (SOC)                                                                  | 27 (11.3)                  | 14 (15.4)                  | 4 (16.7)                   | 0                          | 31 (12.4)             | 7 (9.2)                  | 3 (13.0)                 | 1 (50.0)              |
| Infections and infestations (SOC)                                                         | 79 (32.9)                  | 35 (38.5)                  | 10 (41.7)                  | 0                          | 51 (20.5)             | 9 (11.8)                 | 7 (30.4)                 | 1 (50.0)              |
| Cerebrovascular disorders (SMQ) b                                                         | 2 (0.8)                    | 1 (1.1)                    | 1 (4.2)                    | 0                          | 0                     | 0                        | 0                        | 0                     |
| Anticholinergic syndrome (PT)                                                             | 0                          | 0                          | 0                          | 0                          | 0                     | 0                        | 0                        | 0                     |
| Quality of life decreased (PT)                                                            | 0                          | 0                          | 0                          | 0                          | 0                     | 0                        | 0                        | 0                     |
| Sum of postural hypotension, fall, loss of consciousness, syncope, dizziness, ataxia, and | 12 (5.0)                   | 10 (11.0)                  | 3 (12.5)                   | 0                          | 11 (4.4)              | 3 (3.9)                  | 0                        | 0                     |

<div style=\"page-break-after: always\"></div>

## Effect of Sex

Although breast cancer is a disease occurring largely in the female population, 3 (0.7%) patients in the Combined Pool were male (all from CAPItello-291). In the Monotherapy Pool, 31 (18.8%) patients were male.

## Effect of Race

The overall incidence of AEs, SAEs, and AESIs in the capivasertib + fulvestrant arm of CAPItello-291 was similar across the 2 largest race subgroups (White [N = 201] and Asian [N = 95]). The incidence of CTCAE Grade 3 or higher AEs was higher in the Asian group (48.4%) than in the White group (39.3%). The types of AEs most commonly reported were similar between the race subgroups.

## Effect of Weight

The overall incidence of AEs in the capivasertib + fulvestrant arm of CAPItello-291 was generally similar across the weight subgroups (baseline weight &lt; 50 kg [N = 35], ≥ 50 to &lt; 70 kg [N = 184], ≥ 70 to &lt; 90 kg [N = 101], and ≥ 90 kg [N = 31]).

The types of AEs most commonly reported were similar between the weight subgroups.

The incidence of SAEs was higher in the baseline weight &lt; 50 kg group (25.7%) than in the other groups (≥ 50 to &lt; 70 kg, 16.3%; ≥ 70 to &lt; 90 kg, 12.9%; ≥ 90 kg, 16.1%). The incidence of CTCAE Grade 3 or higher AEs was higher in the baseline weight &lt; 50 kg group (54.3%) than in the other groups (≥ 50 to &lt; 70 kg, 44.0%; ≥ 70 to &lt; 90 kg, 35.6%; ≥ 90 kg, 41.9%).

The incidence of AEs leading to dose reduction of capivasertib was also higher in the baseline weight &lt; 50 kg group (37.1%) than in the other groups (≥ 50 to &lt; 70 kg, 21.7%; ≥ 70 to &lt; 90 kg, 10.9%; ≥ 90 kg, 9.7%).

## Effect of PIK3CA/AKT1/PTEN Alteration Status

Altered population is molecularly defined subgroup with tumours harbouring at least 1 PIK3CA/AKT1/PTEN-qualifying alteration detected in tissue.

The overall incidence of AEs, CTCAE Grade 3 or higher AEs, SAEs, and AESIs in CAPItello-291 was similar between the alteration status subgroups. The types of AEs most commonly reported were also similar between subgroups. The most commonly reported AEs (≥ 20% of patients, by PT) in the capivasertib + fulvestrant arm of CAPItello-291 were as follows:

- Altered (N = 155): Diarrhoea (76.8%), Nausea (34.8%), Fatigue (22.6%), Rash maculo-papular and Vomiting (20.6% each), and Rash (20.0%)
- Confirmed non-altered (N = 142): Diarrhoea (68.3%), Nausea (33.1%), Rash (24.6%), and Vomiting (21.8%)
- Non-altered + unknown (N = 58): Diarrhoea (70.7%), Nausea (37.9%), Fatigue (22.4%), and Decreased appetite, Hyperglycaemia, and Rash (20.7% each).

The incidence of AEs leading to discontinuation of capivasertib was higher in the confirmed non-altered group  (16.9%)  than  in  the  confirmed  altered  group  (10.3%)  or  the  non-altered  +  unknown  group (10.3%) and a total duration of exposure to capivasertib/placebo in confirmed non-altered group was shorter than in altered or non-altered + unknown group (3.6, 6.3 and 7.3 months, respectively).

<div style=\"page-break-after: always\"></div>

## Effect of WHO/ECOG PS

The  overall  incidence  of  AEs,  CTCAE  Grade  3  or  higher  AEs,  and  AESIs  was  similar  between  the WHO/ECOG PS subgroups, however, incidence of SAEs was higher in the WHO/ECOG PS ≥ 1 group (22.1%) than in the WHO/ECOG PS 0 group (12.3%).

## Effect of HbA1C at Baseline and Medical History of Diabetes Mellitus

The  patients  with  controlled  diabetes  type  II  could  be  included  in  the  CAPItello-291,  however  with HbA1C&lt;  8%  at  baseline.  At  baseline  in  CAPItello-291,  34  (9.6%)  patients  in  the  capivasertib  + fulvestrant arm and 20 (5.7%) patients in the placebo + fulvestrant arm had diabetes mellitus.

Considering the small number of patients with a baseline HbA1C ≥ 6.5% (N = 21, CAPItello -291) and only 5.9% of patients in the capivasertib + fulvestrant arm of CAPItello-291, the assessment of the capivasertib's safety profile by these factors should be interpreted with caution.

The overall incidence of AEs was similar between the HbA1C subgroups (97% in the HbA1C &lt; 6.5% group and 90.5% in the HbA1C ≥ 6.5% group, as well as between the subgroups with and without a medical history of diabetes mellitus.

The incidences of CTCAE Grade 3 or higher AEs (66.7% versus 41.6%) and SAEs (28.6% versus 15.4%) were higher in the HbA1C ≥ 6.5% group than in the HbA1C &lt; 6.5% group and also in the medical history of diabetes mellitus group (58.8% versus 41.1% and 23.5% vs 15.3%, respectively).

The overall incidence of AESIs was higher in the HbA1C &lt; 6.5% group (88.3%) than in the HbA1C ≥ 6.5% group (76.2%).

AEs of Hyperglycaemia (PT) were more frequently reported in patients with a baseline HbA1C ≥ 6.5% (6 [28.6%] patients) than those with a baseline HbA1C &lt; 6.5% (51 [15.4%] patients), and also in patients with a medical history of diabetes mellitus (10 [29.4%] patients) than those without a history of diabetes mellitus (48 [15.0%] patients).

AEs of Diabetic ketoacidosis, Diabetes mellitus, and Diabetic metabolic decompensation were reported in one (4.8%) patient each in the HbA1C ≥ 6.5% subgroup. An AE of Diabetic metabolic decompensation was reported in one (0.3%) patient in the HbA1C &lt; 6.5% subgroup.

AEs of Diabetic ketoacidosis and Diabetic metabolic decompensation were reported in one (2.9%) patient each in the subgroup with a medical history of diabetes mellitus.

AEs of Diabetes mellitus and Diabetic metabolic decompensation were reported in one (0.3%) patient each in the subgroup without a medical history of diabetes mellitus.

## Effect of Menopausal Status

The overall incidence of AEs, SAEs, and AESIs was similar between the pre-/peri-menopausal group and the post-menopausal group.

The incidence of CTCAE Grade 3 or higher AEs was higher in the post-menopausal group (45.6%) than in the pre-/peri-menopausal group (30.8%). The types of AEs most commonly reported were similar between the menopausal status subgroups.

Some differences in incidence of AEs between pre-/peri-menopausal and post-menopausal women may be attributed to variables such as age and use of luteinising hormone-releasing hormone agonists in the former.

## Extrinsic factor

## Effect of Prior Use of CDK4/6 Inhibitors

<div style=\"page-break-after: always\"></div>

The overall incidence of AEs, CTCAE Grade 3 or higher AEs, SAEs, and AESIs was similar between the groups with and without prior use of CDK4/6 inhibitors. The types of AEs most commonly reported were similar between patients with or without prior use of CDK4/6 inhibitors.

## Overdose

Table 76 CAPItello-291: Capivasertib or placebo overdose characterisation (SAS)

+

|                                                                           |                                                                           | Capivasertib + fulvestrant (N = 355)   | Placebo + fulvestrant (N = 350)   |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------|-----------------------------------|
| Number of patients (%) experiencing an overdose with capivasertib/placebo | Number of patients (%) experiencing an overdose with capivasertib/placebo | 58 (16.3)                              | 50 (14.3)                         |
| Number of patients (%) with an overdose associated with an AE             | Number of patients (%) with an overdose associated with an AE             | 1 (0.3)                                | 0                                 |
| Number of overdoses per patient                                           | Mean (SD)                                                                 | 2.0 (1.96)                             | 1.6 (1.14)                        |
| Number of overdoses per patient                                           | Median                                                                    | 1.0                                    | 1.0                               |
| Number of overdoses per patient                                           | Min, max                                                                  | 1, 12                                  | 1, 6                              |
| Number of overdoses per patient, n (%)                                    | 1                                                                         | 36 (62.1)                              | 33 (66.0)                         |
| Number of overdoses per patient, n (%)                                    | 2                                                                         | 11 (19.0)                              | 11 (22.0)                         |
| Number of overdoses per patient, n (%)                                    | 3                                                                         | 4 (6.9)                                | 1 (2.0)                           |
| Number of overdoses per patient, n (%)                                    | ≥ 4                                                                       | 7 (12.1)                               | 5 (10.0)                          |

## 2.6.8.5. Immunological events

Not applicable.

## 2.6.8.6. Safety related to drug-drug interactions and other interactions

Please refer to the assessment of clinical pharmacology.

## 2.6.8.7. Discontinuation and dose modification due to adverse events

Table 77 CAPItello-291, FTIH study pool, and combined pool: AEs leading to discontinuation of capivasertib/placebo (reported in ≥ 2 capivasertib -treated patients in CAPItello291) by PT (SAS)

|                                                                         | Number (%) of patients a             | Number (%) of patients a        | Number (%) of patients a          | Number (%) of patients a               |
|-------------------------------------------------------------------------|--------------------------------------|---------------------------------|-----------------------------------|----------------------------------------|
| MedDRA PT                                                               | CAPItello-291                        | CAPItello-291                   | FTIH Study Pool                   | Combined Pool                          |
|                                                                         | Capivasertib + fulvestrant (N = 355) | Placebo + fulvestrant (N = 350) | Capivasertib fulvestrant (N = 75) | + Capivasertib + fulvestrant (N = 430) |
| Patients with any AE leading to discontinuation of capivasertib/placebo | 46 (13.0)                            | 8 (2.3)                         | 6 (8.0)                           | 52 (12.1)                              |
| Rash b                                                                  | 11 (3.1)                             | 0                               | 0                                 | 11 (2.6)                               |
| Diarrhoea                                                               | 7 (2.0)                              | 0                               | 0                                 | 7 (1.6)                                |
| Vomiting                                                                | 7 (2.0)                              | 2 (0.6)                         | 0                                 | 7 (1.6)                                |
| Rash maculo-papular b                                                   | 5 (1.4)                              | 0                               | 1 (1.3)                           | 6 (1.4)                                |
| Pyrexia                                                                 | 4 (1.1)                              | 0                               | 0                                 | 4 (0.9)                                |

<div style=\"page-break-after: always\"></div>

| Alanine aminotransferase increased   | 3 (0.8)   | 0       |   0 | 3 (0.7)   |
|--------------------------------------|-----------|---------|-----|-----------|
| Aspartate aminotransferase increased | 3 (0.8)   | 1 (0.3) |   0 | 3 (0.7)   |
| Nausea                               | 3 (0.8)   | 1 (0.3) |   0 | 3 (0.7)   |
| Acute kidney injury                  | 2 (0.6)   | 0       |   0 | 2 (0.5)   |
| Drug eruption                        | 2 (0.6)   | 0       |   0 | 2 (0.5)   |
| Paraesthesia                         | 2 (0.6)   | 0       |   0 | 2 (0.5)   |
| Sepsis                               | 2 (0.6)   | 0       |   0 | 2 (0.5)   |
| Urticaria                            | 2 (0.6)   | 0       |   0 | 2 (0.5)   |

- a Number (%) of patients with AEs leading to discontinuation of capivasertib/placebo, sorted in descending frequency of PT in the capivasertib + fulvestrant arm of CAPItello-291.

b These PTs are included in the AESI grouped term of rash. MedDRA Version 25.0.

## Adverse events leading to dose modifications

In the safety analysis set of the CAPItello 291 study, the incidence of AEs leading to dose modifications of capivasertib/placebo was higher in the capivasertib + fulvestrant arm (43.9%) compared with the placebo + fulvestrant arm (12.3%).

More patients in the capivasertib arm had dose reductions (30.7%) and dose interruptions (50.7%) in comparison to placebo (6.9% and 22.9%, respectively). Adverse events were the most common reason for the dose reductions, interruptions and delays (only fulvestrant) in both treatment arms.

The  incidence  of  AEs  leading  to  dose  interruptions  of  capivasertib/placebo  only  was  34.9%  in  the capivasertib + fulvestrant arm and 10.3% in the placebo + fulvestrant arm. The AEs most commonly leading to dose interruptions of capivasertib were diarrhoea (9%), rash maculo-papular (6.2%), rash (4.2%), vomiting (3.1%), hyperglycaemia(2.5%), and nausea (2.3%).

The  incidence  of  AEs  leading  to  dose  reductions  of  capivasertib/placebo  only  was  higher  in  the capivasertib + fulvestrant arm (19.7%) compared with the placebo + fulvestrant arm (1.7%). The AEs most  commonly  leading  to  dose  reductions  were  diarrhoea  (7.9%),  rash  maculo-papular  (2.5%), vomiting (1.7%), and rash and nausea (1.4% each). The majority of patients reached a stable dose within 2 months of starting treatment.

## 2.6.8.8. Post marketing experience

Capivasertib was approved in US on 16 November 2023; however, no post -marketing data are available.

## 2.6.9. Discussion on clinical safety

The evaluation of safety is based on data from clinical studies in patients treated with capivasertib in combination with fulvestrant, and supported by data from capivasertib monotherapy studies. Overall, 664 patients are included in the safety database. Although limited, the size of the safety database is considered sufficient for an assessment of the safety profile of capivasertib in the proposed advanced metastatic setting. The primary safety population includes 355 patients from CAPItello-291 and provides the pivotal safety data to evaluate the safety and tolerability of capivasertib + fulvestrant in the target population.

Median total treatment duration was longer in the capivasertib + fulvestrant arm (capivasertib 5.42 months,  fulvestrant  5.75  months)  than  in  the  placebo  +  fulvestrant  arm  (placebo  3.58  months, fulvestrant  3.68  months).  Of  note,  the  comparison  with  the  median  actual  treatment  duration,  5.3 months  for  the  capivasertib  +  fulvestrant  arm  and  3.5  months  for  the  placebo  +  fulvestrant  arm, suggests that administration interruptions had a limited impact on the overall course of the treatment in both arms. The median relative dose intensity of capivasertib was high (93.8%) and this despite dose modifications, including dose interruptions in half of the patients in the capivasertib + fulvestrant arm, which indicates that these interruptions were not long. However, only about half of the patients (52.4%) were exposed to the study treatment for at least 6 months and 27.0% for at least 12 months. The censored data show that 70.1% of the patients of the capivasertib + fulvestrant arm and 60.9% in the placebo + fulvestrant arm are still in survival follow up at the first data cut-off (DCO1: 15-08-2022). With the updated safety data, based on the latest DCO (27 March 2023) with a longer follow-up (and longer exposure to capivasertib), there were some minor increases from DCO1 in the incidence of AEs reported  in  both  treatment  arms  at  the  27  March  2023  DCO  (96.6%  versus  96.9%  [capivasertib  + fulvestrant arm] and 82.3% versus 82.9% [placebo + fulvestrant arm], respectively), however, no new safety signal have been identified for capivasertib. The demographics and baseline characteristics do not raise particular concerns from a safety point of view.  However,  it  is  observed  that  the  proportion  of  patients  with  diabetes  is  slightly  higher  in  the capivasertib + fulvestrant group (9.6 %) compared to the placebo + fulvestrant group (5.7%). Patients from 18 years old could be enrolled, including elderly without upper age boundary. The CAPItello-291 study was conducted in 19 countries. Among the 708 subject enrolled (capivasertib + fulvestrant and placebo + fulvestrant), 395 come from United States, Canada, Australia and Europe ( among them 296 from Europe). Thus, there is no concern on the generalisation of the safety results to the European population. The proportion of subjects who have experienced at least 1 AE is high in both groups, with 96.6% (n=343) in the capivasertib + fulvestrant group, and 82.3% (n=288) in the placebo + fulvestrant group. Overall, higher frequencies of adverse events in any of the category were observed for capivasertib + fulvestrant compared to placebo + fulvestrant, which is expected in a study with a targeted agent added to an endocrine therapy. Overall,  the  AEs  commonly  reported  in  the  pivotal  study  are  consistent  with  the  safety  profile  of capivasertib from the early phase study and its mechanism of action. The safety profile of fulvestrant monotherapy is well known and AEs reported in CAPItello-291 study were consistent with this. While the incidence of commonly reported AEs was generally higher in the FTIH Study Pool than in CAPItello-291,  an  exception  was  observed  for  diarrhoea  (AE  PT  reported  in  72.4%  of  patients  in CAPItello-291 versus 65.3% of patients in the FTIH Study Pool). A possible reason for the difference in reporting  rates  of  diarrhoea  is  the  enhanced  data  collection  that  was  in  place  for  diarrhoea  in  the CAPItello-291 study. Despite the increased reporting rate of diarrhoea in CAPItello-291, the characteristics of diarrhoea AEs were similar to those reported in the FTIH Study Pool. Although the majority of patients in the CAPItello 291 study had AEs with a maximum reported grade of 1 or 2, there were many more patients having AE of CTCAE grade 3 or higher in the capivasertib + fulvestrant arm (42.8%) than in placebo + fulvestrant arm (15.7%). There were almost 6 times more patients with AE of CTCAE grade 3 or higher, possibly related to capivasertib/placebo, in the capivasertib + fulvestrant arm (30.7%) compared to placebo + fulvestrant arm (5.4%). Adverse  events  of  special  interest  included  hyperglycaemia,  diarrhoea  (non-infectious),  rash,  QT prolongation, infective pneumonia, stomatitis and urinary tract infection.

<div style=\"page-break-after: always\"></div>

Hyperglycaemia is an expected adverse reaction of AKT inhibition.

<div style=\"page-break-after: always\"></div>

Overall, the lower incidence of hyperglycaemia reported in the pivotal CAPItello-291 study compared to other safety pools might be explained by a more careful selection of the patient population enrolled (only 21 patient had HbA1C ≥6.5%), slightly lower dose (400 mg) used in the pivotal study and the fact that due to an intermittent schedule (four days on and three days off), a glucose homeostasis temporary recover from the AKT inhibition. In addition, education and recommendations within the protocol were provided to help identify and manage hyperglycaemia early. In section 8.4.3.5 of the CAPItello-291 CSP, there was an instruction that for all grades of hyperglycaemia, patients should receive education on lifestyle changes (i.e., a diabetic diet) and to consider starting home glucose monitoring (i.e. fasting selfblood glucose monitoring once daily).

Nevertheless,  the  risk  of  hyperglycaemia  is  still  4  times  higher  than  in  patients  on  fulvestrant monotherapy. The incidence of hyperglycaemia is expected to be much higher in the clinical setting, especially considering that the applicant proposed no restrictions on use of capivasertib in patients with diabetes mellitus type 1 or 2, The SmPC adequately reflects this lack of efficacy and safety data with capivasertib in patients with Type 1 and Type 2 diabetes requiring insulin (as these were excluded from the pivotal study). However, the lack of information on efficacy and safety in these patients remains a concern addressed in post-authorisation measures. Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment or HbA1c ≥ 8.0% ) is also reflected as missing information in the RMP.

Hyperglycaemia was more frequently reported in patients with a baseline HbA1C ≥ 6.5% (28.6% of patients) than those with a baseline HbA1C &lt; 6.5% (15.4%). Severe hyperglycaemia, associated with ketoacidosis, occurred in patients treated with capivasertib. Patients with a history of diabetes mellitus may require intensified  antidiabetic  treatment  and  should  be  closely  monitored.  Consultation  with  a diabetologist or a healthcare professional experienced  in the treatment  of hyperglycaemia  is recommended  for  patients  with  diabetes.  This  information  has  been  added  to  the  warning  of hyperglycaemia in section 4.4 of the SmPC.

Furthermore, information has been added that before initiating treatment, patients should be informed about the potential of capivasertib to cause hyperglycaemia and to immediately contact their healthcare professional  if  hyperglycaemia  symptoms  (e.g.  excessive  thirst,  urinating  more  often  than  usual  or greater amount of urine than usual, or increased appetite with weight loss) occur. Patients should be tested for fasting blood glucose (FG) levels and HbA1C prior to treatment with capivasertib and at regular intervals during treatment.

A table with the schedule of fasting glucose monitoring and HbA1c in all patients treated with Truqap and in patients with diabetes treated with Truqap has been added as follows:

<div style=\"page-break-after: always\"></div>

## Table 78 Schedule of fasting glucose monitoring and HbA1c in all patients treated with Truqap and in patients with diabetes treated with Truqap

Recommended schedule for the monitoring  of  fasting  glucose  and HbA1c  levels  in  all  patients  treated with TRUQAP

Recommended schedule of monitoring of fasting glucose and HbA1c levels in patients  with  diabetes  treated  with TRUQAP 1

Test for fasting blood glucose (FG) levels, HbA1c, and optimise the patient's level of blood glucose (see Table 3).

## At screening, before initiating treatment with TRUQAP

## After initiating treatment with TRUQAP

Monitor fasting glucose at weeks 1, 2, 4, 6 and 8 after treatment start and monthly thereafter.

Monitor/self-monitor fasting glucose regularly,  more  frequently  in  the  first  4 weeks  and  especially  within  the  first  2 weeks  of  treatment,  according  to  the instructions of a healthcare professional*.

Monitor/self-monitor  fasting  glucose  daily for  the  first  2  weeks  of  treatment.  Then continue  to  monitor  fasting  glucose  as frequently as needed to manage hyperglycaemia according to the instructions of a healthcare professional*.

HbA1c should be monitored every 3 months.

Monitor fasting glucose as clinically indicated (at least twice weekly, i.e. on days on and off capivasertib treatment) until FG decreases to baseline levels.

Counselling of patients on lifestyle changes is recommended.

Consultation  with  a  healthcare  practitioner  with  expertise  in  the  treatment  of hyperglycaemia should be considered.

Based  on  the  severity  of  hyperglycaemia,  TRUQAP  dosing  may  be  interrupted, reduced, or permanently discontinued (see section 4.2, Table 3).

During treatment with anti-diabetic medication, FG should be monitored for at least once a week for 2 months, followed by once every 2 weeks or as clinically indicated.

* All glucose monitoring should be performed at the physician's discretion as clinically indicated.

1  More frequent FG testing is required in patients with medical history of diabetes mellitus, in patients without prior history of diabetes mellitus and showing FG of &gt; ULN 160 mg/dL (&gt; ULN 8.9 mmol/L) during treatment, in patient with concomitant use

of  corticosteroids,  or  in  those  with  intercurrent  infections,  or  other  conditions  which  may  require  intensified  glycaemia management to prevent worsening of impaired glucose metabolism and potential complications, namely diabetic ketoacidosis.

Monitoring  of  HbA1C,  ketones  (preferably  in  blood)  and  other  metabolic  parameters  (as  indicated),  in  addition  to  FG,  is recommended in these patients.

Additionally, at the data cut-off, the hyperglycaemia event was not recovered in 28 of the 60 patients. This is particularly of concern for patients without a history of diabetes and raises the question of a secondary risk to develop diabetes following treatment with capivasertib. This is important given the long life-expectancy of the patient population. The CSP of the study is not prescriptive on the definition of recovery, and this is thus a limitation of the interpretation of the data. Furthermore, regarding other risk factors than history of diabetes that could impact the risk of hyperglycaemia , two subpopulations were identified where a higher incidence of hyperglycaemia was found: in function of BMI and of age. However, this is also mitigated by the fact that the proportion of patients with a medical history of diabetes mellitus was higher in the BMI ≥ 30 kg/m2 group (4/66 [6.1%] patients) compared with the BMI  &lt;  30  kg/m2  group  (6/285  [2.1%]  patients).  The  difference,  which  remains  limited,  could  be therefore partly explained by the history of diabetes. Although the data suggest a higher risk in elderly, the difference remains limited. Hyperglycaemia will be followed in the RMP, and relevant information and recommendations have been included in the SmPC (sections 4.2, 4.4 and 4.8).

Additional  data  on  safety  and  efficacy  in  patients  with  diabetes  are  needed  to  give  evidence-based recommendations to prescribers, when patients with concomitant diabetes mellitus should be part of the target population. Section 4.4 of the SmPC states that these patients can receive capivasertib, but should be closely monitored and may require intensified diabetic treatment. Fasting blood glucose and HbA1C

## If hyperglycaemia develops after initiating  treatment with TRUQAP

<div style=\"page-break-after: always\"></div>

should be assessed and blood glucose optimised prior to treatment. It is considered that optimisation of glucose status should be a prerequisite for the start of capivasertib therapy. Furthermore, the applicant confirms that patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring long-term insulin treatment will be eligible for future studies of capivasertib, such that data can be anticipated in future on the use of capivasertib in this group of patients. The capivasertib Phase IIIb programme consists of studies CAPItana, CAPItrue and CAPIcorn and for all these studies the updated exclusion criteria include: Clinically significant abnormalities of glucose metabolism defined as HbA1c ≥8.0% (63.9 mmol/mol) at screening. Collectively these three studies will enrol ~600 patients. The applicant is recommended to plan subgroup analyses on efficacy (ORR, PFS, OS) in diabetic patients in the individual studies and in the combined analyses. Results of such studies (CAPItana, CAPItrue and CAPIcorn) should be submitted once available (REC). However, it is predicted that insulin dependent diabetic patients will represent only a small percentage of the recruited population. The applicant was therefore requested to investigate the feasibility  of  conducting  a  non-interventional  study  to  jointly  investigate  the  efficacy  and  safety  of capivasertib in patients with type 1 or type 2 diabetes, including those with insulin-dependent diabetes, with  sufficient  patients  to  characterise  efficacy  in  patients  with  diabetes  mellitus  type  1  or  diabetes mellitus type 2 requiring insulin treatment. Overall, the applicant's approach and a proposal to conduct a non-interventional PASS (category 3 study in the RMP) is considered acceptable. In order to provide the  prescribers  with  the  most  recent  recommendations  for  precautionary  measures,  monitoring  and handling of capivasertib-induced hyperglycaemia for all patients (including patients with diabetes or risk factors), sections 4.2 and 4.4, subsection Hyperglycaemia have been updated. 'Safety in patients with type  1  or  type  2  diabetes  (requiring  insulin  treatment,  or  HbA1c  ≥  8.0%)'  is  reflected  as  missing information in the RMP. Successful management of hyperglycaemia induced by capivasertib is of the utmost importance. In the setting of a clinical trial, hyperglycaemia may be considered manageable; however, in the clinical setting, hyperglycaemia  and  related  events  may  be  fatal,  as  they  may  not  be  diagnosed  on  time.  'Acute complications of hyperglycaemia' has been added as an important potential risk in the RMP. The incidence of diarrhoea AESIs was 3.5x higher in the capivasertib + fulvestrant arm. Almost all the cases of Grade 3 occurred in the capivasertib + fulvestrant arm (n=33, 9.3% ; vs. n=1, 0.3% in the placebo + fulvestrant arm). SAEs were reported in 1.7%, and diarrhoea lead to discontinuation in 2% of the patients in the capivasertib + fulvestrant arm. The events typically occurred during the three first weeks of treatments. The management of these events is particularly of concern considering the potential related risk of dehydration, electrolyte disturbances including hypokalaemia and thus a potential risk of cardiac arrhythmia, and acute kidney injury (i.e. Secondary risks of diarrhoea). In the majority of patient, diarrhoea  appeared  to  be  manageable  with  medication  and/or  dose  interruptions/adjustments.  This information has been added to the warning in section 4.4 of the SmPC, advising that based on the severity of the diarrhoea, Truqap dosing may be interrupted, reduced, or permanently discontinued and advising patients to start anti-diarrhoeal treatment at the first sign of diarrhoea and to increase oral fluids  if  diarrhoea  symptoms occur during treatment. Maintenance of normovolaemia and electrolyte balance is required in patients with diarrhoea to avoid complications related to hypovolemia and low electrolyte levels. The applicant agreed to closely monitor 'Acute complications of diarrhoea' and report it in future PSURs. Skin rash is a class-effect observed with PI3K/AKT/PTEN signalling pathway inhibitors. The incidence of rash AESIs was higher in the capivasertib + fulvestrant arm (38.0% vs 7.1%), and occurred with greater severity. Localisation or body surface area of the rash was reported for 13 of the 43 patients with Grade 3 rash (grouped term). Overall, the localisation varied among the patients reported so that no conclusion can be drawn. Grade ≥ 3 skin ADRs (includes Grade ≥ 3 rash AESI, PTs of erythema, rash erythematous, erythema

multiforme,  drug  eruption,  and  dermatitis  exfoliative  generalised)  represent  one  of  the  key  risks  of capivasertib  treatment  and  were  reported  in  53  patients  (14.9%)  in  the  CAPitello-291.  Onset  was typically during the second week of treatment. Capivasertib was interrupted in 39/53 patients (73.6%), and  dose  reduced  in  17/53  patients  (32.1%),  with  total  of  13/53  patients  (24.5%)  discontinuing treatment due to CTCAE ≥ Grade 3 skin ADRs. The most patients recovered or were recovering at the DCO. A warning in section 4.4 of the SmPC has been added informing that skin drug reactions, including erythema  multiforme  and  dermatitis  exfoliative  generalised,  were  reported  in  patients  receiving capivasertib and that patients should be monitored for signs and symptoms of rash or dermatitis and based  on  severity  of  skin  drug  reactions,  the  dosing  may  be  interrupted,  reduced,  or  permanently discontinued.  Early  consultation  with  a  dermatologist  is  recommended  to  ensure  greater  diagnostic accuracy and appropriate management. Additional information describing rash has also been added in section 4.8 under the ADR table.  'Severe cutaneous adverse reactions' will be closely monitored and discussed in PSURs.

<div style=\"page-break-after: always\"></div>

One SAE of anaphylactic reaction (Grade 3) was reported. The event was considered by the Investigator as possibly related to capivasertib and fulvestrant, and the patient experienced previously a Grade 3 rash maculo-papular possibly related to capivasertib. Based on the additional information provided, it cannot be excluded that rash was a sign of sensitisation. However, considering that the patient has also received concomitantly fulvestrant, and that there is no additional cases, it appears difficult to conclude and provide additional guidance. Furthermore, the risk of hypersensitivity and rash are both mentioned in sections 4.4 (rash and other skin drug reactions) and 4.8 (rash and hypersensitivity) of the SmPC.

In most patients, rash was managed with topical corticosteroids or antihistamine treatment, however in a third of the patients requiring treatment, systemic corticosteroids were used. Systemic corticosteroids, among other, are known to induce hyperglycaemia. The applicant provided an additional analysis of the data  from  the  CAPItello  291  and  discussed  the  potential  risk  of  the  concomitant  use  of  systemic corticosteroids and capivasertib. Overall, a slight trend towards higher rate of hyperglycaemia events was reported  in  patients  that  used  systemic  corticosteroids,  and  a  higher  rate  of  patients  receiving systemic corticosteroids required treatment for hyperglycaemia. Although caution should be exercised when interpreting these data due to the small number of patients in the group who received concomitant systemic  corticosteroids  (N  =  40),  it  does  not  diminish  the  fact  that  concomitant  use  of  systemic corticosteroids and capivasertib may pose an additional risk for the patients and this has been reflected in the proposed SmPC, under section 4.4, subsection hyperglycaemia.

In addition, the applicant has clarified that the primary prophylaxis against drug-induced rash was not mandated nor recommended in the protocol for the CAPItello-291 study but was not restricted, whereas secondary  prophylaxis  by  continuing  topical  steroids  and/or  non-sedating  oral  antihistamines  was permitted. Considerations for secondary prophylaxis with antihistamines are included in Section 4.2.

QT prolongation was identified as being an AESI in the CAPItello-291 study based on non-clinical data. The AEs defined by the AESI category of QT prolongation were reported in 11 patients in the capivasertib +  fulvestrant  arm  and  included  electrocardiogram  QT  prolonged,  syncope,  seizure,  and  ventricular arrhythmia.  Although  low  in  incidence,  most  were  reported  as  AEs  of  CTCAE  Grade  3  and  included syncope (6 patients, 1.7%), and electrocardiogram QT prolonged and seizure (each in 1 patient, 0.3%). The events typically occurred within the initial few weeks of treatment. In 2 patients, the events (both electrocardiogram QT prolonged) led to dose interruptions. None led to discontinuation of treatment. Most  had  recovered  or  were  recovering  at  the  time  of  DCO1.  Electrocardiogram  QT  prolonged  was reported in 3 of the 11 patients. In all 3 patients additional risk factors that might have increased the risk  of  a  long  QT  interval  were  identified  (hypokalaemia  due  to  diarrhoea;  co -administration  of indapamide; low calc ium levels). However, in all of these patients, ECG at any visit showed QTcF interval within the normal range.

<div style=\"page-break-after: always\"></div>

Of note, most of ECGs were taken in a days off capivasertib treatment which might have influenced the characterisation of ECGs. The applicant provided a listing of the QT prolongations (Narrow Torsade de pointes/QT prolongation MedDRA SMQ) that were observed in all applicant-sponsored studies. Overall, QT prolongations were reported in 29 patients, mostly were not serious and majority were grade 1 in severity. A case of a ventricular tachycardia (serious) was reported in one patient that received capivasertib 480 mg BID (4 on 3o ff), and drug was permanently discontinued. The  applicant  has  also  informed  that  more  extensive  monitoring  of  ECGs  is  being  conducted  in  the Capitello-290  study  and  the  ECGs  were  recorded  at  the  time  of  steady  state  Cmax.  Therefore,  it  is expected that further characterisation of the ECGs will be possible and the applicant is recommended to address the issue once data from the CAPItello-290 study are available ( REC ). The applicant has provided tables with all AEs in the Cardiac arrhythmias HLGT reported in the CAPItello 291. With a total of 14 (3.9%) patients in the capivasertib + fulvestrant arm and 4 (1.1%) of patients in  the  placebo  +  fulvestrant  arm  that  had  AEs  in  the  Cardiac  arrhythmias  HLGT,  a  slight  imbalance between treatment arms is noted, mostly driven by 4 vs 1 AEs of sinus tachycardia in the capivasertib + fulvestrant vs placebo + fulvestrant arm, respectively. Furthermore, 2 AEs were classified as SAEs but they were not considered related to either of the study treatment. As with patients with QT prolongation AESI, also Cardiac arrhythmias AEs have shown a trend for being reported more frequently in the capivasertib + fulvestrant arm than in the control arm. Not excluding the possibility of chance finding, the contribution of capivasertib  also cannot be completely ruled out. The information that cardiac arrhythmias with hypokalaemia as risk factor have been reported in patients receiving capivasertib plus fulvestrant in clinical trials is therefore included in section 4.4 of the SmPC. Furthermore, a warning has been added to Section 4.4 of the SmPC describing that the CAPItello 291 study excluded patients with medical history of clinically significant cardiac disease including QTcF &gt;470 msec, any factors that increased the risk of QTc prolongation or risk of arrhythmic events or risk of cardiac function impairment and that this should be considered if prescribed in these patients. 'Use in patients with clinically important abnormalities in cardiac rhythm (e.g., QT prolongation)' has also been added as missing information in the RMP. Regarding urinary tract infection, the proportion of patients experiencing the event was higher in the capivasertib + fulvestrant arm, with 14.1% (n=50) compared to the placebo + fulvestrant arm with 6.9% (=24), while all the cases of Grade 3 occurred in the capivasertib + fulvestrant arm (n=7, 2.0%). The event is included in the list of the adverse drug reactions in section 4.8 of the SmPC and no warning in the SmPC has been included at this stage. In the pivotal study, there was a slightly higher proportion of patients with renal AEs of potential interest of all grades in the capivasertib + fulvestrant arm compared to the placebo + fulvestrant arm and the incidence of blood creatinine increased AEs was higher in the capivasertib + fulvestrant arm (4.5% vs 0.3%). Higher rate of blood creatinine increase in capivasertib + fulvestrant arm is probably due to decreased tubular secretion of creatinine, since capivasertib is known to inhibit the renal transporters OCT2, MATE1, and MATE2K in vitro. Further, 5 cases of acute kidney injury during or within 7 days after a diarrhoea AE were reported, indicating that diarrhoea may not be adequately manageable in some patients,  and  also  considering  two  patients  discontinued  capivasertib  treatment  due  to  acute  kidney injury. AKI is currently listed as an ADR in section 4.8 and the risk of AKI in patients with drug-induced diarrhoea is reflected in section 4.4. In non-clinical studies, the liver had been identified as tissues affected by capivasertib. Overall, in the capivasertib pivotal study no signal of increased hepatotoxicity has been so far identified. Liver function-

related findings raised overall no concerns.

<div style=\"page-break-after: always\"></div>

Serious AEs with fatal outcome were reported in 4 patients in the capivasertib + fulvestrant arm, vs. 1 in  the  placebo  +  fulvestrant  arm.  None  were  related  to  the  study  treatment.  As  requested,  the relatedness of the AEs with fatal outcomes was further discussed, but overall, at this stage, it does not lead to draw further conclusion on the safety profile of capivasertib. It may be assumed that better handling the AEs caused by treatment with capivasertib probably could have prevented some of the deaths in capivasertib + fulvestrant arm, which is why adequate measures for management of capivasertib toxicity and patient education are essential for the clinical setting. Serious AEs were also more frequent in the capivasertib + fulvestrant arm. SAEs considered by the investigator  as  possibly  related  to  capivasertib  only  and  reported  in  more  than  1  patient  in  the capivasertib  +  fulvestrant  arm  were  diarrhoea  (6  patients,  1.7%),  rash  maculo-papular  (5  patients, 1.4%), acute kidney injury, hyperglycaemia, and vomiting (each in 3 patients, 0.8%), and asthenia (2 patients, 0.6%). In both the FTIH Study Pool and in the Monotherapy Pool, SAEs were reported in a higher proportion of patients than in the pivotal trial (32.0% vs 43.0% vs 16.1%, respectively). For the Monotherapy pool, this may be explained with a higher dose of capivasertib given to this patient population. Higher incidence of SAEs reported in FTIH Study Pool might be explained with the fact that more heavily pre-treated patients  were  enrolled  in  the  study  (indicating  that  patients  in  the  FTIH  study  had  more  advanced disease). Furthermore, since toxicity management guidelines were revised over time and were more prescriptive for the CAPItello-291 study, this might be the reason why in the CAPItello-291 study the AEs were managed earlier and more aggressively and were less likely to reach the level of an SAE. In the CAPItello 291 study, haematological abnormalities were predominantly Grade 1 or 2; Grade 3 abnormalities  were  comparable  between  the  treatment  arms,  except  for  Grade  3  decreases  in lymphocytes and haemoglobin which were reported more frequently in the capivasertib + fulvestrant arm. Consistent with the haemoglobin data, there were more AEs of anaemia reported in the capivasertib + fulvestrant arm (10.4% vs 4.9%). There were 15 (4.2%) patients in the capivasertib + fulvestrant arm and 2 (0.6%) patients in the placebo + fulvestrant arm with AEs of hypokalaemia during the study. Hypokalaemia AEs were CTCAE Grade 3 in 7 (2.0%) patients and CTCAE Grade 4 in one (0.3%) patient in the capivasertib + fulvestrant arm. The patient reported outcomes focusing on safety/toxicity indicate overall an unfavourable impact on treatment-related symptoms, including diarrhoea, rash and mouth or throat sores when capivasertib is added to fulvestrant. The proportion of patients reporting higher severity, interference, frequency or presence of the assessed PRO-CTCAE items was higher in the capivasertib + fulvestrant arm. Rash and mouth or throat sores symptoms recorded by the patients on the PRO-CTCAE tended to peak in  frequency, intensity, severity, and/or impact on daily life in the early cycles of treatment in both treatment  arms.  Diarrhoea,  on  the  other  hand,  retained  its  frequency  and,  in  a  certain  number  of patients, severity in the later cycles as well. With  regards  to  effect  of  age,  the  overall  incidence  of  AEs,  SAEs,  and  AESIs  in  the  capivasertib  + fulvestrant arm of CAPItello-291 was similar across all 3 age groups presented. The incidence of CTCAE Grade 3 or higher AEs was higher in the 65 to 74 years (58.2%) and ≥ 75 years (54.2%) age groups than in the &lt; 65 years age group (35.8%). Owing to the imbalance in the number patients per age group, differences between groups should be interpreted with caution, and limited conclusions can be drawn for  the  ≥ 75  years  age  group,  which  comprised  only  6.8%  of  patients  in  the  capivasertib  + fulvestrant arm of CAPItello-291. No conclusions can be drawn on effect of sex due to the small number of male patients in capivasertib clinical programme.

<div style=\"page-break-after: always\"></div>

Although overall incidence of AEs in the capivasertib + fulvestrant arm of CAPItello-291 was generally similar  across  the  weight  subgroups,  considering  the  incidences  of  SAEs  and  AEs  leading  to  dose reduction were higher in the baseline weight &lt; 50 kg group, it could be that 400 mg may not be an optimal dose in the baseline weight &lt; 50 kg group (see discussion on clinical pharmacology).

Capivasertib's safety profile was generally consistent between altered, confirmed non-altered subgroup SAS and overall safety analysis set. AEs reported in the altered/ confirmed non-altered subgroup SAS reflected those of the overall SAS, with no notable differences.

The frequency of overdoses was highest in Cycle 1 and seemed to decrease thereafter. Overall, the majority of cases occurred on non-dosing days. This indicates that overdose occurred mainly due to the intermittent capivasertib application, probably as patients were not accustomed of taking medications in this  way.  One  of  these  patients  had  an  overdose  associated  with  an  AE  (SAE  of  diarrhoea,  diabetic metabolic decompensation and renal failure). This patient was exposed to capivasertib for 14 consecutive days during cycle 1 week 1 and cycle 1 week 2. The information that the higher than the indicated dosing of  capivasertib  can  increase  the  risk  of  capivasertib  adverse  reactions,  including  diarrhoea  has  been added in section 4.9. of the proposed SmPC.

Although the incidence of AEs leading to discontinuation of capivasertib was higher in the capivasertib + fulvestrant arm (13.0% vs 2.3% in the placebo + fulvestrant arm), it is considered acceptable for this patient  population.  The  most  frequent  AEs  leading  to  discontinuation  in  the  capivasertib  arm  were rash/rash maculo-papular (4.5%), vomiting and diarrhoea (2.0% each), and pyrexia (1.1%). Most of the discontinuations of capivasertib (regardless of fulvestrant discontinuation) occurred during the early cycles of treatment. Only one patient discontinued capivasertib treatment due to hyperglycaemia. Of note, AEs leading to discontinuation were more frequent in confirmed non-altered group (16.9%) than in the confirmed altered group (10.3%).

Adverse events requiring dose modification were also much more frequent in capivasertib + fulvestrant arm.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics

## 2.6.10. Conclusions on the clinical safety

The safety data from the CAPItello-291 study, supported by pooled safety data from relevant studies with capivasertib are reasonably sufficient to characterise the safety profile of capivasertib administrated in combination with fulvestrant and overall indicate an acceptable tolerability profile, despite the fact that the combination of capivasertib plus fulvestrant was more toxic than fulvestrant monotherapy.

In the pivotal CAPItello 291- study no unexpected toxicities occurred. The rates of AEs across categories were higher in the capivasertib + fulvestrant arm than in the placebo + fulvestrant arm, however, this is expected considering a targeted therapy added to an endocrine therapy. Most adverse events appear to be manageable with standard care measures and dose modifications.

The key risks identified for capivasertib are hyperglycaemia and CTCAE ≥ Grade 3 skin ADRs. Diarrhoea is in general manageable in the majority of patients. Nevertheless, the risk of acute complications of diarrhoea is of concern in the clinical setting.

The lack of efficacy and safety data for capivasertib in patients with Type 1 and Type 2 diabetes requiring insulin (as these were excluded from the pivotal study) is adequately reflected in the SmPC. The applicant confirmed that patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring long-term insulin treatment will be eligible for future studies of capivasertib, such that data can be anticipated in the future on the use of capivasertib in this group of patients. In particular, the capivasertib Phase IIIb programme consists of studies CAPItana, CAPItrue and CAPIcorn and for all these studies the updated exclusion criteria include: Clinically significant abnormalities of glucose metabolism defined as HbA1c ≥8.0% (63.9 mmol/mol) at screening. Collectively these three studies will enrol ~600 patients, however, it  is  predicted  that  insulin  dependent  diabetic  patients  will  represent  only  a  small  percentage  of  the recruited  population.  The  applicant  agreed  to  investigate  the  feasibility  of  conducting  a  noninterventional PASS to investigate the safety as well as the efficacy of capivasertib in patients with type 1  or  type  2  diabetes,  including  those  with  insulin-dependent  diabetes,  with  sufficient  patients  to characterise efficacy in patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment.  Overall,  the  applicant's  approach  and  proposal  to  conduct  a  non-interventional  PASS  is considered acceptable.

<div style=\"page-break-after: always\"></div>

Furthermore,  the  relevant  data  from  the  CAPItello-290  study  for  the  further  characterisation  of capivasertib contribution to QT prolongation will be provided when available (REC).

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

Table 79 Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                          |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                                                                                                                                |
| Important potential risks    | Complications of hyperglycaemia                                                                                                                                                                     |
| Missing information          | Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment, or HbA1c ≥ 8.0%) Use in patients with clinically important abnormalities in cardiac rhythm (e.g., QT prolongation) |

## 2.7.2. Pharmacovigilance plan

Table 80 On-going and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                          | Summary of objectives                                                                                                                                                                                                  | Safety concerns addressed                                                                         | Milestones                       | Due dates    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------|--------------|
| A database study of the safety and effectiveness of TRUQAP (capivasertib) + fulvestrant in patients with advanced breast cancer and type 1 or type 2 diabetes Planned | To assess the effectiveness and safety of TRUQAP + fulvestrant in patients with advanced breast cancer and diabetes (type 1 or type 2; insulin- or non-insulin- dependent) who have received prior endocrine treatment | Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment, or HbA1c ≥ 8.0%) | Submission of feasibility report | July 2024    |
| A database study of the safety and effectiveness of TRUQAP (capivasertib) + fulvestrant in patients with advanced breast cancer and type 1 or type 2 diabetes Planned | To assess the effectiveness and safety of TRUQAP + fulvestrant in patients with advanced breast cancer and diabetes (type 1 or type 2; insulin- or non-insulin- dependent) who have received prior endocrine treatment | Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment, or HbA1c ≥ 8.0%) | Protocol submission              | October 2024 |
| A database study of the safety and effectiveness of TRUQAP (capivasertib) + fulvestrant in patients with advanced breast cancer and type 1 or type 2 diabetes Planned | To assess the effectiveness and safety of TRUQAP + fulvestrant in patients with advanced breast cancer and diabetes (type 1 or type 2; insulin- or non-insulin- dependent) who have received prior endocrine treatment | Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment, or HbA1c ≥ 8.0%) | Interim report completion        | Q3 2027      |
| A database study of the safety and effectiveness of TRUQAP (capivasertib) + fulvestrant in patients with advanced breast cancer and type 1 or type 2 diabetes Planned | To assess the effectiveness and safety of TRUQAP + fulvestrant in patients with advanced breast cancer and diabetes (type 1 or type 2; insulin- or non-insulin- dependent) who have received prior endocrine treatment | Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment, or HbA1c ≥ 8.0%) | Final study report completion    | Q3 2030      |

## 2.7.3. Risk minimisation measures

Table 81 Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                                                                                    | Risk minimisation measures                                                                                                                        | Pharmacovigilance activities                                                                                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risk                                                                          | Important Potential Risk                                                                                                                          | Important Potential Risk                                                                                                                                                                                                                                                                                      |
| Complications of hyperglycaemia                                                                   | Routine risk minimisation measures: • SmPC Section 4.4 • PL Section 2 • Prescription-only medicine. Additional risk minimisation measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Targeted follow-up questionnaire. Additional pharmacovigilance activities: • None                                                                                                                             |
| Missing Information                                                                               | Missing Information                                                                                                                               | Missing Information                                                                                                                                                                                                                                                                                           |
| Safety in patients with type 1 and type 2 diabetes (requiring insulin treatment, or HbA1c ≥ 8.0%) | Routine risk minimisation measures: • SmPC Section 4.4 • PL Section 2 Additional risk minimisation measures: • None                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • A database study of the safety and effectiveness of TRUQAP (capivasertib) + fulvestrant in patients with advanced breast cancer and type 1 or type 2 diabetes |
| Use in patients with clinically important abnormalities in cardiac rhythm (e.g. QT prolongation)  | None.                                                                                                                                             | None.                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 1.3 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did not request alignment of the PSUR cycle with the international birth date (IBD).

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant  to  Article  23(1)  of  Regulation  No  (EU)  726/2004,  Truqap  (capivasertib)  is  included  in  the additional  monitoring  list  as  it  contains  a  new  active  substance  which,  on  1  January  2011,  was  not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The recommended indication reflecting the data evaluated is:

' TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2negative locally advanced or metastatic breast cancer with one or more

<div style=\"page-break-after: always\"></div>

PIK3CA/AKT1/PTEN-alterations  following  recurrence  or  progression  on  or  after  an  endocrine-based regimen (see section 5.1).

In  pre-  or  perimenopausal  women,  TRUQAP  plus  fulvestrant  should  be  combined  with  a  luteinising hormone releasing hormone (LHRH) agonist.

For men, administration of a LHRH agonist according to current clinical practice standards should be considered. '

## 3.1.2. Available therapies and unmet medical need

For metastatic breast cancer the 5-year survival rate is in the range of 38% (Allemani et al, Lancet, 2018). Metastatic breast cancer is the leading cause of death from all cancers in women, accounting for ∼ 3.6% of all deaths in women and 1.8% of all deaths in Europe in 2015 (Dafni et al, Breast Care, 2019).

The combination of endocrine therapy with a CDK4/6 inhibitor (CDK4/6i) is currently considered the standard of care first-line treatment in the majority of patients with oestrogen receptor-positive (ER+), HER2-negative locally advanced or metastatic breast cancer, with improved PFS and OS seen in several trials. For the choice of next-line treatment, disease burden, duration of response to previous endocrine therapy, previously used medicinal agents, treatment availability etc. need to be considered. According to ESMO Guidelines, evidence-based available options for second-line therapy are in principle fulvestrantalpelisib  (for PIK3CA mutated  tumours),  exemestane-everolimus,  fulvestrant  monotherapy,  PARP inhibitors (for tumours harbouring genomic BRCA mutations), trastuzumab deruxtecan (for HER2-low tumours),  elacestrant  (for  ESR1  mutated  tumours),  aromatase  inhibitors,  and  chemotherapy.  After progression on CDK4/6i the optimal sequence is uncertain due to limited data in CDK 4/6i-pretreated patients for several of these options (e.g. alpelisib).

Substances targeting the same signalling pathway as capivasertib are alpelisib and everolimus. In study SOLAR-1, alpelisib was investigated in postmenopausal women in 2 cohorts, PIK3CA mutated tumours and non-mutated tumours. Results for PFS were reported with an HR of 0.65 (95%CI 0.50-0.85) for PIK3CA mutated tumours, whereas no PFS benefit was observed in patients whose tumours did not have a PIK3CA tissue mutation.

Premenopausal  women  should  receive  ovarian  suppression/ablation  when  treated  with  aromatase inhibitors or SERDs.

## 3.1.3. Main clinical studies

Study D3615C00001 (CAPItello-291) (NCT04305496) is an ongoing Phase III, double-blind, placebocontrolled,  parallel-group,  randomised,  multicentre  study  to  investigate  the  efficacy  and  safety  of capivasertib + fulvestrant versus placebo + fulvestrant in 708 patients with ER+, HER2- locally advanced or metastatic breast cancer following disease recurrence or progression on or after aromatase inhibitor therapy. Patients may have received previously CDK 4/6i, up to 2 lines of endocrine treatment and 1 line of  chemotherapy.  Randomisation  (1:1)  was  stratified  by  presence  of  liver  metastases,  prior  use  of CDK4/6 inhibitors and geographic location.

The study was planned to show a statistically significant difference between capivasertib + fulvestrant versus  placebo  +  fulvestrant  in  PFS  in  the Overall  population and  the PIK3CA/AKT1/PTEN-altered Population (dual  primary  endpoints)  and  OS  (key  secondary  endpoint)  in  both  populations.  For  the complimentary non-altered population the same endpoints were exploratory analysed.

Supportive study FAKTION (NCT01992952) is a phase 1b/2 study with a randomised (1:1), double-blind, placebo-controlled phase 2 part comparing capivasertib + fulvestrant versus placebo + fulvestrant in

<div style=\"page-break-after: always\"></div>

140 post-menopausal women with locally advanced or metastatic ER+/HER2- breast cancer following recurrence or progression on or after aromatase inhibitor therapy, no previous CDK4/6 inhibitor. The phase 2 part of the study was published twice: first the primary analysis by Jones et al in 2020 and the updated clinical study and expanded biomarker data by Howell et al. in 2022. Only the publications were provided.

The studied dosing regimen was capivasertib 800 mg daily (400 mg BD with or without food) for 4 days followed by 3 days off treatment, fulvestrant 500 mg was administered on Days 1, 15, and 29, and once monthly thereafter. Study treatment was continued until disease progression or unacceptable toxicity. In  pre/perimenopausal  women,  capivasertib  plus  fulvestrant  was  to  be  combined  with  a  luteinizing hormone releasing hormone (LHRH) agonist.

## 3.2. Favourable effects

The presented data are from the primary analysis for superiority of the primary efficacy endpoint of progression free survival (PFS) assessed by investigator in the PIK3CA/AKT1/PTEN altered population at the data cut-off (DCO) date of 15 August 2022.

Primary endpoint: PFS by investigator in the PIK3CA/AKT1/PTEN altered population (n=289): Median PFS was 7.3 months (95%CI: 5.5, 9.0) in the capivasertib+fulvestrant arm versus 3.1 months (95%CI: 2.0, 3.7) in the placebo+fulvestrant arm, the hazard ratio was 0.50 (95% CI: 0.38 0.65; p &lt; 0.001).

Key secondary endpoint: Overall survival (OS) in the PIK3CA/AKT1/PTEN altered population: HR of 0.69 (95% CI 0.45, 1.05)

The early analysis on OS at the time of the primary PFS analysis did not suggest a detrimental effect on survival of treatment with capivasertib + fulvestrant compared with placebo + fulvestrant. Kaplan-Meier plots appear to diverge early.

Sensitivity analysis of PFS by BICR in the PIK3CA/AKT1/PTEN altered population (HR: 0.51; 95% CI: 0.38 0.68; p &lt; 0.001) was consistent with the primary PFS analyses.

Subgroup analyses of PFS: an homogenous effect in most subgroups (by prior chemotherapy, by prior CDK 4/6i treatment, by metastatic site or primary/secondary endocrine resistance) was observed.

Supportive  FAKTION  study  in  postmenopausal  patients  reported  for  NGS  identified  pathway  altered population for PFS an HR of 0.35 (95% CI 0.20, 0.63) and for OS an HR of 0.43 (95% CI 0.24, 0.78) (Howell et al. 2022).

## 3.3. Uncertainties and limitations about favourable effects

CAPITELLO-291 OS data are immature (28%) in the PIK3CA/AKT1/PTEN altered population ,  and the applicant will submit further OS analyses (REC) .

There remains a level of uncertainty regarding the benefit in pre/perimenopausal patients due to the small size of this subgroup in the CAPITELLO-291 study. The effect size for PFS was smaller and the confidence intervals wide. For this subgroup more unfavourable baseline characteristics were recorded which may have contributed. However further studies investigating capivasertib in combination with other  medicinal  products  (CAPItello-292  and  CAPItello-290)  will  provide  further  efficacy  data  for capivasertib in women in premenopausal state and the results of such studies should be submitted when available (REC).

It is uncertain to what extent the efficacy data in the rather 'fit' and non-diabetic study population from CAPITELLO-291 (with the exclusion of patients with insulin dependent diabetes mellitus or high HbA1C)

<div style=\"page-break-after: always\"></div>

can be extrapolated to the target population with diabetes and on antidiabetic medication. Insulin can act  as  mitogen  activating  MAPK/ERK  and  PI3K/AKT  signalling,  this  systemic  feedback  may  impair treatment efficacy with capivasertib. A post-authorisation study (included as a category 3 in the RMP) is planned to address the safety as well as efficacy in patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring long-term insulin treatment as this is currently lacking. 3 further studies which are part of the capivasertib phase IIIb study program (approximately 600 patients to be included) will allow inclusion of patients with preexisting diabetes and HbA1C ≤8mg/dl. Enrolment of diabetic patients and plan for subgroup analyses on efficacy (ORR, PFS, OS) in diabetic patients in the individual studies and in the combined analyses are encouraged (REC).

There  remains  a  level of uncertainty regarding  the in-vitro diagnostic used  for definition of PIK3CA/AKT1/PTEN  mutational  status  used  in  pivotal  study  CAPItello-291  (FoundationOne ® CDx (F1CDx)): the justification for the definition of biomarker-positivity (i.e. PIK3CA/AKT1/PTEN alterations as specified) is following a scientific rationale mainly based on preclinical data. The exploratory clinical data from the CAPItello-291 study suggest that the definition applied may indeed be predictive. However, this is no final confirmation of clinical validity for all individual genetic alterations included.

As no clinical thresholding for the cut-point defining a tumour as biomarker positive or negative was performed, it remains unclear whether the thresholds / cut-off values applied in study CAPitello-291 were optimal or whether a higher or lower thresholds defining patients as 'PIK3CA/AKT1/PTEN alterationpositive' would lead to an even better benefit-risk ratio.

## 3.4. Unfavourable effects

In the CAPItello 291 study, higher frequencies (≥10%) in the capivasertib + fulvestrant arm compared to the placebo + fulvestrant arm were observed for any TEAEs (96.6% vs 82.3%), treatment-related TEAEs (63.3% vs 43.7%), any TEAEs Grade 3 or higher (42.8% vs 15.7%) and TEAEs leading to dose interruption (15.2% vs 5.2%), to dose reduction (19.7% vs 1.7%) and dose discontinuation (13.0% vs 2.3%).

The most commonly reported AEs (&gt; 20% of patients) in the capivasertib + fulvestrant arm were: diarrhoea (72.4% in the capivasertib + fulvestrant arm vs 20.0% in the placebo + fulvestrant arm), nausea (34.6% vs 15.4%), rash (22.0% vs 4.3%), fatigue (20.8% vs 12.9%), and vomiting (20.6% vs 4.9%). Other AEs occurring more commonly in the capivasertib + fulvestrant arm (&gt; 10% difference between  treatment  arms)  were  decreased  appetite  (16.6%  versus  6.3%),  hyperglycaemia  (16.3% versus 3.7%), and rash maculo-papular (16.1% versus 3.7%).

There was a higher proportion of patients with Grade 3 AEs in the capivasertib + fulvestrant arm (39.2% compared with 12.5%) and similar numbers of patients with Grade 4 AEs in both groups (capivasertib + fulvestrant arm, 2.5%; placebo + fulvestrant arm 2. 9%). The most commonly occurring AEs of CTCAE Grade 3 or higher in the capivasertib + fulvestrant arm were diarrhoea (33 patients, 9.3%), rash maculopapular (22 patients, 6.2%), rash (19 patients, 5.4%), hyperglycaemia and hypokalaemia (8 patients, 2.3% each).

The AESIs for capivasertib include hyperglycaemia, diarrhoea (termed non-infectious diarrhoea in the CSP), rash, QT prolongation, infective pneumonia, stomatitis and UTI.

SAEs were reported in a higher proportion of patients in the capivasertib + fulvestrant arm compared to the placebo + fulvestrant arm (16.1% vs 8.0%) in the CAPItello 291 study. The most frequently reported SAEs were diarrhoea, rash maculo-papular, and vomiting.

87 patients (24.5%) in the capivasertib + fulvestrant arm and 108 patients (30.6%) in the placebo + fulvestrant arm had died, the majority of deaths classified as due to progression of disease. Overall, eight deaths in the capivasertib + fulvestrant and six in the placebo + fulvestrant arm occurred for other reasons including AEs and none was considered by the investigator as related to study treatment.

<div style=\"page-break-after: always\"></div>

The key risks identified with capivasertib are hyperglycaemia and CTCAE ≥ Grade 3 skin ADRs. Diarrhoea is  in  general  considered  manageable  in  the  majority  of  patients.  Nevertheless,  the  risk  of  acute complications of diarrhoea and hypokalaemia as a risk factor for cardiac arrhythmia is of concern in the clinical setting.

QT  prolongation  (identified  as  AESI  based  on  non-clinical  data)  was  reported  in  11  patients  in  the capivasertib  +  fulvestrant  arm  and  included  electrocardiogram  QT  prolonged,  syncope,  seizure,  and ventricular arrhythmia.

## 3.5. Uncertainties and limitations about unfavourable effects

The lack of safety data for capivasertib in patients with Type 1 and Type 2 diabetes requiring insulin is reflected in section 4.4 of the SmPC (as these were excluded from the pivotal study). In order to address this uncertainty, a non-interventional post authorisation safety study (category 3 study in the RMP) will be conducted to investigate the safety of capivasertib in patients with type 1 or type 2 diabetes, including those with insulin-dependent diabetes.

Successful  management of  hyperglycaemia  induced  by  capivasertib  is  of  utmost  importance.  In  the setting of a clinical trial, hyperglycaemia may be considered manageable; however, in the clinical setting, hyperglycaemia and related events may be fatal as they may not be diagnosed on time. Therefore, sections  4.2  and  4.4  of  the  SmPC  include  detailed  information  on  precautions  and  management  of hyperglycaemia.

Although on the available ECG recordings of patients experiencing syncope or seizure, QT prolongation could  not  be  seen,  it  is  still  concerning  and  raises  questions  why  these  have  only  been  reported  in capivasertib + fulvestrant arm and especially because the patients with clinically important abnormalities in cardiac rhythm or any factors that increase the risk of QTc prolongation or arrhythmic events were excluded from the study. Relevant data from the CAPItello-290 study should be provided for the further characterisation of capivasertib contribution to QT prolongation (REC).

## 3.6. Effects Table

Table 82 Effects Table for capivasertib in combination with fulvestrant in the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen CAPItello 291 (data cut-off: 15 August 2022)

| Effect                                   | Short Descriptio n         | Unit                     | Treatme nt         | Control            | Uncertainties/ Strength of evidence                                                                                                       | Refer ences        |
|------------------------------------------|----------------------------|--------------------------|--------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects                       | Favourable Effects         | Favourable Effects       | Favourable Effects | Favourable Effects | Favourable Effects                                                                                                                        | Favourable Effects |
| PFS PIK3CA/AKT1/ PTEN altered population | Progression- free survival | Median in months (95%CI) | 7.3 (5.5, 9.0)     | 3.1 (2.0, 3.7)     | Strengths : RCT, treatment blinded Uncertainties: biomarker test retrospectively performed time-point of assignment to population unclear | CSR                |

<div style=\"page-break-after: always\"></div>

| Effect                                  | Short Descriptio n                                                                                                                            | Unit                     | Treatme nt           | Control              | Uncertainties/ Strength of evidence                       | Refer ences          |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------------------|----------------------|-----------------------------------------------------------|----------------------|
| OS PIK3CA/AKT1/ PTEN altered population | Overall survival                                                                                                                              | Median in months (95%CI) | NC (NC, NC)          | NC (20.3, NC)        | Strengths : RCT, treatment blinded Uncertainties immature | CSR                  |
| Unfavourable Effects                    | Unfavourable Effects                                                                                                                          | Unfavourable Effects     | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                      | Unfavourable Effects |
| AEs                                     | Overall incidence of adverse events                                                                                                           | Proportio n (%)          | 96.6                 | 82.3                 |                                                           | CSR                  |
| Grade 3 or higher                       | Incidence of adverse events of grade 3 or 4                                                                                                   | Proportio n (%)          | 42.8                 | 15.7                 |                                                           | CSR                  |
| SAEs                                    | Incidence of serious adverse events                                                                                                           | Proportio n (%)          | 16.1                 | 8.0                  |                                                           | CSR                  |
| AEs leading to discontinuatio n         | Incidence of discontinuati ons due to adverse events                                                                                          | Proportio n (%)          | 13.0                 | 2.3                  |                                                           | CSR                  |
| Diarrhoea                               | Common adverse event and AESI                                                                                                                 | Proportio n (%)          | 72.4                 | 20.0                 |                                                           | CSR                  |
| Rash                                    | Common adverse event and AESI (includes rash, rash macular, rash maculo- papular, rash papular, rash pruritic)                                | Proportio n (%)          | 38.0                 | 7.1                  |                                                           | CSR                  |
| Hyperglycaemi a                         | Common adverse event and AESI                                                                                                                 | Proportio n (%)          | 16.3                 | 3.7                  |                                                           | CSR                  |
| Grade ≥ 3 skin ADRs                     | includes Grade ≥ 3 rash AESI, PTs of erythema, rash erythematou s, erythema multiforme, drug eruption, and dermatitis exfoliative generalised | Proportio n (%)          | 14.9                 | 0.3                  |                                                           | CSR                  |
| QT Prolongation                         | AESI                                                                                                                                          | Proportio n (%)          | 3.1                  | 0                    |                                                           | CSR                  |

Abbreviations:

Notes: See Figures

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In  CAPITELLO-291,  40.8%  of  the  overall  population  belonged  to  the  PIK3CA/AKT1/PTEN  altered population. In the PIK3CA/AKT1/PTEN altered population, the effect on PFS in favour of capivasertib+fulvestrant  in  the  primary  analysis  is  statistically  significant  and  clinically  relevant  with more than doubling of the median PFS time i.e. 4.2 months. PFS sensitivity and subgroup analyses support the robustness of this favourable effect. Importantly for such heterogeneous target population, the effect on PFS was homogenous over most subgroups, thus it was independent of prior CDK 4/6i treatment, prior chemotherapy in the metastatic setting or site of metastatic disease.

Early analyses on OS did not suggest a detrimental effect on survival and further analyses of OS are planned. Results from other secondary endpoints (ORR, PFS2) are supportive which is reassuring.

Published results from the supportive FAKTION study including mature OS data underline a clinically relevant effect  on  PFS  and  even  reported  an  OS  benefit  in  favour  of  capivasertib+fulvestrant  in  the biomarker  positive  population.  This  is  independent  of  the  detailed  definition  for  PIK3CA/AKT1/PTEN alteration and is most pronounced in the subsequent biomarker analysis for which the same biomarker definitions (NGS-identified) are used as in CAPitello-291.

The key risks identified for capivasertib are diarrhoea, hyperglycaemia and CTCAE ≥ Grade 3 skin ADRs. When interpreting the safety results it has to be kept in mind that patients with frequent and relevant concomitant  diseases  (diabetes,  cardiac  diseases)  or  concomitant  medication  with  influence  on  QT interval were excluded from the pivotal study.

The risk of hyperglycaemia is considered highly important as it is four times higher than in patients on fulvestrant monotherapy. The incidence of hyperglycaemia is expected to be even much higher in the clinical setting, especially considering that the applicant proposes no restrictions on use of capivasertib in patients with diabetes mellitus type 1 or 2. In the patients with a history of diabetes (not requiring insulin at baseline) which were included in the pivotal study, the safety data that was reported indicate a worse safety profile in comparison to patients without a history of diabetes.

A non-interventional post authorisation safety study (category 3 study in the RMP) will be conducted to investigate the safety of capivasertib in patients with type 1 or type 2 diabetes, including those with insulin-dependent  diabetes.  'Safety  in  patients  with  type  1  or  type  2  diabetes  (requiring  insulin treatment, or HbA1c ≥ 8.0%)' is reflected as missing information in the RMP.

Diarrhoea is reported as manageable in general in the clinical trial setting. However, it is considered important for the patient population as it was reported in the majority of patients and with approximately 9% CTCAE ≥ Grade 3. The risk of acute complications of diarrhoea, e.g. dehydration, and hypokalaemia as a risk factor for cardiac arrhythmia are of concern in the clinical setting of a target population that is likely to present with more concomitant diseases than the clinical study population.

The risk of QT prolongation is considered relevant and important. QT prolongation was identified as an AESI based on non-clinical data. QT prolongation was reported in 11/430 patients under capivasertib + fulvestrant treatment versus 0 cases with fulvestrant monotherapy. In order to further characterise the risk of QT prolongation, relevant data from the CAPItello-290 study will be provided (Recommendation).

Thus, for patients with frequent and relevant concomitant diseases, e.g. diabetes or cardiac diseases or concomitant medication impacting QT-interval, there are very relevant safety concerns that need to be outweighed  by  substantial  benefit.  The  exclusion  of  such  patients  from  the  CAPITello-291  study  is reflected in sections 4.4 and 5.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

The benefit in the PIK3CA/AKT1/PTEN altered population has been established in the pivotal study with more than doubling the median PFS time. This benefit is robust and supported by the mature data from the supportive FAKTION study. The benefits of capivasertib outweigh the risks from the combination treatment with fulvestrant.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The  overall  benefit/risk  balance  of  Truqap  is  positive,  subject  to  the  conditions  stated  in  section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Truqap is favourable in the following indication:

TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations  following  recurrence  or  progression  on  or  after  an  endocrine-based regimen (see section 5.1).

In  pre-  or  perimenopausal  women,  TRUQAP  plus  fulvestrant  should  be  combined  with  a  luteinising hormone releasing hormone (LHRH) agonist.

For  men,  administration  of  LHRH  agonist  according  to  current  clinical  practice  standards  should  be considered.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

Conditions or restrictions with regard to the safe and effective use of the medicinal product

<div style=\"page-break-after: always\"></div>

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that capivasertib is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.